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Abstract 
The transcription factor Nuclear factor erythroid 2-related factor 2 (NRF2) orchestrates the 
expression of a battery of cytoprotective genes containing antioxidant response elements 
(AREs) within their promoter sequences. Activation of the NRF2 pathway has been implicated 
in the early stages of drug-induced toxicity, a major cause of drug attrition and public risk, 
and therefore holds potential as a pre-clinical marker of chemical entities liable to toxicity. 
Conversely, the upregulation of NRF2 activity holds great therapeutic potential. Many NRF2 
modulating agents are currently undergoing clinical trials for the treatment of pathologies 
with an underlying oxidative stress component. The establishment of sensitive, accurate 
methods to monitor induction of the transcription factor are therefore vital. This thesis 
focuses on the characterisation of novel methods to measure NRF2 pathway activation 
following both toxic and therapeutic stimulation.  
In chapter 2, I use the transgenic Nrf2-Luciferase (Nrf2-Luc) mouse model (Oikawa et al., 
2012), to test the hypothesis that localised activation of NRF2 represents an early marker of 
chemical stress associated with organ-specific drug toxicity. Following a hepatotoxic dose of 
paracetamol (APAP) a bioluminescent signal was observed in the liver but not kidneys or 
lungs of the Nrf2-Luc mice. On a cellular level, luciferase and Haem oxygenase 1 (Hmox1) 
staining colocalised around the centrilobular region, consistent with the known pathology of 
APAP. In response to a nephrotoxic dose of cisplatin, kidney specific bioluminescence was 
detected and colocalised with activation of the endogenous NRF2 pathway in tubular 
epithelial cells. A key finding was that activation of organ-specific bioluminescence 
correlated well with established biomarkers for liver and kidney injury respectively, 
highlighting the ability of NRF2 to reflect localised cellular insults associated with overt organ 
toxicity.  
Despite the emerging role of NRF2 as a marker of the response to drug toxicity and a 
therapeutic target, there are currently no non-invasive methods for monitoring NRF2 
pathway activation in patients. In chapter 3 of this thesis, I hypothesised that organ-specific 
chemical perturbation instigates changes in NRF2 pathway activity in murine whole blood, 
providing potential markers of organ-specific injury. Here I provide evidence for the 
induction of NRF2-regulated genes in whole blood following exposure of C57BL/6 mice to 
APAP or the therapeutic NRF2-activating compound, CDDO-Me. The induction of NRF2-
regulated transcripts, including Hmox1, was muted in mice administered APAP and the 
clinically used antidote, N-acetylcysteine (NAC). Insight into blood-based activity of the NRF2 
pathway may provide evidence for the role of NRF2 in response to drug toxicity in humans 
and will be an important pharmacodynamic marker with the emergence of NRF2 modulators 
as therapeutic drugs. 
Primary human hepatocytes (PHH) are one of the most physiologically relevant in vitro 
systems for modelling drug-induced hepatotoxicity. However, the NRF2 pathway is not well 
characterised in these cells. In chapter 4, based on previous, unpublished microarray data of 
NRF2 pathway modulation in PHH, a group of potentially novel NRF2-regulated genes were 
identified: Coagulation factor II receptor-like 2 (F2RL2), NmrA-like family domain containing 
1 pseudogene (LOC344887) and Tripartite Motif Containing 16 Like (TRIM16L). Following 
identification of potentially active cis-ARE sites in the promoters of these genes, I assessed 
direct activation by NRF2 using luciferase-based promotor-reporter assays. Despite evidence 
in multiple microarray datasets from our bioinformatic analysis that these genes are indeed 
modulated by NRF2, wild-type and mutant reporter constructs failed to produce differential 
luminescent responses in transfected HepG2 cells exposed to CDDO-Me or following over-
expression of NRF2. During consideration of the well-established Nrf2-regulated gene SRXN1 
as a positive control, I noticed two consecutive ARE sites within the region identified by Singh 
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et al. to which NRF2 directly binds (Singh et al., 2009).  Promotor-reporter analysis implicated 
both sequences in the activation of SRXN1 transcription as only cells transfected with the 
wild-type SRXN1 construct produced luminescence in response to Nrf2-activation. These 
data indicate the necessity of extended AREs for the activation of NRF2-regulated genes.  
The emergence of NRF2-activating compounds in the clinic highlights the application of 
therapeutic induction of the NRF2-dependent oxidative stress responses. The 
isothiocyanate, sulforaphane is among the most well studied clinical activators of NRF2. 
However due to its limited shelf life, stabilised analogues are needed. In the final 
experimental chapter of this thesis, I summarise data generated in collaboration with Evgen 
Pharma to assess the potencies of novel analogues of sulforaphane. Utilizing the H4IIe-8AREL 
reporter cell line, I show analogues with variable methane bridge length and sulfoxide group 
exhibited reduced potency towards NRF2 compared to the parent compound sulforaphane. 
The potencies of a subgroup of analogues as inducers of other luminescent reporters: pGL4-
NQO1 and pGL4-5xARE, in a human liver cell line were also recorded. A key finding was the 
similar rank order of potencies of this subset of compounds in both cell lines.  Development 
of sensitive assays for the in vitro assessment of NRF2 activators will be of increasing value 
as the number of therapeutic NRF2-modulating compounds entering the clinic grow. 
The establishment of robust methods to monitor NRF2 activation will inform key events 
underlying toxicity and provide insight into the subtle changes resulting in upregulation of 
the oxidative stress response to provide either an adaptive phenotype or one that is 
overwhelmed in resulting toxicity. Documentation of these mechanisms at a tissue or cellular 
level will inform adverse outcome pathways (AOPs), improving risk assessment frameworks. 
The specific stimuli NRF2 responds to must be thoroughly characterised to define the role of 
NRF2 and other stress response pathways following exposure to chemical and/or oxidative 
stressors. Conversely, development of effective, novel NRF2 inducers for use in the clinic 
requires sensitive screening platforms to determine the pharmacodynamic effects of these 
compounds.   
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1.1. Introduction  
Adverse drug reactions (ADRs) are a substantial burden to clinical practice and drug 
development. Defined as an unintended, noxious response to a drug at a dose normally used 
in humans, ADRs may be due to single, prolonged or synergistic effects of a drug (Board, 
1973) and can be fatal. For instance the most common cause of acute liver failure is drug-
induced liver injury (DILI) (Lee, 2012). Mortality due to serious ADRs in the US is 
approximately 100,000 deaths/year (Lazarou et al., 1998) while it is the seventh most 
common cause of death in Sweden (Wester et al., 2008). In the UK, up to 6.5% of all hospital 
admissions and approximately 5,000 deaths per year are associated with ADRs (Pirmohamed 
et al., 2004).  
Current preclinical testing identifies less than 25-55% of drugs associated with DILI (Olson et 
al., 2000; Xu et al., 2004). A recent systematic review identified hepatotoxicity as the most 
common reason for medicinal products being withdrawn from the market between 1953 to 
2013 (Onakpoya et al., 2016). Indeed, toxicity is accountable for the attrition of 30% of all 
drug candidates during development (Kola and Landis, 2004). Cessation of candidate drugs 
late in development, due to lack of efficacy and unexpected adverse effects, incurs 
substantial costs. Many of these novel agents can provoke deleterious effects in cells via the 
induction of chemical stress (direct or indirect chemical interaction with one or more critical 
macromolecules) or oxidative stress (accumulation of reactive oxygen species (ROS) due to 
mitochondrial dysfunction, perturbation of cellular oxidase enzymes, or the redox cycling of 
the chemical entity). Both chemical and oxidative stress can inhibit the physiological function 
of specific target proteins, cause damage to DNA and/or provoke lipid peroxidation and 
disruption of cell membrane integrity, ultimately leading to cellular dysfunction or death 
(Finkel, 2011). Therefore, it is imperative that the ability of a chemical entity to provoke 
chemical and/or oxidative stress can be determined prior to human exposure, in order to 
minimise the risk of clinical toxicity and aid the design of safer alternatives. 
In addition to drug-induced toxicity, oxidative stress has been linked to the pathophysiology 
of cardiovascular diseases such as atherosclerosis and hypertension (Griendling and 
FitzGerald, 2003); inflammatory diseases including arthritis and diabetes (García-González et 
al., 2015; Giacco and Brownlee, 2010); neurodegenerative diseases and depression (Black et 
al., 2015; Browne et al., 1999; Nakabeppu et al., 2007; Nunomura et al., 2001). Chronic 
accumulation of free radicals may be linked to the natural aging process (Harman, 1956) and 
ROS-mediated mutagenic damage to DNA and enhanced proliferation contribute to 
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carcinogenesis (Ishikawa et al., 2008; Kumar et al., 2008). As a result, there is much interest 
in the potential therapeutic value of antioxidants in these and other disease contexts.  
Mammalian cells can withstand moderate increases in local concentrations of electrophiles 
and ROS due to the concerted actions of numerous antioxidant proteins. The expression of 
most genes encoding these proteins is regulated by the ubiquitously expressed transcription 
factor Nuclear factor erythroid 2-related factor 2 (Nrf2) (Bryan et al., 2013). Further insight 
into its therapeutic role may aid the development of treatments for diseases with an 
underlying oxidative stress component. In addition, there is evidence to suggest activation 
of the Nrf2 pathway precedes some forms of toxicity and therefore may serve as a marker 
for the screening of compounds with toxic liabilities. This thesis evaluates novel Nrf2 activity 
measures to assess the toxicological and pharmacological effects of drugs. Specifically, this 
work explores the use of Nrf2-Luc mice for the non-invasive measurement of Nrf2-pathway 
activity in response to toxicants; investigates regulation of the Nrf2-pathway in human liver 
cells; characterises the expression of Nrf2-regulated genes in whole-blood following 
toxicological and pharmacological stimulation of the transcription factor and assesses the 
value of luciferase reporter genes for evaluating potencies of novel therapeutic inducers of 
Nrf2.  
 
1.2. Oxidative stress  
Exposure to high or sustained levels of reactive oxygen species (ROS) disrupt the normal 
intracellular redox state causing oxidative stress. Defined as an imbalance between 
antioxidant defence molecules and ROS (Sies, 2015), oxidative stress can damage DNA, lipids 
and protein by the formation of adducts. ROS include peroxides, singlet oxygen, superoxide 
and hydroxyl radicals (·OH).  The unpaired valance electrons within these free radicals 
facilitate oxidation of surrounding lipids, proteins and DNA. Low levels of ROS are generated 
during normal metabolism mostly by oxidative phosphorylation. ROS are also generated by 
phagocytes during the ‘Oxidative burst’ (Babior et al., 1973) and act as both inter and intra 
cellular messengers. Mittal and Murad were the first to discover that ·OH activates the 
second messenger cyclic guanosine monophosphate (cGMP) (Mittal and Murad, 1977). 
Redox signalling has also been implicated in a number of physiological functions including 
regulation of vascular tone, cell adhesion, inflammatory response and apoptosis (Bulua et 
al., 2011; Chiarugi et al., 2003; Matoba et al., 2000). Maintenance of ‘steady state’ 
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concentrations of ROS is determined by the rate of generation and removal by antioxidants. 
When redox-buffering capacity is overwhelmed, oxidative stress occurs.  
 
1.2.1. Oxidative stress and disease  
Oxidative damage has been implicated in the aetiology of many diseases due to deviation 
from redox homeostasis. For instance, oxidative stress is a facet of many cardiovascular 
diseases; excessive generation of ROS in vascular cells results in the oxidation of low-density 
lipoproteins that promote atherosclerosis (Chen et al., 2003; Kunsch and Medford, 1999). 
Release of large amounts of ROS including superoxide and hydroxyl radicals, following 
myocardial ischemia implicates oxidative stress in heart failure and reperfusion injury 
(Arroyo et al., 1987; Zweier et al., 1988). Many antioxidant therapies have proved 
cardioprotective in the clinic (Kurian et al., 2016).  
Inflammation and oxidative stress are closely linked. Inflammatory cells generate and secrete  
ROS while oxidative stress can activate pro-inflammatory responses (Mittal et al., 2014; 
Morgan and Liu, 2011). During carcinogenesis, reactive species enhance cell proliferation, 
tumour invasiveness and mutagenic DNA damage (Franco et al., 2008; Barry Halliwell, 2007). 
Progression of gastric cancer is aided by the generation of reactive species from commensals 
within the gut (Handa et al., 2011). Additionally, patients with to type 2 diabetes mellitus 
exhibit reduced antioxidant capacity (Bruce et al., 2003) and over-production of superoxide 
by the mitochondrial electron transport chain is the common cause of hyperglycaemic 
damage (Nishikawa et al., 2000). Perturbation of the mitochondrial respiratory chain is also 
apparent in patients with chronic kidney disease (Gamboa et al., 2016).  
Multiple neurodegenerative diseases have an underlying oxidative stress component. For 
instance, patients with multiple sclerosis exhibit elevated DNA and lipid oxidation in the brain 
(Haider et al., 2011). One source of reactive species during Alzheimer’s disease is the 
incorporation of amyloid beta peptides within neuronal membranes, resulting in free fatty 
acid release associated with Tau polymerisation (Butterfield et al., 2001; Lauderback et al., 
2001). This is accompanied by an increase in oxidised macromolecules and a reduction in 
antioxidant activity. Additionally, diminished antioxidant capacity and increased protein 
oxidation are associated with aging (Harman, 1956).  
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1.2.2. Drug-induced chemical and oxidative stress 
Formation of reactive intermediates capable of generating ROS underpins a plethora of drug 
toxicities. Perhaps the most well-known hepatotoxin, paracetamol is one such example. Also 
known as acetaminophen (APAP), paracetamol is metabolised by the liver to generate 
unreactive glucuronide and sulfate moieties alongside the reactive metabolite N-acetyl-
parabenzoquinoneimine (NAPQI) (Fig 1.1). This is conjugated to the reduced form of 
glutathione (GSH) to be excreted as mercapturic acid (Dahlin and Nelson, 1982). At 
therapeutic doses, depleted GSH is recoverable. However, the extent of GSH depletion 
associated with APAP overdose allows excess NAPQI to form DNA and protein adducts within 
the liver (Hinson et al., 2010). Increased mitochondrial membrane permeability causes 
cytochrome C release and loss of ATP synthesis (Kon et al., 2004). Ultimately, this results in 
centrilobular hepatic necrosis. 
Aside from bioactivation of drugs to entities that induce oxidative stress, chemical stress is 
induced directly by drugs that undergo covalent binding and the formation of adducts. One 
such example is nephrotoxicity associated with the chemotherapeutic agent cisplatin (cis-
diamminedichloroplatinum). High doses of the cisplatin  are limited due to damage within 
the proximal tubules of the kidney (Aleksunes et al., 2010). Indeed, one third of patients 
suffer from nephrotoxicity when prescribed the drug (Shord et al., 2006). Direct chemical 
stress is caused by cisplatin-DNA crosslinks that result in cell cycle arrest. Cisplatin induces 
intra-strand crosslinks (between adjacent guanines or adenine and guanine), inter-strand 
DNA crosslinks and irreversible DNA-protein crosslinks (Eastman, 1983; Fichtinger-Schepman 
et al., 1985). As the kidneys are the major excretory route of cisplatin, apoptosis of renal 
tubular cells initiates reduced glomerular filtration rate (GFR), and acute renal failure 
(Gonzales-Vitale et al., 1977).  
Further investigation into the underlying mechanisms of bioactivation and covalent binding 
are needed to identify chemical entities capable of inducing oxidative and/or chemical stress 
and improve the sensitivity of current pre-clinical drug safety assessment.  
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Figure 1.1 Bioactivation of paracetamol  
Paracetamol (APAP) is metabolised by the liver to generate unreactive glucuronide and 
sulphate moieties before producing the reactive metabolite N-acetyl-
parabenzoquinoneimine (NAPQI). This forms glutathione conjugates (GSH) and is excreted 
as mercapturic acid. However, the extent of GSH depletion associated with APAP overdose, 
allows excess NAPQI to form DNA and protein adducts within hepatic and renal tissues. 
Following a therapeutic dose of APAP, average percentage of APAP metabolised by the liver 
highlighted in light-blue.  Adapted from (Jaeschke and Bajt, 2010). 
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1.2.3. Cell defence mechanisms  
Following induction of oxidative stress, numerous stress response cascades are activated 
that coordinate the adaptive response to the insult or, when overwhelmed, lead to cell 
death. Enzymatic scavengers of ROS include glutathione reductase, superoxide dismutase 
and catalase. Non-enzymatic scavengers include flavonoids and vitamins A, C and E. Multiple 
signalling cascades are activated, including: mitogen activated protein kinase (MAPK) 
signalling, phosphatidylinositol-3-kinase/Protein kinase B (PI3K-Akt), Protein kinase C (PKC), 
Heat shock protein response, P53 and nuclear factor-KappaB (NF-κB). Localised 
accumulation of ROS may aid specificity of these signals. For example, Woo et al highlighted 
the specific accumulation of hydrogen peroxide (H2O2) around membranes following 
inactivation of the antioxidant peroxiredoxin, facilitating redox-dependent signalling but not 
toxic ROS damage (Woo et al., 2010). Modification of small molecules within these pathways 
affects a diverse range of cellular processes including proliferation, metabolism, 
differentiation and survival.  
Upregulation of cytoprotective genes is also triggered in response to oxidative stress. Redox 
factor 1 (Ref-1) regulates activity of basic leucine zipper (bZIP) transcription factors such as 
Nrf2, DNA lesion and base excision repair, and ultimately activates multiple cell survival 
pathways (Thakur et al., 2014; Xanthoudakis et al., 1992). Cysteine residues within the N-
terminus of Ref-1 are liable to redox modification that facilitates DNA binding (Luo et al., 
2012). The transcription factor nuclear factor kappa b (NF-κB) mediates immune and 
inflammatory responses. Its activation by ROS is debated. Inhibitors of NF-κB such as N‐
acetyl‐l‐cysteine (NAC), were thought to inactivate NF-κB through their antioxidant activity 
but they in fact exert their effects by other mechanisms (Hayakawa et al., 2003). In the case 
of NAC, the compound reduced tumour necrosis factor alpha (TNFα)-mediated NF-κB-
activation. However, exposure to H2O2 inhibits phosphorylation of the NF-κB supressor IkBα 
in some cell lines (Schoonbroodt et al., 2000). NF-κB is also activated following exposure to 
high levels of ROS via the protein kinase C pathway (Imran and Lim, 2013).  
If survival mechanisms are overwhelmed, cell death programs such as apoptosis, necrosis, 
pyroptosis and autophagy are activated. ROS can directly modulate cell death effectors: 
caspases, B-cell lymphoma 2 (Bcl-2) and cytochrome C. Caspases are cysteine-dependent 
proteases that mediate apoptosis via DNA fragmentation, membrane permeablisation and 
cleavage of a range of substrates. Low doses of H2O2 induce caspases while high doses induce 
necrosis (Cai et al., 1999). Bcl-2 is an anti-apoptotic regulatory protein that is antagonised by 
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nitric oxide (NO) mediated oxidation (Cahuana et al., 2004). Excessive ROS trigger the 
peroxidase activity of cytochrome C leading to its release into the cytosol and subsequent 
permeabilization of the mitochondrial membrane (Kagan et al., 2005).  
 
1.2.4. Therapeutic potential of antioxidants  
Antioxidants are defined as ‘any substance that delays, prevents or removes oxidative 
damage to a target molecule’ (B. Halliwell, 2007). This defence network comprises of non-
enzymatic compounds (including Vitamin A, C and E, uric acid) and enzymes (such as 
glutathione peroxidase, superoxide dismutase (SOD) and catalase). Catalase facilitates H2O2 
detoxification to water and oxygen. Superoxide dismutase, originally identified by McCord 
and Fridovich, catalyses the detoxification of superoxide radicals (O2-) (McCord and 
Fridovich, 1969). The therapeutic value of antioxidants in the clinic is debated. Large 
epidemiological cohort studies show higher intake of antioxidants reduces risk of coronary 
heart disease (CHD) (Correa et al., 2000; Hirvonen et al., 2001), cancer (Greenlee et al., 2012) 
and neurodegenerative diseases (Ascherio et al., 2005; Engelhart et al., 2002).  However, as 
an adjuvant therapy, clinical trials highlight mixed results. For instance, one meta-analysis of 
randomised trials of vitamin E (7 studies) and beta carotene (8 studies) over the course of 
1.4 to 12 years showed the dietary supplementation was ineffective at reducing long-term 
cardiovascular mortality (Vivekananthan et al., 2003). A systematic review in 2008, found 
antioxidant therapy ineffective at reducing cognitive decline in aging populations (Jia et al., 
2008). Under certain conditions, antioxidants may act as pro-oxidants and unrelated harmful 
effects of antioxidant therapy must not be overlooked (Bjelakovic et al., 2007). Additional 
reasons why antioxidants may have proven ineffective in human trials include the lack of 
stratification, as the extent of oxidative stress is likely to vary between patients. Oxidative 
damage may not be reduced by a single antioxidant and pathology may be localised to a 
specific area such as an arthritic joint that the therapy does not reach. It may be more 
suitable for antioxidant therapy to be applied as a prophylactic measure and not for 
treatment of established pathology. 
Despite this, a plethora of anti-oxidant drugs have been approved for clinical use including 
N-acetylcysteine (NAC, Acetadote®) as an antidote for paracetamol overdose (Aitio, 2006).  
Edaravone (3-methyl-l-phenyl-pyrazolin-5-on) is routinely used clinically for the reduction of 
neuronal damage after stroke (Watanabe et al., 2008). It reacts strongly with free radicals to 
produce stable products. Alpha-Lipoic acid (Dexlipotam) has been approved for the 
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treatment of diabetic neuropathy (Ziegler et al., 2004). In its reduced form, the compound is 
a potent antioxidant and has been recently introduced a part of a cocktails of antioxidants 
known as Zycose for the treatment of diabetes (Stirban, 2008). The antioxidant drug Probucol 
is currently undergoing the PROSPECTIVE (Probucol Trial for Secondary Prevention of 
Atherosclerotic Events in Patients with Prior Coronary Heart Disease) trial in patients with a 
history of CHD as an antioxidant therapy in combination with statins (Yamashita et al., 2016).  
 
1.3. Nrf2 and the antioxidant response 
Nrf2 is a bZIP transcription factor of the cap’n’collar subfamily first identified by Moi et al. 
(1994) for its ability to bind to the AP1-nuclear factor erythroid 2 (NF-E2) promotor sequence 
during a screen of a cDNA library from a hemin-induced erythroleukemia cell line (Moi et al., 
1994). Encoded by NFE2L2 gene, Nrf2 is expressed ubiquitously in humans and mice (Chan 
et al., 1996; McMahon et al., 2001; Moi et al., 1994). It is highly expressed in organs exposed 
to the external environment, such as the skin and lungs, and those implicated in 
detoxification, including the liver and kidneys. It is thought that the role of Nrf2 evolved from 
the need survive in an oxygen-rich environment (Gacesa et al., 2016). Venugopal et al. 
showed similarity between Nrf1 and Nrf2 binding motifs similar to the antioxidant response 
element (ARE) in human NAD(P)H dehydrogenase quinone 1 (NQO1) and that this cis-
element responded to transfection with Nrf1 and Nrf2 in HepG2 cells (Venugopal and Jaiswal, 
1996). They proposed Nrf2 may be key transcription factor in regulating the genetic response 
to xenobiotic metabolism (Itoh et al., 1997; Venugopal and Jaiswal, 1996). The Yamamoto 
group also observed inducible expression of enzymes like GSTs and NQO1 were lost in liver 
of Nrf2 knock out (KO) mice (Itoh et al., 1997). The transcription factor has since been 
established as the master regulator of the response to chemical and oxidative stress (Fig 1.2). 
Despite the viability of Nrf2 null mice indicating its redundancy during growth and  
development (Chan et al., 1996), Nrf2 is also implicated in proliferation, differentiation, 
cellular growth and apoptosis (Hinoi et al., 2006; Homma et al., 2009; Niture and Jaiswal, 
2012; Zhao et al., 2009).  
The 2.2 kb transcript of Nrf2 was predicted to translate to a protein approximately 66 kDa 
(Moi et al., 1994). However, sodium dodecyl sulfate poly acrylamide gel electrophoresis (SDS-
PAGE) analysis of cellular Nrf2 produces bands at approximately 90 kDa (Lau et al., 2013). 
This is thought to be due to the abundance of acidic residues within Nrf2. Nrf2 consists of six 
highly conserved Neh (Nrf2-ECH homologous) (ECH = erythroid cell-derived protein with CNC 
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homology domains) (Fig 1.2) (Itoh et al., 1995). The Neh1 domain contains a CNC-bZIP 
sequence with the cysteine residue (506)  that is essential for Nrf2 binding to the ARE and 
facilitates heterdimerization with small masculoaponeurotic fibrosarcoma (Maf) proteins to 
bind to DNA (Bloom and Jaiswal, 2003). The Neh2 domain contains two motifs (DLG and 
ETGE) to which the cytosolic inhibitor of Nrf2, Kelch-like ECH-associated protein 1 (Keap1) 
binds (Itoh et al., 1999; Katoh et al., 2005). Deletion of the Neh3 domain resulted in a 
‘transcriptionally silent’ Nrf2 protein, despite maintaining the ability to translocate to the 
nucleus and bind to DNA (Nioi et al., 2005). This implicates the final residues of the C 
terminus are involved transactivation and recruitment of co-activator proteins. The Neh4 
and Neh5 domains are also regarded as transactivation domains that interact with cAMP 
response element binding protein (CREB) independently (Katoh et al., 2001). The Neh6 
domain ensures turnover of Nrf2 during stressed conditions and interacts with β-transducin 
repeat containing E3 ubiquitin protein ligase (β-TrCp) (Fig 1.2) (Chowdhry et al., 2013; 
McMahon et al., 2004). 
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Figure 1.2 Overview of the Nrf2-Keap1 pathway 
Under basal conditions, the cellular abundance and activity of Nrf2 is repressed through 
ubiquitination (Ub) via the Cullin-dependent E3 ubiquitin ligase Cul3 bound to Keap1 
homodimers, or Cul1 bound to β-TrCP. The latter interaction is promoted via GSK-3β -
mediated phosphorylation of Nrf2. Chemical and oxidative stressors activate Nrf2 signalling 
via stimulation of the PI3K pathway, or chemical/oxidative modifications of cysteine-
containing pockets (diamonds) in Keap1. The latter process stabilises the Keap1-Nrf2 
complex, by inactivating Keap1 or stimulating the dissociation of Cul3, allowing newly-
synthesised Nrf2 to accumulate in the cell and translocate to the nucleus, where it forms 
heterodimers with Maf proteins and transactivates ARE-regulated genes to coordinate an 
adaptive response to chemical/oxidative stress. 
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Figure 1.3 Functional domains of Nrf2 and Keap1 
Nrf2 includes six highly conserved Neh (Nrf2-ECH homologous) domains.  Neh2 is responsible 
for interactions with Kelch-like ECH-associated protein 1 (Keap1). Neh4 and Neh5 interact 
with co-activator proteins for transactivation, as does Neh3. Neh6 interacts with β-TrCp and 
is phosphorylated by GSK3β. Neh1 contains the DNA binding domain to which small Maf 
proteins bind. Keap1 consists of the bric-a-brac/tram-track/broad complex (BTB), 
intervening linker region (IVR) which interact with Cullin3 and other Keap1 molecules to form 
homodimers. The double glycine repeats (DGR) and C-terminal region (CTR), also known as 
the DC domain, bind with Nrf2.  
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1.3.1. Regulation by Keap1  
Under basal conditions, Nrf2 is repressed via cytoplasmic tethering and ubiquitination 
mediated by the redox-sensitive Kelch-like ECH-associated protein 1 (Keap1) (Itoh et al., 
1999). Keap1-/- mice do not survive to adulthood due to hyperkeratosis of the gastrointestinal 
tract and ulceration of the stomach (Wakabayashi et al., 2003). Mouse embryonic fibroblasts 
(MEFs) from the knock out mice exhibited constitutive Nrf2 activation. Yeast two hybrid 
analysis identified the strong interaction between Keap1 and the Neh 2 binding domain of 
Nrf2 (Itoh et al., 1999) (Fig 1.3). Co-immunoprecipitation of Keap1 with anti-actin antibody 
highlighted direct binding of Keap1 to the actin-cytoskeleton via the Kelch domain facilitating 
cytoplasmic tethering of Nrf2 under basal conditions (Kang et al., 2004). The cullin-
dependent E3 ubiquitin ligase complex associates with a Keap1 homodimer to facilitate 
proteasomal degradation of Nrf2 (Cullinan et al., 2004; Zhang et al., 2004) (Fig 1.2). Inhibition 
of the proteasome results in accumulation of Nrf2 protein and induction of Nrf2-regulated 
genes (Nguyen et al., 2003; Sekhar et al., 2000; Stewart et al., 2003).  
Keap1 is endowed with a relatively high number of cysteine residues (27) (Miseta and 
Csutora, 2000). These residues are incorporated into the functional domains of the protein 
and are sensitive to changes in cellular redox state. The ‘cysteine code’ hypothesis was first 
proposed by Kobayashi et al. (2009) following the discovery of distinct sets of cysteine 
residues are altered when exposed to a range of Nrf2 activating compounds (Kobayashi et 
al., 2009). This enables plasticity of the Nrf2 mediated response to a plethora of stimuli.  
The hinge latch hypothesis is based on differential affinity of Keap1 homodimers to the ETGE 
and DLG motifs within Neh 2 domain of Nrf2 (Tong et al., 2006). Only when both sites are 
bound to the Keap1-Cullin ligase complex, can lysine residues within Nrf2 be ubiquitinated 
facilitating its proteasomal degradation. Under conditions of chemical and oxidative stress, 
modification of thiols within Keap1 inhibit its ability to bind to the DLG motif of Nrf2 and 
efficiently target it for ubiquitination, thus inhibiting its proteasomal degradation. Keap1 
molecules become saturated and de novo synthesised Nrf2 translocates to the nucleus. 
However, the mechanism by which Nrf2 is able to move freely within the cell is debated. 
Partial and complete dissociation of Nrf2 from Keap1 was observed following exposure to 
electrophiles (Levonen et al., 2004; Niture et al., 2009). Exposure to electrophiles also 
resulted in in the loss of Cullin3 from Keap1-Nrf2 complexes (Gao et al., 2013; Rachakonda 
et al., 2008). In some instances, exposure to Nrf2 activators including tert-butylhydroquinone 
(tBHQ), facilitate ubiquitination of Keap1 (Zhang et al., 2005). Others postulate transient 
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nuclear shuttling of Keap1 supresses Nrf2 (Nguyen et al., 2005). However, this is contested; 
Watai et al. observed no change in the cytoplasmic localisation of Keap1 in MEFs following 
exposure to diethyl malate or the nuclear export inhibitor Leptomycin B (Watai et al., 2007). 
Additionally, proteins with motifs comparable to the ETGE sequence, compete with NRF2 for 
binding with KEAP1, thus indirectly activating the transcription factor. These include P62 and 
DPP3 (Dipeptidyl Peptidase 3) (Lau et al., 2010).  
 
1.3.2. Phosphorylation of Nrf2 
Nrf2 contains many serine, threonine and tyrosine residues. Phosphorylation of Nrf2 has 
been reported by a myriad of kinases including protein kinase C, tyrosine kinase Fyn, JNK, 
ERK, PERK and MAP kinases (Bryan et al., 2013). In particular, MAP kinase P38 phosphorylates 
Nrf2 improving its association with Keap1 (Keum et al., 2006). Recent evidence also 
implicates phosphorylation of Nrf2, mediated by glycogen synthase kinase 3β (GSK-3β), as a 
Keap1-independent regulatory mechanism, (Fig 1.2). Salazar et al. highlighted 
phosphorylation of Nrf2 by GSK-3β resulted in nuclear exclusion of the transcription factor 
(Salazar et al., 2006). This acts independently of Keap1 regulation. Rada et al. demonstrated 
GSK-3β inhibitor SB216367 stabilized Nrf2 expression in Keap1-/- MEFs while an Nrf2 ETGE 
motif mutant, impervious to Keap1 degradation, accumulated following GSK-3β inhibition in 
HEK293T cells (Rada et al., 2011). Knock down of GSK-3β also resulted in accumulation of 
Nrf2 protein. Phosphorylated Nrf2 binds to the adaptor protein β-TrCp (β-transducin repeat-
containing protein) that recruits Cullin-1 to form an E3 ligase. Both McMahon and Rada 
groups identified a redox independent degron within Neh 6 of Nrf2 (McMahon et al., 2004; 
Rada et al., 2011). The former by analysing deletion mutants in the fibroblast-like kidney cell 
line COS1 following exposure to sulforaphane. The latter via bioinformatic analysis of the β-
TrCp consensus motif in both mouse and human Nrf2. GSK-3β mediated phosphorylation of 
the Ser344 and Ser347 residues within Neh 6 of human Nrf2 allows β-TrCP to bind and facilitate 
E3 ligase mediated degradation (Rada et al., 2012).  
A second Neh6-based degron, identified by Chowdhry et al., has the amino acid sequence 
DSAPGS and can bind to β-TrCp (Chowdhry et al., 2013). However, the phosphorylated 
binding site described by Rada et al. (amino acid sequence: DSGIS) has a stronger affinity to 
the adaptor protein (Rada et al., 2011). Nrf2 target gene expression and GSH levels increased 
in the hippocampus of neuron-specific GSK-3β knock out mice and those treated with GSK-
3β inhibitor (Rada et al., 2012). GSK-3β is downstream of multiple kinase cascades: PI3K, AKT, 
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mTOR signalling (Maurer et al., 2014). The serine-threonine kinase has been implicated in 
glycogen metabolism, Wnt signalling, microtubule stability and apoptosis (Anderton et al., 
2001; Ding et al., 2000; Hoeflich et al., 2000; Yoshino and Ishioka, 2015).  
1.3.3. Antioxidant response element-regulated genes 
Increases in intracellular concentrations of electrophiles and ROS interfere with the ability of 
Keap1 to repress Nrf2, and PI3K signalling inhibits phosphorylation of Nrf2 (Salazar et al., 
2006). This facilitates accumulation of the transcription factor in the nucleus and 
upregulation of cell defence genes that contain the cis-acting antioxidant response element 
(ARE) within their promoter regions (Fig 1.2). Nrf2 forms heterodimers with Jun and small 
Maf proteins for high affinity binding to DNA (Itoh et al., 1997). Originally identified by 
Rushmore et al. from rat GSTYa1 and NQO1, the ARE consensus sequence has since been 
revised (Erickson et al., 2002; Nioi et al., 2003; Rushmore et al., 1991; Wyeth W. Wasserman 
and Fahl, 1997). Kuosmanen et al. define the core sequence into three motifs: n-‘TGA’-n-
‘TCA’-n-‘GC’ after comparing variation in Nrf2 ChIP-seq datasets (Kuosmanen et al., 2016). 
The Nrf2 interactome is thought to include around 7469 transcription factor-DNA 
interactions (Papp et al., 2012) Single nucleotide polymorphisms (SNPs) within ARE 
sequences can alter Nrf2 binding. Also, SNPs within the Nrf2 promotor are associated with 
increased incidence of acute lung injury (Marzec et al., 2007). The first genome-wide study 
of Nrf2 binding via ChIP-seq identified 242 high confidence binding sites in the genome of 
human lymphoblastoid cells following sulforaphane exposure (Chorley et al., 2012). Common 
functions of Nrf2-regulated genes include xenobiotic metabolism, antioxidant defence 
systems, the immune response, regulation of the proteasome, haem, lipid and carbohydrate 
metabolism (Table 1.1).  
The Nrf2 promotor contains two ARE sequences and the transcription factor has been shown, 
by chromatin immunoprecipitation, to bind directly to its own promoter region (Kwak et al., 
2002). Autoregulation of Nrf2 by Nrf2-dependant Keap1 expression also occurs, via an ARE 
within the Keap1 promotor (Chorley et al., 2012). This negative feedback loop ensures 
sustained levels of Nrf2 induces Nrf2-dependent production of Keap1 causing suppression of 
Nrf2. Nrf2 also regulates expression of Cul3-Rbx1 (Kaspar and Jaiswal, 2010) and its 
heterodimeric partner MafG (Yamamoto et al., 2006). Some ARE-regulated genes, such as 
sequestosome 1 (p62/SQSTM1), act as both an Nrf2 target and inducer (Copple et al., 2010, 
2010).  p62 binds to Keap1 directly, competing with Nrf2 and forming a positive feedback 
loop.  
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Conserved Nrf2 target genes include NAD(P)H dehydrogenase (quinone) 1 (NQO1), 
sulfiredoxin 1 (SRXN1) and haem oxygenase 1 (HMOX1) (Table 1.1). Mutation analysis of the 
ARE sequence within the promotor region of NQO1 lead to revision of the accepted ARE 
consensus sequence of the time (Nioi et al., 2003). Nrf2-/- mice had reduced basal expression 
and impaired induction of NQO1 (Nioi et al., 2003). NQO1 is a cytosolic phase 1 drug-
metabolising enzyme (introduces functional groups to xenobiotics) that forms homodimers 
with the cofactor Flavin adenine dinucleotide (FAD). It catalyses the two or four- electron 
reduction of quinones to hydroqinones (Lars Ernster, 1958). Detoxification of quinones is 
essential to avoid ‘redox cycling’ and production of reactive semi-quinones. NQO1-/- mice 
were indistinguishable from wild-type mice aside from increased susceptibility to quinone 
toxicity when exposed to the drug menadione (Radjendirane et al., 1998). The enzyme is also  
negatively regulated by the transcription factor BACH1 (BTB and CNC homolog 1)  
(Dhakshinamoorthy et al., 2005). ChIP analysis of BACH1 overexpression in HepG2 cells 
revealed competitive binding to the ARE site with Nrf2 suggesting a balance between the 
two transcription factors is needed to regulate ARE-driven genes.  
Srxn1 catalyses the ATP-dependent reduction of hyperoxidized peroxiredoxins (Prx) (Biteau 
et al., 2003). Also known as thioredoxin peroxidases, Prx contain cysteine residues that 
enable them to catalyse the reduction of ROS (Chae et al., 1994). Overexpression of Srxn1 
prevents hyperoxidation of Prx following oxidative insult (Woo et al., 2005). SRXN1 
expression is abolished in Nrf2 knockout mice (Soriano et al., 2008). Hmox1, also known as 
Heat shock protein (HSP) 32, is regarded as a typical Nrf2-regulated gene. Haem oxygenases 
catalyse the rate limiting step during haem catabolism, cleaving haem to form biliverdin, 
carbon monoxide and iron (Eisenstein et al., 1991; Tenhunen et al., 1968). Three isoforms of 
haem oxygenase have been identified: the inducible isoform Hmox1 (32 kDa), the 
constitutively active isoform Hmox2 (36 kDa) and Hmox3 that lacks catalytic activity. Hmox1 
null mice developed iron retention disorders and displayed significant serum iron deficiency 
(Poss and Tonegawa, 1997).  However, Hmox1 may have additional functions. Nuclear 
translocation of Hmox1  was stimulated in rat foetal lung cells (RFL-6) following hypoxic 
stress (Suttner et al., 1999) and elevated Hmox1 in hypoxic conditions is associated with 
increased activation of antioxidant responsive promotor (Lin et al., 2007). Localisation of 
Hmox1 to the mitochondria may indicate a role in the turnover of mitochondrial haem 
proteins (Converso et al., 2006). Hmox1 expression is regulated by a plethora of stress-
response transcription factors: HSF, AP-1 and NF-κB (Alam and Cook, 2007a). Inactivation of 
Bach1 is also required to induce Hmox1 (Reichard et al., 2007). This occurs independently 
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from nuclear accumulation of Nrf2 as removal of the repressor facilitates the low basal levels 
of nuclear Nrf2 to induce Hmox1 transcription. Hmox1 is therefore seen as an early indicator 
and potential biomarker of general chemical stress.  
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Table 1.1 Human genes positively regulated by Nrf2   
Evidence for direct binding of Nrf2 to ARE in genes highlighted green. Adapted from (Chorley 
et al., 2012; Hayes and Dinkova-Kostova, 2014). 
Function 
Gene 
symbol 
Gene Validated ARE References 
Phase 1 - 
drug 
oxidation, 
reduction 
and 
hydrolysis 
  
AKR1B1 
Aldo-keto reductase family 1, member 
B1 (and 1BB and 1B10) 
 
(Agyeman et al., 
2012; Jung et al., 
2013; MacLeod et 
al., 2009) 
AKR1C1  
Aldo-keto reductase family 1, member 
C1 (and 1C2 and 1C3) 
TCAGGGTGACTCAGC
AGCTTG 
(Agyeman et al., 
2012; Lou et al., 
2006) 
AKR1C2 
Aldo-keto reductase family 1 member 
C2 
TCAGGGTGACTCAGC
AGCTTG 
(Lou et al., 2006; 
MacLeod et al., 
2009) 
ALDH3A
1 
Aldehyde dehydrogenase 3 family, 
member A1 (and 3A2) 
 
(Agyeman et al., 
2012; Paek et al., 
2012) 
CBR1 Carbonyl reductase 1 (and 3) 
 
(Agyeman et al., 
2012) 
EPHX1 Epoxide hydrolase 1 microsomal   (Jung et al., 2013) 
PTGR1 
Prostaglandin reductase 1 (also called 
LTB4DH)  
(MacLeod et al., 
2009) 
NQO1 NAD(P)H dehydrogenase [quinone] 1 
TCACAGTGACTCAGC
AGAATC 
(Dhakshinamoort
hy et al., 2005; Li 
and Jaiswal, 
1992) 
NQO2 
NQO2 (NAD(P)H Quinone 
Dehydrogenase 2 
AGGTGGTGATGTTG
CATCACA 
(Wang and 
Jaiswal, 2006) 
Phase 2 - 
drug 
conjugatio
n 
  
CES1A1 Carboxylesterase 1 
AGATCGTGAGACAG
CATTAAT 
(Maruichi et al., 
2010) 
MGST1 
Microsomal glutathione S-transferase 
1 (and 2) 
 
(Agyeman et al., 
2012; Jung et al., 
2013) 
SULT1A
1 
Sulfotransferase family cytosolic 1A 
member 1  
(Agyeman et al., 
2012) 
UGT1A1 
UDP Glucuronosyltransferase1 family 
polypeptide 1A 
AAACCCGGACTTGGC
GCTTGG 
(Yueh and Tukey, 
2007) 
UGT1A6 
UDP Glucuronosyltransferase Family 1 
Member A6 
GAAAGCTGACACGG
CCATAGT 
(Münzel et al., 
2003) 
TCTGTCTGACTTGGC
AAAAAT 
(Münzel et al., 
2003) 
UGT2B7 
UDP Glucuronosyltransferase 2 family 
polypeptide B7 
AACTACTGACTCGGC
TGGTCT 
(Nakamura et al., 
2008) 
Phase 3 - 
drug 
transport 
  
ABCB6 
ATP-binding cassette subfamily B 
(MDR/TAP) member 6  
(Chorley et al., 
2012) 
ABCC1 
ATP Binding Cassette Subfamily C 
Member 1 
TCTGTGTGACTCAGC
TTTGGA 
(Kurz et al., 2001) 
ABCC2 
ATP-binding cassette subfamily C 
(CFTR/MRP) member 2  
(Agyeman et al., 
2012) 
ABCC3 
ATP-binding cassette subfamily C 
(CFTR/MRP) member 3  
(Jung et al., 2013) 
ABCB11  
ATP-binding cassette, sub-family B 
member 11 
CCAAGGTGAATCAG
CAATTTC 
(Weerachayaphor
n et al., 2009) 
Antioxida
nt 
enzymes 
  
SAT Sulfate adenylyltransferase 
CCGCTATGACTAAGC
GCTAGT 
(Wang et al., 
1998) 
SOD1 Superoxide dismutase AACTAATGACATTTC
TAGACA 
(Dreger et al., 
2009; Park and 
Rho, 2002) 
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Antioxida
nt (GSH-
based) 
GCLC 
Glutamate-cysteine ligase catalytic 
subunit 
TCCCCGTGACTCAGC
GCTTTG 
(Mulcahy et al., 
1997) 
GCLM 
Glutamate-cysteine ligase modifier 
subunit 
TAACGGTTACGAAGC
ACTTTC and 
AGACAATGACTAAGC
AGAAAT 
(Erickson et al., 
2002) 
GGT1 Gamma-glutamyltraseferase 1 
 
(Agyeman et al., 
2012) 
GLRX Glutaredoxin 1 
 
(Agyeman et al., 
2012) 
GLS Glutaminase 
 
(Agyeman et al., 
2012) 
GPX2 Glutathione peroxidase 2 CCAGGATGACTTAGC
AAAAAC 
(Banning et al., 
2005; Paek et al., 
2012) 
GSR1 Glutathione reductase 
 
(MacLeod et al., 
2009) 
GSTP1 Glutathione S-Transferase Pi 1 
GCGCCGTGACTCAGC
ACTGGG 
(Montano et al., 
2004) 
SLC7A11 Cysteine/glutamate transporter 
 
(MacLeod et al., 
2009) 
Antioxida
nt (TXN-
based) 
PRDX1 Peroxiredoxin 1 TGTAACTGAATCAGC
ATCAGC 
(Chorley et al., 
2012; Kim et al., 
2007)  
PRDX6 Peroxiredoxin 6 
GCAACGTGACCGAG
CCCCGCA 
(Chowdhury et 
al., 2009) 
SRXN1 Sulfiredoxin 1 
CCAGGGTGAGTCGG
CAAAGCC 
(Soriano et al., 
2008) 
TXN Thioredoxin 
TCACCGTTACTCAGC
ACTTTG 
(Kim et al., 2003) 
TXNRD1 
Thioredoxin reductase 1 
TCATTCTGACTCTGG
CAGTTA  and 
TCAGAATGACAAAGC
AGAAAT 
(Hintze et al., 
2003) 
Carbohydr
ate 
metabolis
m and 
NADPH 
regenerati
on  
G6PD 
Glucose-6-phosphate 1-
dehydrogenase 
 
(Jung et al., 2013) 
 
HDK1 Hexokinase domain containing 1 
 
(Agyeman et al., 
2012)  
ME1 
Malic enzyme 1, NADP dependent 
cytosolic 
CTGCCATGACTCAGC
GCTTCT 
(Chorley et al., 
2012)  
PGD 6-phosphogluconate dehydrogenase  (Paek et al., 2012)  
TALDO1 Transaldolase 
 
(Agyeman et al., 
2012; Chorley et 
al., 2012)  
TKT Transketolase isoform 1 
 
(Agyeman et al., 
2012) 
  
UGDH UDP-glucose dehydrolase 
 
(Agyeman et al., 
2012) 
Haem and 
iron 
metabolis
m 
BLVRA Biliverdin reductase A 
 
(Agyeman et al., 
2012)  
BLVRB 
Biliverdin reductase B (flavin reductase 
(NADPH))  
(Agyeman et al., 
2012)  
FECH Ferrochelatase  
 
(MacLeod et al., 
2009) 
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FTH1 Ferritin heavy polypeptide 1 
CCTCCATGACAAAGC
ACTTTT and 
CCACCGTGACTCAGC
ACTCCG 
(Tsuji, 2005) 
 
FTHL12 Ferritin heavy polypeptide-like 12 
 
 
(MacLeod et al., 
2009)  
FTHL17 Ferritin heavy polypeptide-like 17 
 
(Agyeman et al., 
2012)  
FTL1 Ferritin light polypeptide  
TCAGCATGACTCAGC
AGTCGC 
(Hintze and Theil, 
2005)  
HMOX1 Haem oxygenase (decycling) 1 
GGACCGTGACTCAG
CAGGAAA and 
GGACCGTGACTCAG
CGAAAAC and 
AGACCGTGACTCAGC
GAAAAC 
(Keum et al., 
2006; MacLeod et 
al., 2009) 
Lipid 
metabolis
m  
  
APOA1 Apolipoprotein A1 
CAGCTCTGTCCCTGG
GGCTGG 
(Mooradian et al., 
2004) 
TBXAS1 
Thromboxane A synthase 1  (Converts 
prostaglandins to thromboxane) 
AAGGAATGAATCAG
CAACTTT 
(Yaekashiwa and 
Wang, 2003) 
Transcript
ion factors 
and 
associated 
proteins 
/signal 
transducti
on 
  
ATF3 Activating Transcription Factor 3 
TTAAGGTGACACAGC
ATCTAA 
(Kim et al., 2010) 
GNAI2 
Guanine Nucleotide Binding Protein (G 
Protein), Alpha Inhibiting Activity 
Polypeptide 2 
AGCCTGTGACTGGG
CCGGGGC 
(Arinze and 
Kawai, 2005) 
MAFG MafG protein TCACGCTGACTCAGC
ACATTG 
(Chorley et al., 
2012; MacLeod et 
al., 2009) 
PPARG 
Peroxisome proliferator-activated 
receptor gamma (PPARy)  
(Chorley et al., 
2012) 
PPARGC
1B 
Peroxisome proliferator-activated 
receptor gamma coactivator 1-beta  
(Chorley et al., 
2012) 
RXRA Retinoid X receptor alpha 
 
(Chorley et al., 
2012) 
S100A6 
S100 calcium binding protein A6 (cell 
cycle progression and differentiation) 
GACACGTGACTCGG
CAAGGGG 
(Leśniak et al., 
2005) 
Ubiquitin - 
proteaso
me 
  
KEAP1 Kelch-like ECH-associated protein 1 
 
(Chorley et al., 
2012) 
PSMA3 
Proteasome (Prosome, Macropain) 
Subunit, Alpha Type, 3 
AGCCAATGAGCGGG
CCTGTTA 
(Takabe et al., 
2006) 
Cytoskelet
on  
Keratin 
16 
KRT16 
GAACCTGGAGTCAG
CAGTTAG 
(Endo et al., 
2008) 
Immune 
response  
  
ETS1 
Protein C-ets-1 – expression of 
cytokine and chemokine genes 
AGCGGGTGACCAAG
CCCTCAA 
(Wilson et al., 
2005, p. 200) 
PTGS2 
Prostaglandin-Endoperoxide Synthase 
2  (inflammatory prostaglandin 
production)  
TTTTAGTGACGACGC
TTAATA 
(Sherratt et al., 
2003) 
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1.3.4. Nrf2 activation in response to drug toxicity  
While Nrf2-/- mice survive to adulthood, they exhibit lowered basal and inducible levels of 
ARE-regulated genes in multiple tissues (Enomoto et al., 2001).  They are highly susceptible 
to pathologies associated with exposure to chemical toxicants, such as acetaminophen 
hepatotoxicity (Chan et al., 2001; Enomoto et al., 2001), cisplatin nephrotoxicity (Aleksunes 
et al., 2010) and bleomycin lung fibrosis (Cho et al., 2004). Conversely, tissue-specific 
ablation of the KEAP1 gene confers resistance to acute drug toxicity in vivo (Okawa et al., 
2006). Based on these observations, and evidence that Nrf2 pathway activity is perturbed in 
diseases with an oxidative stress component, there is an increasing interest in the 
therapeutic value of targeting Nrf2 with small molecules (Mutter et al., 2015). 
A number of toxic chemicals and drugs have also been shown to induce Nrf2-mediated 
adaptive responses in cell and animal models. For example, the bioactivation of 
acetaminophen to the reactive metabolite NAPQI has been associated with the rapid 
accumulation of Nrf2 and induction of target genes in mouse liver (Goldring et al., 2004). 
Importantly, dose-dependent activation of the Nrf2 pathway was evident in animals 
receiving non-toxic and toxic doses of acetaminophen (Goldring et al., 2004), highlighting the 
ability of Nrf2 to report early chemical stress associated with drug-induced liver injury. 
Consistent with these findings, direct application of NAPQI to mouse hepatoma cells has 
been shown to cause chemical adduction of selected cysteine residues in Keap1 and the 
activation of Nrf2 signalling (Copple et al., 2008a). Accumulation of Nrf2 and/or induction of 
its target genes have been observed in response to other model hepatotoxins, including 
diclofenac (Fredriksson et al., 2014) and carbon tetrachloride (Randle et al., 2008). It has also 
been observed  in response to nephrotoxins such as cisplatin (Aleksunes et al., 2010) and 
cyclosporin A (Wilmes et al., 2011), and the neurotoxins 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (Chen et al., 2009) and 6-hydroxydopamine (Tobón-Velasco et al., 2013).  
In addition, many electrophilic skin sensitisers appear to be capable of stimulating Nrf2 
signalling; this is the rationale for use of the in vitro Keratinosens™ assay, in which a human 
HaCaT keratinocyte cell line equipped with an ARE-regulated luciferase reporter transgene 
is used to classify the skin sensitisation hazard associated with new chemical entities (Emter 
et al., 2010). The above evidence demonstrates that Nrf2 can respond to diverse chemical 
toxins in multiple cell types, both in vitro and in vivo. 
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1.4. Identifying oxidative and chemical stressors 
Identification of compounds liable to bioactivation and subsequent induction of oxidative 
stress is vital for the prevention of drug-induced toxicity. However, monitoring oxidative 
stress is hampered by the ephemeral nature of free radicals. A multitude of fluorescent and 
chemiluminescent probes have been developed for the indirect quantification of ROS 
generation. Oxidative damage to proteins lipids and DNA can be readily assayed. However, 
in order to avoid drug-induced oxidative damage, computational platforms to predict a 
chemical’s propensity for bioactivation have been established. While these in silico methods 
can identify chemical liability, they are not capable of predicting the biological consequences 
of metabolic bioactivation in vivo. Therefore, better detection and prediction systems are 
needed to avoid drug-induced oxidative stress.  
 
1.4.1. Detection of oxidative stress 
Direct measurement of ROS is difficult due to their transient nature and low abundance. For 
instance, nitric oxide (·NO) has a half-life of only 4 seconds (Hakim et al., 1996). Electron spin 
resonance (ESR) and paramagnetic resonance (EPR) identifies the unpaired spins of free 
radicals but with limited sensitivity. In order to increase signal strength, spin traps are 
employed to measure free radicals indirectly. Spin trapping involves the addition of nitroxyl 
probes that react with free radicals to generate more stable radical adducts. However the 
half-life of the detectable products remains short, for instance, the hydroxyl adduct of PBN 
(N-tert-butyl-a-phenylnitrone) has a half-life of 38 s (Janzen et al., 1992). Lack of signal 
penetration and potential toxicity of the probes limits their application in human imaging.  
Fluorescent and chemiluminescent probes offer a more sensitive and versatile method of 
ROS detection. One of the most commonly used probes, dichlorodihydroflurorescein (DCFH-
DA) is oxidised to the fluorescent compound 2′,7′-dichlorofluorescein (DCF). DCFH-DA reacts 
readily with carbon trioxide (CO3·-) and nitrogen dioxide (NO2·) but has low reactivity to the 
more abundant H2O2 and O2- radicals (Wrona et al., 2005). However, DCFH-DA can react with 
oxygen to generate free radicals itself (Yazdani, 2015) and  generates artifactual fluorescence 
when oxidised by cytochrome C and haem peroxidases (Burkitt and Wardman, 2001). 
Chemiluminescent reactions emit light without excessive heat production. The most widely 
used probe Lucigenin (bis-N-methylacryidinium nitrate) is oxidised by superoxide to the 
intermediate dioxetane, which cleaves spontaneously to the excited product N-
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methylacridone that emits a photon of light (Peters et al., 1990). Other luciferin-based 
probes such as Luminol and methyl-cypridine-luciferin analogue (MCLA), also lack specificity. 
 Genetically encoded fluorescent and chemiluminescent protein reporters facilitate 
measurement of ROS activity in vivo and ex vivo. HyPer was the first genetically encoded 
fluorescent sensor specific for H2O2 activity (Belousov et al., 2006). It consists of cpYFP 
(circulatory permuted yellow fluorescent protein) inserted into the regulatory region of 
OxyR, a prokaryotic H2O2-sensing protein. Subsequent HyPer mutants offer increased 
dynamic range and faster redox kinetics (Bilan et al., 2013; Markvicheva et al., 2011). 
However, in order to achieve reversible fluorescence quenching many fluorescent probes 
are pH sensitive, which could lead to erroneous signal (Schwarzländer et al., 2014; X. Wang 
et al., 2013).  Many genetically encoded sensors employ the luciferase-dependent catalytic 
conversion of luciferin to oxyluciferin and bioluminescence for the detection of ROS. 
Luciferase genes have been derived from a plethora of species including firefly, clickbeetle, 
sea pansy (Renilla reniformis), and Copepod (Huh et al., 2009; Shimomura, 1985; Steghens 
et al., 1998). Gaussia luciferase (GLuc) is the smallest known secretory luciferase (Szent-
Gyorgyi et al., 1999). Subsequent variants such as fLuc8 exhibit increased stability to changes 
in pH and temperature and extend the half-life of the probe. Peroxy caged luciferin-1 (PCL-
1), a chemoselective bioluminescent probe, facilitates real-time detection of H2O2 in mice 
(Bittner et al., 2010). Expressed in all tissues, the reporter is sensitive to both inducible and 
basal levels of H2O2 in vivo. While numerous probes exist for the enhancement of ROS 
detection, they are limited by their stability, signal strength, and specificity. Probes may 
perturb the system being studied producing artefactual signal. The probe signal may be 
stimulated or quenched by off target reactions, such as changes to pH, while specific 
measurement of individual ROS is hampered by a probes sensitivity to other ROS and 
antioxidants such as the case with DCFH-DA. The recently established chemiluminescent 
probes offer an alternative to fluorescent indicators but further optimization is needed to 
improve signal strength and stability.  
 
1.4.2. Measurement of antioxidant levels  
Measurement of individual antioxidant activity such as GSH can give insight into the extent 
of cellular oxidative stress. GSH is a tripeptide thiol present in all tissues that neutralizes free 
radicals in combination with many detoxifying enzymes such as glutathione peroxidases and 
glutathione-S-transferases (Fig 1.5). Quantification of the ratio between reduced GSH and its 
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oxidised state (GSSG) or total GSH levels is possible via a rapid colorimetric assay (Rahman 
et al., 2007). Measurement of individual antioxidants are also influenced by bioavailability, 
metabolism, location, distribution, fate of anti-oxidant derived radicals and interaction with 
other antioxidants/ combinations of radicals. 
Wayner et al developed the first assay to quantify ‘total antioxidant capacity’ (TAC) by 
measuring oxygen consumption after adding peroxyl radicals to a biological fluid (Wayner et 
al., 1985). Low total antioxidant capacity of serum may indicate oxidative stress or increased 
susceptibility to oxidative damage. Contrary to their name, TAC assays do not measure the 
entire antioxidant capacity, instead the low molecular weight antioxidants such as urate, 
ascorbate and thiols, thus correlate poorly with other assays that include quantification of 
enzymes such as catalase and superoxide dismutase (Costantini and Verhulst, 2009). 
Individual expression patterns of antioxidant molecules give more insight than TAC 
assessment (Pompella et al., 2014).  
Currently no single biomarker has the specificity, sensitivity and potency to monitor the 
response to oxidative stress. While markers of oxidative damage are more stable than 
reactive species themselves, these cannot provide predictive insight. In addition, the variable 
extent and onset of oxidative damage leads to poor correlation between markers of damage 
and levels in healthy tissue. Artificial oxidation from sample handling and oxidised 
protein/lipids from dietary sources may also lead to false positives.  
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Figure 1.5 The Glutathione system  
The reduced form of glutathione (GSH) is generated by glutamate cysteine ligase (GCL) which 
converts L-glutamate to γ-glutamyl-cysteine in an ATP-dependent reaction. Glutathione 
synthetase (GS) converts this product with glycine to GSH (comprised of the amino acids 
cysteine, glutamate and glycine). Glutathione-S-transferases (GST) catalyse the formation of 
GSH conjugates that facilitate detoxification of xenobiotics. GSH is oxidised (GSSG) by lipid 
peroxides and ROS such as hydrogen peroxide (H2O2). Glutathione reductase catalyses the 
NADPH-dependent reduction of GSSG. Adapted from (Lehane et al., 2012). 
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1.4.3. Identifying potential chemical stressors 
Identification of chemicals liable to metabolise into covalently reactive species early in the 
drug development process reduces costs and avoids post-market withdrawal. Idiosyncratic 
adverse drug reactions, though low in incidence, can be fatal (Uetrecht and Naisbitt, 2013). 
Currently, no consensus exists for the reactive metabolite risk assessment strategies because 
of the challenges faced when quantifying reactive metabolites and the complex mechanisms 
of toxicity (Thompson et al., 2016). A number of in silico techniques have been developed to 
predict the reactive nature of drug-candidates. Identifying structural motifs with propensity 
to form reactive metabolites is a useful tool to guide drug design. For instance, quantitative 
structure-activity relationship (QSAR) modelling predicted candidate drugs with the 
propensity to form reactive metabolites based on structures previously associated with that 
risk (Liew et al., 2012). Hsiao et al., used density functional theory calculations to predict 
sites of metabolism in lead compounds by cytochrome P450 enzymes (Hsiao et al., 2012). 
While predictive tools can provide insight into potential formation of reactive species, this 
does not imply actual formation nor does it inform on biological consequences of 
bioactivation. Relying solely on this approach may rule out or overlook potentially effective 
compounds.  
The majority of in vitro assays for the detection of reactive metabolites assess covalent 
binding of a drug-candidate via ‘trapping’ agents or radiolabelling of the compound. 
Nucleophilic trapping agents such as GSH are employed to analyse a compounds liability for 
bioactivation. Srivastava et al., highlighted the propensity of lead compounds to from 
reactive intermediates using trapping agents GSH and NAC when incubated with human and 
rat liver microsomes (Srivastava et al., 2014). Structural modification in succeeding 
analogues negated this risk. However, within the body, the metabolite is expected to be 
trapped by protective molecules such as GSH and therefore this approach may not accurately 
identify compounds liable to bind covalently with proteins in vivo.     
Integrated risk assessments incorporate other chemical insults occurring during drug toxicity 
in order to reflect more accurately events in vivo. For instance, DILI mechanisms of initial 
injury include immune responses, direct cell and mitochondrial stress (Russmann et al., 
2009). It is therefore important to incorporate assessment of actual metabolic activation of 
the compound and not exclusively its chemical propensity to from reactive metabolites. The 
generation of increasing sophisticated co-cultures aids physiologically relevant risk 
assessment. Recently, microphysiological systems have been designed to include immune 
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component 3D cultures (Choucha Snouber et al., 2013; Tsamandouras et al., 2017). This 
information aids the expansion of adverse outcome pathways (AOPs). Developed by the 
Organisation for Economic Co-operation and Development (OECD), AOPs aim to delineate 
the underlying mechanisms of toxicity from molecular initiating events (MIEs) and 
toxicological endpoints (Ankley et al., 2010; Vinken, 2013). Combining this data along with 
structural information about a drug-candidate may increase the specificity and sensitivity of 
current methods to detect chemical stressors. 
 
1.5. Monitoring activity of the Nrf2 pathway 
While established toxicological endpoints, such as decreases in cellular adenosine 
triphosphate levels and leakage of lactate dehydrogenase into cell culture media, 
unquestionably demonstrate the ability of a compound to provoke cell death, their 
sensitivity is generally not sufficient to identify sub-lethal chemical insults that initiate 
adaptive stress responses but do not culminate in overt cytotoxicity. These stress responses 
encompass the Nrf2-driven antioxidant response, but also the DNA damage response 
(effected by the tumour suppressor p53), the unfolded protein response (effected by 
activating transcription factor 4/X-box binding protein 1, in response to endoplasmic 
reticulum stress), and the heat shock response (effected by heat shock factors), amongst 
others (Jennings et al., 2013). Such responses encapsulate some of the earliest biochemical 
signals that precede the initiation of toxic cascades, and can thus provide sensitive and 
mechanistic insights into the deleterious effects of a chemical entity (Wink et al., 2014). In 
this regard, stress responses represent important components of AOPs. There is much 
interest in the value of monitoring stress responses and other components of AOPs to 
minimise reliance on animal models and improve the mechanism-based identification of 
hazardous chemical entities (Vinken, 2013).  
 
1.5.1. In vitro models 
To overcome some of the technical barriers of measuring Nrf2 directly (including a historic 
lack of sensitive antibodies for the detection of the low-abundance Nrf2 protein and relative 
stability of Nrf2 mRNA during activation of the pathway), researchers have developed novel 
strategies for monitoring Nrf2 pathway activity. These include the use of stable ARE-driven 
reporters, fluorescent-tagged Nrf2 or target genes and, transcriptomic analysis of dynamic 
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changes in gene signatures that have been shown (for example, in ChIP data) to be 
representative of the battery of Nrf2-regulated genes.   
One example of a stable reporter is 8AREL, established in H4IIE and HEK293 cell lines 
(Kratschmar et al., 2012). 8AREL contains an eight times repeated ARE sequence from the 
promoters of rat GSTA2 and mouse GSTa1 controlling a luciferase reporter gene (Wang et 
al., 2006). This cell line was used to  assess the in vitro therapeutic index of Nrf2 activators 
(CDDO-Me, sulforaphane and DMF) (Copple et al., 2014). In addition, the keratinosensTM 
assay utilizes a luciferase reporter gene directed by Aldo-Keto reductase family 1, member 
C2 (AKR1C2) ARE sequence in HaCaT cells to identify the skin sensitization hazard of novel 
chemicals (Emter et al., 2010). It has been adopted as an OECD test guideline.  
Many other ARE reporters have been constructed. The AREc32 cell line also contains eight 
copies of the ARE sequence in human mammary cell line MCF7 (Wang et al., 2006). The Nrf2 
CALUX assay utilizes an ARE-luciferase construct consisting of a 4 x ARE sequence: consensus 
ARE, NQO1 ARE, hGCLM ARE and hGCLC ARE transfected into the human bone-derived cell 
line U2OS (van der Linden et al., 2014). The reporter responded to compounds whose toxicity 
was due to oxidative stress but failed to respond to drugs that needed bioactivation. This is 
one limitation of test systems utilising a homogenous cell culture. Motahari et al. were the 
first to generate an ARE-luciferase base reporter driven by a construct containing one copy 
of an extended consensus response element (from the NQO1 promotor) (Motahari et al., 
2015). Transfected human hepatoma cells (Huh7) respond as early as 4 h following exposure 
to hydroquinone and p-benzoquinone and the antioxidant curcumin. While incorporating a 
single ARE element into a reporter provides specificity, multiple ARE elements may increase 
the sensitivity of the reporter and better reflect activity of the Nrf2 pathway.  
As part of the Tox21 initiative to identify better in vitro models of toxicity assessment, Kim 
et al. employed an ARE-bla (β-lactamase) reporter to assess Nrf2 pathway activation 
following exposure to a library of 10,000 compounds (Kim et al., 2016). This reporter was 
part of a panel designed to assess activation of stress responses prior to cell death that were 
consistent with the structure or class of compound. Broad relationships identified in this 
study would inform the development of AOPs. Identifying compounds that provoke toxicity 
in the early stages of an AOP instead of reaching the toxicological endpoint will aid the 
development of assays that avoid toxicity in animals. Aside from ARE-based reporters, 
Smirnova  et al. highlight the ability of a Neh2-luc reporter to be recognised, ubiquitinated 
and degraded by the proteasome (Smirnova et al., 2011). The reporter successfully identified 
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Nrf2 activators from a library of 2000 compounds, including a novel activator Genunin. ARE-
based reporter signal follows the stabilization of Nrf2-target gene expression whereas the 
Neh based system allows immediate monitoring of drug induced Nrf2 accumulation.  
Automated, high-content imaging of cell lines expressing fluorescent-tagged Nrf2 or target 
gene products provide insight into subcellular localization of constituents of the Nrf2 
pathway in real time. For instance, an SRXN1-GFP reporter has been incorporated in the 
novel (geno)toxicity assay: ToxTracker (Hendriks et al., 2012). ToxTracker incorporates 
mouse embryonic stem cell lines with either Bscl2-GFP (ATR-Chk1 signalling pathway), Btg2-
GFP (P53 pathway) or SRXN1-GFP reporters and provides mechanistic insight into 
oxidative/genotoxic manifestations of toxicity. In order to distinguish DILI compounds that 
initiate either Nrf2 or NF-κB defence pathways, Herpers et al. established a novel GFP-
reporter, GFP-SRXN1, expressed in the immortalised human hepatoma cell line HepG2 
(Herpers et al., 2016). Through high quality live cell imaging, they also observed altered 
nuclear translocation of NF-κB subunit via the reporter GFP-P65.   
Holistic profiling of transcriptional changes following oxidative insult has shown substantial 
involvement of the battery of Nrf2-regulated genes. For instance, following exposure to 
cyclosporine A (CsA) in the human proximal tubule cell line RPTEC/TERT1, the resulting 
transcriptomic, metabolomic and proteomic response was integrated to elucidate cell stress-
induced signalling cascades (Wilmes et al., 2013). This was the first study to highlight ‘CsA-
induced stress not linked to primary pharmacology’. Gene expression alone does not give 
insight into alternative splicing, post-translational modifications or protein expression. By 
employing all three ‘omics’ approaches, Wilmes et al.  identified Nrf2 pathway activation 
alongside mitochondrial dysfunction and the unfolded protein response in CsA-exposed 
cells. NQO1 and Hmox1 were induced at early time points. Transcriptomic analysis of long-
term repeat dose toxicity studies in the RPTEC/TERT1 cell line revealed global and compound 
specific responses to particular nephrotoxins (Aschauer et al., 2014). The majority of the 
compounds induced a strong Nrf2 response (most prominent: CsA chloroacealdehyde and 
cadmium chloride). 
Whilst the cytoprotective genes regulated by Nrf2 are relatively well conserved amongst 
mammals (Table 1), the majority of these genes are also regulated by other transcription 
factors, including those that govern the activity of discrete stress responses (Limonciel et al., 
2015). Therefore, the consolidation of these gene signatures is vital to unravelling the roles 
of different molecular pathways in the cellular response to chemicals that have diverse 
Chapter 1 
43 
 
pharmacological and toxicological effects. These efforts will be enhanced by detailed 
assessments of the gene networks that are regulated by Nrf2 in human primary cells. As the 
toxicological phenotypes associated with activation of the Nrf2 stress response become 
clearer, it is envisaged that monitoring the activity of this pathway will contribute to the 
continuing drive toward in vitro and in silico approaches for predicting the human hazard 
posed by chemicals and new drugs. 
 
1.5.2. In vivo models 
An important limitation of the above cell-based models is their lack of key physiological traits, 
which can limit their predictive value. For example, in the case of drug-induced liver injury, 
the current lack of stable hepatocyte cell models that retain the capacity to metabolise many 
drugs, and the dedifferentiation of primary hepatocytes following their isolation from liver 
tissue (Elaut et al., 2006), renders such systems more suitable for identifying direct, 
metabolism-independent hepatotoxins. Whilst recent advances in stem cell technology are 
increasingly being used to address these shortcomings, state-of-the-art protocols currently 
generate only hepatocyte-like cells, given that their complement of cytochrome P450 
enzymes and ability to metabolise drugs remains inferior to their primary counterparts 
(Takayama et al., 2014). At least until these barriers are overcome, animal models will 
continue to provide a unique opportunity to consider aspects of drug disposition in the 
toxicological effects of a given compound.  
Several lines of transgenic mice have been established with a reporter construct under the 
transcriptional control of an ARE. For instance, the ARE-hPAP reporter mice contain the 
human placental alkaline phosphatase (hPAP) reporter gene under the control of an ARE 
from the promotor of NQO1 (Johnson et al., 2002). Primary cortical cultures from ARE-hPAP 
mice exhibited dose-dependent induction of hPAP activity following exposure to tBHQ 
alongside induction of endogenous Nqo1. Treatment with the antioxidant GSHEE (cell-
permeable GSH) blocked DEM-mediated ARE activation; while LY 294002 (a selective PI3-
kinase inhibitor) blocked tBHQ-mediated ARE activation. Following exposure to the 
excitotoxin kainate, as a model of neurodegeneration, the ARE-hPAP reporter mice showed 
ARE activation within damaged hippocampus (Kraft et al., 2006). ARE-hPAP mice have been 
used as a model of the neurodegenerative disorder Alexander disease that is due to mutated 
intermediate filament protein (GFAP) forming Rosenthal fibres. ARE-hPAP mice crossed with 
transgenic mice over-expressing hGFAP were more susceptible to kainite-induced seizures 
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with alkaline phosphatase activity localised to white matter within the murine brain, 
implicating the Nrf2-pathway in progression of this disease (Hagemann et al., 2005). 
Hmox1-Luc reporter mice established by Zang et al. facilitates non-invasive imaging of 
Hmox1 activity (Zhang et al., 2001a). The transgene consists of the Hmox1 promotor 
sequence fused to firefly luciferase. The transgenic line have since been used to analyse 
Hmox1 induction to known toxicants including cadmium chloride (CdCl2), doxorubicin and 
thioacetamide (Malstrom et al., 2004a). Tissue damage, predominantly in the liver, kidney 
and intestines, was more pronounced than luciferase expression. This may be because the 
reporter acts downstream of Nrf2. While these transgenic lines hold potential for the in vivo 
screening of compounds that induce luciferase signal as a marker of toxicity, a reporter 
capable of responding to earlier activation of the Nrf2 pathway may avoid toxic damage. 
Oikawa et al. recently established the OKD48-luc mouse model that expresses a 
transcriptionally inactive luciferase-tagged human Nrf2, under the transcriptional control of 
endogenous Nrf2, mediated through an ARE sequence repeated three times, from the 
promotor of GSTYa (Oikawa et al., 2012) (Fig 1.6). Microinjection of the transgene into 
fertilised embryos facilitated random integration of the reporter gene into the C57BL/6J 
background. Whilst the transgene product is able to interact with Keap1, and is therefore 
repressed in the absence of an Nrf2-inducing stimulus, general or oxidative stressors such as 
sodium arsenite cause the accumulation of luciferase-tagged Nrf2 via inhibition of Keap1-
mediated turnover and transcriptional induction of the transgene by endogenous Nrf2. This 
dual-regulating mechanism produces a bioluminescent signal, detectable via whole animal 
and ex vivo organ imaging, upon activation of the Nrf2 response. By facilitating non-invasive, 
real-time measurement of Nrf2 activity in vivo, this model provides a platform to examine 
the relationship between drug disposition, activation of Nrf2 stress response signalling and 
organ-specific drug toxicity.  
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Figure 1.6 Overview of the OKD48 reporter   
The OKD48 transgene consists of the Neh2 domain of human Nrf2 bound to flag-tagged 
Luciferase, driven by 3xARE promoter. Dual regulation of construct expression under normal 
conditions limits background signal and increases specificity via Keap1-mediated 
degradation of endogenous Nrf2 and leaked expression of the fusion protein. In response to 
oxidative stress, endogenous Nrf2 transactivates expression of the construct, which evades 
repression following inactivation of Keap1. This induces a luminescent signal in the presence 
of the substrate luciferin. 
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1.6. Therapeutic potential of Nrf2 modulators  
The diverse, protective role of Nrf2 makes it an attractive candidate for therapeutic 
modulation. A myriad of small-molecule inducers of Nrf2 have been established for clinical 
use. Application of in vitro systems to monitor the Nrf2 pathway facilitate high through put 
(HTP) screening of potential inducers and provides insight into the chemical structures and 
motifs of compounds capable of preventing oxidative stress. Further investigation may aid 
the establishment of treatment for a range of diseases with an underlying oxidative stress 
component.     
1.6.1. Compounds in the clinic  
Aside from toxic compounds, a range of small-molecules have been shown to induce Nrf2 
therapeutically and are currently undergoing pre/clinical trials (Fig 1.7). The most potent of 
these is the triterpenoid CDDO-Me, a methylated variant of CDDO (2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oic acid), a synthetic triterpenoid. Derived from oleanolic acid, 
triterpenoids have been associated with a plethora of therapeutic properties including anti-
tumour, anti-inflammatory, anti-microbial, cardio protective, wound healing, and hepato-
protective effects (Liby and Sporn, 2012). CDDO-Me appears to activate Nrf2 via covalent 
modification of cysteine residues in Keap1 to stimulate Nrf2 mediated cytoprotective gene 
expression (Cleasby et al., 2014; Wong et al., 2016). A 5-fold increase in the mRNA level of 
NQO1 has been reported in peripheral blood mononuclear cells (PBMCs) obtained from 
patients with advanced solid tumours or lymphomas who received a daily dose of CDDO-Me 
for three weeks (Hong et al., 2012). Also known as Bardoxolone methyl, CDDO-Me was a 
leading candidate for the treatment of Type 2 diabetes mellitus and chronic kidney disease 
in the Phase 3 BEACON trial. Early phase 1 trials indicated and improved eGFR in patients 
(Hong et al., 2012). However, the daily 20 mg dose increased the number of heart failure 
events via fluid overload resulting in termination of the study (de Zeeuw et al., 2013). 
Following reassessment of the cohort, it was clear that only patients with increased risk 
factors for heart failure (elevated D-type natriuretic peptide and prior hospitalisation for 
cardiac injury) experienced fluid overload (Chin et al., 2014). Therefore, clinical trials 
excluding at-risk patients are currently ongoing to assess CDDO-Me for the treatment of 
Alport syndrome (CARDINAL, NCT03019185) and CKD patients with comorbidities such as 
diabetes melitus (TSUBAKI, NCT02316821). The compound is also undergoing trials for the 
treatment of pulmonary hypertension and associated connective tissue disease in the 
CATALYST (NCT02657356), and LARIAT trials (NCT02036970). Another synthetic triterpenoid 
RTA 408 (Reata Pharmaceuticals Inc.) is currently undergoing phase 2 trials (PRIMROSE) for 
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protection against dermatitis, a common side effect of radiation therapy during the 
treatment of breast cancer (NCT02142959). Preclinical data in mice highlighted its dose-
dependent reduction of epidermal thickening and skin ulcers after irradiation (Reisman et 
al., 2014).   
Dimethyl fumarate (Tecfidera® or BG-12) is an oral therapy prescribed for multiple sclerosis 
(MS). Derived from fumaric acid, the compound was originally used as a radiosensitizer and 
later as and oral treatment for psoriasis (Fumaderm) (Held et al., 1988; Mrowietz et al., 
2007). Two randomised phase 3 clinical trials DEFINE (Determination of the efficacy and 
safety of oral fumarate in relapsing-remitting multiple sclerosis) and CONFIRM (Comparator 
and an oral fumarate in relapsing-remitting multiple sclerosis) highlighted the reduced risk 
of MS progression by 34-38% after 2 years and 44 - 55 % reduction of the annual relapse rate 
(Fox et al., 2012; Gold et al., 2012). Adverse events associated with dimethyl fumarate 
include gastrointestinal disturbances, elevated aminotransferases and decreased 
lymphocyte counts. The electrophilic compound and its metabolite monomethyl fumarate 
(MMF) modify cysteine residues within Keap1, including Cys151, resulting in the activation 
of Nrf2 (Linker et al., 2011). However, the compounds anti-inflammatory effects may be 
modulated by Nrf2-independent mechanisms. Dimethyl fumarate reduces the number of 
pro-inflammatory T-cells, resulting in many patients developing lymphopenia (Longbrake et 
al., 2016). 
Isolated from broccoli, the isothiocyanate sulforaphane is a potent inducer of the Nrf2 
pathway (Zhang et al., 1992). This is achieved by reacting with cysteine residues within Keap1 
to disrupt Nrf2-Keap1 binding (Dinkova-Kostova et al., 2002). Sulforaphane is absorbed, 
conjugated to GSH and metabolised through the mercapturic acid pathway in humans. The 
anti-apoptotic and anti-inflammatory activity of sulforaphane are independent of Nrf2 
activation (Greaney et al., 2016; Kallifatidis et al., 2009). In a randomised double-blind clinical 
trial in males suffering from autism spectrum disorder, daily doses of sulforaphane improved 
behaviour and verbal communication over an 18 week period (Singh et al., 2014). Phase 1 
trials for sulforaphane as a treatment of autism spectrum disorder are currently ongoing 
(NCT02561481). Many analogues of sulforaphane have been produced for use in the clinic. 
Sulforadex® (SFX-01) is a sulforaphane-cycoldextrin compound with a longer shelf life than 
its parent compound. It has completed a randomised, double-blind trial assessing the safety, 
pharmacodynamics and pharmacokinetics of Sulforadex in healthy male subjects 
(NCT02055716) and is now part of the SAS (SFX01 after subarachnoid haemorrhage) trial, 
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currently investigating the efficacy of Sulforadex as a treatment for haemorrhage 
(NCT02614742). The compound has also been proposed as a combination therapy with 
tamoxifen for the treatment of breast cancer following evidence in primary cell culture that 
the combination therapy reverses cancer stem-cell like cell mediated resistance greater than 
tamoxifen alone (Simões et al., 2015).  
Veda-1209, developed by Cureveda (USA), is another Nrf2 activator currently undergoing 
preclinical testing for the treatment of ulcerative colitis (Gao et al., 2014). The dithiolethione 
Oltipraz (4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione) induces many antioxidant and 
phase 2 enzymes that may account for its anti-carcinogenic effects (Ramos-Gomez et al., 
2003; Sharma et al., 2006) and inhibits liver cirrhosis in rodents (Kim et al., 2013). The 
compound has completed phase 3 trials for the treatment of liver fat reduction in patients 
with non-alcoholic fatty liver disease (NCT02068339). However, in a phase 2 trial, weekly 
doses of Oltipraz failed to reduce the number of DNA adducts in the blood or lung epithelial 
cells of smokers (Kelley et al., 2005). The compound is also capable of generating superoxide 
radicals in human kidney cell culture (Velayutham et al., 2005).  
While a number of promising Nrf2-activating compounds have been developed, the 
consequences of acute/chronic activation of Nrf2 and underlying mechanisms of action are 
unknown. Constitutive activation of Nrf2 occurs in many cancers, generating a favourable 
environment for tumour cell survival (DeNicola et al., 2011). In addition, Nrf2 deletion in 
ApoE-/- mice resulted in a reduction of atherosclerotic lesions, indicating Nrf2 has a pro-
atherosclerotic role (Barajas et al., 2011), whereas overexpression of Nrf2 increased liver 
lipogenic gene expression and levels of hepatic cholesterol that may play a role in increased 
atherosclerosis (Jiansheng Huang et al., 2010). Keap1 knockout mice are also not viable due 
to constitutive activation of Nrf2 in the upper digestive tract (Wakabayashi et al., 2003). 
Further understanding of the consequences of pharmacologically targeting Nrf2 is needed to 
ensure adverse effects do not outweigh the transcription factors protective effects.  
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Figure 1.7 Nrf2 inducing compounds  
(A) CDDO-Me, a synthetic triterpenoid, is derived from the potent Nrf2 inducer CDDO. (B) 
The isothiocynate Sulforadex is an analogue of sulforaphane bound to cyclodextrin (Evgen). 
(C) Dimethyl fumarate is a derivative of fumaric acid and (c) Oltipraz is a dithiolethione.   
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1.6.2. Identification of Novel Nrf2 modulators  
The HTP detection of Nrf2 inducers, via the screening of compound libraries, holds promise 
for the identification of novel drug candidates. Many screening platforms utilise in vitro ARE 
based reporters and bioinformatics to identify compounds liable to prevent oxidative stress. 
For instance, 47,000 compounds were screened using  the AREc32 cell line described earlier 
(Wu et al., 2012). Chemical structure relationship analysis of hits (238 compounds) inducing 
the strongest luminescent signal highlighted the enrichment of four structural motifs. Insight 
into the structure of potent Nrf2 activators will aid the design of analogues. Shukla et al. 
utilized ARE-bla and ARE-Luc based assays in HepG2 cells to screen a US National toxicology 
program library of 1,408 compounds (Shukla et al., 2012). The ARE-bla reporter consisted of 
a three times repeat of the ARE form the promotor of NQO1 while the ARE-luc construct 
contained a seven times repeat of the consensus ARE sequence (Simmons et al., 2011). Both 
reporter systems were employed as the ARE-luc reporter identified Nrf2-specific activity in 
response to stress, while the ARE-bla assay identified compounds inducing ARE through 
complex interactions. It also aided the identification of false positives.  
In silico screening offers a cost effective, fast method to identify compounds for drug 
development. The quantum model established by Williamson et al., screened over 18 million 
commercially available compounds for structures predicted to activate the Nrf2-pathway 
(Williamson et al., 2012). The computational process predicts significant potency against 
targets based on the structure of known Nrf2 inducers. Top hits were validated in primary 
cell culture using an ARE-hPAP reporter. This process identified a novel family of activating 
structures with comparable potency of tBHQ.  
While primary cell cultures are more physiologically relevant than immortalised cell lines, 
prolonged culture conditions and accessibility are limited. Stem cells derived from accessible 
tissues and reprogrammed, offer a viable alternative culture system. Höing et al., developed 
a stem cell-based phenotypic assay for the screening of neuroprotective compounds in 
microglia (Höing et al., 2012). Initial in silico analysis identified compounds that were 
metabolically stable and able to cross the blood-brain barrier. Co-culture of stem cell-derived 
motor neurons and astrocytes expressing GFP were used to screen over 10,000 small 
molecules and identify ‘hits’ increasing cell survival. Expression profiling of these cells 
implicated many of the hits as Nrf2 activators. Inducers of Nrf2 were also identified using a 
cell-based luciferase enzyme fragment complementation (EFC) assay whereby N and C 
terminal domains of firefly luciferase fused to respective interacting proteins in the HEK293T 
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cell line (Ramkumar et al., 2013). NLuc-Keap1 and CLuc-Nrf2 complexes dissociated following 
Nrf2 activation facilitating non-invasive imaging of Nrf2 activation. The most potent 
compound identified in the screen, Pterostilbene, reduced luciferase activity significantly in 
tumour xenografts of the HEK293T cells in mice following a daily dosing regimen. The search 
for Nrf2 inducing compounds has been accelerated, thanks to HTP screening systems 
establishing direct evidence for Nrf2 activation or Keap1 modification. In silico and in vitro 
systems, prioritise chemicals for further detailed mechanism-based higher content studies. 
Insight into the compounds activity in relevant cell types and involvement in other stress 
response pathways such as DNA damage and inflammation is needed prior to therapeutic 
application.  
1.7. Thesis aims 
Currently, the lack of predictive biomarkers for drug-induced injury hinders the ability to 
screen novel compounds for toxicity. Nrf2 is the master regulator of the response to 
oxidative stress stimulated by bioactivation of drugs to form chemically reactive metabolites. 
Insight into the Nrf2 pathway may aid the analysis of novel or repurposed drug’s propensity 
to induced oxidative stress linked to drug toxicity. Additionally, identifying clinically relevant 
markers of Nrf2-pathway activity may aid the early identification or status of patients 
suffering from drug-induced injury. As DILI is the most common form of drug-induced injury, 
the regulation and function of the Nrf2-pathway in liver cell culture is of particular 
importance. Therapeutic manipulation of the Nrf2 pathway is becoming more common in 
the treatment of diseases with an underlying oxidative stress component. Understanding the 
pharmacodynamics of novel Nrf2 activators may aid future generation of effective Nrf2-
inducing compounds. Therefore, this thesis focuses on monitoring the Nrf2 pathway with the 
ultimate aim to improve testing strategies to identify chemicals and drugs that are likely to 
provoke toxicity in humans. The principle aims of this thesis were to investigate novel ways 
to measure activation of the Nrf2 pathway: 
1. To characterise the response of Nrf2-Luc mice to organ-specific toxicants APAP and 
cisplatin.   
2. To assess Nrf2 pathway activity in whole blood as a means of monitoring Nrf2 pathway 
status in vivo.   
3. To characterise putative novel Nrf2-regulated genes in human liver cells.  
4. To develop and use novel Nrf2-responsive reporter platforms to evaluate the 
potencies of novel analogues of the Nrf2-activating compound, Sulforaphane.   
Chapter 2 
52 
 
 
 
 
 
 
Chapter 2 
 
 
Bioluminescent imaging of Nrf2 reveals localised chemical stress associated with drug-
induced organ toxicity 
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2.1. Introduction 
Nrf2 activation has been implicated in the early stages of drug-induced toxicity.  A myriad of 
toxic drugs are associated with activation of Nrf2, including APAP and cisplatin (Cho et al., 
2008; Goldring et al., 2004). There is increasing interest in the transcription factor’s ability to 
differentiate between drugs likely to produce oxidative or chemical stress and those which 
are not toxic. For instance, predictive, Nrf2-based assays such as the ARE-bla  reporter from 
the Tox21 initiative and KeratinosensTM assay have been developed (Emter et al., 2010; Kim 
et al., 2016).  
Previous work from this laboratory has shown that the Nrf2 pathway is elevated in the 
murine liver following exposure to APAP (Copple et al., 2008b; Eakins et al., 2015; Goldring 
et al., 2004). This entailed endpoint analysis of a large number of liver tissues from wild-type 
mice, limiting the scope of examination. The recently established OKD48-Luc (hereafter 
referred to as Nrf2-Luc) mice provide the ability to monitor the Nrf2-mediated response to 
oxidative and chemical stress non-invasively and in real-time (Oikawa et al., 2012). This gives 
greater insight into the activity of Nrf2 over time, in the same individual and simultaneously 
reduces the number of animals needed in a study. This is in line with current 3R’s guidelines 
(Russell and Burch, 1959; Tannenbaum and Bennett, 2015).  
Nrf2-Luc mice respond to oxidative stress induced by sodium arsenite, UV radiation (Oikawa 
et al., 2012) and, more recently, during the onset of cerebral malaria (Imai et al., 2014). 
However, the value of these mice for investigating drug-induced organ toxicity has not been 
determined.I hypothesised that the Nrf2-Luc mice would respond to drug-induced organ 
toxicity and produce a localised bioluminescent signal to organ-specific forms of chemical 
stress. In order to test this hypothesis, Nrf2-Luc mice were exposed to the hepatotoxin APAP 
or the nephrotoxin cisplatin and their bioluminescent response quantified alongside classical 
markers of toxicity such as alanine transaminase and blood urea nitrogen. The results of 
these investigations are presented here and as part of the recent publication ‘Real-time in 
vivo imaging reveals localised Nrf2 stress responses associated with direct and metabolism-
dependent drug toxicity’ (Forootan et al., 2017).  
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2.2. Materials and Methods 
All reagents were purchased from Sigma Aldrich unless otherwise stated.   
2.2.1. Animals 
All animal experiments were conducted according to the Animals (Scientific Procedures) Act 
1986 guidelines under the Home Office project licence PPL 40/3678 and approved by the 
University of Liverpool Animal Welfare Committee.  
2.2.1.1. Wild-type mice 
Male, wild-type C57BL/6J mice between 8-10 weeks old, were purchased from Charles River 
and had a 5 day acclimatisation period prior to experimentation. Animals were maintained 
in a 12 hour light/dark cycle in a temperature and humidity controlled, specific pathogen-
free environment. Mice were fed CRM (P) diet (Special Diets Services) ad-libitum. Mice were 
administered APAP (300 mg/kg) or 0.9 % saline via intraperitoneal (IP) injection in groups of 
five mice per experimental time point. Mice were fasted for 16 h prior to administration of 
APAP. Mice were culled at 0, 2, 6 and 24 h with a rising concentration of CO2.   
Blood was collected via cardiac puncture using a 25 G needle and 1 ml syringe to collect blood 
directly from the heart. The needle was removed from the syringe before decanting the 
blood into eppendorfs in order to avoid haemolysis. Freshly isolated blood was left to clot at 
room temperature for 30 min and centrifuged at 2000 g for 10 min. Serum was decanted 
and stored at -80 °C.  
2.2.1.2.  Nrf2-Luc reporter mice 
A breeding colony of Nrf2-Luc C57BL/6J mice were established in Liverpool from founder 
mice kindly donated by Dr Takao Iwawaki, Gunma, Japan. Initial attempts to generate 
homozygous Nrf2-Luc mice were unsuccessful therefore all studies were performed with 
heterozygous mice. Litters of 4 week old Nrf2-Luc mice were genotyped by Transnetyx, using 
ear snips. Heterozygous Nrf2-Luc were identified using the primers specific for firefly 
luciferase. Four separate studies using Nrf2-Luc mice are described in this chapter: one study 
using female mice exposed to a single dose of sulforaphane; one male and one female time 
course study following a single dose of APAP and one female time course study following the 
administration of cisplatin. Mice were selected for each study with similar genotyping scores.  
Firstly, wild-type and heterozygote male Nrf2-Luc mice were administered sodium arsenite 
as a positive control for the holistic induction of the Nrf2-Luc transgene. Wild-type and 
heterozygote Nrf2-Luc mice were administered either 13 mg/kg sodium arsenite via IP 
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injection (n=1). Injections were administered using a 1 ml syringe and short (16 mm) 25 G 
needle or insulin needle. Mice were anaesthetised and bioluminescence was quantified after 
6 h (see section 2.2.2 for protocol). Mice were culled after 6 h by a lethal dose of 
pentobarbital (100 mg/kg), a Schedule 1 method. Organs were removed for ex vivo 
bioluminescence quantification.   
During the APAP studies, male or female Nrf2-Luc mice were fasted for 16 h and given a 
single dose of either 0.9 % saline or 300 mg/kg APAP (n=5).. At 2, 6 and 24 h mice were 
anaesthetised and bioluminescence quantified. Mice were culled after 24 h by a lethal dose 
of pentobarbital and blood was collected by cardiac puncture. Organs were removed for ex 
vivo imaging. Following bioluminescence quantification, half of the hepatic central lobe was 
fixed and the rest of the liver was snap frozen.  
In the cisplatin study, female mice were exposed to 0.9 % saline and 5 mice to 20 mg/kg 
cisplatin, administered via IP injection (n=4). At 24, 48, 72 and 96 h the mice were 
anaesthetised and bioluminescence quantified. Mice were culled after 96 h with an overdose 
of pentobarbital via IP injection and blood collected by cardiac puncture. The kidneys and 
livers were removed for ex vivo imaging. From each mouse, one kidney was fixed in formalin 
and one kidney was snap frozen.   
2.2.2. Bioluminescence imaging 
Bioluminescence was quantified using the in vivo imaging system (IVIS) spectrum (Perkin 
Elmer, Waltham USA). This machine facilitates non-invasive imaging of live mice and 
produces a topographical image of the bioluminescent signal. Firefly luciferase, generated 
by the OKD48 transgene, produces light in an ATP dependent reaction with luciferin (Fig 1.6). 
In order to visualise the bioluminescent signal, mice were anaesthetised with isoflurane and 
either their torsos or backs were shaved with electric clippers. Mice were weighed and 
administered 150 mg/kg luciferin via IP injection using short 25 G needles. After 5 min, 
bioluminescence was quantified using the IVIS. Up to five mice were placed in the chamber 
in nose cones connected to anaesthetic supply. The mice were orientated either on their 
front or back, and images were taken using Living Image® Software. Exposure times was set 
to ‘Auto’, binning was set to ‘medium’ and F/stop kept at 1 with the excitation filter closed 
and emission filter open.  
Bioluminescence of organs were also quantified ex vivo. After the animal had been culled, 
the organs were dissected and rinsed in phosphate buffered saline (PBS). These were 
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subsequently incubated in 150 µg/ml in vivo grade luciferin in PBS for 2 min at room 
temperature. The organs were transferred to small petri-dishes and imaged using the IVIS. 
Bioluminescence in the region of interest (ROI) was calculated using Living Image® Software 
(Fig 2.1).  
Organs were rinsed in PBS after imaging and either fixed in 4 % paraformaldehyde or snap 
frozen in liquid nitrogen.  
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Figure 2.1 Calculation of region of interest  
(A) Within the living image software, images were quantified in radiance (p/sec/cm2/sr). (B) 
Using the image adjust settings, min and max colour scales were set to the same range for 
all images of one experiment. The region of interest (ROI) was defined (red circle) and 
quantified (C).   
 
  
A. B. 
C. 
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2.2.3. Alanine transaminase quantification 
Alanine transaminase (ALT) catalyses the conversion of α-ketoglutarate and alanine to 
glutamate and pyruvate. Clinically, measurement of ALT reflects liver function and is used to 
diagnose liver pathophysiology. ALT quantification using lactate dehydrogenase (LDH) and 
nicotinamide adenine dinucleotide (NADH) was initially described by Wroblewski and LaDue 
(WRÓBLEWSKI et al., 1956). HereI used the Infinity ALT Kit TR71121 (Thermo Scientific). This 
assay utilizes the production of pyruvate to convert a nearly colourless probe to a colourful 
product. This signal is proportional to pyruvate quantity. The change in optical density (OD) 
is measured over time as this is a kinetic assay for the measurement of enzymatic activity. 
Murine serum was thawed only once to avoid ALT degradation and used immediately. 
Samples from APAP-treated mice were diluted 1:30 in 0.9 % saline and loaded in duplicate 
in a 96 well plate (30 µl / well). Samples from saline-treated mice were loaded neat. Blank 
wells were loaded with 0.9 % Saline. Undiluted normal and abnormal control serum (Data 
TrolTM) were included on the plate as negative and positive controls respectively. The plate 
reader and ALT reagent were heated to 37 °C, prior to the addition of 300 µl ALT reagent to 
the samples. The OD was measured at 340 nm using a Varioskanner Flash (Thermo Scientific). 
ALT activity was expressed in U/L:  
ALT activity (U/L): Abs/min x 1746 
1746 = [Total reaction volume (ml) x 1000] / [Absorption coefficient of NADH at 340 nm x 
sample volume (ml) x cuvette pathlength (cm)]  
 
2.2.4. Glutathione quantification 
Total GSH content can be quantified by the 5-5’-Dithiobis(2-nitrobenzoic acid) (DTNB)-based 
‘recycling’ method described by Vandeputte et al. (Vandeputte et al., 1994). The assay 
utilises the following reactions, the latter catalysed by GSH reductase to generate the 5’thio-
2-nitrobenzoic acid (TNB) chromophore: 
2GSH + DTNB = GSSG + TNB 
GSSG + NADPH + H+ = 2GSH + NADPH+ 
Glutathione stock buffer was generated (11.15 g sodium dihydrogen phosphate 
monohydrate NaH2PO42H2O and 1.17 g Ethylenediaminetetraacetic acid (EDTA) in 500 ml 
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dH2O) at pH 7.4. 100 mg of liver tissue was homogenised in 400 µl GSH stock buffer and 200 
ul 6.5 % sulfosalicylic acid using an oscillating mill (Retsch) and magnetic ball bearings, for 3 
min at 30 s-1. Samples were left on ice for 10 min, then centrifuged at 18000 g for 5 min. The 
supernatant was snap frozen and stored at -80 °C. 1 ml of 1 M NaOH was added to the pellet 
and incubated at 60 °C for 1 h. Pellets were resuspended and frozen at -80 °C. Total protein 
content was quantified by Bradford assay (see section 2.2.7).  
1 mM glutathione (in glutathione stock buffer) was prepared. This was diluted 1:10 to a 0.1 
mM glutathione solution and used to make solutions for the standard curve (1, 2, 5, 10, 20, 
40 and 80 nM glutathione in GSH stock buffer). Supernatant samples were defrosted on ice 
and diluted 1 in 10 in GSH stock buffer, vortexed and 20 µl added to wells of a 96 well plate 
in duplicate. Standard curve samples were loaded in a similar manner. 20 µl GSH stock buffer 
was added to each well, to neutralise the pH. The plate was left on ice.  
The Daily assay reagent was generated (9.908 mg Ellman’s reagent (DTNB), 7.08 mg NADPH 
in 25 ml GSH stock buffer). 10 ml of diluted GSH reductase was generated (in GSH stock 
buffer) and kept on ice. The quantity of enzyme to be diluted was based on the following 
reaction: 
Volume (µl) = [(6.96 units/ml x 10 ml) / (Units/ml of stock reductase)] x 1000  
200 µl daily assay reagent was added to each well. After 5 min, 50 µl GSH reductase was 
added to each well. The OD was read at 405 nM using the Varioskanner Flash (Thermofisher).  
2.2.5. Blood urea nitrogen quantification 
Secreted by the kidneys, urea is the product of protein catabolism. Increased levels of 
circulating urea are associated with renal pathology, congestive heart failure and diabetes. 
Blood urea nitrogen (BUN) levels indicate the amount of nitrogen in the blood from urea. 
Developed by Jung et al. quantification of BUN consists of two steps (Jung et al., 1975). Firstly 
ortho-phthaldialdehyde reacts with urea. The product undergoes a rapid reaction with 
primaquine diphosphate that yields red coloured product proportional to concentration of 
urea in the sample. 
Serum was thawed once only, to avoid degradation. BUN levels were quantified using 
QuantiChromTM Urea Assay Kit DIUR-500 (BioAssay Systems), following the kit instructions. 
Samples were diluted 1 in 50, in dH2O. Samples and standard were loaded in duplicate into 
a 96 well plate (5 µl / well). The kit standard contained 50 mg/dL Urea. Distilled H2O was used 
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as a blank sample. Samples were incubated with working reagent (Reagent A and B in equal 
volumes) for 20 min at room temperature. OD was measured at 520 nm using the 
Varioskanner Flash. Urea concentration was calculated in the following manner: 
Urea concentration (mg/dL) = [ (OD sample – OD blank) / (OD standard – OD blank) ] x dilution 
factor (50) x 50 mg/dL  
As blood urea nitrogen is the mass of nitrogen within urea, BUN levels were calculated using 
the following calculation: 
BUN (mg/dL) = Urea concentration (mg/dL) / 2.14 (MW of urea (60)/ MW of urea nitrogen 
(28) = 2.14) 
2.2.6. Histological examinations 
For the histological and immunohistological examinations, liver sections from the central 
lobe, and kidney cross sections were fixed in 10 % buffered formalin for 48 h, trimmed and 
routinely paraffin wax embedded. Sections (3-5 µm) were prepared and routinely stained 
with haematoxylin-eosin (HE). Processing and staining for histology was performed by Dr. 
Julie Haigh, Histology Laboratories, Department of Veterinary Pathology and Public Health, 
Institute of Veterinary Sciences, University of Liverpool.  
The HE-stained sections were examined for any pathological alterations and the changes 
consistent with DILI were scored according to a previously applied scoring system (Table 2.2) 
(Antoine et al., 2009), whereas changes consistent with drug induced kidney injury (DIKI) 
were scored according to a previously published system by Zhang et al. (Table 2.3)  (Zhang 
et al., 2009) by Prof. Anja Kipar, Laboratory for Animal Model Pathology, Vetsuisse Faculty, 
University of Zurich and Institute of Global Health, University of Liverpool. 
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Table 2.2 Drug-induced liver injury scoring criteria 
From(Antoine et al., 2009) 
Score Description 
0 Tissues are normal with no hepatic necrosis. 
1 Hepatocyte loss and necrosis – minimal to mild 
Focal 
Limited to centrilobular region 
Less than ¼ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
2 Hepatocyte loss and necrosis – mild to moderate 
Focal and multifocal 
Extends from central to midzonal lobular region 
½ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
3 Hepatocyte loss and necrosis – moderate to severe 
Multifocal 
May extends from centrilobular to portal region 
More than ½ to ¾ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
4 Hepatocyte loss and necrosis – severe 
Multifocal 
More than ¾ of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
5 Massive hepatocyte loss and necrosis – severe, involving entire 
lobules 
Hepatocytes loss extends from central vein to portal area 
Hepatocytes loss extends o adjacent lobules (multilobular necrosis) 
Associated with vacuolar degeneration or haemorrhages 
 
Table 2.3 Drug-induced kidney injury score criteria 
From (Zhang et al., 2009) 
Score Description 
0 Normal tubules, glomerulus, interstitium and vessels 
1 Scant number of tubular epithelial cells showing minimal degeneration, mild tubular dilatation, small number of 
proteinaceous casts, no regeneration, no definitely significant necrosis or apoptosis. No changes in the 
glomerulus, interstitium and vessels 
2 <25% of tubular epithelial cells showing mild degeneration (large cytoplasmic vacuoles, few hyaline droplets in 
the cytoplasm), mild degree of tubular dilation and proteinaceous casts, slight change in tubular brush border 
loss, acute tubular necrosis in individual cell or small group of cells, a few apoptotic cells, no regeneration. No 
changes in the glomerulus, interstitium and vessels 
3 25-50% of tubular cells showing moderate degeneration (multiple large-sized cytoplasmic vacuoles, multiple foci 
of hyaline droplets), mild regeneration, moderate tubular brush border loss, moderate tubular necrosis in small 
groups of tubule and increased number of apoptotic cells. Little involvement of mild glomerular vacuolization. 
No changes in interstitium and vessels 
4 51-75% of tubular epithelial cells showing extensive moderate degeneration; moderate regeneration; severe 
tubular brush border loss; severe acute tubular necrosis; large number of apoptotic cells with apoptotic bodies 
in clusters of tubules. Little involvement of mild glomerular vacuolization and interstitial lymphocytic infiltration 
5 >75% of tubular epithelial cells showing severe degeneration, regeneration, severe tubular brush border loss, 
acute tubular necrosis, large number of apoptotic cells with numerous apoptotic bodies. Mild involvement of 
glomerular injury (vacuolization, mesangial cell proliferation, increase in mesangial matrix) and interstitial 
lymphocyte infiltration. No significant changes in the vessels 
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2.2.6.1. Immunohistochemistry 
Consecutive sections (3-5 µm) from the paraffin blocks were stained by 
immunohistochemistry to detect luciferase and Hmox1 expression. Briefly after 
deparaffination, sections were pre-treated with EDTA buffer (1mM EDTA, 0.05% Tween 20) 
at pH 9, for 20 min at 98 °C (Staining for luciferase) and citrate buffer (10 mM sodium citrate 
and 0.05 % Tween 20) at pH 6, for 20 min at 98 °C (Staining for Hmox1), respectively. To avoid 
endogenous peroxidase activity, all sections were incubated for 10 min with Peroxidase 
blocking reagent (Dako, S2023) at room temperature. All following incubations were 
conducted at room temperature. Between each incubation sections are washed with TBS-
Tween (Buffer described in section 2.2.8) for 10 min at room temperature. Sections were 
incubated with the primary antibodies: mouse anti-luciferase (Clone Luci17) ab16466 abcam, 
or mouse anti-Hmox1 (clone MA1-112) Thermo Fischer Scientific, diluted 1:100 in Dilution 
buffer (Dako) for 1 h. To detect the antibody binding, sections were incubated in Envision 
Mouse HPR reagent (Dako) for 30 min. The reaction was visualised by incubating the sections 
for 10 min with DAB (3,3'-diaminobenzidine), and counterstained with Gills haematoxylin 
(1:20 in dH2O) for approximately 2 sec. Sections from a mouse spleen were used as a positive 
control for Hmox1 staining and sections from a mouse tumour exhibiting a luciferase 
expressing protein served as positive controls for luciferase. Sections incubated with a non-
reactive mouse monoclonal antibody instead of the primary antibodies served as negative 
controls.  
2.2.7. Total protein quantification 
Protein concentration was determined via Bradford assay (Bradford, 1976). The assay utilises 
the coomassie brilliant blue G-250 dye reagent that binds to amino acids facilitating the 
colour change from brown to blue which is proportional to protein content. Liver lysates 
were defrosted on ice. 15 mg liver tissue was added to 500 µg RIPA buffer and lysed using an 
oscillating mill for 3 min at 30 s-1 (Retsch).  
A standard curve was generated with known concentrations of bovine serum albumin (BSA). 
A 500 µg/ml BSA stock solution was generated in dH2O and diluted to the following 
concentrations: 0.25, 0.2, 0.15, 0.1, 0.05 and 0.025 mg/ml. Tissue lysates were diluted 1 in 
300 in dH2O. 20 µl of standards or samples were loaded in duplicate in to the wells of a 96 
well plate. Distilled H2O was loaded as a blank sample. Protein Assay Dye Reagent 
Concentrate (BioRad) was diluted 1 in 4 with dH2O. The diluted reagent was added to the 
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plate (200 µl / well) and the plate was incubated at room temperature for 5 min. Absorbance 
was measured at 595 nm using the Varioskanner Flash.  
2.2.8. Western blotting 
Western blotting facilitates the semi-quantitative detection of specific proteins via gel-based 
separation and antibody staining (Burnette, 1981). NuPAGE 4x LDS Sample Buffer 
(Invitrogen) and NuPAGE 10x Sample Reducing Agent (Invitrogen) were added together in a 
ratio 7:3 to generate loading buffer. 5 µl loading buffer was added to 20 µg liver lysate and 
incubated at 90 °C for 10 min to denature the protein. Samples were centrifuged briefly and 
loaded into wells of NuPAGE Novex 4-12 % Bis-tris Polyacrylamide Gels (Invitrogen). 
Precision-Plus Kaleidoscope Protein Standards (BioRad) were included as reference markers. 
A 20x 3-(N-morpholino)propanesulfonic acid (MOPS)  buffer was generated (209.2 g MOPs, 
121.2 g Tris base, 20 g, SDS and 6 g EDTA in 1 L dH2O). Gels were resolved for 1 h at 170 V in 
1 x MOPs buffer.  
Once resolved, proteins were transferred to Nitrocellulose Membranes (GE Healthcare, 
Amersham). A 10 x Transfer buffer was generated (150.2 g Glycine, 30.3 g Tris base in 1 L 
dH2O). The transfer was conducted in Transfer Tanks (BioRad) filled with 1x Transfer buffer 
(100 ml 10x Transfer buffer, 200 ml Methanol and 700 ml dH2O) for 1 h at 230 mA. 
Confirmation of successful transfer was obtained by incubating membranes for 3 min in 
ponceau S solution.  
A 20x Tris-buffered saline (TBS) stock solution was generated (175.2 g NaCl, 4.48 g KCl and 
60.6 g Tris base in 1 L dH2O) at pH 7. Membranes were blocked with 10 % (w/v) Blotting grade 
blocker (BioRad) in TBS-Tween (TBST) (50 ml 20x TBS, 10 ml 10 % (v/v) Tween20 and 940 ml 
dH2O) for 2 h or overnight at 4 °C. Blots were incubated with antibodies listed in Table 2.4 in 
2 % (w/v) Blotting grade blocker in TBST. Following secondary antibody incubation, blots 
were washed for 30 min with TBST.  
Blots were developed with ECL reagent (Perkin-Elmer) and exposed to HyperfilmTM (GE 
Healthcare) in a dark room for 1 – 120 sec. Photographic film was incubated in Developer 
(Carestream Health Inc.) diluted 1 in 5 with H2O for 1 min. The film was then incubated in 
Fixer (Carestream Health Inc.) diluted 1:5 with H2O for 1 min and rinsed with H2O. Once dry, 
films were scanned and densitometry performed using ImageJ (Schneider et al., 2012). 
Density of bands were normalised to β actin intensity as a loading control.  
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Table 2.4 Antibody concentration and conditions for Western blot  
Primary 
Antibody  
Dilution (in 
2 % Milk in 
TBST) 
Incubation 
time 
Washing 
steps (using 
TBST) 
Secondary 
antibody  
Dilution (in 2 
% Milk in 
TBST) 
Incubation 
time 
(h) 
β Actin 
(ab6276) 
Monoclonal 
1:20,000 10 min 4 x 5 min Anti-Mouse-
HRP (A9044, 
Sigma) 
Polyclonal 
1:10,000 1 
Hmox1 
(ab13243) 
Polyclonal  
1:5,000 Overnight 3 x 10 min Anti-Rabbit-
HRP (A9169, 
Sigma) 
Polyclonal 
1:5,000 1 
Keap1 
(1050-3-2-
AP, Protein-
tech) 
Polyclonal 
1:2,000 Overnight 3 x 10 min Anti-Rabbit-
HRP (A9169, 
Sigma) 
Polyclonal 
1:5,000 1 
Txnrd1 
(ab124954) 
Monoclonal 
1:5,000 Overnight 4 x 5 min Anti-Rabbit-
HRP (A9169, 
Sigma) 
Polyclonal 
1:5,000 1 
Nqo1 
(ab2346) 
Polyclonal 
1:2,000 Overnight 4 x 5 min Anti-Goat-
HRP (P0449, 
Dako) 
Polyclonal 
1:5,000 1 
Nrf2 
(16396-1-
AP, Protein-
tech) 
Polyclonal 
1:1,000 Overnight 6 x 10 min Anti-Rabbit-
HRP (A9169, 
Sigma) 
Polyclonal 
1:5,000 1 
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2.2.9. Gene expression analysis 
Expression of Nrf2 target genes was determined using quantitative (real-time) polymerase 
chain reaction (qPCR). Isolated RNA was converted to cDNA and quantified using the 
fluorescent dye SYBR green. This dye intercalates with double stranded DNA to produce a 
fluorescent signal (Ponchel et al., 2003).  
2.2.9.1. RNA extraction  
In this chapter, RNA was isolated using the spin column-based purification RNeasy Mini Kit 
(Qiagen, Hilden Germany). Guanidium thiocyanate is used to facilitate binding of nucleic 
acids to silica (Boom et al., 1990). The mini kit spin columns contain silica-membranes and 
tissues were lysed in a guanidine-thiocyanate containing buffer. This lysis buffer also inhibits 
RNase activity within the sample.  
Liver tissue was weighed and 20 mg lysed in 350 µl of buffer RLT using the oscillating mill. 
Lysates were centrifuged for 3 min at 18,000 g and the supernatant transferred to new 
eppendorfs. Samples were vortexed after the addition of 350 µl of 70 % (v/v) ethanol in dH2O 
and loaded onto the spin column above a 2 ml collection tube. Spin columns were 
centrifuged for 15 sec at 8,000 g and the flow-through discarded.  The silica membranes were 
subsequently washed with 700 µl buffer RW1 and 500 µl buffer RPE two times. After loading 
the buffer, spin columns were centrifuged and flow through discarded. The spin column was 
spun at 8,000 g a final time to dry the membrane and RNA eluted in 30 µl RNAse-free dH2O. 
The eluate was loaded back onto the spin column and centrifuged a second time to ensure a 
high RNA yield. The yield was quantified using the Nanodrop Spectrophotometer ND-1000 
(Labtech International, Heathfield UK). Purity of the samples were based on the 260/280 
ratio. Only those with a ratio between 1.9 and 2.1 were used. All RNA samples were stored 
at -80 °C. 
2.2.9.2. cDNA synthesis 
RNA samples were reverse transcribed to cDNA using the GoScriptTM Reverse Transcription 
System (Promega, Madison USA). In a semi-skirted 96 well plate (Starlab, Hamburg 
Germany), between 0.1 - 0.5 µg RNA was added per well, along with 0.5 µl random A primer 
(500 µg/ml) and 0.5 µl oligo dt primer (500 µg/ml). Reactions were made up to 10 µl with 
dH2O. Reactions included both sets of primers to increase cDNA yield. The plate was sealed 
and incubated at 70 °C for 5 min and cooled on ice for 2 min. A master mix was generated (8 
µl 5x reaction buffer, 4 µl 25 mM MgCl2, 2 µl 10 mM dNTPs, 2 µl reverse transcriptase and 
14 µl dH2O per reaction) in excess of the total number of reactions and 30 µl added to each 
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well. The plate was then incubated at an annealing temperature of 25 °C for 5 min, an 
extension temperature of 42 °C for 1 h and inactivation of the enzyme was achieved by 
incubating at 70 °C for 15 min. cDNA samples were stored at -20 °C.   
2.2.9.3. qPCR  
qPCR analysis was conducted using the Via7 qPCR machine (Life technologies, Carlsbad USA). 
Reactions were loaded into wells of a semi-skirted 96 well plate. cDNA was diluted 1 in 3 with 
nuclease free dH2O and 6 µl loaded per well. 5 µM primer pair solutions were generated by 
diluting the 100 uM stocks and combining both forward and reverse primers (Table 2.5). 
Master mixes were generated for each primer combination (10 µl Power SYBR green master 
mix (Life technologies, Carlsbad USA) and 4 µl 5 µM primer pair solution per well). 14 µl of 
Master Mix were added to each well of a 96 well plate. This made each reaction a final 
volume of 20 µl. Each sample was run in duplicate alongside wells with 6 µl Nuclease free 
water, substituting cDNA as a negative control. The plate was heated using the Via7 (program 
listed in Table 2.6) and fluorescence quantified at 60 °C. Ct threshold was set using Via7TM 
software v1.2.2. Ct values for each sample were averaged and fold changes generated using 
the following equation:  
Ct (Gene of interest) – Ct (Housekeeping gene) = ΔCt 
ΔCt (Experimental sample) – ΔCt (Control sample) = ΔΔCt 
(2-ΔΔCt) x 100 = mRNA level (% control) 
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Table 2.5 Mouse qPCR primer sequences  
Gene Primer Sequence 
Mouse Nqo1 Fwd 5’- TTT AGG GTC GTC TTG GCA AC -3’ 
 Rev 5’- GTC TTC TCT GAA TGG GCC AG -3’ 
Mouse Gsta1 Fwd 5’-CAG CCT GGC AGC CAG AGA -3’ 
 Rev 5’-TCT GTG GCT CCA TCA ATG CA -3’ 
Mouse Srxn1 Fwd 5’- AAA GTG CAG AGC CTG GTG -3’ 
 Rev 5’- CTT TGA TCC AGA GGA CGT CG -3’ 
Mouse Nrf2 Fwd 5’- CAT GAT GGA CTT GGA GTT GC -3’ 
 Rev 5’- CCT CCA AAG GAT GTC AAT CAA -3’ 
Mouse Keap1 Fwd 5’- CAC AGC AGC GTG GAG AGA -3’ 
 Rev 5’- CAA CAT TGG CGC GAC TAG A -3’ 
Mouse Hmox1 Fwd 5’- GTC AAG CAC AGG GTG ACA GA -3’ 
 Rev 5’- ATC ACC TGC AGC TCC TCA AA -3’ 
Mouse Gapdh Fwd 5’- TGT CCG TCG TGG ATC TGA C -3’ 
 Rev 5’- CCT GCT TCA CCA CCT TCT TG -3’ 
 
Table 2.6 qPCR Program 
Number of 
cycles 
Temperature (°C) Time 
1 95 10 min 
40 95 15 sec 
60 1 min 
 
2.2.10. Statistical analysis 
Standard deviation (SD) was calculated using Graphpad Prism7. All bar graphs shown as 
mean ± SD. Normality was assessed by Shaprio Wilk test. Statistical significance of unpaired 
data was assessed by Student’s T test, for parametric data, or Mann Whitney U test, for data 
with a non-parametric distribution. Where F values relating to variance were significant, 
Welch’s correction was employed. For multiple comparisons, one-way ANOVA with Tukey’s 
post-hoc analysis or Kruskal Wallis with Dunn’s multiple comparisons tests, were used. 
Correlations were calculated either by Pearson’s or Spearman’s R test. P value notations are 
as follows: */@ P ≤ 0.05, **/@@ P ≤ 0.01 and ***/@@@ P ≤ 0.001.   
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2.3. Results  
2.3.1. Nrf2-Luc mice characterization 
Initial characterization of Nrf2-Luc mice was conducted to identify basal activity of the Nrf2 
pathway and GSH levels. This was vital to ensure the transgene did not interfere with gene 
expression or the major detoxification pathway of APAP, making the Nrf2-Luc mice more 
sensitive or more tolerant to chemical stress. 
Untreated male and female wild type and heterozygote Nrf2-Luc mice were culled with a 
rising concentration of CO2 and hepatic GSH levels quantified (Fig 2.2 A). No significant 
difference was observed between genotypes of male and female by unpaired t-test (P = 
0.154 and 0.786 respectively). Basal activity of hepatic Nrf2-regulated transcriptome 
revealed no significant difference between WT and Het female mice (Fig 2.2 B).  
Oikawa et al. demonstrated the sensitivity of the Nrf2-Luc mice to sodium arsenite (ASN) as 
a systemic inducer of oxidative stress (Oikawa et al., 2012). To show mice from our breeding 
colony were also sensitive to Nrf2 induction in this manner, one wild-type and one 
heterozygous Nrf2-Luc mouse were exposed to 13 mg/kg ASN for 6 h.  In vivo 
bioluminescence imaging following 6 h exposure revealed a strong signal in the lower 
abdominal region (Fig 2.3 A).  Ex vivo analysis identified a hepatic luminescent signal specific 
to the heterozygous mouse.  
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Figure 2.2 Basal expression of glutathione and Nrf2 pathway activity in Nrf2-Luc mice.  
Wild type (WT) and heterozygote (Het) Nrf2-Luc mice were culled with a rising concentration of CO2 (n=4) (A) Hepatic glutathione (GSH) levels were quantified 
and showed no significant difference between genotypes and sex via unpaired t-test. (B) Basal hepatic activity of the Nrf2-pathway was quantified by qPCR. 
No significant differences between WT and Het mice for each gender were calculated by one-way ANOVA.  
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Figure 2.3 In and ex vivo bioluminescence of Nrf2-Luc mice exposed to Sodium Arsenite (13 
mg/kg). 
(A) Male wild-type (WT) and heterozygous Nrf2-Luc mice (Het) (n=1) were exposed to 13 
mg/kg sodium arsenite (ASN) by IP injection and their bioluminescence observed after 6 h 
using the IVIS spectrum. The liver from each mouse was excised and incubated in luciferin 
solution (150 µg/ml in PBS) for 2 min. (B) Ex vivo signal was quantified.  
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2.3.2. Response to APAP toxicity in wild type C57BL/6J mice  
Firstly, the dose and time needed to induce APAP toxicity in wild type mice of a similar 
background to the Nrf2-Luc mice (C57BL/6J) were determined. Male wild type mice were 
treated with a single dose of APAP (300 mg/kg) or with 0.9 % saline and five mice culled at 
either 2, 6, 24 or 48 h. One mouse, within the 48 h treatment group had to be culled at 8 h 
due to surpassing the severity threshold of the procedure. Data from this mouse was 
excluded from further analysis. Classical biomarkers of liver injury were monitored including 
serum ALT and hepatic GSH levels.  
In APAP-treated mice, serum ALT peaked after 24 h exposure to APAP and had decreased by 
48 h (Fig 2.4). ALT levels were significantly different to the 0 h treatment group at 6 and 24 
h after exposure to APAP (both p < 0.0001). Serum ALT levels in the 6 h saline treatment 
group were not elevated.  
Glutathione content in the liver was rapidly depleted 2 h following exposure to APAP (Fig 
2.5). Subsequent recovery of hepatic GSH content was observed between 6 and 48 h to levels 
similar to the saline 6 h treatment group. The 0 h treatment group GSH content significantly 
differed from the 2, 24 and 48 h APAP-treatment groups (P = 0.027, 0.033 and 0.026 
respectively). The 6 h saline-treatment group was also significantly different to the 0 h group 
(P = 0.0032).  
Gene and protein expression in the livers of wild-type mice were assessed for Nrf2 pathway 
activity. Upregulation of Nrf2-regulated were evident after as little as 2 h exposure to APAP 
(Fig 2.6 A). Hmox1, Gsta1, Srxn1 and Nqo1 activity peaked at 6h though extent of induction 
varied between genes. Hmox1 induction at 2 and 6 h was significantly different to Hmox1 
activity in the 0 h treatment group (both p <0.0001). Gsta1 and Srxn1 activity was significantly 
increased at all time-points when compared to the gene activity at 0 h. Gene activity in the 
6 h Saline-treated group did not differ from 0 h. However, all genes measured at 6 h were 
significantly elevated compared to the 6 h saline treatment group (Hmox1 = p <0.0001, Gsta1 
= p 0.0025, Srxn1 = p <0.0001, and Nqo1 = p <0.0001). Hmox1 protein expression peaked at 
24 h and was significantly different at 6, 24 and 48 h compared to the 0 h treatment group 
(All p <0.0001) (Fig 2.6 B and C). When compared to the 6 h saline group, Hmox1 protein 
expression was significantly greater in the 6 h APAP treatment group (P = 0.0051).     
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Figure 2.4 Elevated serum alanine transaminase in wild-type mice exposed to a single 
dose of APAP (300 mg/kg).  
C57BL/6J wild-type mice (n=4) were exposed to a single dose of APAP or 0.9 % saline via IP 
injection. Blood was collected at 0, 2, 6, 24 and 48 h by cardiac puncture. ALT levels were 
significantly different at 2, 6 and 24 h compared to the 0 h treatment group, using Kruskal 
Wallis (**P ≤ 0.01 and *** P ≤ 0.001). 
 
 
Figure 2.5 Glutathione depletion in wild-type mice exposed to a single dose of paracetamol 
(300 mg/kg). C57BL/6J wild-type mice (n=4) were exposed to a single dose of APAP or 0.9 % 
saline via IP injection. Mice were culled at either 0, 2, 6 24 or 48 h. GSH was quantified from 
liver lysates. GSH levels were significantly different when compared to 0 h treatment group, 
using one-way ANOVA (* P ≤ 0.05).  
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Figure 2.6 Upregulation of the Nrf2-pathway in wild-type mice exposed to a single dose of 
paracetamol (300 mg/kg).  
(A) qPCR analysis of expression of Nrf2-target genes in the livers of wild-type C57BL/6J mice 
(n=4) exposed to APAP (300 mg/kg) or 0.9 % saline via IP injection (n=4). (B) Western blot for 
Haem oxygenase 1 (Hmox1) of representative liver lysates from 0, 2, 6, 24 and 48 h 
exposure. (C) Densitometry of immunoblotting from all liver lysates (n=4). Significant 
difference in gene and protein expression compared to 0 h treatment group was calculated 
by Kruskal Wallis (* P ≤ 0.05, **P ≤ 0.01 and *** P ≤ 0.001) or compared to the 6 h saline 
treatment group (@@ P ≤ 0.01 and @@@ P ≤ 0.001).  
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2.3.3. Nrf2-Luc respond to APAP toxicity  
Nrf2-Luc mice were exposed to the hepatotoxin APAP as a model of drug induced liver injury. 
A dose of 300 mg/kg had been shown to induce toxicity and activate Nrf2 signalling over 24 
h (See 2.3.2). Therefore, a similar dose and time course was used with male and female Nrf2-
Luc mice. In both cases, serum ALT levels were significantly higher than in the saline 
treatment group after 24 h exposure to APAP (P = 0.0079 and 0.0002 respectively) (Fig 2.7). 
In vivo bioluminescence was quantified at 2, 6 and 24 h following exposure to 300 mg/kg 
APAP or 0.9 % Saline. In males, a strong bioluminescent signal within the region of the liver 
was seen after 6 h (Fig 2.8). However, the signal strength varied between individuals. Two of 
the APAP treated-mice had a strong signal in the liver region that peaked at 6 h and had 
reduced by 24 h. In one mouse the signal peaked in the liver region at 24 h, while two mice 
failed to show strong luminescence for the duration of the study. Additionally, low levels of 
bioluminescence were present in two saline-treated mice. This signal localised to the lungs 
and lymph node areas and was not present in the liver region.  
Ex vivo analysis highlighted the liver-specific signal of the male APAP treated mice after 24 h 
exposure (Fig 2.9 A). Significantly different bioluminescence between saline and APAP –
treated mice was observed in the liver (P = 0.0079) but not the liver or kidneys (Fig 2.9 B). In 
three of the mice treated with APAP, there was low bioluminescence in the lungs. This signal 
was also present in one of the saline-treated mice suggesting that this may be caused by the 
anaesthetic.  
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Figure 2.7 Serum alanine transaminase significantly elevated in male and female Nrf2-Luc 
mice exposed to paracetamol (300 mg/kg)  
Serum ALT levels were significantly increased in both male and female heterozygous Nrf2-
Luc mice 24 h after exposure to a single dose of APAP (300 mg/kg) compared to the saline 
treatment group (**P ≤ 0.01 and *** P ≤ 0.001). Significance was calculated by Mann-
Whitney U-test.  
 
 
M a le  F e m a le
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
A
L
T
 A
c
ti
v
it
y
 U
/L
0 .9  %  S a lin e
3 0 0  m g /k g  A P A P
** *  0 .0 0 0 2
* *  0 .0 1
U n p a ire d  t te s t
* * *
* *
Chapter 2 
77 
 
 
Figure 2.8 In vivo bioluminescence induced in male Nrf2-Luc mice exposed to paracetamol (300 mg/kg)  
Male heterozygous mice (n=5) were exposed to a single dose of APAP (300 mg/kg) or 0.9 % Saline via IP injection and their bioluminescence observed at 2, 6 
and 24 h using the IVIS spectrum. 
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Figure 2.9 Ex vivo bioluminescence induced in male Nrf2-Luc mice exposed to paracetamol 
(300 mg/kg)  
Male heterozygous mice exposed to a single dose of APAP (300 mg/kg) or 0.9 % saline via IP 
injection were culled after 24 h (n=5). The liver, kidney and lung from each mouse was 
excised and incubated in luciferin solution (150 µg/ml in PBS) for 2 min. (A) Bioluminescence 
was quantified using the IVIS spectrum. (B) Region of interest (ROI) values were calculated 
within each petri dish, with significantly greater bioluminescence in the livers from the APAP 
treatment group when compared to the saline treatment group (** P ≤ 0.01). This was 
calculated by Mann Whitney U test.    
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Females exhibited a more consistent and stronger bioluminescent signal following exposure 
to APAP, compared to the male mice (Fig 2.10). Bioluminescence almost exclusively from the 
liver region was evident after 6 h and in most mice peaked at 24 h, though a substantial signal 
in one mouse peaked at 6 h. No bioluminescence was present in the saline treatment group 
for the duration of the experiment.  
A stronger ex vivo signal was detected in female APAP-treated mice, than in males (Fig 2.11 
A). Bioluminescence was present in all livers of the APAP treatment group and was 
significantly greater than those from the saline-treated mice (Fig 2.11 B) (P = 0.0079). The 
lungs of two APAP-treated mice also had signal resulting in significantly greater 
bioluminescence in the lungs from the APAP treatment group when compared to mice 
treated with saline (P = 0.317).  No bioluminescence was present in the organs of the saline 
treatment group similar to the in vivo analysis.  
Significant correlation between ALT and bioluminescence was observed in both male (Fig 
2.12 A) and female (Fig 2.12 B) APAP-exposure studies. However, ALT values were higher and 
more variable in the APAP-treated male mice when compared to their female counterparts.  
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Figure 2.10 In vivo bioluminescence induced in female Nrf2-Luc mice exposed to paracetamol (300 mg/kg)  
Female heterozygous mice were exposed to a single dose of acetaminophen (APAP) (300 mg/kg) or 0.9 % Saline via IP injection (n=5). (A) Bioluminescence 
was observed at 2, 6 and 24 h using the IVIS spectrum. 
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Figure 2.11 Ex vivo bioluminescence induced in female Nrf2-Luc mice exposed to 
paracetamol (300 mg/kg)  
Female heterozygous mice exposed to a single dose of acetaminophen (APAP) (300 mg/kg) 
or 0.9 % saline via IP injection were culled after 24 h. The liver and kidney from each mouse 
was dissected and incubated in luciferin solution (150 µg/ml in PBS) for 2 min. 
Bioluminescence was quantified using the IVIS spectrum (n=5). (A) Bioluminescence was 
observed using the IVIS spectrum. (B) Region of interest (ROI) values were calculated with no 
significant difference between bioluminescence in livers from the APAP and Saline treatment 
groups (* p ≤ 0.05 and ** P ≤ 0.01). This was calculated by Mann Whitney U test.     
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Figure 2.12 Serum alanine transaminase and ex vivo bioluminescence in male and female 
Nrf2-Luc mice exposed to paracetamol (300 mg/kg)  
(A) Ex vivo bioluminescence in the region of interest (ROI) of the livers from the male mice 
compared to serum ALT levels at 24 h. (B) ROI and ALT values from female mice (n=5). APAP 
treatment groups labelled with animal ID numbers. Statistical analysis was performed using 
Pearson’s R test (* p ≤ 0.05 and ** P ≤ 0.01). 
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Extensive liver damage was also evident following histological analysis of the APAP-treated 
mice. In males, large areas of necrosis were present around the portal vein (Fig 2.13 A). 
Luciferase and Hmox1 staining also localised to this pericentral area. Four out of the five 
APAP-treated mice had a DILI score of 2 (Fig 2.13 B) indicative of moderate hepatocyte loss 
from the central to midzonal region (Table 2.2). Luciferase and Hmox1 staining was not 
present in the male saline-treated mice. Matched ALT scores were between 1627.7 – 3797.7 
U/L.  
In comparison to males, necrosis was muted in the female APAP-treated mice (Fig 2.14 A). 
Although, Luciferase and Hmox1 staining followed a similar pattern to the male APAP-treated 
mice. DILI scores were lower than males with three out of the five mice assigned a DILI score 
of 1 (Fig 2.14 B). This is indicative of mild necrosis restricted to the pericentral region in less 
than 25 % of the hepatic lobules. One female APAP-treated mouse had a DILI score of 0, 
despite exhibiting the greatest bioluminescent signal at 6 h (Fig 2.10 A). Consistent with the 
DILI scores, ALT levels were lower in the female mice compared to the male APAP-treated 
mice, ranging between 682.4 – 3055 U/L.  
As the females responded in a more consistent manner, they were used for further analysis 
of endogenous Nrf2 pathway responses to APAP.  In female mice, all the Nrf2-regulated 
genes measured in the livers of the mice from the APAP treatment group were significantly 
elevated compared to the saline treatment group after 24 h (Fig 2.15 A). At the protein level, 
Hmox1 was significantly induced in the APAP group (P = 0.0079) but not Nqo1 (P = 0.54) (Fig 
2.15 B and C).  
Finally, assessment of renal and hepatic Nrf2 pathway activation in wild-type mice 
highlighted the significantly greater perturbation of endogenous Nrf2-regulated genes in the 
liver, compared to the kidneys of APAP-treated mice (Fig 2.16). This data consolidates the 
liver-specific induction of the endogenous Nrf2 pathway alongside the bioluminescent 
reporter in response to a hepatotoxic dose of APAP.  
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B.  
 
Figure 2.13 Immunohistochemistry of livers from male Nrf2-Luc mice exposed to 
paracetamol (300 mg/kg)  
(A) Sections of liver tissue from male mice exposed to a single dose of 300 mg/kg APAP or 
0.9 % Saline for 24 h were stained with H&E and probed for Luciferase and Hmox1 (n=5). 
Substantial necrosis surrounding the portal vein (black arrow) is shown in the light pink 
staining of the H&E treated sections (white arrow) from livers exposed to APAP but not 
saline. (B) Extent of necrosis is proportional to drug induced liver injury (DILI) score and 
alanine transaminase (ALT) levels.  
 
 Saline APAP 
DILI 
Score 0 2 2 2 2 1-3 
ALT (U/L) 0.8 2937.6 3247.2 3797.7 3446.7 1627.7 
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B. 
 Saline APAP 
DILI 
Score  0 1 2(-3) 0 1 1(-2) 
ALT (U/L)  10.3 682.4 3053.0 1117.9 732.8 2746.2 
 
 
Figure 2.12 Immunohistochemistry of livers from female Nrf2-Luc mice exposed to 
paracetamol (300 mg/kg)  
(A) Sections of liver tissue from female mice exposed to a single dose of 300 mg/kg APAP or 
0.9 % Saline for 24 h were stained with H&E and probed for Luciferase and Hmox1 (n=5). 
Substantial necrosis surrounding the portal vein (black arrow) is shown in the light pink 
staining of the H&E treated sections (white arrow) from livers exposed to APAP but not 
saline. (B) Extent of necrosis is proportional to drug induced liver injury (DILI) score and 
alanine transaminase (ALT) levels.  
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Figure 2.15 Nrf2-Luc signal corresponds with upregulation of the Nrf2 pathway in livers of 
female Nrf2-Luc mice exposed to paracetamol (300 mg/kg)  
(A) qPCR analysis of the livers from female mice exposed to either 0.9 % Saline or 300 mg/kg 
APAP for 24 h highlighted induction of Nrf2-regulated genes (n=5). Significant induction 
compared to saline treatment group was calculated by Unpaired T test. (B) Western blots of 
Nrf2-regulated protein expression and (C) densitometry in these livers also highlighted 
significant induction of Hmox1 but not Nqo1, calculated by Mann Whitney U test (* p ≤ 0.05, 
**P ≤ 0.01 and *** P ≤ 0.001).  
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Figure 2.16 Endogenous Nrf2 pathway activity in the livers and kidneys of wild-type mice 
exposed to paracetamol (300 mg/kg) 
qPCR analysis of the liver and kidneys from male wild-type mice (n=5) exposed to either 0.9 
% Saline or 300 mg/kg APAP for 24 h. Significant induction of hepatic Nrf2 pathway compared 
to renal gene expression was calculated by Unpaired T test (* p ≤ 0.05, **P ≤ 0.01 and *** P 
≤ 0.001) (Dotted line = 100 %). 
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2.3.4. Nrf2-Luc mice respond to cisplatin toxicity  
In order to assess the response to other forms of drug-induced organ toxicity, the Nrf2-Luc 
mice were exposed to the nephrotoxin cisplatin under conditions previously shown to 
activate Nrf2 signalling in renal tissue (Miyagi et al., 2014). Female Nrf2-Luc mice were used 
due to the stronger bioluminescent response they displayed to paracetamol toxicity. 
Following 96 h exposure to cisplatin, serum BUN levels were significantly elevated when 
compared to their saline-treated counterparts (P = 0.0007) (Fig 2.17).  
Bioluminescence in the cisplatin-treated mice localised to the kidney region after 72 h (Fig 
2.18). The strength of the signal varied between individuals and was also hampered by the 
skin pigmentation of the mice. Large black ‘moles’, typically observed in C57BL/6J mice 
(Curtis et al., 2011), inhibited the signal resulting in partial luminescence in some mice. In the 
saline treatment group, no signal was observed in the kidney region. However, low levels of 
luminescence were present at the base of the neck in two of the four mice. This signal 
intensity faded through the course of the experiment.  
In light of the interference from skin pigmentation in some mice, it was particularly important 
to perform ex vivo imaging of relevant organs. Ex vivo signal was specific to the kidneys in all 
four mice treated with cisplatin (Fig 2.19 A). No signal was present in the livers of the mice 
from either treatment group. There was a significant difference between the kidney 
bioluminescence in cisplatin and saline treated mice, at 96 h (P = 0.023) (Fig. 2.19 B). In 
comparison with matched BUN levels, ex vivo bioluminescence at 96 h significantly differed 
between the cisplatin and saline treatment groups (Fig 2.20).   
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Figure 2.17 Serum blood urea nitrogen significantly elevated in female Nrf2-Luc mice 
exposed to cisplatin (20 mg/kg) 
Serum blood urea nitrogen (BUN) levels were significantly higher in the Nrf2-Luc mice treated 
with a single dose of cisplatin (20 mg/kg) than those treated with 0.9 % saline after 96 h (n=4) 
(*** P ≤ 0.001), by Unpaired T test. 
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Figure 2.18 In vivo bioluminescence induced in female Nrf2-Luc mice exposed to Cisplatin 
(20 mg/kg)  
Female heterozygous Nrf2-Luc mice were exposed to a single dose of Cisplatin (20 mg/kg) or 
0.9 % Saline via IP injection and their bioluminescence observed at 24, 48, 72 and 96 h using 
the IVIS spectrum (n=4).  
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Figure 2.19 Ex vivo bioluminescence induced in female Nrf2-Luc mice exposed to Cisplatin 
(20 mg/kg)  
Female heterozygous mice exposed to a single dose of Cisplatin (20 mg/kg) or 0.9 % saline 
via IP injection were culled after 96 h. The liver and kidney from each mouse was dissected 
and incubated in luciferin solution (150 µg/ml in PBS) for 2 min. (A) Ex vivo bioluminescence 
was quantified using the IVIS spectrum (n=4). (B) Bioluminescence of the kidneys were 
significantly increased in the cisplatin treatment group when compared to the saline-treated 
group (* p ≤ 0.05) via Mann Whitney U test.  
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Figure 2.20 Serum BUN and ex vivo bioluminescence in female Nrf2-Luc mice exposed to 
cisplatin (20 mg/kg) 
Comparison of serum BUN (blood urea nitrogen) levels obtained at 96 h with ex vivo 
bioluminescence in region of interest (ROI) of kidneys from female heterozygous mice (n=4). 
Data points labelled with animal ID numbers. Statistical analysis was performed using 
Pearson’s R test (* p ≤ 0.05). 
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Necrosis was evident in the proximal tubule region of kidneys from the cisplatin-treated mice 
(Fig 2.21 A). Hmox1 and luciferase staining co-localised to this region also. The extent of 
staining was proportional to the DIKI score and BUN values (Fig 2.21 B).  
qPCR analysis of the kidneys from cisplatin-treated mice revealed only Gsta1 expression was 
significantly upregulated in the cisplatin treatment group, when compared to the vehicle 
control group (Fig 2.22 A) (P = 0.28). Renal Hmox1 was elevated at the protein level in kidneys 
of mice treated with cisplatin for 96 h although not significantly different to the saline 
treatment group (Fig 2.22 B and C) (P = 0.091). Analysis of Nrf2-pathway activation in the 
livers of cisplatin-treated mice revealed no significant induction of Nrf2-regulated genes (Fig 
2.23).  
 
  
Chapter 2 
96 
 
 
 
Chapter 2 
97 
 
B. 
 Saline Cisplatin 
DIKI Score  0 2 2 3 2 
BUN 25.2 62.7 44.0 46.8 53.4 
 
Figure 2.21 Immunohistochemistry of female Nrf2-Luc mice exposed to Cisplatin (20 
mg/kg)  
Mice were culled after 96 h (n=4). (A) Sections of renal tissue were stained with H&E and 
probed for Luciferase and Hmox1.  Luciferase and Hmox1 staining localised to the proximal 
tubule (black arrow). H&E staining shows significant damage in this region also. (B) Extent of 
necrosis is proportional to drug induced kidney injury (DIKI) score and blood urea nitrogen 
(BUN) levels.   
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Figure 2.22 Gene and protein expression in kidneys of female Nrf2-Luc mice exposed to 
Cisplatin (20 mg/kg)  
(A) qPCR analysis of the kidneys from female mice exposed to either 0.9 % saline or 20 mg/kg 
cisplatin for 96 h (n=4). Significant differences between saline and cisplatin treatment groups 
calculated by Mann Whitney U test (* p ≤ 0.05). (B) Western blot for Haem oxygenase 1 
(Hmox1) in liver lysates from 96 h exposure. (C) Densitometry of the Hmox1 protein 
expression was not significantly increased compared to saline-treated mice. This was 
calculated by Unpaired T Test.  
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Figure 2.23 Gene expression in livers of female Nrf2-Luc mice exposed to Cisplatin (20 
mg/kg)  
qPCR analysis of the kidneys from female mice exposed to either 0.9 % saline or 20 mg/kg 
cisplatin for 96 h highlighted no significant induction of Nrf2-regulated genes by Student T-
Test (n=4).  
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2.4. Discussion  
Here, I have performed real-time, in vivo bioluminescence imaging of transgenic Nrf2-Luc 
mice to test the hypothesis that localised activation of Nrf2 represents a marker of chemical 
stress associated with organ-specific drug toxicity. Following exposure to APAP, upregulation 
of the hepatic Nrf2 pathway alongside classical markers of toxicity was observed in wild-type 
mice. A similar response was seen in Nrf2-Luc mice exposed to APAP, accompanied by liver-
specific bioluminescence in vivo and ex vivo. The bioluminescent signal intensity correlated 
with serum ALT and degree of hepatic tissue damage. In response to cisplatin, Nrf2-Luc mice 
exhibited a kidney-specific bioluminescent signal in vivo and ex vivo, proportional to renal 
tissue damage that coincided with activation of the renal Nrf2 pathway. These findings 
further support the use of Nrf2 as a marker of chemical stress associated with drug toxicity 
and demonstrate the value of Nrf2-Luc mice for identifying localised stress responses 
through real-time in vivo bioluminescence imaging. 
There is increasing interest in the value of stress response pathways as indicators of cellular 
perturbation that could lead to overt toxicity. This is emphasised by the integration of 
adaptive stress response pathways as vital components of adverse outcome pathways 
(AOPs) to clarify the underlying mechanisms of toxicity rather than rely on toxicological 
endpoints to identify chemical liabilities (Vinken et al., 2013). Current in vitro platforms 
include a plethora of cell-based reporters established in primary hepatocytes and cell lines 
for the detection of Nrf2 pathway activation associated with DILI (Kim et al., 2016; Wink et 
al., 2017). However, these in vitro platforms cannot inform in vivo distribution of a 
compound. While cisplatin induced an ARE-driven fluorescent reporter in HepG2 cells, 
observed by Wink et al., no hepatic bioluminescent signal was present in the Nrf2-Luc mice 
exposed to the drug in this chapter. Whole-body distribution is therefore important to 
consider in the analysis of in vitro data. The Nrf2-Luc mouse model reflects organ-specific 
insult. However, a delayed response was observed when compared to the endogenous 
pathway induction seen in the WT time-course study. This may be due to the requirement 
for accumulation of endogenous Nrf2, to upregulate the transgene at the protein level prior 
to luminescent signal generation. Despite this, endogenous protein matched transgene 
bioluminescent signal, therefore allowing chemical/oxidative stress responses detected in 
cell-based models to be placed in a whole-body context, with consideration of drug 
distribution and pharmaco/toxicokinetics. Further analysis of compounds identified in these 
screens for extra-hepatic activity using the Nrf2-Luc model would also be of interest.  
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In response to APAP and cisplatin, the intensity of the Nrf2-Luc bioluminescent signal 
reflected the extent of drug-induced tissue insult. Indeed, on a cellular level, exposure to a 
single hepatotoxic dose of APAP resulted in the co-localisation of Hmox1 and luciferase 
staining in centrilobular hepatocytes specifically, consistent with the known pathology of 
APAP (Hinson et al., 2010). However, the bioluminescent signal varied greatly between mice. 
For instance, one female mouse with the strongest bioluminescent signal, had a DILI score 
of 0 and moderate increase in serum ALT, perhaps due to the protective response of Nrf2 
pathway activation. Additionally, the response to APAP differed greatly between genders. 
Males exhibited, on average, higher serum ALT levels, DILI scores and lower Nrf2-Luc 
bioluminescent signal when compared to APAP-treated females. It is widely accepted that 
male C57BL/6J mice are more susceptible than females to APAP-induced liver damage (Dai 
et al., 2006; McConnachie et al., 2007; Mohar et al., 2014). This is thought to be due to 
excessive GSH depletion and preferential adduction of mitochondrial Prdx6 in males (Mohar 
et al., 2014). While similar levels of NAPQI-mediated covalent binding were recorded 
between genders, female C57BL6-129/Sv mice exhibited slower metabolism of APAP, lower 
basal expression of CYP1a2 and lower induction of cyp1a2 and 3a11, along with GSTpi mRNA 
levels significantly lower than in males (Dai et al., 2006). Female Nrf2-Luc mice, on average, 
had stronger ex vivo liver bioluminescence than APAP-treated males. Rohrer et al. observed 
lower induction of hepatic Nrf2 in female mice compared to male mice following exposure 
to APAP (Rohrer et al., 2014). This may be due to the extensive damage seen in male liver 
tissue, resulting in depleted transgene activity.  
In response to cisplatin, renal bioluminescence was induced in female Nrf2-Luc mice. This 
was clearly evident in ex vivo analysis despite the muted in vivo signal due to skin 
pigmentation. Significantly elevated BUN levels confirmed nephrotoxicity in the cisplatin-
treatment group. This was proportional to the amount of luciferase and Hmox1 staining 
around the proximal tubules. As a chemotherapeutic, intercalation of cisplatin with DNA 
halts cellular proliferation, however, it primarily targets the S3 segment of the proximal 
tubule due to basolateral drug-transporters such as OCT2 which facilitate the accumulation 
of the drug within these cells (Hu et al., 2017). In order to avoid dark skin pigmentation, it 
would be necessary to cross the Nrf2-Luc strain into C57BL/6J albino mice. This would also 
reduce the duration of anaesthesia suffered by the mice as the signal may penetrate through 
the white hair, removing the need for shaving the mice prior to imaging.  
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While activation of renal Hmox1 was observed at the protein level, the Nrf2-regulated 
transcriptome did not significantly differ between cisplatin and saline treatment groups at 
96 h. Microarray analysis of WT C57BL6 mice exposed to 20 mg/kg cisplatin at 0, 24, 48 and 
72 h by Pelegrini  et al revealed Nrf2 pathway activation peaked at 24 h (Pellegrini et al., 
2014). BUN levels peak at 96 h post-cisplatin exposure, in many strains of mice, including 
C57BL6 (Parrish et al., 2009; Sharkey, 2013). Yet it is possible that 96 h is too late a time point 
to observe upregulation of Nrf2-regulated genes at the mRNA level, whereas protein levels 
such as Hmox1 remained significantly higher than in the vehicle control group.  
Further assessment in more detailed dose and time-course studies are required to reveal the 
sensitivity of the Nrf2-Luc reporter to subtle chemical/oxidative stress that are not 
associated with overt organ injury. Other applications of the OKD48 mouse model to study 
cerebral malaria (Imai et al., 2014) and periodontitis (Kataoka et al., 2016) highlight the 
tissue-specific expression of Hmox1 coincides with bioluminescent signal. This is similar to 
our findings. The latter study assessed luminescence over seven days. The ability of the Nrf2-
Luc model to monitor chronic exposure to oxidative insult may render it useful for monitoring 
adaptation in the context of chronic dosing.  
Many probes exist for the real-time, in vivo detection of ROS during hepatocellular injury 
from APAP. Shuhender et al. utilize CF-SPN nano-probes, for the detection of ROS and OONO- 
s, to show in real-time the inhibition of APAP associated hepatotoxicity by ABT, GSH and the 
CYP2E1 inhibitor trans-1,2-dichloroethylene (Shuhendler et al., 2014). Vasquez et al. 
generated near-infra red imaging probes to monitor cell death (Annexin-Vivo 750), 
inflammation (MMPSense-750-FAST) and metabolism (Transferrin-Vivo 750) which were 
stimulated following 18-22 hours exposure to 300 mg/kg APAP in C57BL6 mice (Vasquez and 
Peterson, 2017). These probes are administered to mice prior to imaging and react either 
with ROS entities themselves or downstream pathways induced by oxidative damage. 
Advantages of the use of probes compared to transgenic mice include the use of WT mice, 
avoiding the necessity of extensive breeding programs that require large numbers of 
animals. Probes are also more sensitive to temporal changes in ROS than the delayed 
transcription of the Nrf2-Luc transgene. However, redox-sensitive probes cannot inform on 
the biological response to ROS, only their presence.  
Other bioluminescent Nrf2-based reporter models have been utilised for measuring 
responses to drug toxicity, including the Hmox1-Luc mice (Malstrom et al., 2004b). This 
transgenic reporter consists of the Hmox1 promotor region controlling the expression of 
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firefly luciferase and responded to toxic exposure to cadmium chloride, doxorubicin and 
thioacetamide (Malstrom et al., 2004b). Bioluminescence correlated with endogenous 
Hmox1 induction. However, Hmox1 expression is repressed by Bach1 and regulated by  many 
other transcription factors (Alam and Cook, 2007b; Fuse et al., 2015; Sun et al., 2014). 
Therefore, activation of the pathway may be missed when relying solely on the Hmox1 
promotor or produce false positives when activation is driven by other transcription factors.  
McMahon et al. generated a Hmox1 reporter model consisting of multiple reporter 
molecules including a β galactosidase, human chorionic gonadotrophin (hCG) and firefly 
luciferase, all under the control of the endogenous Hmox1 promotor (McMahon et al., 2018). 
Exposure of heterozygous reporter mice to BHA activated hepatic Nqo1, Gsta1 and Gstm1 at 
the protein level but not Hmox1 or the luminescent reporter after 96 h exposure. Dissimilar 
to our findings, treatment with APAP did not produce a significantly different luminescent 
response compared to the saline treatment group after 24 h. This is likely due to the lack of 
repeated ARE sequence, facilitating amplification of the endogenous transcription factor 
activation.  
Unlike other lines of transgenic mice established with a reporter construct under the 
transcriptional control of an ARE (Johnson et al., 2002; Zhang et al., 2001b), the Nrf2-Luc 
model offers insight into the induction of Nrf2 in response to toxicity in a non-invasive 
manner. As such, our studies entailed a detailed analysis of Nrf2 activity in real time and a 
substantial reduction in number of animals required, complying with the current 3R’s 
guidelines. This allows multiple measurements to be collected throughout a study instead of 
relying on end-point analysis, directed at specific tissues.I propose the utility of this model 
would be best served within the latter stages of pre-clinical testing rather than as an initial 
screening tool. Further assessment is needed to identify the sensitivity of the model to other 
DILI training compounds. The apparent embryo lethality of the homozygote Nrf2-Luc mice is 
a substantial limitation of the model as half to a third of each litter is wild-type and unusable. 
This lethal recessive phenotype may be due to the location of the transgene, disrupting vital 
gene function and further characterisation of the transgene locus within the Nrf2-Luc mice 
genome is needed.  
In conclusion, Nrf2-Luc mice offer a novel insight into the activation of Nrf2 during the early 
stages of chemical stress associated with organ-specific drug toxicity. In response to acute 
hepato- and renal-toxicity, bioluminescent signal coincided with the cell-specific response to 
insult. This model provides holistic visualisation of chemical/oxidative stress resulting in the 
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evocation of the Nrf2-mediated stress response. Incorporation of the model into pre-clinical 
testing may aid the identification of toxic liabilities. In light of the emerging role of Nrf2 as a 
therapeutic target by drugs such as CDDO-Me, the utility of the Nrf2-Luc mice to screen 
therapeutic compounds would also be of interest.  
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Blood-based analysis of Nrf2 pathway activity 
  
Chapter 3 
106 
 
Contents 
3.1. Introduction ............................................................................................................. 107 
 
3.2. Methods ................................................................................................................... 108 
3.2.1. Animals ..................................................................................................................... 108 
3.2.1.1. Whole blood analysis studies ....................................................................... 108 
3.2.2. Histology .................................................................................................................. 108 
3.2.3. RNA extraction, cDNA synthesis and qPCR .............................................................. 109 
3.2.4. ALT quantification .................................................................................................... 110 
3.2.5. Statistical analysis .................................................................................................... 110 
 
3.3. Results ...................................................................................................................... 111 
3.3.1. Validation of organ-specific qPCR primers............................................................... 111 
3.3.2. Blood-based analysis of Nrf2-pathway response to APAP....................................... 115 
3.3.3. Blood-based analysis of Nrf2-pathway following intervention of APAP Toxicity .... 119 
3.3.4. Blood-based analysis of Nrf2-pathway response to therapeutic Nrf2 stimulation . 125 
 
3.4. Discussion ................................................................................................................ 131 
 
 
  
Chapter 3 
107 
 
3.1. Introduction  
The emerging role of Nrf2 as a therapeutic target and in the response to drug toxicity have 
resulted in the establishment of numerous approaches to monitor activation of the Nrf2 
pathway in cells and tissues. The work in Chapter 2 demonstrates the use of transgenic Nrf2-
Luc mice for monitoring in vivo Nrf2 response in real-time, through bioluminescent imaging. 
However, at present there is a lack of non-invasive methods for measuring Nrf2 activity in 
wild-type animals in vivo or in patients.  
Recently, interest in the circulating transcriptome as a source of potential medical 
biomarkers has grown. For example, cell-free mRNA has provided a wealth of biomarkers for 
the diagnosis and prognosis of cancer therapies (García et al., 2008; Silva et al., 2007). 
Albumin mRNA can be used to assess hepatic complications in patients following liver 
transplant (Chan et al., 2013) and hepatocellular carcinoma recurrence (Cheung et al., 2008). 
Small, regulatory molecules known as microRNAs (miRNAs) are also detectable in plasma 
(Mitchell et al., 2008) and hold potential as non-invasive biomarkers for a range of diseases 
(Chen et al., 2008; Nielsen et al., 2012; Wang et al., 2010). Following DILI, miR-122 has been 
shown to be more sensitive to hepatotoxicity than ALT and AST (Antoine et al., 2013; Starkey 
Lewis et al., 2011). Toxicogenomic profiling following DILI highlighted the rapid gene 
expression changes in blood compared with classical markers of liver injury (Bushel et al., 
2007). However, analysis of blood-based mRNA expression is limited, mostly to studies in 
rats (Bushel et al., 2007; Lobenhofer et al., 2008). Moreover, a specific investigation of the 
response of the blood mRNA complement to stimulation of the Nrf2 pathway has not been 
performed.  
The ability to monitor Nrf2 activity in the blood may provide insight to the 
pharmacodynamics of Nrf2 modulating compounds and evidence for the role of Nrf2 in 
response to drug toxicity in humans. In this chapter, I assess the utility of murine whole blood 
to monitor Nrf2 activation. Following, exposure to APAP, APAP and N-acetyl cysteine (NAC), 
or the Nrf2 activator CDDO-Me, I ask whether whole blood can reflect toxicological and 
pharmacological changes in the Nrf2-pathway in vivo.  
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3.2. Materials and Methods 
 
3.2.1. Animals  
All mice used in these studies were wild-type male C57BL6 mice aged 8- to 10-week-old or 
8-week-old BALB/c mice purchased from Charles River (Wilmington, USA). These were 
maintained under the same conditions described in section 2.2.1. 
3.2.1.1. Whole blood analysis studies 
Firstly, mice were fasted for 16 h and exposed to 300 mg/kg APAP or 0.9 % saline by IP 
injection (See section 2.2.1).  At 6 and 24 h the mice were culled with a rising concentration 
of CO2. Blood was collected by cardiac puncture and 100 µl added to RNAprotect tubes 
(Qiagen, Hilden, Germany). Each tube was inverted 8 times before being stored in the fridge. 
The rest of the blood was placed in a separate Eppendorf and left to clot at room 
temperature for 30 min. Serum was isolated by centrifugation at 2000 g for 10 min and 
stored at -80 °C. The liver and kidneys were snap frozen in liquid nitrogen and stored at -80 
°C. 
In the second study, fasted mice were exposed to either APAP or saline at 0 h, using the same 
method applied in the first study. Subsequent IP injections of either 500 mg/kg NAC or 0.9 % 
Saline were administered at 1 and 12 h post-APAP dosing. NAC at this dosage abrogates APAP 
hepatotoxicity in the short term (Lundbäck et al., 2016). Mice were culled at 24 h with a rising 
concentration of CO2 and blood and tissue were collected, as above.  
The third study comprised of mice exposed to 10 mg/kg CDDO-Me or 100 % DMSO via IP 
injection. This dose was shown previously to be tolerable and activate the Nrf2 pathway 
(Shelton et al., 2015; Walsh et al., 2014). Mice were culled with a rising concentration of CO2 
at 6 and 24 h. Blood and tissue were collected as above.  
As repeated exposure is more likely in the clinic (Hong et al., 2012), in the fourth study, mice 
were exposed to three doses of DMSO or CDDO-Me. At 0, 72 h and 144 h (day 3 and 6), 
Balb/c mice were administered either 3 mg/kg CDDO-Me or 100 % DMSO via IP injection. At 
this dose, CDDO-Me has been shown to activate the Nrf2 pathway after 24 h by ITRAQ 
analysis in C57BL6 mice (Walsh et al., 2014). Mice were culled with a rising concentration of 
CO2 at 150 and 172 h (6 and 28 h after the final dose).  
3.2.2. Histology  
See section 2.2.6. DILI scoring criteria listed in Table 2.2.  
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3.2.3. RNA extraction, cDNA synthesis and qPCR  
RNA was extracted from the whole blood using the RNeasy Protect Animal Blood Kit (Qiagen, 
Hilden, Germany). RNAprotect tubes, containing 100 µl whole blood, were left at room 
temperature overnight to increase RNA yield.  The blood was centrifuged at 5000 g for 3 min 
and the supernatant was discarded. The pellet was vortexed in 1 ml RNAse-free water and 
pelleted at 5000 g for 3 min. The supernatant was discarded and the pellet was vortexed in 
240 µl buffer RSB until dissolved. This solution was added to 200 µl RBT buffer and 20 µl 
Proteinase K and incubated for 10 min at 55 °C in a shaker-incubator at 800 rpm. The solution 
was added to a QIAshredder column (Qiagen, Hilden, Germany) and centrifuged at 18 000 g 
for 3 min. The flow through was added to 240 µl of 100 % ethanol and vortexed.  
The solution was added to an RNeasy MinElute spin column, which was placed above a 2 ml 
collection tube and centrifuged for 1 min at 8000 g. The column was washed with 350 µl 
buffer RW1 and centrifuged at 8000 g for 15 sec. On column DNase digestion was performed 
using 10 µl DNase 1 stock solution and 70 µl RDD buffer. The columns were incubated at 
room temperature for 15 min and 350 µl RW1 buffer was added before being centrifuged at 
8000 g for 15 sec. The column was centrifuged in a similar manner after the addition of Buffer 
RPE. A solution of 80 % (v/v) ethanol in dH2O was generated and 500 µl added to the column 
before being centrifuged at 8000 g for 2 min. The column was placed in a new 2 ml collection 
tube and centrifuged at 18 000 g for 5 min with the lid of the column open to dry the 
membrane. RNA was eluted in 30 µl REB buffer by centrifugation at 8000 g for 1 min and the 
yield was quantified using the Nanodrop.  
RNA extraction from tissue was conducted in a similar manner to section 2.2.9.  
For reverse transcription and SYBR green qPCR analysis see section 2.2.9. Additional qPCR 
primers for murine genes are detailed in Table 3.1. Gene expression quantified in 96 well-
plate format normalising Ct values to GAPDH levels.   
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Table 3.1 Additional Mouse qPCR primers  
Gene Primer Sequence 
Ambp 
Fwd 5’ AAGAGAGTGAGGGGTCAG 3’ 
Rev 5’ CAGGGGCCTTCTGAGTAAT 3’ 
Apoa2 
Fwd 5’ CACAGAATCGCAGCACTGTTC 3’ 
Rev 5’ GCTCCTTCCAGGCTACAGAT 3’ 
Aqp2 
Fwd 5’ GGTTGCCATGTCTCCTT 3’ 
Rev 5’ CGGATTTCTACAGGGGTA 3’ 
Nphs2 
Fwd 5’ CGGTCCATAGCGTTCT 3' 
Rev 5’ AGCCAAGGCCAAAGAA 3' 
 
3.2.4. ALT quantification  
See section 2.2.3. 
3.2.5. Statistical analysis  
See section 2.2.10. 
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3.3. Results  
3.3.1. Validation of organ-specific qPCR primers 
Liver- and kidney- specific primers were designed to assess the levels of tissue-specific genes 
in whole blood following liver damage (Fig 3.1 A, B, C and D) (sequences listed in Table 3.1). 
The liver-specific α-1-microglobulin/bikunin precursor (Ambp) has been shown to circulate 
in blood following APAP exposure and treatment with other hepatotoxic compounds in rats, 
concurrently with ALT (Miyamoto et al., 2008; Okubo et al., 2013). Additionally, elevated 
Apolipoprotein A2 (Apoa2) has been recorded in plasma of C57BL6 mice following APAP 
administration (K. Wang et al., 2013). GTEx, Illumina, BioGPS, and CGAP SAGE datasets, 
collated in the Genecards database, indicated tissue specific expression of these transcripts. 
Both Podocin (Nphs2) and aquaporin 2 (Aqp2) are exclusively expressed in the kidney. None 
of these genes have been reported to be regulated by Nrf2.  
The tissue specificity of the genes was validated in livers and kidneys from mice exposed to 
0.9 % saline for 24 h (Fig 3.1 E and F). In the livers, Ct values of liver-specific genes were much 
lower than kidney-specific genes. In the kidneys, Ct values of kidney-specific genes were 
lower than liver-specific Ct values. When normalised to housekeeping gene expression, ΔCt 
values of organ-specific primers were lower in the tissue of origin indicating higher 
expression and tissue specificity. 
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A.
B.
Alpha-1-Microglobulin/Bikunin Precursor (AMBP)
Apolipoprotein A2 (APOA2)
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C.
D.
Podocin (NPHS2)
Aquaporin 2 (AQP2)
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Figure 3.1 – Validation of organ specific primers  
Screenshots from http://www.genecards.org of liver–specific Alpha-1-
Microglobulin/Bikunin Precursor (Ambp) (A) and Apolipoprotein A2 (Apoa2) (B), and kidney-
specific Podocin (Nphs2) (C) and aquaporin 2 (Aqp2) (D) gene expression. Data based on 
GTEx, Illumina, BioGPS, and CGAP SAGE datasets. Cts and ΔCts from qPCR analysis of mouse 
liver (E) or kidney (F) lysates from animals exposed to 0.9 % saline for 24 h shown as mean ± 
SD (n=5).  
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3.3.2. Blood-based analysis of Nrf2-pathway response to APAP  
To investigate the response of the blood-based Nrf2 pathway following liver injury, whole 
blood samples were taken from mice exposed to a single dose of 300 mg/kg APAP.  In these 
mice, serum ALT was significantly elevated at 6 and 24 h compared to their saline-treated 
counterparts (Fig 3.2 A) (P = 0.0343 and 0.0013 respectively). This coincided with activation 
of the Nrf2 pathway in liver tissue (Fig 3.2 B). Hmox1, Srxn1 and Gsta1 expression were all 
significantly induced at 6 h (All p values <0.0001) compared to the 6 h saline-treatment 
group. Gsta1 expression remained significantly elevated at 24 h (P = 0.0002). Liver-specific 
genes AMBP and APOA2 were not significantly induced at either time-point.  
In the kidneys, activation of the Nrf2-pathway activity was evident at 6 h (Fig 3.2 C) with 
Hmox1 and Srxn1 significantly upregulated (P = <0.0001 and 0.0339). However, these fold 
changes were lower than those observed in the liver at 6 and 24 h.  Kidney-specific genes 
Nphs2 and Aqp2 were not induced at either time-point. 
Whole blood qPCR analysis revealed significantly elevated Gsta1 levels in the APAP-treated 
mice at 24 h compared to the saline treatment group (Fig 3.2 D) (P = <0.0001). Hmox1 
expression increased after 24 h exposure, but varied considerably between mice.  
To test the hypothesis that Nrf2-regulated mRNA was present in whole blood as a result of 
release into circulation following cell damage, liver- and kidney- specific gene expression was 
measured in the whole blood samples. At 24 h, liver-specific ΔCts in the APAP-treated mice 
were significantly lower than time-matched vehicle controls (Fig 3.3) (Both Ambp and Apoa2 
P values <0.001). The expression levels of kidney-specific genes did not differ between 
treatment groups and ΔCts were large in all cases. However, there was considerable 
variability within groups. Therefore, elevated Nrf2-regulated gene expression in whole blood 
coincides with release of liver-specific mRNA into circulation, following APAP-induced liver 
damage.  
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Figure 3.2 Induction of Nrf2 pathway in whole blood following a toxic dose of paracetamol 
Male C57BL6 mice were administered either 0.9 % Saline or 300 mg/kg acetaminophen 
(APAP) by IP injection (n=5). Blood was collected by cardiac puncture at 6 and 24 h. (A) Serum 
ALT levels were significantly different between saline and APAP treatment groups. qPCR 
analysis of gene expression in murine livers (B), kidneys (C) and whole blood (D) showing 
activation of Nrf2-regulated genes. Significant difference in ALT levels and gene expression 
compared to time-matched saline treatment groups were calculated by one-way ANOVA and 
Kruskal Wallis (* P ≤ 0.05, **P ≤ 0.01 and *** P ≤ 0.001) (Dotted line = 100 %).  
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Figure 3.3 – Increased liver-specific gene expression in whole blood of paracetamol-treated 
mice 
ΔCts of liver-specific genes (Ambp and Apoa2) compared to kidney-specific gene (Nphs2 and 
Aqp2) in whole blood for mice exposed to 0.9 % saline or 300 mg/kg acetaminophen (APAP) 
for 6 and 24 h. Mean ΔCt ± SD shown. Significance between time-matched APAP and Saline 
treatment groups were calculated by one-way ANOVA (*** P ≤ 0.001). 
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3.3.3. Blood-based analysis of Nrf2-pathway following intervention of APAP Toxicity  
To ascertain whether changes in the whole blood levels of Nrf2-regulated genes were 
proportional to liver damage, APAP-treated mice were administered two doses of NAC at 1 
and 12 h. In mice administered this intervention, there was significantly lower serum ALT 
activity (Fig. 3.4) (P = <0.0001). Histological analysis revealed pericentral necrosis in the 
APAP-treated mice (Fig 3.5 A). Hmox1 staining was also present in the region surrounding 
the portal vein. Compared to the APAP + Saline treatment group, necrosis and Hmox1 
staining was muted in the APAP + NAC treated tissues. DILI scoring of liver tissue was 
proportional to serum ALT (Fig 3.5 B). Four of the five livers of APAP + NAC treated mice had 
a DILI score of between 0-1, while one mouse exposed to APAP+NAC presented with higher 
serum ALT and a DILI score of 1-2. In the APAP + Saline treatment group, all mice scored 
between 1-2.  
The hepatic Nrf2-pathway was upregulated in the APAP + Saline and the APAP + NAC treated 
mice (Fig 3.6 A). When compared to saline-treated mice, Srxn1 and Gsta1 were upregulated 
significantly in the livers of APAP-treated mice (P = 0.019 and <0.0001). Gsta1 was also 
significantly elevated in the APAP + NAC treatment group (P = 0.216). Nqo1 was elevated in 
these groups but not significantly. Hmox1 expression was elevated in the APAP-treated mice 
but not APAP + NAC treated mice. Gsta1 expression was significantly reduced in the APAP + 
NAC treated livers compared to the APAP + Saline treatment group (P = <0.0001). Expression 
of liver-specific genes Ambp and Apoa2 did not differ significantly in APAP + Saline or APAP 
+ NAC treatment-groups compared to controls.  
In the kidneys, Nqo1 and Gsta1 were significantly induced in the APAP-treated mice when 
compared with the saline treatment group (Fig 3.6 B) (P = <0.0001 and 0.0493 respectively). 
Nqo1 expression was significantly reduced in the kidneys of APAP + NAC treated mice, when 
compared to the APAP + Saline treatment group (P = <0.0001). There was little difference in 
expression of the other genes across treatment groups. Expression of kidney-specific genes 
Nphs2 and Aqp2 did not differ between groups.   
Analysis of whole blood revealed significant induction of Hmox1 in the APAP-treated mice 
compared to the vehicle control group (Fig 3.6 C) (P = 0.0002) and APAP + NAC treatment 
group (P = 0.0108). Hmox1 was elevated in whole blood from the APAP + NAC treatment 
group but this was not significant when compared to expression in saline treated mice. Gsta1 
expression was very variable in the APAP + Saline treated mice and to a lesser extent in the 
APAP+NAC treated mice.  
Chapter 3 
120 
 
Organ-specific gene expression in whole blood from this study, again was extremely variable 
(Fig 3.6 D). However, the mean ΔCt values for liver-specific genes in the APAP + Saline group 
were lower (AMBP: 5.55 and APOA2: 3.56) than the mean ΔCt in the APAP+NAC (AMBP: 8.10 
and APOA2: 5.86) and control treatment groups. While not significant, this indicates a trend 
towards lower ΔCts in liver-specific gene expression in the APAP + Saline group indicative of 
the release of liver-specific genes into the circulation being proportional to the degree of 
liver injury. Kidney-specific ΔCts did not vary between groups. Therefore, damaged 
hepatocytes remain a potential source of the Nrf2-regulated mRNA in whole blood, as 
expression levels were relative to the extent of perturbation.   
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Figure 3.4 – Muted elevation of serum alanine transaminase in response to N-
acetylcysteine exposure following paracetamol toxicity  
Male C57BL6 mice were administered either 0.9 % Saline or 300 mg/kg acetaminophen 
(APAP) by IP injection (n=5) at 0 h. At 1 and 12 h exposure, mice were administered 500 
mg/kg N-acetylcysteine (NAC) or 0.9 % Saline. Blood was collected by cardiac puncture at 24 
h and serum ALT levels quantified. Significant difference between treatment groups were 
calculated by one-way ANOVA (*** P ≤ 0.001).  
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Figure 3.5 – Muted necrosis and Hmox1 staining in mice administered N-acetylcysteine in response to paracetamol toxicity  
Male C57BL6 mice were administered either 0.9 % Saline or 300 mg/kg acetaminophen (APAP) by IP injection (n=5) at 0 h. At 1 and 12 h post-APAP exposure, 
mice were administered 500 mg/kg N-acetylcysteine (NAC) or 0.9 % Saline. All groups were culled after 24 h. (A) Sections of the central hepatic lobule were 
stained with H&E and probed for Hmox1. Necrosis surrounding the central vein (black arrow) is shown in the light pink staining of the H&E treated sections. 
Hmox1 staining was also present in the pericentral region. (B) Extent of necrosis is proportional to drug induced liver injury (DILI) score and alanine 
transaminase (ALT) levels.  
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Figure 3.6 – Gene expression in tissues and whole blood from mice treated with 
paracetamol and N-acetylcysteine   
Male C57BL6 mice were administered either 0.9 % Saline or 300 mg/kg acetaminophen 
(APAP) by IP injection (n=5) at 0 h. At 1 and 12 h exposure, mice were administered 500 
mg/kg N-acetylcysteine (NAC) or 0.9 % Saline. Blood was collected by cardiac puncture at 24 
h. qPCR analysis of gene expression in murine livers (A), kidneys (B) and whole blood (C) 
highlighted activation of Nrf2-regulated genes (Dotted line = 100 %). (D) ΔCts of liver-specific 
gene (Ambp and Apoa2) compared to kidney-specific gene (Nphs2 and Aqp2) expression in 
whole blood samples. Mean ΔCt ± SD shown. Significant difference in gene expression 
compared to Saline + Saline group (* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001) or APAP + Saline 
compared to APAP + NAC (@ p ≤ 0.05 and @@@ p ≤ 0.001) were calculated by one-way 
ANOVA and Kruskal Wallis.  
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3.3.4. Blood-based analysis of Nrf2-pathway response to therapeutic Nrf2 stimulation 
Following administration of CDDO-Me, hepatic Srxn1 expression was significantly elevated 
after 6 and 24 h, when compared to time-matched DMSO-treated counterparts (Fig 3.7 A) (P 
= <0.0001 and 0.0066 respectively). Nqo1 and Gsta1 were significantly elevated in the livers 
of CDDO-Me-treated mice after 24 h exposure, compared to the DMSO-treatment group 
(Both P values <0.0001). Liver-specific gene expression did not differ between groups 
In the kidneys of CDDO-Me-treated mice, Nqo1, Hmox1 and Srxn1 were induced significantly 
at 6 h (Fig 3.7 B) (P = 0.0008, 0.0008 and <0.0001 respectively). Nqo1 and Srxn1 gene 
expression was also significantly greater than the DMSO-treated mice at 24 h (P = <0.0001 
and 0.0154). In general, the induction of Nrf2-regulated genes was lower in kidneys than in 
the liver. Expression of kidney specific genes Nphs2 and Aqp2 did not change at either time-
point.   
Whole blood qPCR analysis revealed significant elevation of Srxn1 and Gsta1 in CDDO-Me-
treated mice after 24 h exposure compared to the DMSO-treatment group (Fig 3.7 C) (P = 
0.0453 and 0.0001 respectively). Consistent with a lack of tissue damage, liver- and kidney-
specific ΔCt values in whole blood from mice exposed to CDDO-Me or DMSO showed no 
significant differences but varied greatly within treatment groups (Fig 3.7 D).   
To recapitulate repeated exposure to CDDO-Me, as seen in the clinic (Ongoing trials include 
CATALYST (NCT02657356), and LARIAT (NCT02036970)), BALB/c male mice were exposed to 
three consecutive 3 mg/kg doses via IP injection. Hepatic Nrf2-pathway induction was 
evident at 6 h after the final dose of CDDO-Me (Fig 3.8 A), with significant induction of Srxn1 
and Gsta1 compared to time-matched DMSO-treated mice (P = <0.0001 and 0.0193 
respectively). Nqo1, Srxn1 and Gsta1 were significantly upregulated 28 h after the final dose 
of CDDO-Me (All p <0.0001). Induction of the Nrf2 pathway in livers following chronic 
exposure to CDDO-Me was less than the fold changes measured after a single dose of CDDO-
Me (Fig 3.7 A). However, variability within treatment groups was reduced.  
Renal Nrf2 pathway activity was induced at 6 h after the final dose of CDDO-Me (Fig 3.8 B), 
with significantly greater levels of expression of Nqo1, Hmox1, Srxn1 and Gsta1 compared to 
the time-matched DMSO-treatment group (P = 0.014, <0.0001, <0.0001 and 0.0175 
respectively). At 28 h after the final dose of CDDO-Me, both Nqo1 and Gsta1 were 
significantly induced (All P <0.0001).   
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Whole blood qPCR analysis revealed variable changes in Nrf2-regulated genes within 
treatment groups (Fig 3.8 C). Elevations of Nrf2-regulated transcripts were observed after 6 
h although variability within groups resulted in these changes not being significantly different 
from time-matched DMSO-treated controls. ΔCts of organ-specific genes were also 
extremely variable between individual mice (Fig 3.8 D). Aside from the variability within 
groups, this data highlights the activation of Nrf2-regulated gene expression in whole blood 
following therapeutic induction in mice exposed to CDDO-Me.  
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Figure 3.7 Induction of Nrf2 pathway in tissues and whole blood by CDDO-Me  
qPCR analysis of gene expression in the livers (A), kidneys (B) and whole blood (C) of male 
C57BL6 mice, exposed to either 100 % DMSO or 10 mg/kg CDDO-Me by IP injection for 6 or 
24 h (n=5 animals) (Dotted line = 100 %). (D) ΔCts of liver-specific gene (Ambp and Apoa2) 
compared to kidney-specific gene (Nphs2 and Aqp2) in whole blood samples. Mean ΔCt ± SD 
shown. Significant differences in gene expression compared to time-matched DMSO 
treatment groups were calculated by one-way ANOVA and Kruskal Wallis test (* P ≤ 0.05 and 
*** P ≤ 0.001)   
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Figure 3.8 Upregulation of the Nrf2 pathway in response to chronic exposure to CDDO-Me  
qPCR analysis of gene expression in the livers (A), and kidneys (B) and whole blood (C) of 
male BALB/c mice, exposed to three doses of either 100 % DMSO or 3 mg/kg CDDO-Me by 
IP injection over the course of 6 days (n=5 animals). Tissues were collected 6 or 28 h after 
the final dose of CDDO-Me (Dotted line = 100 %). (D) ΔCts of liver-specific gene (Ambp and 
Apoa2) compared to kidney-specific gene (Nphs2 and Aqp2) expression in whole blood 
samples. Mean ΔCt ± SD shown. Significant differences in gene expression compared to time-
matched DMSO treatment groups were calculated by one-way ANOVA (* P ≤ 0.05 and *** P 
≤ 0.001).   
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3.4. Discussion  
In this chapter, I analysed activity of the Nrf2 pathway, in vivo, in whole blood following 
toxicological and pharmacological stimulation. Induction of Nrf2-regulated transcripts in 
response to APAP exposure, was muted in mice administered NAC, the antidote to APAP 
toxicity. This coincided with reduced liver-specific but not kidney-specific transcripts in whole 
blood. Following exposure to the therapeutic Nrf2-inducing compound CDDO-Me, murine 
whole blood exhibited variable induction of Nrf2-regulated mRNA. Further analysis into the 
expression patterns within the sub-components of whole blood may shed light on the source 
and potential function of these RNA molecules.  
Previously, extensive toxicogenomic profiling of blood following DILI in rats has showed that 
gene expression changes in blood preceded elevation of classical markers of liver injury 
(Bushel et al., 2007; Lobenhofer et al., 2008) and that these transcripts can accurately predict 
extent of toxicity, mirroring ALT level (J. Huang et al., 2010; Zhang et al., 2012). In this 
chapter, APAP exposure resulted in significant induction of both the renal and hepatic Nrf2 
pathway after 6 h. However, significant activation of the pathway in whole blood was only 
evident after 24 h exposure, alongside induction of liver-derived transcripts Ambp and 
Apoa2. This coincides with the findings of Umbright et al. who showed that many genes 
upregulated in the rat liver following APAP-induced damage, were also upregulated in the 
blood (Umbright et al., 2010). Microarray analysis of RNA from leukocytes, isolated from rats 
administered APAP, highlighted induction of Nrf2-regulated genes Thioredoxin reductase 1 
(Txnrd1), Peroxiredoxin 5 (Pdrx5) and Nqo1. In an earlier study, Prdx5 was induced over two-
fold and Srxn1 showed a 21-fold increase in plasma from rats following APAP-induced 
hepatotoxicity (Wetmore et al., 2010). In addition to elevated Nrf2-regulated mRNA, liver-
specific transcripts were only increased with hepatotoxicant exposure, APAP or D-
galactosamine, and not myotoxic doses of bupivacaine HCl. Next-generation sequencing of 
total RNA from plasma of female C57Bl6 mice exposed to 350 mg/kg APAP revealed changes 
in the levels of 1459 transcripts within plasma – the majority of which were increased 
following APAP overdose (K. Wang et al., 2013). Comparable to our findings, Wang et al. 
observed elevated Gsta1 alongside glutathione reductases and synthetases in the liver at 24 
h post-APAP administration. Apoa2 was identified as one of the 5493 transcripts present in 
both liver and plasma.  
Loss of hepatic GSH-dependent enzymes such as GSTA1 in Nrf2 KO mice result in the strain’s 
sensitivity to chemical stressors (Chanas et al., 2002). In humans, liver necrosis associated 
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with hypertension resulted in elevated GSTA1 protein levels in plasma (Knapen et al., 1998). 
Omics profiling of blood and urine from healthy human volunteers after oral administration 
of 4 doses of APAP in the form of two 500 mg tablets every 6 h over 24 h (resulting in a total 
dose of 4 g) lead to upregulation of transcripts associated with the oxidative stress response 
25 h after the first dose (Jetten et al., 2012). Glutathione-S-transferases such as GSTM3 
mRNA were elevated in whole blood compared to 0 h samples, although expression varied 
between donors. Fannin et al. also observed distinct transcriptional gene expression 
signatures in peripheral blood from six healthy volunteers exposed to a single dose of 4 g 
APAP compared to the placebo-treated control group (Fannin et al., 2010). After 48 h, down-
regulation of genes associated with oxidative phosphorylation were observed in the APAP-
treatment group. However, out of the 795 differentially expressed genes, Nrf2 pathway 
activity was not observed. The authors reported greater variability in gene expression 
patterns within the earlier 24 h time-point. Larger cohort analysis is needed to avoid skewed 
datasets from variable populations. Additionally, insight into expression patterns in the 
peripheral tissues of APAP-treated patients may inform mechanisms underlying toxicity. 
Circulating RNA can originate from a variety of sources. Passive release of mRNA into 
circulation can occur during tissue necrosis (Wetmore et al., 2010). Active secretion of mRNA 
transcripts has been documented in association with exosomes, microvesicles and apoptotic 
bodies (Halicka et al., 2000; Skog et al., 2008; Valadi et al., 2007). In this chapter, qPCR 
analysis highlighted significantly increased levels of liver-specific genes (Ambp and Apoa2) in 
whole blood samples compared to time-matched, saline-treated controls. Kidney-specific 
gene expression (Nphs2 and Aqp2) remained low across treatment groups. This highlights 
the presence of liver-specific and NRF2-regulated transcripts in whole blood after 24 h 
exposure to APAP that may be derived from damaged hepatocytes following DILI.  
Bioactivation of APAP to NAPQI occurs in the liver, however reactive metabolites may 
migrate into circulation. Radioactively-labelled APAP exposure led to dose-dependent 
radioactive labelling of haemoglobin alongside hepatic and renal proteins in mice (Axworthy 
et al., 1988). The authors surmised that these effects were due to migration of reactive 
metabolites from the liver to erythrocytes, and not direct alkylation of haemoglobin by APAP 
within erythrocytes, due to the similarity of the dose-response curves of APAP binding to 
liver proteins and haemoglobin, and the fact that activation of cytochrome P450 enzymes, 
via IP administration of phenobarbital or 3-methylcholanthrene, did not alter the ratio of 
haemoglobin- to liver protein-adducts. Interestingly, APAP overdose in cats and dogs causes 
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haemolysis and methaemoglobinemia due to the generation of the deacetylation product of 
APAP: p-aminophenol by erythrocytes (McCONKEY et al., 2009). Inactive forms of NAPQI 
have been detected in circulation as cysteine conjugates (Muldrew et al., 2002) or bound 
covalently to proteins. For instance, NAPQI-albumin adducts have been detected at low 
levels in serum from mice exposed to APAP (Switzar et al., 2013). In vitro, increased protein 
content of culture medium has been observed following exposure of PHHs to NAPQI (McGill 
et al., 2013). This indicates the potential for NAPQI itself being released into circulation 
alongside APAP-protein adducts. Mass spectrometric analysis of NAPQI and its conjugated 
forms would shed light on the potential for the induction of the Nrf2 pathway in whole blood 
to be the result of effects in blood cell, themselves. 
To assess the hypothesis that the increase of Nrf2-regulated genes within whole blood is 
proportional to extent of hepatotoxicity and thus more likely to be the result of mRNA 
leaking from damaged hepatocytes, mice were administered APAP and the antidote, NAC. 
Intervention of APAP toxicity, by repeated exposure to NAC, resulted in reduced pericentral 
necrosis and co-localised Hmox1 staining. In the liver, GSTA1 and in the kidneys, NQO1 
expression was reduced significantly after 24 h. Interestingly, reduced Nrf2 pathway activity 
was also identified in the whole blood of mice exposed to both APAP and NAC. Circulating 
miRNA levels rapidly decline in APAP overdose patients receiving NAC therapy (Krauskopf et 
al., 2015; Ward et al., 2014). However, little is known about the modulation of circulating 
mRNA following exposure to NAC. Here, liver-specific mRNA transcripts were reduced in 
whole blood from mice exposed to APAP and NAC compared to mice treated with APAP and 
saline. Complete suppression of Nrf2-regulated gene induction was not expected due to the 
1 h delay in NAC treatment, following exposure to APAP. However, further analysis is needed 
to confirm that the liver is the source of these Nrf2-regulated transcripts and to identify the 
mechanism of mRNA release in response to APAP toxicity.  
Evidence suggests that exosomal shuttling of RNA can confer protection in recipient cells 
following oxidative stress (Eldh et al., 2010). Nrf2-regulating miRNAs have been detected 
within exosomes extracted from serum of rats experiencing chronic heart failure, that were 
not present in sham controls (Tian et al., 2017). Overexpression of these miRNAs in 
cardiomyocytes in vitro resulted in downregulation of Nrf2, consistent with observations of 
Nrf2 downregulation in murine models of heart failure. This raises the question of whether 
functional Nrf2-transcripts are actively secreted into circulation following liver injury. 
Without thorough characterization of exosomes derived from hepatocytes following DILI one 
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cannot confirm Nrf2 pathway activation was due to Nrf2-mRNA cargo within exosomes or 
other vesicles. Further analysis of exosomal content may confirm the presence of Nrf2-
activating and/or Nrf2-regulated mRNA released in response to APAP toxicity.   
Aside from liver-derived exosomes, Nrf2 transcripts can be actively expressed by cells 
circulating within whole blood. Hematopoietic cells, including lymphocytes, dendritic and 
mast cells secrete exosomes (Blanchard et al., 2002; Skokos et al., 2001; Théry et al., 2001). 
Additionally, platelet-derived extracellular vesicles are secreted in response to agonists such 
as thrombin and lipopolysaccharide (LPS) (Aatonen et al., 2014). Ex vivo analysis of peripheral 
blood mononuclear cells (PBMCs) in culture highlight their sensitivity to Nrf2 modulation. For 
example, during the first in human trial of CDDO-Me, PBMCs isolated from participants at 
both 2 and 22 days after exposure and cultured ex vivo, exhibited increased expression of 
Nqo1 (Hong et al., 2012).  
Here, in response to acute CDDO-Me exposure, both the renal and hepatic Nrf2 pathways 
were activated at 6 and 24 h. This was similar to previous analysis of the renal activation of 
Nrf2 pathway in wildtype mice, after 24 h exposure to CDDO-Me (Shelton et al., 2015). This 
coincided with significant induction of Srxn1 and Gsta1 in whole blood after 24 h exposure. 
A potential source of these Nrf2-regulated transcripts in whole blood are circulating blood 
cells themselves, as triterpenoids have been shown to influence PBMC gene expression. 
PBMCs and neutrophils isolated from healthy donors, exposed to CDDO-Im and CDDO-Me ex 
vivo, exhibited increased expression of antioxidant genes and were protected against LPS-
induced oxidative damage (THIMMULAPPA et al., 2007). However, in PBMCs from patients 
with septic shock, treatment with CDDO-Me resulted in increased Nqo1 and decreased 
Hmox1 expression (Noel et al., 2014). Monocytes from healthy donors treated with 50 nM 
CDDO-Me in vitro exhibited induced Nqo1 at 8 and 16 h post LPS stimulation (Noel et al., 
2014). PBMCs from burn victims and healthy donors, treated with CDDO-Me exhibited 
induced NQO1 and HMOX1 (Eitas et al., 2017). Primary peripheral blood lymphocytes from 
C57BL6 mice, immunised with MOG 33-55 (Model of experimental autoimmune 
encephalomyelitis), and stimulated with repeated doses of CDDO-TFEA (a triterpenoid 
analogue of CDDO-Me) over 5 days and cultured ex vivo, exhibited induced Nrf2 and Hmox1 
mRNA levels compared to vehicle-treated mice (Pareek et al., 2011). 
Here, chronic exposure to CDDO-Me resulted in similar Nrf2-pathway activation in the liver 
and kidneys, with lower fold changes than the single dose study but less variability within 
groups. However, the Nrf2 pathway was not significantly induced in whole blood. This may 
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be due to time or dose not being sufficient to maintain maximal induction of the pathway. It 
is also important to note that this study was conducted in the BALB/c background and may 
not be directly comparable with the acute CDDO-Me study in C57BL6 mice.  
A prominent finding, following the assessment of circulating mRNA in response to toxicant 
exposure is the chemical-specific gene expression profiles observed in blood samples. These 
expression profiles were capable of discerning organ-specific toxicities in rodents (Umbright 
et al., 2010; Wetmore et al., 2010) and can differentiate toxic and non-toxic  doses (Bushel 
et al., 2007). Lobenhofer et al. identified overt drug ‘signatures’ in transcriptional profiles of 
whole blood from rats exposed to a panel of eight acute hepatotoxicants (Lobenhofer et al., 
2008). These transcriptomic markers, when applied to an independent study, were able to 
predict APAP-induced liver toxicity in rats with 92.1 % accuracy (J. Huang et al., 2010). While 
the results presented in this chapter show that Nrf2-regulated gene expression in whole 
blood was not evident until latter time points and therefore could not compete with current 
clinical markers of DILI, non-invasive sampling for Nrf2 pathway activation in blood may aid 
pre-clinical screening of drug candidates.  
Throughout this chapter, whole blood analysis revealed variable gene responses within 
treatment groups that may be due the inter-individual variability. Future studies with larger 
cohorts may better take this variability into account in order to be identify outliers. 
Additionally, there is debate as to the length of transcripts in circulation. Many claim the 
concentration of mRNA in plasma is misrepresented due to the fact that most circulating 
RNAs are not full length (K. Wang et al., 2013; Zhong et al., 2008). However, one of the 
longest human mRNA transcripts recovered from the serum of patients suffering from oral 
squamous cell carcinoma, included 93.4 % of the full length GAPDH sequence indicating 
intact cell-free mRNAs are present in circulation (Li et al., 2006). These intact cell-free RNA 
molecules are likely to be protected within vesicles (El-Hefnawy et al., 2004). To be confident 
of the extent of induction of Nrf2-regulated genes in whole blood, optimisation of primers 
annealing across different regions of the transcripts are needed. Moreover, factors such as 
diet and exercise can significantly impact gene expression in peripheral blood cells (Radom-
Aizik et al., 2008; van Erk et al., 2006). Further studies would need to control for these 
variables.  
While the data in this chapter confirms the presence of Nrf2-regulated transcripts in whole 
blood in response to APAP toxicity and that induction of these mRNA are muted in mice 
receiving the antidote, NAC, further work is needed to identify the sources of these 
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transcripts. It is appealing to surmise that these transcripts are released into circulation from 
damaged liver cells. Other circulating RNA molecules such as miR122 have been shown to 
confer protective effects on peripheral tissues following acute kidney injury in rodents (Fan 
et al., 2016). Analysis of vesicles such as exosomes, released from hepatocytes following 
toxicity may identify a potential source of these transcripts. Alternatively, Nrf2-regulated 
transcripts may be derived directly from circulating blood cells. Another interesting question 
is the function of these transcripts within whole blood. Does Nrf2-regulated mRNA within 
whole blood retain functionality and does this provide protection to peripheral tissues? The 
increasing use of Nrf2 activating compounds in the clinic demands thorough characterisation 
of the response to drug exposure. Ultimately more detailed time course and whole blood 
fraction analysis is needed to fully characterise the response of the circulating Nrf2-pathway 
to pharmacological and toxic stimuli.  
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4.1. Introduction 
Activation of the NRF2-mediated protective response to chemical and oxidative stress, is an 
early event in adverse outcome pathways, following exposure to many compounds 
associated with DILI (Herpers et al., 2016). As a result, NRF2-regulated genes are increasingly 
being incorporated into assays for the assessment of compounds liable to provoke toxicity. 
Many ARE-based reporters incorporating single or repeated cis-elements of promoter 
regions from a particular NRF2-regulated gene have been reported for the detection of 
NRF2-activating compounds (Kim et al., 2016; Motahari et al., 2015; Shukla et al., 2012). 
Primary human hepatocytes (PHH) are considered the ‘gold standard’ of in vitro DILI 
assessment due to their maintenance of liver-specific functionality for up to 72 h post-
isolation (Gómez-Lechón et al., 2014). Despite this, little is known about the molecular 
landscape of the NRF2 pathway in PHH. Therefore, thorough characterisation of the PHH 
NRF2 pathway is vital. Previous work from this laboratory included microarray analysis of 
PHHs transfected with siRNA targeting NRF2 or KEAP1 (Manuscript in preparation). This 
dataset can be used to identify putative novel NRF2-regulated genes that may act as useful 
molecular markers of the NRF2 pathway and potentially reflect perturbations associated 
with DILI. In this chapter, I aim to define the regulatory sites responsible for the NRF2-
dependent activation of putative novel Nrf2-regulated. Additional insight into the regulation 
of NRF2-target gene induction may provide novel means of monitoring the NRF2 pathway in 
response to chemical and oxidative stress and improve predictive models for drug safety 
assessment.  
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4.2. Materials and Methods  
 All materials and reagents were sourced from Sigma (Poole, UK) unless otherwise stated.  
4.2.1.  Bioinformatic analysis  
In response to small interfering RNA (siRNA), genes significantly downregulated by siNRF2 
and significantly upregulated by siKEAP1 in PHH were collated.  
Initial comparison of this shortlist of genes to other human microarray datasets was achieved 
using the publicly available datasets GSE28813 and GSE38332 (Agyeman et al., 2012; Singh 
et al., 2013). Singh et al. assessed NRF2 pathway activity following siRNA-mediated 
knockdown of NRF2. When multiple probes were included, the smallest value relating to the 
most downregulated probe, was used. Agyeman et al. compared NRF2 pathway activation 
following siKEAP1 or sulforaphane exposure. In this instance, where multiple probes were 
included, the highest upregulated probe following siKEAP1 and sulforaphane exposure was 
considered.  
The response of the putative Nrf2-regulated genes to toxic stimuli known to activate NRF2 
signalling via exposure of PHH to butylated hydroxyanisole (BHA) and diethyl maleate (DEM) 
was assessed using the TG-GATES dataset (Igarashi et al., 2014). Data was accessed via 
Toxygates, a platform for accessing the TG-GATES database (Nyström-Persson et al., 2013). 
The fold change of gene expression following 24 h exposure to low, medium and high doses 
were considered. Where multiple probes were used for a specific gene, the probe with the 
highest fold change was included in the analysis.  
Assessment of ARE sequence location within and around the gene locus was achieved using 
data from the mathematical algorithm for ARE sequence identification developed by  
Kuosmanen et al. (Kuosmanen et al., 2016). This model, based on chromatin 
immunoprecipitation (ChIP-Seq) data, scored potential ARE sites throughout the genome by 
their predicted propensity for NRF2 binding. Data kindly provided by Prof. Anna-Liisa 
Levonen, was uploaded to the human genome assembly GRCh37/hg19 in the University of 
California Santa Cruz (UCSC) Genome Browser and was categorised in individual ‘tracks’ 
based on predicted NRF2-binding strength: strong, medium-strong, medium, medium-weak 
and weak. Screen shots of binding regions within the gene or 5 kb upstream of the gene start 
site were collected.  
We utilised data generated by Chorley et al. documenting the NRF2 binding following 
sulforaphane treatment in human lymphoblastoid cells (Chorley et al., 2012). The publicly 
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available ChIP-Seq dataset, was uploaded to human genome assembly NCBI36/hg18 in the 
UCSC genome browser. Data from vehicle and sulforaphane treated cells were uploaded in 
separate ‘tracks’. If either track included a ‘peak’ region, the data view scaling of both tracks 
were configured to the highest peak. Screen shots of ‘peak’ regions within and under 5 kb to 
the gene start site were compiled. The location of ARE sites from the Kuosmanen dataset 
was compared to the Chorley dataset to identify active ARE sites.  
4.2.2. Antioxidant response element-reporter construction  
Promoter regions spanning 1-2 Kb upstream of the gene start site ATG were synthesised 
(GeneMill, Liverpool, UK). NQO1 and SRXN1 ARE sites were included as positive controls. 
During analysis of the SRXN1 promotor region, an ARE element was identified -274 to -193 
bp from the transcriptional start site of SRXN1 responsible for its regulation (Singh et al., 
2009). However, this sequence contains two putative ARE sites. Constructs of both ARE sites 
were synthesised.  
Johnson et al.  identified the region within LOC344887 as the site responsible for activation 
and therefore the region 1kb around this ARE was included instead of the promotor region 
for synthesis (Johnson et al., 2016). Mutated ARE sequences within the inserts were designed 
by replacing the bases T with G and A with C and vica-versa (Table 4.1).  
The OR5T3 promotor locus was included as a negative control as it contained no ARE sites 
and was not modulated by NRF2 in our analysis. These regions were sub-cloned into the 
pGL4.20 vector (Promega, Madison, USA) using Kpn1 and Nhe1 restriction sites.  
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Table 4.1 Wild-type and mutated ARE sequences within synthesised constructs 
Wild type (WT) and mutated (MUT) ARE sequences. The SRXN1 promotor region contains 
two potential ARE sites, which were mutated individually or in combination.  
Insert ARE1 ARE2 
F2RL2 WT TGCTCTGTCAC n/a 
F2RL2 MUT GTAGAGTGACA n/a 
LOC344887 WT GTGACAGAGCG n/a 
LOC344887 MUT TGTCACTCTAT n/a 
NQO1 WT GTGACACAGCT n/a 
NQO1 MUT GTGACTCAGCA n/a 
TRIM16L WT GTGACACAGCT n/a 
TRIM16L MUT TGTCACACTAG n/a 
SRXN1 WT TGCAAACTCAC CTGAGTCAGCC 
SRXN1 ARE1 MUT GTACCCAGACA CTGAGTCAGCC 
SRXN1 ARE2 MUT TGCAAACTCAC AGTCTGACTAA 
SRXN1 ARE 1+2 MUT GTACCCAGACA AGTCTGACTAA 
 
4.2.2.1. Preparation of inserts for cloning 
Inserts from the synthesised construct were either isolated and purified following restriction 
digestion (Kpn1 and Nhe1) from MIDI prepped DNA (QIAgen, Hilden, Germany) or, when 
these yields were low, amplified from these plasmids using PCR.  
 
4.2.2.2. PCR amplification of inserts  
Inserts were amplified in reactions using an M13 forward primer (M13) 5’-
GTTTTCCCAGTCACGAC-3’ and a vector-specific reverse primer (Promoter_reverse) 5’-
AGCGCCCAATACGCAAGG-3’ (Table 4.2) and amplified for 35 cycles with 58 °C annealing and 
an extension stage of 1 min/Kb product. Following PCR, a small amount of the reactions were 
resolved on 1.5 % agarose gels to ensure amplification.  
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Table 4.2 Q5 polymerase PCR reaction conditions  
Reagent Volume (µl) 
5x Q5 buffer 10 
10 mM dNTPs 1 
5 uM Forward Primer  2.5 
5 uM Reverse Primer 2.5 
Template (25 ng/ul) 1 
DNase-free H2O  32.5 
Q5 polymerase  0.5 
 
4.2.2.3. Restriction enzyme digestion and gel extraction 
Following amplification, inserts were incubated with 0.5 µl Dpn1 (NEB, Hitchin, UK) for 30 
min at 37 °C to digest methylated DNA. Reactions were cleaned up using the Wizard® SV gel 
and PCR clean-up system following the kits instructions (Promega, Madison, USA).  
Inserts and pGL4.20 plasmid were digested with Kpn1-HF and Nhe1-HF restriction enzymes 
(New England Biosciences, Ipswich, USA) in 80 µl reactions (Table 4.3) for 2 h, at 37 °C. 
Reactions were subsequently resolved on a 1.5 % agarose gel for 1 h, at 135 V. Inserts were 
excised from the gel using a scalpel and purified using the Wizard® SV gel and PCR clean-up 
system. Inserts from MIDI prepped DNA were obtained by digestion as described above and 
purified from the remainder of the plasmid by gel extraction.  
Digested pGL4.20 was resolved with uncut plasmid and the rest of the reaction cleaned up.  
The concentration of all digest products was measured using the Nanodrop 
Spectrophotometer ND-1000 (Labtech International, Heathfield, UK) and inserts ligated into 
digested pGL4.20. Briefly, 50 ng pGL4.20 was ligated with increasing ratios of insert DNA (1:1, 
1:2 and 1:4) and 50 ng/µl T4 ligase (NEB, Hitchin, UK). Ligation reactions were incubated 
overnight at 4 °C prior to transformation.  
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Table 4.3 Insert digestion reaction  
Reagent Volume (µl) 
10 ug plasmid DNA X 
10x CutSmart buffer  8 
Kpn1-HF  2 
Nhe1-HF 2 
DNase-free H2O  Up to 80 
 
4.2.2.4.  Transformation of pGL4.20 ligations  
Ligation reactions were incubated with competent STBL3 Escherichia coli (Thermo Fischer 
Scientific, Waltham, USA) on ice for 30 min prior to heat shock at 42 °C for 1 min. Following 
recovery on ice for 2 min, super optimal broth with catabolite repression (SOC) medium was 
added to bacteria and incubated for 1 h at 37 °C with shaking. Bacteria were subsequently 
plated onto agar plates containing 100 µg/ml Carbenicillin and cultured at 37 °C overnight. 
 
4.2.2.5. Colony screening 
Successful ligation into pGL4.20 was initially determined by screening transformed colonies. 
Screening PCR reactions consisted of an RV3 forward primer and an insert-specific reverse 
primer (Table 4.4 A), and were amplified with GoTaq Polymerase (NEB, Hitchin, UK) (Table 
4.4 B). Colonies were picked using a pipette tip and added to the PCR reactions by pipetting 
up and down. Reactions were amplified over 35 cycles with 58 °C annealing temperature and 
extension stage of 1 min/Kb product. PCR products were resolved on a 1.5 % agarose gel. 
Plates were left at room temperature to allow colony regrowth and positive colonies were 
picked into 5 ml LB medium containing 0.1 µg/ml Carbenicillin for overnight culture.    
All positive clones were purified and sent for Sanger sequencing (Source-Biosciences, 
Rochdale, UK) to confirm correct integration and sequence of the insert using forward primer 
(RV3) 5’ CTAGCAAAATAGGCTGTCCC 3’ and reverse primer 5’ GGTGGCTTTACCAACAGTACCG 
3’. Correct clones were MIDI prepped (Qiagen, Hilden, Germany). DNA was quantified using 
the Nanodrop. Purity of the samples were based on the 260/280 ratio. Only those with a 
ratio between 1.7 and 1.9 were used.   
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Table 4.4 Colony screening reactions 
(A) Screening primers (B) PCR reactions to confirm successful transformation of plasmids.   
 
Primer Sequence 
F2RL2 Screening primer 5’ – CACACAGATTTCTACCCAG – 3’ 
LOC344887 Screening primer 5’ – CACCACATCCAGTTAATCAC – 3’ 
NQO1 Screening primer   5’ – CTTCCCTATAACTGCTATCTC – 3’ 
TRIM16L Screening primer  5’ – CTGTTTGGCTCTTGTGG – 3’ 
OR5T3 Screening primer  5’ – GATAAACAAGGTACAGAGG – 3’ 
SRXN1 Screening primer  5’ – GCTTGTCTTCGACCGAG – 3’ 
Forward primer RV3  5’ – CTAGCAAAATAGGCTGTCCC – 3’ 
 
 
Reagent Volume (µl) 
One Taq
TM
 polymerase 5 
10 µM Screening primer pair 1 
DNase-free H2O  4 
 
4.2.3. Cell culture 
All cells lines were maintained at 37 OC with 5 % CO2. HepG2 cells were cultured in media 
consisting of Dulbecco’s Modified Eagle’s medium (DMEM), supplemented with 10 % (v/v) 
heat-inactivated Foetal bovine serum (FBS) and 1 % (v/v) Penicillin / streptomycin.    
Once confluent, cells were dissociated from culture flasks with trypsin. Briefly, the monolayer 
was washed with 5 ml 0.02 % (v/v) Ethylenediaminetetraacetic acid (EDTA) in PBS. This was 
then replaced with 2 ml 0.25 % Trypsin and incubated at room temperature for 1 min. Trypsin 
was removed and the flask incubated at 37 OC for 5 min. Cells were resuspended in media 
and counted using a haemocytometer. HepG2 cells were dissociated through a 21G needle 
prior to counting. Cells were passaged every 4 days up to 25 passages before being discarded. 
Cultures were regularly tested for mycoplasma using the ‘eMyco kit’ (Lonza, Slough, UK). 
4.2.3.1. Primary hepatocyte isolation 
Surgical excess tissue from hepatobiliary surgery performed at Aintree Hospital (Liverpool, 
UK) was obtained with informed consent. Ethical approval was granted by the NReS 
A.  
B.  
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committee Northwest Liverpool Central. Written consent was taken from all patients and the 
study protocol adhered to the 1975 Declaration of Helsinki. Liver parenchyma was taken 
from non-cancerous margins and ideally, with most of the outer capsule intact. Tissue was 
stored on ice in perfusion buffer (10 mM HEPES, 5 mM KCl, 136 mM NaCl and 0.5 % (w/v) 
glucose (Thermo-Fisher Scientific, Waltham, USA) in dH2O) for approximately 30 min during 
transport to the University laboratories.  
PHH were isolated by Dr Amy Schofield, Dr Monday Ogese and Dr Laleh Kamalian via two-
step collagenase digestion as previously described (LeCluyse et al., 2005). The tissue was 
weighed and transferred to a laminar flow cabinet for digestion. Firstly, the sample was 
perfused with perfusion buffer until the tissue appeared blanched in colour, indicating the 
removal of blood. This was achieved using a Heidolph Pump Drive 5006 (Thermo Fischer 
Scientific, Waltham, USA) at a flow-rate of between 15-30 ml/min, depending on tissue size 
and capsule integrity.  
The tissue was then perfused with digestion buffer (0.5 mg/ml Collagenase IV (400-600 
U/mg) and 700 µM CaCl2 in perfusion buffer) at a similar flow rate, until the tissue appeared 
to crack and sag beneath the capsule. Perfusion with digestion buffer did not exceed 20 min. 
At this point, the capsule was minced with sterile scissors and the cell suspension passed 
through a 125 µm nylon mesh (Clarcor UK, Warrington, UK) to remove large undigested 
material. The suspension was centrifuged at 80 g for 5 min at 4 °C and gently resuspended 
in Williams E medium. Cells were counted, and viability assessed using Trypan blue. Only cell 
suspensions with ≥ 75 % viability were used for experiments. Cells were resuspended in 
complete medium (1 % (v/v) insulin-transferrin-selenium (Life Technologies, Carlsbad, USA), 
2 mM L-glutamine, 100 nM dexamethasone and 1 % (v/v) penicillin/streptomycin in Williams 
E medium) and plated at 250 000 cells/cm2 in collagen-coated plates (Corning Life Sciences, 
Amsterdam, Holland). After 3 h, culture medium was replaced to remove any unattached 
cells.  
4.2.3.2. Drug treatment  
Cells were seeded in a 6 well-plate at 1 million cells per well, per 2 ml media, 24 h prior to 
treatment to allow adherence. 100 or 200x stock solutions were generated for each drug 
concentration. Drug-treated media was generated by diluting the stock solutions 1 in 200 
and used to replace existing media. The resulting concentration of DMSO was 1 or 0.5 % per 
well respectively. CDDO-Me and Doxycycline (DOX) was purchased from Sigma (Poole, UK).  
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4.2.3.3. Transfection  
Cells were reverse transfected using jetPEITM (Polyplus, New York, USA). The pRL-SV40 
construct was kindly donated by Johnathan Po, University of Liverpool and pSB-tet-NRF2 by 
Dr. Nick Harper, University of Liverpool. DNA was diluted to 12.5 ng/ul in 150 mM NaCl. jetPEI 
reagent was diluted 1 in 20, in 150 mM NaCl. All solutions were vortexed before adding 10 
µl (125 ng) diluted DNA to 10 µl diluted jetPEI per well. These transfection reactions were 
vortexed and incubated at room temperature for 20 min while a cell suspension of 25 000 
cells per 180 µl medium was generated for each transfection reaction. Cell suspension and 
transfection reactions were combined and 200 µl added dropwise to the wells of a 96 well 
plate.  
For Western blotting, cells in 12 well-plates were reverse transfected in a similar manner. 
The ratio of reagents per well in this instance was 100 000 cells per 800 µl media with 200 µl 
transfection reaction. Transfection reactions consisted of 2 µl jetPEITM in 100 µl 150 mM NaCl 
and 250-1000 ng plasmid DNA in 100 µl 150 mM NaCl.  
Subsequent drug treatments were achieved by replacing the media 24 – 48 h post 
transfection with drug-treated media, as described previously.  
4.2.4. In vitro luciferase assays 
All luminescence assays were performed in white-walled 96 well plates (Greiner Bio-one, 
Kremsmünster, Austria) to avoid signal interference between wells. To measure expression 
of Firefly luciferase, cells were incubated with in vivo grade D-luciferin (Promega, Madison, 
USA). Cells were washed with PBS and 100 µl 150 µg/ml luciferin in PBS was added to each 
well. Plates were incubated at room temperature for 5 min and luminescence quantified 
using the Varioskanner Flash. 
To quantify both Firefly luciferase and Renilla luciferase expression, Bright-Glo and Renilla-
Glo luciferase assay kits (Promega, Madison, USA) were used. Medium was removed, and 
Cell lysis was achieved by adding 200 µl 1x Glolysis buffer (Promega, Madison, USA) to each 
well, and shaking the plate for 5 min at 700 RPM on an OrbitTM plate shaker (Labnet, New 
Jersey, USA). 100 µl of the cell lysates were transferred to a second white-walled 96 well 
plate and placed on ice.  The Bright-Glo assay was performed on the first plate. 20 µl Bright-
Glo reagent was added to each well and the plate was shaken at 700 RPM for 15 sec. 
Luminescence was quantified using the Varioskanner Flash. To the second plate, 20 µl 
Renilla-Glo reagent was added. This plate was shaken for 15 sec at 700 RPM and incubated 
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at room temperature for 10 min. Renilla luciferase expression was then quantified in a similar 
manner.  
4.2.5.  qPCR and Western blotting 
qPCR analysis described in section 2.2.8. In this chapter, primers designed for human gene 
products were used (Table 4.5). Western blotting completed using the method described in  
section 2.2.9.  
Table 4.5 Human qPCR primers  
Gene Primer Sequence 
F2RL2 
Fwd 5’- ACT GAG GTG AAA TTG TGC TCC A -3’ 
Rev 5’- TTT CCA TGC CAC TCT GAC AA -3’ 
LOC344887  
Fwd 5’- CTG GAG AAC GTC AAG CGA CT -3’ 
Rev 5’- GGG ATG CCA ATG GAC CAG AA -3’ 
NQO1 
Fwd 5’- AGG ACC CTT CCG GAG TAA GAA -3’ 
Rev 5’- TGG AAG CCA CAG AAA TGC AGA -3’ 
NRF2 
Fwd 5’- GAG AGC CCA GTC TTC ATT GC -3’ 
Rev 5’- TTG GCT TCT GGA CTT GGA AC -3’ 
SRXN1 
Fwd 5’- GAT CCG GGA GGA CCC AGA CA -3’ 
Rev 5’- CAA GGA GGC TGC TAC TGC AA -3’ 
GAPDH 
Fwd 5’- GGC CTC CAA GGA GTA AGA CC -3’ 
Rev 5’- AGG GGT CTA CAT GGC AAC TG -3’ 
TRIM16L  
Fwd 5’ – CCA ATG TAA GTT GTG AAC G - 3' 
Rev 5’ – GAA ACC TAG ATG AGA GAT GG - 3'  
OR5T3  
Fwd 5’ – GAC TCC ACT TTC ACA GG - 3' 
Rev 5’ – CTT CAG TCT TGT TCT TCA GT - 3'  
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4.3. Results  
4.3.1. Bioinformatic analysis reveals putative NRF2-regulated target genes 
Previous work from our laboratory identified genes modulated by NRF2 in PHH (Manuscript 
in preparation). To generate these data, PHH were transfected with either siRNA targeting 
either NRF2 or KEAP1 for 48 h. Gene expression in samples was assessed using the SurePrint 
G3 human gene 8x60K v2 microarray kit (Agilent technologies, Santa Clara, US). Transcripts 
that were both significantly up-regulated in response to KEAP1 knockdown and down-
regulated following NRF2 silencing were selected as they exhibited proportional activity to 
NRF2 and therefore may be potential markers of NRF2 activity.  
Initially, the list of genes most responsive to NRF2 pathway modulation in PHH was compared 
to the literature (See examples in Table 1.1) for prior evidence of direct regulation by NRF2. 
This resulted in a subgroup of 77 genes without previous direct association with NRF2 (Table 
A1). 
To further refine this list of putative Nrf2-regulated genes, bioinformatic analysis was 
applied. Firstly, I compared similar siRNA microarray datasets for evidence of the 
responsiveness of the genes to NRF2 regulation (Fig 4.1 A). As many Nrf2-regulated are 
implicated in the response to chemical stress, genes were analysed for their sensitivity to 
activation by toxic stimuli known to induce NRF2 (Fig 4.1 B). Finally, potential ARE sites within 
the promoter regions of the remaining genes were identified and their activation in response 
to sulforaphane exposure assessed (Fig 4.1 C).     
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Figure 4.1 Work flow of microarray hit comparison with existing datasets.  
The 76 potentially novel Nrf2-regulated genes were compared in turn with other microarray 
datasets in which cells were exposed to siNRF2 or siKEAP1 (A). Secondly, the dataset was 
compared to gene expression profiles of primary human hepatocytes (PHH) exposed to toxic 
compounds, known to stimulate Nrf2 activity (B). Finally, location of predicted ARE sites 
within gene promoter regions and evidence for the site’s potential for activation were 
assessed using Kousmanen motif discovery algorithm and Chorley ChIP-Seq dataset within 
UCSC genome browser (C). Analysis included positive (NQO1 and SRXN1) and negative 
(OR5T3) controls throughout.  
 
4.3.1.1. Comparison with other microarray datasets 
Firstly, the responsiveness of the 76 potentially novel NRF2-regulated genes to siRNA 
modulation of the pathway in other human cell lines was assessed, utilising previously 
published microarray datasets (Table A1) (Agyeman et al., 2012; Singh et al., 2013).  
Singh et al. (GSE38332) evaluated the transcriptomic response of A549 lung cancer cells to 
siNRF2 compared to non-targeting siRNA (luciferase siRNA) as a control. 266 transcripts were 
down-regulated to 50 % or lower, than control-treated cells (Singh et al., 2013). These 
repressed genes were mainly associated with carbohydrate and xenobiotic metabolism 
pathways. From the 76 genes modulated by NRF2 in PHH, 23 were not present in the Singh 
dataset. OR5T3 expression was not assessed.  Out of the 56 genes measured, 8 genes were 
expressed at a similar level to samples exposed to control siRNA, 35 were down regulated 
between 99 – 50 % of the control group and 13 genes were down regulated to <50 % 
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expression (Table A1). Within the top 10 most down-regulated genes included NQO1 and 
SRXN1. 
Agyeman et al. (GSE28813) assessed NRF2 induction following exposure to sulforaphane or 
KEAP1 knockdown in MCF10A, a human breast epithelial cell line. Significant modulation of 
1710 transcripts were observed in response to KEAP1 knockdown while 6378 transcripts 
were up- or down-regulated more than 1.5-fold by sulforaphane. 879 transcripts were 
induced by both stimuli. From the 76 potentially novel NRF2-regulated genes in PHH, 24 
genes were not measured in the Agyeman datasets, additionally OR5T3 was not measured. 
However, 55 genes were measured in both Agyeman datasets (Table A1). In response to 
siKEAP1, 44 genes were induced, 18 of which were induced over 200 % compared to cells 
transfected with control siRNA. The 10 most upregulated genes included NQO1 and SRXN1 
(Table A1). In response to sulforaphane exposure, 44 out of the 76 transcripts were induced 
alongside NQO1 and SRXN1 (Table A1). Over 200 % induction compared to vehicle treated 
controls were seen in 29 of these transcripts. Genes activated over two-fold by both siKEAP1 
and sulforaphane exposure included: LOC344887, MAP2, F2RL2, SPP1, ADHFE1, EID3, SRXN1, 
ABHD4, TRIM16L, SULT1A2, NQO1, KYNU, ALDH3A1, IKBKG, PPARA, and MLLT11.  
In comparison with the Agyeman dataset, 12 genes were shared across datasets that were 
down-regulated by at least 50 % by siNRF2 treatment and upregulated over two-fold by both 
siKEAP1 and sulforaphane exposure, compared to vehicle controls. These genes were: 
ALDH3A1, F2RL2, KYNU, LOC100506922, LOC344887, MAP2, MYEOV, NQO1, NRG1, SFN, 
SPP1, and SRXN1. Therefore, comparison of putative Nrf2-regulated genes identified by this 
laboratory with other microarray datasets following modulation of NRF2, highlights similar 
gene expression patterns in other human cell lines. This further supports the hypothesis that 
these genes are indeed directly regulated by NRF2. 
 
4.3.1.2. Response to toxic stimuli  
To identify genes that responded to toxic stimuli, known to activate hepatic NRF2 signalling, 
I assessed the 77 genes (alongside positive and negative control genes) for modulation by 
the compounds butylated hydroxyanisole (BHA) and diethyl maleate (DEM) (Hiemstra et al., 
2017; Yuan et al., 2006). The carcinogen BHA is bioactivated to electrophilic metabolites 
including tert-butylhydroquinone (tBHQ) capable of activating the NRF2 pathway via 
modification of KEAP1 cysteine residues (Abiko et al., 2011). DEM depletes glutathione via 
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sulfhydryl group alkylation resulting in induction of oxidative stress and activation of NRF2-
regulated genes (Katsuoka et al., 2005; Kaur et al., 2006). Here, I utilise the TG-GATES 
database, which consists of gene expression data from PHH exposed to a wide range of 
hepatotoxic compounds (Igarashi et al., 2014).  
In response to a 200 µM dose of BHA in vitro, 34 genes from our microarray dataset were 
included in the top 1000 hits collated in the TG-GATES database (Table A1). SRXN1 and NQO1 
were induced over two-fold compared to vehicle-treated controls. Fold changes in response 
to BHA ranged from 116 – 402 % across the 36 genes. Likewise, PHH exposed to 1500 µM 
DEM exhibited induction of 21 genes from the list of 76 and controls: NQO1 and SRXN1 (Table 
4.8). Expression levels of these genes ranged from 133 – 1532 % in DEM-treated cells, 
compared to vehicle-treated controls. The most upregulated of which was F2RL2. Where 
multiple probes for the same target were used, the probe with the highest fold change was 
included only. The negative control gene OR5T3 was not present in the top 1000 hits 
modulated by BHA or DEM.  
Therefore, there is some homology between NRF2 pathway activity in response to siRNA and 
toxic stimuli in PHH. Putative NRF2-regulated genes that respond to both would make 
exciting candidates for novel markers of NRF2 pathway activation in response to chemical 
stress.    
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4.3.1.3. Sequence-based analysis 
To identify candidate ARE sites within and around the promotor of genes modulated by NRF2 
in PHH, I utilised data from Kuosmanen et al. documenting ARE sequence variation in the 
human genome (GRCh37/hg19) (Kuosmanen et al., 2016). In this study, AREs were 
categorised by the probability of NRF2-binding and given a strong to weak value. All 76 genes 
contained at least a weak ARE within, or 2 kb upstream of, the gene start site: ATG (Data not 
shown). OR5T3, a gene not modulated by NRF2 in PHH, was used as a negative control (Table 
4.6).  
To identify functional AREs, I compared these data to locations of NRF2-binding to the human 
genome (NCBI36/hg18) (Chorley et al., 2012). The authors exposed six different human 
lymphoid cell lines to sulforaphane and NRF2-binding sites were identified by chromatin 
immunoprecipitation sequencing (ChIP-Seq). From the 242 high-confidence NRF2-binding 
sites identified by Chorley et al., 17 were within or close to the promotors of the 76 genes 
not previously associated with direct regulation by NRF2 (Table 4.6). These genes contained 
‘peak’ regions on the genome wide density plots exhibiting a density greater than 50 units. 
The negative control, OR5T3 did not contain an NRF2-binding site within the Chorley dataset. 
When compared with the Kuosmanen dataset, many ChIP-Seq ‘peak’ regions aligned with 
predicted ARE sites (For example see Fig 4.2). As both datasets were affiliated with different 
genomes, I compared the location of ARE from the Kuosmanen dataset with the ChIP-seq 
peaks of the Chorley dataset manually. Out of the 17 putative NRF2-regulated genes 
exhibiting a peak in response to sulforaphane exposure, 3 were aligned with Strong ARE, 6 
with medium strong, 3 with medium, 4 with medium weak and 1 with weak AREs (Table 4.6). 
The positive control genes NQO1 and SRXN1 aligned with strong and medium strong sites 
respectively.  
Therefore, I identified a subgroup of putative NRF2-regulated genes associated with 
functional ARE sites responsive to sulforaphane exposure, providing strong evidence for 
direct regulation by NRF2.  
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Figure 4.2 Alignment of ChIP-Seq peaks with predicted antioxidant response elements  
ChIP-seq regions identified by Chorley et al. at the NQO1 locus to which NRF2 binds, in response to sulforaphane (SFN) exposure (A) and (B) corresponding 
predicted ‘strong’ ARE site, identified by Kuosmanen et al., circled  in red (Chorley et al., 2012; Kuosmanen et al., 2016).   
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Table 4.6 Genes with antioxidant response elements responsive to sulforaphane 
Green = Genes included in further analysis 
Genes with AREs 
responsive to 
sulforaphane   
Predicted ARE category  Overlapping ChIP-seq Peak 
(Chorley et al., 
2012) 
(Kuosmanen et al., 2016) (Chorley et al., 2012) 
LUCAT1 strong  
NLN strong  
NQO1 strong  
SLC48A1 strong  
Chapter 4 
156 
 
GBE1 medium strong  
LOC101927592 medium strong  
SCCPDH medium strong + 
medium  
SLC22A3 medium strong  
TRIM16L medium strong  
Chapter 4 
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UGDH medium strong + weak  
ABHD4 medium  
ALDH1L1 medium  
PANX2 medium  
SRXN1 medium  
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ICK medium weak  
LOC344887 medium weak + weak  
TCEB3 medium weak  
MPP3 medium weak  
ALDH3A1 weak  
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OR5T3 weak  
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4.3.1.4. Gene shortlist 
Following comparison with similar microarray datasets based in alternative cell lines, 
expression analysis in response to chemical stress, and location of ARE sites around the 
promoter that respond to sulforaphane exposure, I decided to focus on a subgroup of 
putative NRF2-regulated genes for further analysis: F2RL2, TRIM16L and LOC344887.  
Expression of F2RL2 and LOC344887 were significantly altered in other microarray datasets 
modulating the NRF2 pathway (Table 4.6). Additionally, all three genes were significantly 
upregulated by sulforaphane (Agyeman et al., 2012). While TRIM16L was not considerably 
down-regulated by siNRF2 exposure in the Singh dataset, the response to siKEAP1 and 
sulforaphane exposure in both the Agyeman and Chorley datasets provide strong evidence 
for its direct regulation by NRF2. In response to toxic stimuli, all three genes were induced 
by BHA but only LOC344887 and F2RL2 were activated by DEM. Despite significant activation 
by sulforaphane in the Agyeman dataset, F2RL2 was not associated with a ChIP-seq peak 
(Chorley et al., 2012). Due to the gene’s significant induction to toxic stimuli and modulation 
in Singh and Agyeman datasets, F2RL2 was included for further analysis.  
 
4.3.2. Putative NRF2-regulated gene activation in human liver cells 
To confirm the response of these potentially novel NRF2-regulated genes, PHH were exposed 
to NRF2-activating compounds: CDDO-Me and sulforaphane for 24 h. qPCR analysis revealed 
significant induction of F2RL2 and TRIM16L by CDDO-Me, compared to gene expression in 
vehicle-treated cells (P = 0.0005 and 0.0021 respectively) (Fig 4.3 A). Following sulforaphane 
exposure, F2RL2 expression was also significantly elevated compared to the DMSO 
treatment group (P = < 0.0001) (Fig 4.3 B). While changes in the other genes in response to 
both CDDO-Me and sulforaphane were not significant, expression levels in all four donors 
were clearly elevated compared to vehicle-treated cells. Variability between donors may be 
due to differences in pathology, age and weight (Fig 4.3 C). For instance, Donor 207 was the 
only patient suffering from COPD and taking a substantial list of medications, displayed the 
greatest induction of NQO1 and F2RL2 in response to NRF2 induction. 
In HepG2 cells, exposure to CDDO-Me resulted in upregulation of F2RL2 and LOC344887 (Fig 
4.4 A). F2RL2 was significantly induced (P = <0.0001). This effect was NRF2 dependent as 
target gene activation by CDDO-Me was inhibited in HepG2 cells transfected with siNRF2. In 
these samples NRF2 was significantly knocked down to between 29 -15 %, compared to cells 
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transfected with siCON and exposed to DMSO (Fig 4.4 B) (P = 0.0001). In cells transfected 
with siNRF2 and exposed to CDDO-Me, TRIM16L expression was significantly reduced 
compared to cells transfected with control siRNA and exposed to CDDO-Me (P = = <0.0001). 
As a similar response was evident between PHH and HepG2 cells, the immortalised cell line 
was chosen for transfection with luciferase promotor-reporter constructs (the generation of 
which is described in 4.3.3).  
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Figure 4.3 Gene expression in primary human hepatocytes exposed to CDDO-Me 
Primary human hepatocytes (PHH) isolated from four donors were exposed to either 100 nM 
CDDO-Me (A) or 10 µM sulforaphane (B) for 24 h.  Gene expression normalised to cells 
treated with 0.5 % DMSO. Significant induction compared to vehicle-treated cells was 
assessed by one-way ANOVA or Kruskal Wallis (** P ≤ 0.01 and *** p ≤ 0.001) (Dotted line = 
100%). Age, body mass index (BMI,) comorbidities (such as chronic obstructive pulmonary 
disease (COPD)) and medication taken by the donors (C).  
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Figure 4.4 Gene expression in HepG2 cells exposed to CDDO-Me 
HepG2 cells were transfected with siNrf2 or siCON for 24 h and exposed to 100 nM CDDO-
Me or 0.5 % DMSO for a further 24 h (n=4). (A) qPCR analysis HepG2 cells transfected with 
siNrf2 and exposed to DMSO. (B) qPCR analysis of HepG2 cells exposed to siNRF2 or siCON 
and CDDO-Me. (Dotted line = 100 %) Significant differences in gene expression between 
siCON + CDDO-Me and siCON+ DMSO treated samples was calculated by one-way ANOVA 
(@@@ p ≤ 0.001). Significant differences between siCON and siNrf2 + CDDO-Me treatment 
groups were also calculated by one-way ANOVA (*** p ≤ 0.001).  
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4.3.3. Clone construction  
In order to investigate potential ARE target sites through which Nrf2 mediates the expression 
of F2RL2, LOC344887 and TRIM16L, I next generated luciferase reporters under the control 
of the relevant gene promotor regions. Promotor regions were synthesised commercially by 
GeneMill, Liverpool (For example Fig A1). Mutated ARE sequences within the inserts were 
designed by replacing the bases T with G and A with C and visa-versa (Table 4.1). These 
inserts were sub-cloned into the pGL4.20 vector (Fig A2) utilising the restriction sites for Kpn1 
and Nhe1 within the multiple cloning site of pGL4.20 (Fig A3 A). Successful linearization of 
the vector (Fig A3 B) and digestion of the WT and MUT inserts (Fig A3 C) were achieved using 
the restriction enzymes Kpn1 and Nhe1. The TRIM16L WT insert was amplified by PCR due 
to repeatedly low DNA yield by miniprep. DNA products were extracted from the agarose 
gels, cleaned up and ligated with the pGL4 vector (For example Fig A4).  
Transformed bacteria were screened for successful clone integration and miniprepped DNA 
sequenced (Fig 4.5 A to D). Fidelity of the WT and MUT ARE sequences were maintained. 
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Figure 4.5 Confirmation of pGL4 clones by Sanger sequencing 
Aligned sequences of wild type (WT) (Top) pGL4-WT (middle) and pGL4-MUT (bottom) sequences of NQO1 (A), F2RL2 (B), LOC344887 (C) and TRIM16L (D) 
promotor reporter constructs. ARE site highlighted green. Misaligned MUT ARE sequences highlighted red. Genomic WT sequence from UCSC genome Hg38.  
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4.3.4. Assessment of SRXN1 antioxidant response elements 
Inclusion of AREs from both NQO1 and SRXN1 were considered as positive controls for the 
promotor-reporter assay. Utilising a similar luciferase-based promotor-reporter assay, Singh 
et al. identified an NRF2-responsive element -274 to -193 bp from the transcriptional start 
site of SRXN1 (Singh et al., 2009). However, I noticed this sequence contains two putative 
ARE sites (Fig 4.6). Both sequences fall within ChIP-Seq region of NRF2-binding identified by 
Chorley et al. (Chorley et al., 2012) (Table 4.6). Further analysis is needed to identify the 
necessity of either/both of these ARE sites for NRF2-dependent activation and so WT and 
MUT constructs of both ARE sites were synthesised in a similar manner to section 4.3.3.  
 
 
 
Figure 4.6 Potential ARE sites within the SRXN1 promotor 
The region -274 to -193 bp from the transcriptional start site of SRXN1, identified by Singh et 
al. as an NRF2-responsive element (Singh et al., 2009). However, this sequence contains two 
putative ARE sites highlighted.  
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4.3.5. ARE-reporter construct response to pharmacological induction of NRF2  
Initial transfections were conducted in the readily transfectable HEK293T cell line. Following 
24 h exposure to CDDO-Me, luminescence was quantified in the transiently transfected cells 
(Fig 4.7 A). Cells transfected with the empty pGL4 vector and the negative control construct 
pGL4-OR5T3 WT did not produce a luminescent response greater than their vehicle-treated 
counterparts. pGL4-NQO1 WT transfected cells produced significantly greater luminescence 
than those transfected with pGL4-NQO1 MUT, following CDDO-Me exposure (P = <0.0001) 
(Fig 4.7 A). Amongst the novel gene reporters, only cells transfected with pGL4-Trim16L WT 
and pGL4-Trim16L MUT produced luminescence greater than DMSO-treated counterparts 
(Fig 4.7 B). Unexpectedly HEK293T cells transfected with pGL4-TRIM16L MUT produced more 
luminescence than those exposed to pGL4-TRIM16L WT. However, these data are only n=1.  
Following successful transfection in HEK293T cells, the construct response to CDDO-Me was 
assessed in HepG2 cells. When transiently transfected with the pGL4-constructs and exposed 
to CDDO-Me for 24 h, a similar luminescent response to the HEK293T cells were observed 
(Fig 4.8 A). Following induction of NRF2 by CDDO-Me, pGL4-NQO1 WT produced a 
significantly stronger luminescent signal than the mutant construct (P = <0.0001). Cells 
transfected with pGL4-TRIM16L MUT also produced significantly greater luminescence than 
cell transfected with pGL4-TRIM16L WT (P = <0.0001), consistent with the findings in 
HEK293T cells.    
Firefly luminescence (fLuc) induced by CDDO-Me was subsequently normalised to renilla 
luminescence (rLuc) expression to account for in-well transfection efficiency and potential 
discrepancies in cell viability (Fig 4.8 B and C). In this assay HepG2 cells were co-transfected 
with the constitutively active, rLuc-based, pRL-SV40 construct. Both fLuc and rLuc activity 
were normalised to DMSO-treated, equivalently transfected cells. fLuc activity was then 
expressed as a percentage of rLuc activity. When normalised to renilla luciferase expression, 
luminescence did not differ greatly from the initial analysis. HepG2 cells transfected with 
pGL4-NQO1 WT produced significantly more luminescence than the mutated construct (P = 
0.0286) (Fig 4.8 B). Cells transfected with pGL4-OR5T3 did not produce a luminescent 
response to CDDO-Me exposure. Therefore, while positive and negative control promotor-
reporter constructs exhibited expected luminescence values, lack of induction of F2RL2 WT, 
LOC344887 WT and TRIM16L WT greater than their MUT counterparts (Fig 4.7 C), indicated 
potentially indirect mechanisms for NRF2 activation in response to CDDO-Me exposure.   
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Figure 4.7 pGL4-construct response to CDDO-Me in HEK293T cells  
Luminescence in HEK293T cells transiently transfected with promoter-reporter constructs 
and exposed to 100 nM CDDO-Me for 24 h. (A) Luminescent response of empty vector, 
positive and negative control plasmids (n=3). (B) Luminescent response of WT and MUT 
constructs (n=1). Luminescence normalised to DMSO-treated, transfected counterparts. 
Significant difference between WT and MUT construct luminescence calculated by Student’s 
T test (*** p ≤ 0.001). Mean + SD shown. 
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Figure 4.8 pGL4-construct response to CDDO-Me in HepG2 cells 
(A) Luminescence in transiently transfected HepG2 cells following exposure to 100 nM 
CDDO-Me for 24 h (n=3). Luminescence normalised to 0.5 % DMSO-treated, transfected 
counterparts. Significance difference of wild-type (WT) and mutant (MUT) construct 
luminescence was calculated by one-way ANOVA. (B) Firefly (fLuc) and renilla (rLuc) 
luciferase expression was subsequently quantified in HepG2 cells co-transfected with either 
the empty vector, positive or negative control constructs and pRL-SV40, then treated with 
CDDO-Me in a similar manner (n=3). fLuc normalised to rLuc activity and expressed as a 
percentage of the DMSO-treatment groups. (C) fLuc expression of pGL4- WT and MUT 
constructs normalised to rLuc of pRL-SV40 vector in transiently transfected HepG2 cells 
stimulated with CDDO-Me (n=1). Significant difference between WT and MUT construct 
luminescence calculated by one-way ANOVA or Kruskal Wallis (* p ≤ 0.05 and *** p ≤ 0.001). 
Mean + SD shown.  
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4.3.6. ARE-reporter response to overexpression of NRF2  
To minimise off target effects of pharmacological activation of the NRF2 pathway, construct 
luminescence in response to NRF2 overexpression was assessed. As similar luminescence 
expression was evident with and without normalisation to rLuc expression of the pRL-SV40 
control plasmid, this control was not included in further experiments. Induction of NRF2 was 
achieved using the pSB-tet-NRF2 inducible construct (Fig A5). This plasmid utilises the 
‘tetracycline (Tet) on’ system, established by Gossen et al., whereby the constitutively active 
Tet repressor binds to the TRE promotor region, inhibiting transcription (Gossen et al., 1995). 
In cells transfected with pSB-tet-NRF2, repression of the NRF2 sequence is relieved following 
exposure to the tetracycline analogue, Doxycycline (DOX). This results in NRF2 
overexpression. Firstly, HEK293T cells were transfected with increasing amounts of pSB-tet-
NRF2, and NRF2 expression was induced by treatment with 6 µg/ml DOX for 24 h (Fig 4.9 A). 
Similar levels of NRF2 protein expression, compared with 24 h exposure to 100 nM CDDO-
Me and 2 h exposure to 10 µM MG132 were observed. To identify the optimal concentration 
of DOX for induction of the pGL4-reporter constructs in HepG2 cells, cells transfected with 
either pGL4-NQO1 WT or MUT constructs were exposed to increasing concentrations of DOX 
for 24 h (Fig.4.9 B). When normalised to DMSO-treated equivalents, doses of 5-8 µg/ml DOX 
induced the greatest difference between pGL4-NQO1 WT and MUT luciferase expression. 
Time course analysis revealed luminescence in HepG2 cells transfected with pGL4-NQO1 WT 
peaked at 12 h exposure to DOX (Fig 4.9 C).  
Based on these preliminary experiments, HepG2 cells transfected with the pGL4 promotor 
constructs were exposed to 6 µg/ml DOX and luminescence quantified after 12 h (Fig 4.10). 
Luminescence was normalised to DMSO-treated equivalents. Cells transfected with pGL4-
NQO1 WT produced significantly greater luminescent response to NRF2 overexpression 
compared to those transfected with pGL4-NQO1 MUT (P = 0.0026). Cells transfected with 
the other pGL4 reporters exhibited a similar luminescent response to that induced by CDDO-
Me (Fig 4.12 A). Therefore, despite testing alternative methods for NRF2-activation, the 
luminescence expression patterns of cells transfected with either WT or MUT constructs 
remained similar. 
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Figure 4.9 Optimisation of NRF2 overexpression by pSB-tet-NRF2 
(A) Western blot of HEK293T cells transfected with increasing amounts of pSB-tet-NRF2 and 
exposed to either 1 % DMSO or 6 µg/ml Doxycycline (DOX) in comparison with untransfected 
HEK293T cells treated with 1 % DMSO, 6 µg/ml DOX or 100 nM CDDO-Me for 24 h or 10 µM 
MG132 for 2 h. (C) Luminescence in HepG2 cells co-transfected with pSB-tet-NRF2 and 
exposed to increasing concentrations of DOX. Luminescence was quantified after 24 h (n=1). 
(C) Time course analysis of pGL4-NQO1 induction at 2, 6, 12 and 24 h post DOX administration 
(n=1) (dotted line = 100 %).  
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Figure 4.10 pGL4-construct response to NRF2 overexpression in HepG2 cells 
HepG2 cells were co-transfected with a promotor-reporter construct and pSB-tet-NRF2. 
After 12 h, NRF2 overexpression was induced via exposure to 6 µg/ml Doxycycline. 
Luminescence normalised to DMSO-treated, transfected counterparts (n=3). Significant 
difference in WT compared to MUT construct induction was calculated by One-way ANOVA 
and Kruskal Wallis (*** p ≤ 0.001). Mean + SD shown.  
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4.3.7. SRXN1 ARE assessment 
To assess the necessity of both ARE sites within the binding-region identified by Singh et al. 
as responsible for SRXN1 activation, WT and MUT reporter constructs were generated. In 
CDDO-Me-treated, transiently transfected HepG2 cells, pGL4-SRXN1 WT luminescence was 
greater than the three mutant-ARE-constructs (P = <0.0001 for all) (Fig 4.11 A). Interestingly, 
luminescence was not significantly different between the pGL4-SRXN1 ARE1, ARE2 or ARE 
1+2 mutants. When normalised to rLuc expression of a constitutively active construct, a 
similar expression pattern was observed, indicating transfection with the pGL4-SRXN1 WT 
and MUT constructs did not affect cell viability and transfection efficiency varied little 
between wells (Fig 4.11 B).  
In response to NRF2-overexpression, significantly greater luminescence was observed in 
HepG2 cells transfected with pGL4-SRXN1 WT compared to cells transfected with MUT 
constructs (P = <0.0001 for all) (Fig 4.11 C). Again, the luminescence responses between the 
pGL4-SRXN1 ARE1, ARE2 and ARE 1+2 mutants did not significantly differ.  
Therefore, while luminescence from cells transfected with the pGL4-SRXN1 WT construct 
was significantly greater than the other constructs in response to both CDDO-Me exposure 
and Nrf2 overexpression, luminescence of the pGL4-SRXN1 ARE1, ARE2 and ARE 1+2 mutants 
did not differ. Thus, highlighting the role both sites play in this extended ARE site during 
SRXN1 activation by NRF2.  
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Figure 4.11 Induction of wild-type but not mutant pGL4-SRXN1 constructs following NRF2 activation 
Luminescence of (A) HepG2 cells transiently transfected with promoter-reporter constructs and exposed to 100 nM CDDO-Me or 0.5 % DMSO for 24 h (n=3). 
Significance difference of wild-type (WT) and mutant (MUT) construct luminescence was calculated by one-way ANOVA. (B) Firefly (fLuc) and renilla (rLuc) 
luciferase activity was quantified in HepG2 cells co-transfected with pGL4-SRXN1 constructs and pRL-SV40, exposed to CDDO-Me or its vehicle control (n=1). 
fLuc was normalised to rLuc activity. (C) Luminescence of HepG2 cells co-transfected with pGL4-SRXN1 constructs and pSB-tet-NRF2, exposed to 6 µg/ml 
Doxycycline (DOX) or 1 % DMSO for 12 h. Significant difference in WT compared to MUT construct induction was calculated by one-way ANOVA (*** p ≤ 
0.001). Mean + SD shown.   
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4.4. Discussion  
Thorough understanding of the regulatory role of NRF2 in human hepatic cells may inform 
models of pathway activation for the identification hepatotoxic compounds. The aim of this 
chapter was to determine whether NRF2 directly regulates the expression of Coagulation 
factor II receptor-like 2 (F2RL2), NmrA-like family domain containing 1 pseudogene 
(LOC344887) and Tripartite Motif Containing 16 Like (TRIM16L), via specific ARE elements 
located in the promoter regions of these genes. Data mining publicly accessible datasets 
revealed these genes responded to NRF2 modulation by genetic and pharmacological stimuli 
(Agyeman et al., 2012; Igarashi et al., 2014; Singh et al., 2013). In particular, both LOC344887  
and TRIM16L exhibited responsive elements to sulforaphane exposure that aligned with ARE 
binding sites (Chorley et al., 2012; Kuosmanen et al., 2016). ARE sites identified via 
bioinformatic analysis were sub-cloned into the luminescent pGL4.20 vector. In response to 
NRF2 overexpression and pharmacological induction by CDDO-Me in vitro, the pGL4-Nqo1 
WT and pGL4-SRXN1 WT constructs produced significantly stronger luminescent signals than 
their mutant counterparts. The negative control plasmid pGL4-OR5T3 was not induced under 
any conditions. However, the luminescent response of wild-type pGL4-F2RL2, -LOC344887 
and -TRIM16L were never greater than cells transfected with their mutant counterparts, 
indicating the promotor regions included in this analysis may not be solely responsible for 
NRF2-mediated gene activation.  
LOC334887 is a transcriptionally active, duplicated pseudogene containing an RNA 
polymerase 2 and various transcription factor binding sites, identified by combining large-
scale RT-PCR-Seq of pseudogenes with gene annotation datasets including HAVANA (Human 
and vertebrate analysis and annotation)  (Pei et al., 2012). Located on chromosome 3, the 
pseudogene contains 10 introns and is associated with 8 mRNA splice variants (Thierry-Mieg 
and Thierry-Mieg, 2006). Initially described by Jacq et al., pseudogenes share similar 
sequences to functional genes but lack protein-coding ability due to the accumulation of 
mutations, absence of transcriptional activity or ability to encode RNA (Jacq et al., 1977). 
They may arise from the incorporation of mRNA into the chromosome (processed 
pseudogenes) or the accumulation of mutations over time (unprocessed and unitary 
pseudogenes)(reviewed by Groen et al., 2014). The encyclopaedia of DNA elements 
(ENCODE) project identified 863 pseudogenes within the human genome that are 
transcriptionally active and related to active chromatin (Pei et al., 2012). Expression of non-
coding RNA can act as endogenous siRNA or conversely compete with its functional paralog 
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for mRNA binding complexes resulting in enhanced stability and translation of mRNA 
associated with the parent gene of the pseudogene.  
Induction of LOC344887 in vitro has been demonstrated following exposure of cells to: 1,2,4-
benzenetriol (A reactive metabolite of benzenoxide) (Miyahara et al., 2014), cigarette smoke 
(Boylston and Brenner, 2014), airborne free radicals (Sun et al., 2012), and sodium arsenate 
(Qiu et al., 2015). Johnson et al. describe LOC344887 mediated co-activation of NRF2 
resulting in induction of NQO1 (Johnson et al., 2015). The authors treated colon cell lines 
with NRF2 inducers, sulforaphane, oltipraz and tert-butylhydroquinone, which resulted in 
induction of LOC344887. The pseudogene was also sensitive to knock down of NRF2. 
Chromatin immunoprecipitation identified potential NRF2 and MAFk binding regions while 
RNA immunoprecipitation supplied evidence for direct binding to MafK. The authors 
hypothesized that LOC344887 acts as a scaffold for MafK/NRF2 or other transcription factors 
on the promoter region of NQO1. Johnson et al. identify the ‘TGACAGAGCCG’ sequence 
(named ARE2) between exon1 and 2 as the location of NRF2 and Mafk co-localisation. This 
ARE site was incorporated into our pGL4-LOC344887 WT vector. However, the authors also 
note the binding of MafK to the ARE1 sequence (TGACACTGCA) in the pseudogene’s 
promotor region. This ARE site was part of the 390 bp region deleted in the CRISPR/Cas9 
knock out cell line. The ARE1 sequence was not included in our promotor reporter analysis 
and, if MafK is an essential cofactor for expression of LOC344887 in hepatocytes stimulated 
with sulforaphane, may therefore be the reason for the lack of induction of the pGL4-
LOC344887 WT plasmid.  
F2RL2 encodes protease activated receptor 3 (PAR3), a member of the G protein coupled 
receptor family. The gene extends across two exons encoding the signal peptide and mature 
protein, seven transmembrane helices, a pro-domain, three intracellular loops, three 
extracellular loops and a carboxyl terminus (Kahn et al., 1998). PAR3 also contains a hirudin-
like binding domain within the amino terminus, to which prothrombin binds. There are four 
PARs present in humans and mice which are activated following proteolysis of the N-
terminus either by thrombin or other proteases including trypsin and coagulation factors 
(Reviewed by Coughlin, 2000). Originally identified by Ishihara et al., there is little evidence 
to suggest PAR3 functions autonomously and is therefore classed as an non-signalling 
receptor (Ishihara et al., 1997).  However, increasing evidence indicates its role as a cofactor 
for activation of other PARs including heterodimerization with PAR1 (McLaughlin et al., 
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2007). X-ray crystallography highlighted the role of PAR3 as a cofactor for the activation of 
PAR4 via cleavage of prothrombin (Bah et al., 2007).   
Knockdown of PAR3 in human pancreatic adenocarcinoma (PANC1) cells lead to: faster 
adhesion to plastic and madrigal-coated plates, slower ‘wound closure’ in a 2D assay, and  
increased expression of integrins and E-cadherin (Segal et al., 2014). While, knock down of 
PAR3 in human osteoarthritis synovial fibroblasts (OASFs) significantly abolished thrombin 
mediated upregulation of HMOX1 (Liu et al., 2012). Exposure to a PAR3 agonist, resulted in 
significant increases in HMOX1. It is thought that thrombin induces HMOX1 via PAR1 and 
PAR3 interactions with NRF2 signalling in OSAFs. Other proteases have been shown to 
activate Nrf2-regulated: PAR2 activates NQO1 in keratinocytes (HaCaT cells) by stabilizing 
NRF2 to facilitate its translocation (Kim et al., 2014).  
Similar to LOC344887, increased expression of F2RL2 alongside HMOX1 was evident 
following treatment with 1% cigarette smoke extract in human bronchial epithelial cells 
(Boylston and Brenner, 2014). F2RL2  is down-regulated in activating transcription factor 3 
(ATF3) KO mice (Akram et al., 2010). ATF3 has been shown to interact directly with NRF2 in 
order to repress NRF2 pathway activation (Brown et al., 2008). However, microarray analysis 
of global gene expression within the non-small cell lung cancer (NSCLC) cell line A549, 
revealed down-regulation of F2RL2 in comparison to untreated cells, following 48 h of 
stimulation with 50 μM quercitrin, a potent antioxidant and NRF2 activator (Cincin et al., 
2014). This may be due to the 48 h time point or tissue specific F2RL2 activity. 
TRIM16L, also known as TRIM70, shares significant homology to the TRIM16 sequence (Yu 
et al., 2016). As members of the tripartite motif-containing (TRIM) family, these genes 
contain a motif consisting of a ring domain, at least one B-box domain and an associated 
coiled-coil domain in the N-terminus (Hatakeyama, 2011). In response to laminar sheer 
stress, microarray analysis of human umbilical vein endothelial cells (HUVECs) identified 
upregulation of TRIM16 alongside NRF2-regulated genes including HMOX1, NQO1 and GCLM 
(Warabi et al., 2004). Other members of the TRIM family, such as TRIM21 have been shown 
to regulate NRF2 expression via direct ubiquitination of P62, inhibiting KEAP1 degradation, 
resulting in suppression of NRF2 pathway activity (Pan et al., 2016). In human non-small cell 
lung carcinoma tumours with mutations in KEAP1 and exons within the KEAP1 binding sites 
of NRF2, both TRIM16 and TRIM16L mRNA expression was elevated compared to tumours 
without these mutations (Goldstein et al., 2016). However, the role of TRIM16L and its place 
in the NRF2 pathway are yet to be discovered.  
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In this chapter, I utilised a luciferase-based promotor-reporter assay to determine the ARE 
sites responsible for NRF2-mediated activation. This technique, among others, has been used 
previously, to identify NRF2-regulation of genes. The electrophoretic mobility shift assay 
(EMSA) and super-shift assay document the slower migration of DNA-protein complexes 
through a gel compared to DNA alone (Fried and Crothers, 1981; Garner and Revzin, 1981). 
However, these ‘peak’ regions often span large areas, impeding identification of exact 
binding sequences. HereI applied mutational analysis of promotor regions of putative NRF2-
regulated genes to provide direct evidence of NRF2 binding to putative ARE sites.  
The consensus ARE sequence has undergone many revisions. Initial identification of the motif 
in rat GSTA1 and NQO1 revealed the sequence RGTGACnnnGC (R=A or G) (Rushmore et al., 
1991). Assessment of mouse Gsta2, Nqo1, Gstp1, and Ftl indicated 
TMANNRTGAYNNNGCRWWWW (W=A/T M=A/C) was more representative (W. W. 
Wasserman and Fahl, 1997). Observation of two ARE sites within the human GCLM promoter 
revised the sequence to T,G/T,A,C/T,NNNGCA (Erickson et al., 2002). Comparison of well-
established ARE motifs across human, mouse and rat genomes confirmed nucleotides 
TNANNNNGC were constant and TGACNNNGC as the most-likely core consensus sequence 
(Wang et al., 2007). However previous mutational analysis by Nioi et al. highlighted 
divergence between mouse and human ARE sequences, stating a universal ARE consensus 
sequence may not be possible (Nioi et al., 2003). In this chapter ARE sequences from NQO1, 
F2RL2, LOC344887 and TRIM16L, included in our mutational analysis, all contained the 
TGACNNNGC motif (Table 4.1).  
Despite using both genetic and pharmacological methods of NRF2 activation, luminescence 
in cells transfected with pGL4-LOC344887 and pGL4-F2RL2 WT and MUT constructs were not 
significantly different. Lack of differential activation of WT and MUT construct luminescence 
may suggest these genes are not regulated by NRF2. However, this is unlikely as 
bioinformatic analysis highlighted modulation in variety of cell types exposed to different 
stimuli known to modulate NRF2 (Agyeman et al., 2012; Igarashi et al., 2014; Singh et al., 
2013). Expression may be indirectly regulated by the transcription factor. Nrf2 has been 
shown to modulate miRNAs that influence transcription of other genes (Chorley et al., 2012; 
Singh et al., 2013). In Nrf2-/- fibroblasts, rescue of GCLC promoter-reporter construct 
activation, in response to tBHQ via Nrf2 overexpression was inhibited when activator protein 
1 (AP-1)  transcription factor binding sites within the GCLC promoter were mutated  (Yang et 
al., 2005). Additionally there is cross-talk between NRF2-regulated genes and those 
containing xenobiotic response elements (XRE) sites regulated by the transcription factor 
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aryl hydrocarbon receptor (AHR) (Yeager et al., 2009). Many of the genes listed in Table A1 
had XRE sites close to the gene start site (data not shown). NRF2 itself is regulated by AHR 
(Miao et al., 2005). Conversely NRF2-/- mice exhibited reduced expression of AHR and NRF2 
has been shown to directly bind to an ARE site 250 bp upstream from the transcription start 
site of AHR (Shin et al., 2007). Alternatively, the promotor elements included in the reporter 
constructs may not contain the specific ARE sequence or additional enhancer sites necessary 
for activation. For instance, the ARE sites identified in the Kuosmanen dataset upstream of 
the F2RL2 start site, do not align with a binding site within the Chorley dataset. One way to 
assess this would be to co-transfect promotor-reporter and trans-acting enhancer-reporter 
constructs similar to those utilized in massively parallel reporter assays (MPRAs) to identify 
sequences necessary for gene activation.  
In response to different forms of NRF2 stimulation, pGL4-TRIM16L MUT luminescence was 
consistently significantly greater than in cells transfected with the WT construct. 
Introduction of another ARE site within the MUT construct may explain the additional 
luminescent activity however none were found. Interestingly, both 1 kb inserts contained 
the canonical AP-1 binding site, or TPA-responsive element (TRE): TGAGTCA, 52 base pairs 
from the transcription start site. This may be the reason for the substantial induction of 
luminescence observed in cells transfected with pGL4-TRIM16L WT and MUT constructs, 
compared to the other reporters.   CDDO-Me is thought to activate AP-1  via induction of c-
Jun expression (Zou et al., 2004). Additionally, c-JUN-Nrf2 heterodimers have been shown to 
activate Nrf2-regulated genes such as CYP2J2 (Lee and Murray, 2010). Generation of 
constructs with promotor regions of different lengths (i.e. 100/200/500 bp from 
transcription start site) would aid identification of the site responsible for pGL4-TRIM16L WT 
and MUT reporter construct activation. Diminished activation of luminescence following 
knock down of AP-1 expression, in cells transfected with the pGL4-TRIM16L constructs would 
also highlight the role the TRE site plays in the reporter activation. Additionally, sequential 
base changes to the ARE within the TRIM16L promotor would highlight the region 
responsible for increased luminescence seen in the pGL4-TRIM16L MUT construct.  
The ARE region identified by Singh et al. as the NRF2 binding site in A549 lung cells, when 
stimulated by tBHQ, contains two ARE sites (Singh et al., 2009). Mutation of one or both ARE 
sites in the promotor region of SRXN1, identified by Singh et al., showed no difference in 
luminescent response (Singh et al., 2009). This lack of significant induction of luminescence 
in cells transfected with MUT constructs with either or both ARE sites compromised, 
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compared to pGL4-SRXN1 WT, indicates potential for the extended ARE site to be essential 
for NRF2-mediated regulation. Consistent with our findings, Soriano et al. mutated bases 
within the ARE2 region (mutations highlighted in bold: CTGCAAACTCACCCTGAGTCAGCCC) 
that lead to diminished activation of luciferase-based reporter constructs exposed to CDDO-
TFEA in neuronal cells (Soriano et al., 2008). One possibility is that the active ARE site bridges 
the two mutant constructs. Point mutational analysis across the entire extended sequence 
would highlight the exact region required for NRF2 binding. 
In this chapter, mining of publicly available transcriptomic datasets corroborated our 
microarray analysis of genes sensitive to NRF2-pathway modulation in PHH. Activation of 
potentially novel NRF2-regulated genes F2RL2, TRIM16L and LOC344887 were assessed by 
promotor-reporter assay. Further assessment of the promoter and potential enhancer 
elements of these genes, either by ChIP or EMSA of PHH lysates, is needed to confirm the 
direct or indirect NRF2-mediated induction of these transcripts. Assessment of multiple ARE 
sites in the promotor region of SRXN1, highlighted, for the first time, the necessity of both to 
facilitate transcription in response to NRF2 stimulation. Ultimately, delineation of the Nrf2-
regulated transcriptome will shed light on the role of the pathway within the cell and provide 
markers to improve assessment of NRF2 pathway activity.  
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5.1. Introduction 
The dietary isothiocyanate sulforaphane is currently undergoing clinical trials for the 
treatment of a range of different diseases including schizophrenia (NCT02880462), autism 
(NCT02909959), lung cancer (NCT03232138), skin aging following UV exposure 
(NCT03126539), prostate cancer (NCT01950143), colon cancer (NCT01344330) and type 2 
diabetes (NCT02801448). The electrophilicity of isothiocyanates facilitates the formation of 
covalent bonds with cysteine residues (Lewis et al., 2017). Dinkova-Kostova et al. recorded 
cysteine modifications of murine Keap1 in the presence of sulforaphane using UV-VIS and 
mass-spectroscopy (Dinkova-Kostova et al., 2002). In particular, the cysteine residue C151 in 
the BTB domain of KEAP1 mediates NRF2 activation as expression of a mutant KEAP1-C151 
protein repressed NRF2 pathway activation by sulforaphane (Zhang and Hannink, 2003). This 
was confirmed using biotin-switch technique whereby unstable cysteine adducts were 
biotinylated and precipitated using streptavidin beads (McMahon et al., 2010). Additionally, 
sulforaphane has also been shown to augment NRF2 synthesis by promoting ribosomal 
internalization of NRF2 mRNA for protein synthesis (Li et al., 2010). Recently, Clulow et al. 
identified over 500 proteins potentially liable to modification by sulforaphane (A. Clulow et 
al., 2017). Sulforadex® (SFX-01), the α-cycoldextrin coated sulforaphane produced by Evgen 
pharma, is currently undergoing clinical trials for the treatment of sub arachnoid 
haemorrhage (NCT02614742) and metastatic breast cancer (NCT02970682).  
Regulatory authorities such as the OECD have endorsed the integration of cell-based 
reporters for screening compounds in a medium- to high-throughput manner for NRF2 
pathway activation linked to certain forms of drug toxicity (Emter and Natsch, 2015; Mutter 
et al., 2015). Initiatives such as ToxCast and Tox21 demonstrate the utility of in vitro high-
throughput screening to identify activation of NRF2 (Huang et al., 2016; Richard et al., 2016). 
The latter employed fluorescent reporters such as SRXN1-GFP to inform on the mechanisms 
of toxicity in human cell lines. Conversely, a number of ARE-driven reporter cell models have 
been used to screen for the therapeutic activation of NRF2 (Ramkumar et al., 2013; Wu et 
al., 2012). For instance, the luminescent AREc32 cell line established by Wang et al., 
identified NRF2-inducers from a panel of 54 natural dietary compounds such as curcumin 
and quercetin (Wang et al., 2006; K. C. Wu et al., 2014).   
Here, I exemplify the use of a rat liver cell line, H4IIe-8AREL, stably transfected with a 
luciferase reporter driven by an eight times repeated ARE sequence from the promotor of 
rat Gsta2 (Kratschmar et al., 2012), to assess the potencies of a sulforaphane analogue series 
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to guide the selection of back up compounds for the SFX-01 development program. To 
improve the human relevance of this approach, I also describe the generation of a luciferase 
reporter under the control of a quintupled ARE sequence and demonstrate its use as a 
screening tool for NRF2 activators in human HepG2 liver cells.  
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5.2. Materials and Methods 
All reagents were purchased from Sigma unless otherwise stated. 
5.2.1. Cell culture, drug treatment and reverse transfection 
H4IIe-8AREL cells, kindly donated by Prof. Alex Odermatt (Basel University, Switzerland), 
were cultured in conditions similar to those previously described in section 4.2.3. Culture 
media consisted of DMEM supplemented with 1x Non-essential amino acids (Life 
Technologies, Carlsbad, USA), 10 mM HEPES (Life Technologies, Carlsbad, USA), 1 % (v/v) 
Penicillin/streptomycin and 10 % heat-inactivated FBS. Cells were seeded 25,000 cells per 
well of a 96 well plate.  
Sulforaphane and its analogues were produced by Dr. Noureddine Khiar (Consejo Superior 
de Investigaciones Cientivicas, Seville, Spain) with support from EVGEN pharma (Liverpool, 
UK). Drug treatments were conducted in a similar manner to those described in section 
4.2.3.2, in a 96 well-plate format. Concentrations at which there is 200 % luciferase activity, 
proportional to NRF2 activity (CD values) were calculated using Graph-pad prism previously 
described (Copple et al., 2014). Briefly, non-linear regression of the concentration-response 
curves facilitates interpolation of the CD concentration.  
HepG2 cells were transiently transfected with plasmids as previously described in section 
4.2.3.3.  Induction of the pSB-tet-NRF2 plasmid was achieved upon exposure of HepG2 cells 
to 6 µg/ml Doxycycline (DOX) in comparison with vehicle-treated cells (1 % DMSO).  
5.2.2. Annealed Oligo cloning 
Annealed oligonucleotides provide a fast, cost-effective method of generating short double-
stranded DNA sequences. Primers are first heated to break any hydrogen bonds and 
generate single-stranded DNA sequences. Subsequent slow cooling facilitates hybridisation 
of the complementary sequences. The following primers were annealed and ligated into the 
linearized pGL4 plasmid (Table 5.1). Forward and reverse primers were incubated at 94 °C 
for 10 min in 10 µl reactions consisting of: 1 µl 100 µM Fwd primer, 1 µl 100 µM Rev primer, 
1 µl 10x ligase buffer and 7 µl dH2O. Reactions were left to cool slowly to room temperature 
for 1 h. Inserts were diluted 1 in 12.5 with dH2O. Ligation reactions consisted of: 0.5 µl 50 ng 
linearized pGL4.20, 4 µl of diluted insert, 1 µl 10x ligase buffer, 0.5 µl T4 ligase and 4 µl dH2O. 
These were incubated at 16 °C overnight. Bacteria were transformed, and successful ligations 
screened and sequenced in a similar manner to section 4.2.2.3. HepG2 cells were reverse 
transfected with either the pGL4-5xARE WT, MUT or empty vector.    
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Table 5.1 Annealed oligo cloning primers  
WT and MUT ARE sequences underlined.  
Insert  Primer Sequence 
NQO1 ARE 5x WT Fwd 5’ – CCCCGTGACTCAGCACCCGTGACTCAGCACC 
CGTGACTCAGCACCCGTGACTCAGCACCCGTGACT
CAGCACCCG – 3’ 
Rev 5’ – CTAGCGGGTGCTGAGTCACGGGTGCTGAGTC 
ACGGGTGCTGAGTCACGGGTGCTGAGTCACGGGT
GCTGAGTCACGGGGGTAC – 3’  
NQO1 ARE 5x MUT Fwd 5’ – CCCCCGTCAGACTACCCCGTCAGACTACCCC 
CGTCAGACTACCCCGTCAGACTACCCCGTCAGACT
ACCCCG – 3’ 
Rev 5’ – CTAGCGGGTAGTCTGACGGGGTAGTCTGA 
CGGGGTAGTCTGACGGGGTAGTCTGACGGGGTA
GTCTGACGGGGGTAC– 3’ 
 
5.2.3. ATP quantification  
ATP was quantified using the Cell-Titer-Glo kit (Promega, Madison, USA). 20 µl ATP reagent 
was added per well of a 96 well-plate. The plate was shaken for 1 min at 700 RPM. 100 µl of 
cell lysate was transferred from each well to a white-walled 96-well plate (Greiner Bio-one, 
Kremsmünster, Austria) and incubated for 5 min at room temperature. Luminescence was 
quantified using the Varioscan Flash.  
5.2.4. In vitro luciferase assays 
See section 4.2.4.  
5.2.5. Statistical analysis  
See section 2.2.10. Non-Linear regression was calculated using Prism.  
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5.3. Results  
5.3.1. Sulforaphane analogues produce a bioluminescent response in H4IIe-8AREL cells 
Firstly, concentration-dependent activation of the 8AREL reporter was assessed in response 
to established and clinically used NRF2 activators (Fig 5.1 A and B). At toxic concentrations 
of CDDO-Me and sulforaphane, both luminescence and cellular ATP content decreased. CD 
values associated with these compounds were 0.001 and 0.829 µM respectively. SFX-01 is 
sulforaphane coated in α-cyclodextrin. No induction of luminescence or loss of cell viability 
was observed following treatment with the coating substrate alone (Fig 5.1 C). However, SFX-
01-treatment resulted in a CD value of 1.468 µM comparable to that of sulforaphane (Fig 5.1 
D). The resulting rank order of potency as inducers of the 8AREL reporter was CDDO-
Me>>sulforaphane>SFX-01 (Fig 5.1 E).   
Subsequently, I applied this screening technique to determine the potency of NRF2-
activiating compounds on a larger scale. The H4IIe cell line was subsequently exposed to 42 
sulforaphane analogues, as part of the SFX-01 development program in collaboration with 
EVGEN Pharma (Liverpool, UK). CD values were calculated, and compounds ranked for their 
NRF2 activating potencies (Table A2). These ranged from 1.45 to 89.33 µM. The sulforaphane 
parent compound (EVG01) was assessed as a positive control and, out of all the compounds 
included in the SFX-01 program, produced a CD value much lower than the experimental 
compounds (1.45 µM).   
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Figure 5.1 Decreased luciferase NRF2-reporter activity following toxicity 
Potencies and toxicities of (A) CDDO-Me, (B) Sulforaphane, (C) α–cyclodextrin and (D) Sulforadex® (SFX-01). H4IIe cells were exposed to the indicated 
concentrations of drug or vehicle control. Following 24 h exposure, luciferase-reporter activity (bold line) and ATP content (dotted line) were quantified (n=4). 
Mean and SD shown. CD values were calculated by non-linear regression (E).  
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To assess the relative potencies of the sulforaphane analogues compared to the parent 
compound, CD values were calculated from dose-response curves documenting activity of 
the H4IIe-8AREL reporter. Identification of analogues with similar potencies to sulforaphane 
may provide candidates for clinical application.  
To calculate the CD values of the sulforaphane analogues, non-linear regression of the dose-
response curve, excluding toxic concentrations associated with luminescence reduction was 
applied. Apart from five compounds (EVG07, EVG08, EVG11, EVG12 and EVG31), all 
analogues exerted a two-fold enhancement of luminescence in comparison with vehicle-
treated controls (Fig A6). Seventeen compounds had CD values exceeding 20 µM, ranging 
from between 20.04 ± 3.17 to 89.33 ± 18.39 µM (Fig A7). Of these compounds, EVG15 had 
the lowest CD value (Fig A7 A), whereas EVG33 had the highest CD value (Fig A7 Q). Of the 
remaining compounds, CD values ranging from 15.17 ± 7.44 to 19.63 ± 5.27 µM were 
observed from five analogues (Fig A8), whereas, fifteen of the compounds generated CD 
values below 15 µM ranging from 11.04 ± 2.31 to 14.80 ± 8.36 µM (Fig A9). EVG01 and EVG02, 
with CD values of 1.453 ± 0.24 and 5.493 ± 2.28 µM respectively, exhibited potencies closest 
to the parent compound, sulforaphane (Fig A10).  
Taken together, these findings demonstrate a broad range of potencies for the analogues of 
the SFX-01 development program. Additionally, all analogues are less potent than the parent 
compound and commercially-available sulforaphane.  
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5.3.2. Construction and validation of pGL4-5xARE reporter 
To generate a bioluminescent reporter that could be transiently (and ultimately stably) 
transfected into human cells, wild-type (WT) and mutated (MUT) quintupled consensus ARE 
constructs (5xARE) were synthesised and sub-cloned into the luminescent pGL4.20 vector 
(Fig 5.2 A). The mutated ARE sequence was generated by replacing the nucleotide bases T 
with G and A with C, and vica-versa. A string of three cytosine nucleotides was used to 
separate each ARE repeat sequence, similar to the repeat regions within the eight-times 
repeated AREc32 reporter (Wang et al., 2006). Both WT and MUT constructs were 
successfully sequenced (Fig 5.2 B and C).  
To validate successful generation of WT and MUT reporter constructs, luminescence was 
quantified in transiently transfected HepG2 cells exposed to 100 nM CDDO-Me for 24 h. This 
dose of CDDO-Me had previously been shown to induce the Nrf2-pathway in HepG2 cells 
(See Chapter 4). Following CDDO-Me exposure, HepG2 cells transfected with pGL4-5xARE 
WT produced significantly greater luminescence compared to those transfected with pGL4-
5xARE MUT, when normalised to transfected cells treated with 0.5 % DMSO (P = 0.0018) (Fig 
5.3 A). Luminescence normalised to renilla luciferase signal in cells co-transfected with the 
pRL-SV40 construct, highlighted a similar increase in WT luminescence compared to controls 
(Fig 5.3 B). Therefore, this indicated that cell viability and transfection efficiency were not 
influencing the strength of luminescent responses.  
To assess the reporter’s sensitivity to other forms of NRF2 stimulation, the response of the 
5xARE constructs to NRF2 overexpression, induced by doxycycline (DOX) exposure of HepG2 
cells co-transfected with either WT or MUT reporter constructs and pSB-tet-NRF2 was also 
measured (Fig 5.4). Comparison against DMSO-treated controls, whereby NRF2 
overexpression was not induced, demonstrated significantly greater luminescence from WT-
transfected cells than in the MUT-transfected counterparts (P = 0.0052).  
As findings demonstrated that the pGL4-5xARE WT construct was more responsive to NRF2 
induction by chemical and pharmacological stimuli than the mutant construct, I subsequently 
utilized this ARE reporter, in HepG2 cells, to characterise a subset of sulforaphane analogues 
with a range of potencies.   
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Figure 5.2 5xARE reporter construction 
The five times repeated ARE sequences (5xARE) of wild-type (WT) or mutated (MUT) human NQO1 were sub-cloned into the pGL4.20 vector (A). Miniprepped 
DNA from bacterial colonies transformed with pGL4-5xARE WT or MUT constructs were screened (B) for successful insert ligation (*) prior to sequencing. (C) 
Sanger sequencing confirmed insert integration (MUT ARE sequences highlighted red).   
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Figure 5.3 Response of pGL4-5xARE reporter to CDDO-Me in HepG2 cells 
HepG2 cells transfected with wild-type (WT) or mutant (MUT) pGL4-reporter constructs exposed to either 100 nM CDDO-Me or 0.5 % DMSO and luminescence 
quantified after 24 h (A) (n=3). HepG2 cells co-transfected with pRL-SV40 and luminescence normalised to rLuc expression (B) (n=1). Significant difference in 
WT compared to MUT construct induction was calculated by Students T-test (** p ≤ 0.01). Mean + SD shown. Solid line = baseline against which normalisation 
was performed.   
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Figure 5.4 Response of pGL4-5xARE reporter to NRF2 overexpression 
HepG2 cells co-transfected with pSB-tet-NRF2 and either wild-type (WT) or mutant (MUT) 
pGL4-reporter constructs. Cells were exposed to 6 µg/ml Doxycycline or DMSO and 
luminescence quantified after 12 h (n=3). Significant difference in WT compared to MUT 
construct induction was calculated by students t-test (** p ≤ 0.01). Mean + SD shown. Solid 
line = baseline against which normalisation was performed.   
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5.3.3. pGL4-5xARE reporter activated by sulforaphane analogues in HepG2 cells 
To investigate the human relevance of the ARE reporter screening approach, selected 
sulforaphane analogues from the SFX-01 development program were assessed for their 
potency to activate the pGL4-5xARE reporters and the pGL4-NQO1 WT plasmid (generated 
in chapter 4) in HepG2 cells. Cells transfected with the reporters were exposed to increasing 
concentrations of compounds shown previously to have high, medium or low CD values 
when evaluated in the H4IIe-8AREL cell line. These compounds were EVG33 (CD = 89.33 µM) 
(Fig A7 Q), EVG40 (CD = 34.914 µM) (Fig A7 N), and EVG01 (CD = 1.45 µM) (Fig A10 A).  
In cells transfected with pGL4-NQO1 WT, only EVG40 and EVG01 induced a two-fold greater 
luminescence than vehicle-treated controls (Fig 5.5 A), producing CD values of 2.009 µM and 
0.717 µM respectively. In pGL4-5xARE-transfected cells, EVG40 and EVG01 had CD values of 
8.035 µM and 3.729 µM respectively (Fig 5.5 B). These cells were also observed to display 
more variable luminescent responses than pGL4-NQO1 WT-transfected cells, based on the 
size of the standard deviation. Additionally, as mentioned, CD values of EV40 were vastly 
different between the two NQO1-based reporters (Fig 5.5 C).  
In summary, here I observed a similar trend in the rank order of sulforaphane analogue 
potencies but absolute CD values varied greatly between cell lines and reporter constructs.  
Chapter 5 
195 
 
 
Figure 5.5 Response of pGL4-NQO1 and 5xARE reporter constructs to sulforaphane analogues in HepG2 cells 
HepG2 cells, transfected with either pGL4-NQO1 WT (A) or pGL4-5xARE WT (B) and exposed to the parent compound EVG01 and analogues identified to 
induce the NRF2 pathway in the H4IIe cell line at high (EVG33), medium (EVG40) or low (EVG01) concentrations (n=3). After 24 h, luminescence was quantified. 
CD values (C) were calculated following non-linear regression analysis.  
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5.4. Discussion  
The data in this chapter summarises the characterisation of a range of sulforaphane 
analogues, generated as part of the SFX-01 development program. Here I show the 
application of the rat hepatoma cell line H4IIe-8AREL for the medium-throughput screening 
of these analogues, to assess the relative potencies needed to activate the NRF2 pathway. 
Following the construction of a similar luminescent reporter plasmid containing multiple 
consensus AREs (pGL4-5xARE WT), I hypothesised analogous luminescent responses would 
be induced in transiently transfected human hepatocarcinoma, HepG2 cells. The similar 
trend in rank order of analogue potencies towards activation of ARE-based reporters gives 
confidence in the ability of the 5xARE-reporter to predict the potencies of novel activators 
to induce the NRF2 pathway. 
The potency of electrophilic, canonical NRF2 activators such as sulforaphane, are determined 
by their reactivity towards KEAP1 thiols including the highly reactive C151 but also cysteines 
within the KELCH domain (Hu et al., 2011). This is mediated by the highly reactive 
isothiocyanate group (-N=C=S). Previous assessment of sulforaphane analogue potencies 
have focused on the compounds ability to double NQO1 activity.  Initially this was quantified 
using a colorimetric assay in which reduction of the dye 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) is proportional to enzyme activity (Prochaska and 
Santamaria, 1988). Utilizing this technique, Posner et al. assessed activity of linear 
sulforaphane analogues, replacing sulfoxide group (C-SO-C) with other polar groups, to 
induce Nqo1 in mouse Hepa1c1c7 cells (Posner et al., 1994). However, none were as potent 
as sulforaphane itself, indicating the importance of the sulfoxide group as well as the 
isothiocyanate group to activate NRF2. By replacing the isothiocyanate group with 
alternative sulfoxythiocarbamate groups, Ahn et al. produced analogues of sulforaphane 
capable of forming stable adducts with KEAP1 (Ahn et al., 2010). The length of the methylene 
bridge between the isothiocyanate and sulfoxide groups is also important as modification 
reduced potency (Zhang et al., 1992).  
Although the focus of this chapter was not on deciphering detailed structure activity 
relationships of the analogues, it was apparent that most compounds with non-determined 
CD values contained a ‘trioxaundecane’ group. Additionally, many compounds containing the 
‘heptaoxatricosane-1-sulfinamide’ group exhibited CD values greater than 25 µM. The 
addition of extensive structures to the compound may cause steric hinderance, interfering 
with the interaction with its target site and reducing potency. None of the analogues 
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exhibited a modified isothiocyanate group. Modification of this region may yield analogues 
with greater potency towards the Nrf2 pathway.  
Several ARE-based reporter assays have been established for the high-throughput screening 
of Nrf2 activating compounds. Previous work from our laboratory has demonstrated the 
application of the H4IIe-8AREL cell line for the assessment of therapeutic index of Nrf2 
activating compounds such a CDDO-Me (Copple et al., 2014). In this chapter, induction of 
luminescence in HepG2 cells following exposure to EVG40, EVG33 or EVG01 resulted in a 
similar rank order of potencies towards activation of the pGL4-5xARE WT or pGL4-NQO1 WT 
reporter, established in chapter 4. This was comparable to the compounds’ potency towards 
the 8AREL reporter in H4IIe cells, i.e. EVG01>EVG33>EVG40. This trend, observed in a limited 
number of compounds is encouraging. Previous assessment of NRF2 activators using the 
H4IIe cell line have shown strong correlation with potencies calculated by induction of Nqo1 
in the murine Hepa1c1c7 cell line (Copple et al., 2014; Dinkova-Kostova et al., 2005). The 
contrast between absolute potencies observed in this chapter may be explained by the 
differences in cell line and reporter constructs.  
While absolute CD values differed greatly between ARE-based reporters exposed to the same 
sulforaphane analogue, this is likely due to inherent differences in the assays.  Inclusion of 
multiple repeated ARE sites have previously been shown to increase luciferase-based 
reporters sensitivity to pathway activation (Nguyen et al., 1994; Wang et al., 2006). Here, I 
observed lower CD values in cells transfected with pGL4-NQO1 WT rather than pGL4-5xARE 
WT. For example, EVG01 produced CD values of 0.717 µM and 3.729 µM respectively. 
Luminescence was more variable in the pGL4-5xARE transfected cells for all compounds 
measured when compared to the responses quantified in pGL4-NQO1 WT transfected cells. 
This may be due to the inclusion of the extended promotor region in the pGL4-NQO1 WT 
plasmid, providing opportunity for the recruitment of other cis-acting factors to aid 
transactivation compared to the limited five-times repeated consensus sequence 
incorporated within pGL4-5xARE.  
One limitation of this dataset is the lack of transfection efficiency assessment. Although 
characterisation of the pGL4-5xARE reporter in response to CDDO-Me, showed no obvious 
detriment to cell viability or transfection efficiency (Fig 5.3 B). The application of NQO1-based 
reporters when basal expression of NQO1 in HepG2 cell line is substantial (Gray et al., 2016), 
may also influence the lack of reporter induction in this cell line. Analysis of the induction of 
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pGL4-SRXN1 WT construct (previously characterised in Chapter 4) in HepG2 cells exposed to 
these compounds, would give credence to this theory. Comparison of the ability of selected 
sulforaphane analogues to activate the NQO1-based reporter in the recently established 
HUH7-1x-ARE-Luc cell line (Motahari et al., 2015), would also be of interest. Motahari et al. 
generated the pGL4.26-1x-ARE-Luc reporter consisting of a single copy of the ‘extended’ 
NQO1 ARE sequence (Motahari et al., 2015). HUH7 cells, stably transfected with this 
reporter, produced luminescence in response to both toxic (hydroquinone and p-
benzoquinone) and therapeutic (Curcumin) activation of the NRF2 pathway.  
A limitation of these ARE-based reporter assays is the inclusion of only one form of ARE 
sequence from a single NRF2-regulated gene. The data from previous chapters highlights the 
differential responses of the array of NRF2-regulated genes to different stimuli. Reporter 
constructs consisting of multiple ARE sequences could be advantageous, as reliance on 
expression of a single gene of interest may miss NRF2 pathway activation from exposure to 
certain compounds; ultimately generating false-negative results. To this effect, Rizzi et al. 
established a bicistronic reporter under the control of repeated ARE sequences from the 
promotor regions of Hmox1, Nqo1, GstYa and Gsr (Rizzi et al., 2017). These transgenic mice 
produced a bioluminescent response to ASN across tissues although interestingly, 
luminescence in muscle was not as high as the induction of endogenous Hmox1 expression. 
It would be interesting to see the region of the multiple ARE reporter construct to which 
NRF2 binds as ARE sequence variation has been shown to influence binding affinity of NRF2-
small MAF complexes (Kuosmanen et al., 2016). 
Construction of an Neh2-Luc reporter facilitated the monitoring of Nrf2 stabilisation in 
response to drug exposure (Smirnova et al., 2011). The inclusion of the Nrf2 domain instead 
of an ARE-site from a downstream gene allows monitoring of direct Nrf2 activation but does 
not provide evidence that this accumulation leads to functional pathway induction. Inclusion 
of this site into a β-galactosidase (LacZ) reporter construct, generated a signal faster than 
ARE-based luciferase reporters within MEFs exposed to DEM and tBHQ  (Hirotsu et al., 2011). 
However, inclusion of the Neh2 region only, is not sensitive to NRF2 activators that do not 
target KEAP1 binding.  
Within the extended ARE site included in the reporter assay developed by Hirotsu et al.  is 
an AP-1 binding site (Hirotsu et al., 2011). Incorporation of multiple reporter assays would 
provide more evidence of off-target effects of compounds and the specificity of the drug to 
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activate the Nrf2 pathway. Off-target effects of sulforaphane include inhibition of histone 
deacetylase (Myzak et al., 2004), and reduced activation of NF-κB (Heiss et al., 2001). High-
throughput toxicity screens are beginning to incorporate a range of reporters driven by ‘hub’ 
genes of major toxicity pathways to identify chemicals liable to toxicity (Herpers et al., 2016; 
Steinberg et al., 2017; Wink et al., 2017). Employment of a similar panel of redox sensitive 
transcription factors for screening Nrf2-activating compounds may aid the identification of 
off-target modification of cysteine residues by electrophilic compounds.  
The utility of cell-based reporters for the screening of compound libraries is limited by the 
physiological relevance of current in vitro models. For instance, comparison of in vivo toxicity 
data from the ToxRefDB database with in vitro data from phase 1 of the ToxCastTM initiative, 
highlighted the inability of in vitro assays to mimic individual diversity, bioactivation of a 
compound and toxico-kinetics (Knudsen et al., 2011). Additionally, assessment of NRF2-
pathway activation in a single cell line dose not facilitate visualisation of the holistic pathway 
response. Extra-hepatic activation of the NRF2 pathway was not considered in these data. 
Luciferase reporter constructs have been utilised within 3D cultures to monitor cell viability 
in an environment more relevant to that seen in vivo. For instance, hepatocellular carcinoma 
HUH1 cells in 2D and 3D spheroids cultures expressing a β-catenin luciferase reporter 
produced differing responses when exposed to drugs known to inhibit wnt signalling (Takai 
et al., 2016). HCT116 cells stably transfected with a pTRAF-Nrf2 reporter were used to 
monitor transcription factor expression and localisation throughout spheroid formation 
(Kipp et al., 2017). The Nrf2-Luc mouse model described in chapter 2 offers insight into Nrf2 
pathway activation across multiple tissues. Many compounds in the clinic pleiotropically 
activate NRF2, for instance the breast cancer drug, tamoxifen induces NQO1 (Krishnamurthy 
et al., 2012) and NSAIDs upregulate HMOX1 within the gastric mucosa (Aburaya et al., 2006). 
Assessment of off-target modifications of cysteine residues by electrophilic activators of 
NRF2 is essential to avoid adverse effects and ensure potency towards KEAP1 binding. 
In conclusion, the H4IIe-8AREL luminescence-based reporter cell line can be applied on a 
medium throughput scale to screen compounds for their potency to activate the NRF2 
pathway. Construction and characterisation of NQO1 ARE-based human reporter constructs, 
highlighted in this chapter, provide a model for assessment of NRF2 pathway activation 
within a human cell line. While absolute CD values differed between reporters exposed to 
the same compound, a similar trend in rank order of potencies across ARE-based reporters 
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in rat and human hepatocyte cell lines is encouraging. Development of sensitive assays for 
the in vitro assessment of Nrf2 activators are of increasing value as the number of 
therapeutic Nrf2-modulating compounds entering the clinic grows. 
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6.1. Introduction 
The transcription factor NRF2 has been increasingly implicated in response to drug-induced 
toxicity. Electrophilic compounds have been found to directly modulate KEAP1 repression of 
the NRF2 pathway (Bryan et al., 2013). Activation of the NRF2 pathway to sub-toxic 
concentrations of compounds (Goldring et al., 2004), demonstrate the transcription factor’s 
utility to provide sensitive insight into the mechanisms of a toxic chemical entity, making it 
an attractive pre-clinical marker of chemicals liable to cause toxicity. Additionally, a growing 
number of pathologies have been implicated with an underlying oxidative stress component. 
In response to this a range of NRF2-activating agents have begun clinical trials as antioxidant-
based therapies (Fox et al., 2012; Gold et al., 2012; Liby and Sporn, 2012). Thorough 
characterisation of the NRF2-mediated oxidative stress response is therefore vital, not only 
to provide effective therapeutic strategies, but also to improve pre-clinical safety assessment 
of drugs liable to induce oxidative damage. This thesis aimed to assess novel methods of 
monitoring NRF2 pathway activation, to improve testing strategies to identify chemicals and 
drugs that are likely to provoke toxicity in humans and potent activators of the NRF2 pathway 
with therapeutic potential. 
 
6.2. Key aims and major findings  
The major aims of this thesis were:  
1. To characterise the response of Nrf2-Luc mice to organ-specific toxicants APAP and 
cisplatin.   
2. To assess Nrf2 pathway activity in whole blood as a means of monitoring Nrf2 pathway 
status in vivo.   
3. To characterise putative novel Nrf2-regulated genes in human liver cells.  
4. To develop and use novel Nrf2-responsive reporter platforms to evaluate the potencies 
of novel analogues of the Nrf2-activating compound, Sulforaphane.  
The major findings of this thesis were: 
1. Data from Nrf2-Luc mice studies show the sensitivity of the mouse model to organ-
specific toxicity. The bioluminescent signal localizes to the site of toxicity and reflects 
the extent of damage.  
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2. Quantification of Nrf2-regulated mRNA in whole blood revealed their presence in 
circulation following DILI. Levels of these transcripts were muted following 
administration of NAC highlighting damaged hepatocytes as a potential source of the 
Nrf2-regulated mRNA.  
3. Bioinformatic analysis of putative novel Nrf2-regulated genes corroborated microarray 
analysis of genes sensitive to Nrf2 modulation in PHH and identified potential ARE 
sequences responsible for regulation. However, mutational analysis indicated these 
sequences are not responsible for induction of F2RL2, LOC344887 and TRIM16L on 
their own, i.e. without enhancer elements.  
4. Data from promoter-reporter assays show that the sequence responsible for Nrf2-
mediated activation of SRXN1 consists of two consecutive ARE sites that are both 
essential for gene transcription. 
5. Using well established and novel ARE-based luciferase reporters, I show similar rank 
order of potency of analogues of sulforaphane within the SFX-01 development program 
towards activation of NRF2 in rat and human hepatic cell lines. 
 
6.3. General discussion of findings  
 
6.3.1. Expanding the tool box for monitoring NRF2 pathway activation 
Novel methods for monitoring the activity of cytoprotective responses mediated by NRF2 is 
vital due to the lack of sensitive, non-invasive strategies currently used. The Nrf2-Luc mouse 
model offers, the ability to monitor  whole-body activation of the NRF2 pathway non-
invasively (Oikawa et al., 2012). The data presented in chapter 2 highlights the utility of the 
bioluminescent Nrf2-Luc mouse model to monitor activation of the pathway in response to 
organ-specific drug-induced toxicity. In response to hepatotoxic doses of APAP or 
nephrotoxic doses of Cisplatin, luminescence was measured non-invasively in organs 
undergoing damage.  This bioluminescent signal correlated closely with traditional markers 
of toxicity and reflected pathological scoring of the affected tissues.  Application of the Nrf2-
Luc model in late stage pre-clinical toxicity testing on subgroup of compounds would 
facilitate the detection of chemicals liable to provoke chemical/oxidative stress in vivo. A key 
advantage of this model is the holistic visualization of NRF2 activation provides data on 
potential off-target effects, offering an overview of pathway modulation during late stage 
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preclinical assessment. Further development of immortalized cell lines from these mice, 
could also be utilized for HTP toxicity testing within specific tissues.  
Additionally, methods for monitoring activation of the NRF2 pathway in peripheral, 
accessible tissues such as blood, may provide insight into pharmaceutical assessment. In 
chapter 3I aimed to assess the ability of the circulating NRF2-regulated transcriptome to 
reflect organ-specific toxicity. These data show a muted induction of NRF2-regulated 
transcripts in C57BL6 mice receiving the antidote for APAP-induced hepatotoxicity, NAC, 
compared to mice receiving APAP alone. This aligns with previous studies highlighting the 
correlation of many mRNA transcripts with the extent of APAP-induced liver damage in 
rodents (Umbright et al., 2010; K. Wang et al., 2013; Wetmore et al., 2010). Monitoring 
markers of the Nrf2-pathway in peripheral tissues that reflect organ-specific insult, may hold 
prognostic value in the clinic. While other biomarkers of DILI are elevated in the early stages 
of toxicity such as miR-122 (Starkey Lewis et al., 2011), Nrf2 activity may inform the 
cytoprotective capacity of the compromised organ, indicative of the extent of damage. Drug 
induced toxicity is a substantial burden to both the clinic and pharmaceutical industry. 
Implementation of peripheral tissue assessment during pre-clinical testing may aid the 
identification of drugs liable to toxicity and therefore enhance current assessment platforms.  
 
6.3.2. Role of NRF2 in toxicity testing  
Activation of the NRF2 pathway forms a common stage in many adverse outcome pathways. 
PHH are considered the gold standard for toxicity assessment, but little is known about the 
NRF2 pathway in these cells. In chapter 4I aimed to identify the ARE sites responsible for the 
activation of potentially novel Nrf2-regulated, implicated in PHH as being responsive to both 
NRF2 and KEAP1 knockdown. In comparison with other microarray datasets, it became 
apparent that F2RL2, LOC344887 and TRIM16L were responsive to NRF2 modulation in 
additional cell lines and contained potentially active AREs close to their transcription start 
site. Unexpectedly, the data in this chapter suggests NRF2 does not directly regulate the 
above-mentioned genes via the ARE sites identified here. This may be due to lack of inclusion 
of vital enhancer sites. For instance, Johnson et al. identify the ARE site incorporated within 
our reporter assays as the site of Nrf2 binding to the LOC344887 locus, via ChIP-seq (Johnson 
et al., 2016). However, an additional ARE sequence to which the authors show MAFG/K 
interacts, was not included in our reporter constructs. It is therefore likely that inclusion of 
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additional enhancer sites within the LOC344887 promoter region may be essential for Nrf2-
dependent activation of the pseudogene. Assessment for other transcription factor binding 
sites may reveal indirect regulation of these genes by NRF2. A key finding from this chapter 
is the extended ARE sequence in the promotor of SRXN1 consists of two consecutive ARE 
sequences, identified by Soriano  et al. and Singh et al. (Singh et al., 2009; Soriano et al., 
2008).However, these data, for the first time, highlight the essential nature of both 
sequences for Nrf2-dependent activation.  
Identification of the specific stimuli Nrf2 responds to and the downstream pathway activity 
in response to chemical/oxidative stressors will inform the utility of incorporating the 
pathway in risk assessment. For example, a distinct set of Nrf2-regulated genes were 
upregulated in response to carcinogens and DILI-related compounds with a propensity to 
induce hepatotoxicity (Souza et al., 2017). Nrf2 has been shown to influence and be 
regulated by other stress response pathways (Rushworth et al., 2012; Wakabayashi et al., 
2014), and therefore combining models from multiple stress-response pathways may be 
required to more completely predict risk of toxicity. Discussions from a recent workshop 
suggested a tiered approach to pathway-based toxicity risk assessment, moving away from 
animal-based toxic end-point analysis (Middleton et al., 2017). Firstly, chemicals would be 
assessed for their ability to activate a broad range of stress response pathways in tissues 
liable to exposure such as the liver and kidneys. Following tiers would focus on impeded cell 
viability and function in relation to pharmacokinetic/pharmacodynamic data. Utilizing this 
approach, it would be interesting to see if chemicals liable to bioactivation are associated 
with perturbation of multiple stress response pathways or a specific subset.  
Incorporation of Nrf2 pathway responses within predictive computational platforms to 
model the chemical and cellular events implicated in AOPs may aid risk assessment. 
Integration of data from in vitro ARE-based assays improved the sensitivity of predictive 
models of drug sensitivity assessment (Hirota et al., 2018; Jaworska et al., 2015). However, 
to minimize assumptions in computational models, generation of in vitro systems with 
greater physiological relevance is necessary. Acute exposure of single cell models cannot 
inform the effects of chronic exposure, especially as many cell lines exhibit impaired 
metabolic activity to primary cells (Hart et al., 2010). Establishment of cell models, such as 
3D HepG2 spheroid cultures that exhibited increased CYP450 metabolism compared to 2D 
cultures (Ramaiahgari et al., 2014), that are amenable to HTP toxicity screening will better 
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inform modelling platforms. Further development of in vitro models combining multiple 
organs within a single bioreactor, such as the heart-lung-liver organ-on-a-chip model 
developed by Skardal et al. (Skardal et al., 2017) may provide insight into the influence of 
drug distribution on the likelihood of an organ-specific stress-response occurring in vivo. 
However, at present these assays cannot rival the context provided by in vivo models such 
as the Nrf2-Luc mouse.  
A key factor that must be agreed is the level of NRF2 activation necessary to imply pre-
emptive toxicity and not solely an adaptive response. Definition of these ‘tipping points’ 
corresponding to adverse or adaptive outcomes will inform risk assessment frameworks. For 
instance, activation of stress response pathways was dampened at toxic doses of the model 
oxidant, zinc, in bronchial epithelial cells, when compared to activation at recoverable 
exposures (Currier et al., 2016). Identification of the dose and time at which this threshold 
of activation is likely to be breeched is challenging and will need further time-course analysis 
in physiologically relevant models to inform AOPs. To monitor pathways associated with 
overt toxicity instead of specific toxicological endpoints, these in vitro measurements must 
be related to in vivo exposure and responses of known chemicals liable to toxicity. 
Specifically, NRF2 activity in response to toxic moieties should be compared to the relative 
activity of the transcription factor induced by therapeutic drugs to gauge the likelihood of 
stress occurring in patients. Relating pathway activation in AOP models to actual levels of 
human exposure is also needed to increase the translational relevance of this framework. In 
patients, it is unlikely this threshold will be the same between individuals. Mutations within 
NRF2 and KEAP1 strongly influence pathway activity (Konstantinopoulos et al., 2011; Levings 
et al., 2017). Additional individual adaptive responses may be compromised due to co-
pathologies, sub-clinical infections and polypharmacy. 
 
6.3.3. Future of NRF2-based therapeutics  
Therapeutic activation of the NRF2 pathway has been shown to be beneficial in a variety of 
different disease pathologies. As more NRF2-activating compounds undergo clinical trials for 
the therapeutic pathway induction, it is vital to develop robust, translational ways to test 
their potency. The data presented in chapter 5, utilises the luminescent H4IIe-8AREL cell line 
to assess the potencies of sulforaphane analogues as part of the SFX-01 development 
program. A key finding of this chapter was the reduced potency towards NRF2 pathway 
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activation in all analogues, compared to the parent sulforaphane compound. In addition, 
following the development of luminescent reporter plasmids, a similar rank order of 
potencies of a small group of sulforaphane analogues to activate different ARE-based 
reporters in both H4IIe and HepG2 cells, was observed. Similar commercially available HepG2 
cells expressing an ARE-Luc reporter (BPS bioscience San Diego, USA) have been used for the 
assessment of novel Nrf2 activating compounds, that correlated with endogenous Nrf2 
pathway activation (Khoo et al., 2018). This cell line produced an EC50 for sulforaphane at 
1.16 µM, similar to our findings, however, the exact ARE sequence in this reporter cell line is 
commercially protected.    
Electrophilic compounds, such as CDDO-Me and sulforaphane, have the potential for off-
target effects due to their pleotropic modification of thiol groups. Considering this, a range 
of non-electrophilic activators of NRF2 are an exciting addition to therapeutic activators. This 
includes the development of peptides and small molecules that disrupt interactions between 
KEAP1-NRF2 via the ETGE sequence, KEAP1-CUL3 or homodimers of KEAP1 (Hancock et al., 
2012; Jiang et al., 2014). These may be more specific than electrophilic NRF2-activators, 
however it is important to note KEAP1 interactions with other proteins such P62 through the 
STGE motif which shares significant homology to the ETGE sequence (Komatsu et al., 2010). 
Targeting of competitive binding partners for KEAP1 may reveal a potent class of NRF2-
activating compounds. Alternatively, targeting other regulatory molecules that influence 
NRF2 such as those targeting the NEH6 phosphodegron (Rojo et al., 2012), or specific 
ubiquitin ligases (Lo et al., 2017, p. 23; T. Wu et al., 2014, p. 1) have been shown to activate 
the NRF2 pathway. Ultimately, further understanding of NRF2-pathway regulation and the 
location of specific deleterious ROS generation is vital for the development of effective, safe 
therapeutic activators of NRF2.  
To this effect, robust screens for the development of novel NRF2 activators have been 
established. Many ARE-driven luciferase assays, in a variety of cell lines have been used to 
screen activators of the Nrf2 pathway, including astrocytes (Ajit et al., 2016), pulmonary cells 
(Thekkeveedu et al., 2017), and hepatocytes (Copple et al., 2014). Conversely these reporters 
have also been used to screen for NRF2 inhibiting compounds (Choi et al., 2017). Methods 
to monitor Nrf2-pathway modulation in patients are limited to the analysis of peripheral 
tissues such as blood. Assessment of Nrf2-pathway activation in the DEFINE and CONFIRM 
clinical trials for the use of DMF to treat multiple sclerosis, was achieved by quantification of 
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NQO1 and HMOX1 mRNA in whole blood isolated from DMF-treated patients (Gopal et al., 
2017). Significant induction of these genes was observed after 12 and 48 weeks respectively.  
The authors also assessed PBMCs cultured from healthy volunteers to ex vivo stimulation 
with DMF which also lead to up regulation of these Nrf2-regulated genes (Gopal et al., 2017). 
Reliable assays for the assessment of Nrf2-regulated proteins in circulation have yet to be 
established. Elevated Nrf2 pathway activity has also been observed in peripheral tissues of 
patients suffering from pathologies with an underlying oxidative stress component, including 
synovial fluid extracted from patients with rheumatoid or osteo-arthritis (NRF2 mRNA 
correlated with preoperative reactive metabolite levels) (Kondo et al., 2017). The 
establishment of robust methods to monitor Nrf2 pathway modulation in accessible patient 
tissues will aid the pharmacodynamic assessment of Nrf2 activators and decipher the 
therapeutic role of NRF2 activation relative to other off target effects of a compound.  
Additionally, the development of sensitive screening platforms will aid the generation of 
targeted antioxidant therapies. Oxidative eustress emphasises the beneficial effects of redox 
signalling that are not associated with oxidative damage (Sies, 2018). Targeted antioxidant 
therapies at specific intracellular locations of aberrant ROS generation are essential to avoid 
interference with reactive species necessary for stress-response hormesis. Additionally, the 
effects of sustained therapeutic NRF2 activation on the diverse role of the transcription 
factor to regulate processes such as protein turnover and  glucose metabolism are yet to be 
assessed (Hirotsu et al., 2012).  The risks and therapeutic effects of NRF2 pathway 
modulation in man are not fully understood. Further insight into chronic exposure of 
antioxidant therapies in disease models are needed and the emerging therapeutic strategies 
entering the clinic are well primed to provide answers. 
 
6.4. Conclusions and future directions 
The growing need to monitor NRF2 pathway activity in response to toxicological and 
therapeutic stimuli has prompted the generation of novel methods of assessing modulation 
of the transcription factor. This thesis has characterised both in vivo and in vitro novel 
methods of Nrf2 pathway assessment. The ability to monitor the status of the NRF2 pathway 
across the whole body, in the Nrf2-Luc mouse model, allows an overview of organs that 
might not have been assessed in the early stages of pre-clinical toxicity testing. Additionally, 
this study has assessed potential the Nrf2-dependent regulation of putative novel NRF2-
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regulated genes. Understanding the regulation of the Nrf2 pathway fully will aid the 
development of novel NRF2 activating compounds but also improve toxicity assessment. 
Delineation of the specific expression profiles of NRF2-regulated genes following chemical 
insult may provide insight into the type of ROS being generated and its sub-cellular 
localisation. Identifying the point at which activation of the NRF2 pathway switches from 
providing an adaptive response to responding to adverse conditions will improve toxicity 
assessment by informing phenotypic outcomes. In vitro assays with increasing physiological 
relevance provide the context for NRF2 induction and resultant modulation of the pathway 
Several further studies should be conducted to validate and build upon the findings of this 
thesis. In chapter 2, the Nrf2-Luc mouse model was assessed for its ability to respond to 
organ specific toxicity. Future studies utilising these mice should investigate the sensitivity 
of this model to respond to stress not associated with overt toxicity to identify major ‘tipping 
points’ within Nrf2 pathway activation. This would aid delineation of MIEs within AOPs. 
However, this would be dependent on the sensitivity of the transgene to subtle changes in 
Nrf2 activity. Additionally, application of Nrf2-Luc mice to assess a wider range of compounds 
liable to toxicity in various organs. This would aid the definition of the group of toxic moieties 
associated with Nrf2 activation during toxicity and will inform the integration of the model 
into preclinical screening of compounds.    
In this thesis I describe the modulation of mRNA transcripts within murine whole blood in 
response to APAP-induced hepatotoxicity. Future work to establish the source of the Nrf2 
regulated transcripts is vital to show whether these elevations reflect organ-specific injury. 
Our data highlights the muted induction of Nrf2-regulated transcripts in response to 
hepatotoxic intervention implicating damaged hepatocytes as a potential source. 
Assessment of hepatocyte secretions in culture media following APAP-induced toxicity may 
reveal the presence of vesicle/protein-bound Nrf2-regulated mRNA. The functionality of 
these Nrf2-regulated transcripts could be assessed by treatment of cells with Nrf2-regulated 
mRNA from exosomes/conditioned media to assess the ability of the transcripts to influence 
basal gene expression in recipient cells or provide protective effects against subsequent 
damage to recipient cells. One limitation of the data in this chapter is the lack of assessment 
in human whole blood. The human blood-based NRF2 pathway is modulated in response to 
type 2 diabetes (Siewert et al., 2013) and myeloproliferative neoplasms (Hasselbalch et al., 
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2014). Measurement of Nrf2-regulated mRNA in blood samples from DILI patients may 
highlight the translational relevance of these findings.  
This study has assessed ARE sites within the promoter-regions of potentially novel Nrf2-
regulated genes for their ability to interact with NRF2. Further analysis of other ARE sites 
close-to or within the putative Nrf2-regulated genes transcription start site may identify the 
ARE sequence necessary for activation. Identification of these regions could be informed by 
ChIP-seq analysis of PHH to identify cell-specific NRF2 binding regions. Additionally, inclusion 
of enhancer sites within promotor-reporter constructs may facilitate NRF2 interactions. 
Identification of essential co-factors needed for gene activation could be assessed by 
stimulating Nrf2 activation in cells with specific MAFs knocked down. Aside from F2RL2, 
LOC344887 and TRIM16L other genes from microarray analysis are worth investigating, such 
as Pannexin 2 (PANX2), EP300 interacting inhibitor of differentiation 3 (EID3) and Secreted 
phosphoprotein 1 (SPP1) as these genes were all modulated by stimuli in bioinformatic 
analysis. 
Finally, the utility of ARE-based reporters for the screening of compounds has been 
demonstrated in this thesis. The generation of stably transfected human cell lines with lower 
basal Nrf2-pathway activity may facilitate a luciferase-based signal with greater range, that 
reflect endogenous Nrf2 pathway activation.  Ultimately generation of reporter constructs 
such as those described by Rizzi et al. consisting of multiple ARE sequences, will facilitate a 
more sensitive, representative signal of pathway induction  to various stimuli (Rizzi et al., 
2017).  
  
 212 
 
References 
Aatonen, M.T., Öhman, T., Nyman, T.A., Laitinen, S., Grönholm, M., Siljander, P.R.-M., 2014. Isolation and characterization of 
platelet-derived extracellular vesicles. J. Extracell. Vesicles 3. https://doi.org/10.3402/jev.v3.24692 
Abiko, Y., Miura, T., Phuc, B.H., Shinkai, Y., Kumagai, Y., 2011. Participation of covalent modification of Keap1 in the activation 
of Nrf2 by tert-butylbenzoquinone, an electrophilic metabolite of butylated hydroxyanisole. Toxicol. Appl. 
Pharmacol. 255, 32–39. https://doi.org/10.1016/j.taap.2011.05.013 
Aburaya, M., Tanaka, K.-I., Hoshino, T., Tsutsumi, S., Suzuki, K., Makise, M., Akagi, R., Mizushima, T., 2006. Haem oxygenase-1 
protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. J. Biol. Chem. 281, 33422–33432. 
https://doi.org/10.1074/jbc.M602074200 
A. Clulow, J., M. Storck, E., Lanyon-Hogg, T., A. Kalesh, K., H. Jones, L., W. Tate, E., 2017. Competition-based, quantitative 
chemical proteomics in breast cancer cells identifies new target profiles for sulforaphane. Chem. Commun. 53, 5182–
5185. https://doi.org/10.1039/C6CC08797C 
Agyeman, A.S., Chaerkady, R., Shaw, P.G., Davidson, N.E., Visvanathan, K., Pandey, A., Kensler, T.W., 2012. Transcriptomic and 
proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common 
expression profiles. Breast Cancer Res. Treat. 132, 175–187. https://doi.org/10.1007/s10549-011-1536-9 
Ahn, Y.-H., Hwang, Y., Liu, H., Wang, X.J., Zhang, Y., Stephenson, K.K., Boronina, T.N., Cole, R.N., Dinkova-Kostova, A.T., Talalay, 
P., Cole, P.A., 2010. Electrophilic tuning of the chemoprotective natural product sulforaphane. Proc. Natl. Acad. Sci. 
107, 9590–9595. https://doi.org/10.1073/pnas.1004104107 
Aitio, M.-L., 2006. N-acetylcysteine – passe-partout or much ado about nothing? Br. J. Clin. Pharmacol. 61, 5–15. 
https://doi.org/10.1111/j.1365-2125.2005.02523.x 
Ajit, D., Simonyi, A., Li, R., Chen, Z., Hannink, M., Fritsche, K.L., Mossine, V.V., Smith, R.E., Dobbs, T.K., Luo, R., Folk, W.R., Gu, 
Z., Lubahn, D.B., Weisman, G.A., Sun, G.Y., 2016. Phytochemicals and botanical extracts regulate NF-κB and Nrf2/ARE 
reporter activities in DI TNC1 astrocytes. Neurochem. Int. 97, 49–56. https://doi.org/10.1016/j.neuint.2016.05.004 
Akram, A., Han, B., Masoom, H., Peng, C., Lam, E., L. Litvack, M., Bai, X., Shan, Y., Hai, T., Batt, J., Slutsky, A.S., Zhang, H., Kuebler, 
W.M., Haitsma, J.J., Liu, M., dos Santos, C.C., 2010. Activating Transcription Factor 3 Confers Protection against 
Ventilator-induced Lung Injury. Am. J. Respir. Crit. Care Med. 182, 489–500. https://doi.org/10.1164/rccm.200906-
0925OC 
Alam, J., Cook, J.L., 2007a. How Many Transcription Factors Does It Take to Turn On the Haem Oxygenase-1 Gene? Am. J. Respir. 
Cell Mol. Biol. 36, 166–174. https://doi.org/10.1165/rcmb.2006-0340TR 
Alam, J., Cook, J.L., 2007b. How Many Transcription Factors Does It Take to Turn On the Haem Oxygenase-1 Gene? Am. J. Respir. 
Cell Mol. Biol. 36, 166–174. https://doi.org/10.1165/rcmb.2006-0340TR 
Aleksunes, L.M., Goedken, M.J., Rockwell, C.E., Thomale, J., Manautou, J.E., Klaassen, C.D., 2010. Transcriptional regulation of 
renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced 
nephrotoxicity. J. Pharmacol. Exp. Ther. 335, 2–12. https://doi.org/10.1124/jpet.110.170084 
Anderton, B.H., Betts, J., Blackstock, W.P., Brion, J.P., Chapman, S., Connell, J., Dayanandan, R., Gallo, J.M., Gibb, G., Hanger, 
D.P., Hutton, M., Kardalinou, E., Leroy, K., Lovestone, S., Mack, T., Reynolds, C.H., Van Slegtenhorst, M., 2001. Sites 
of phosphorylation in tau and factors affecting their regulation. Biochem. Soc. Symp. 73–80. 
Ankley, G.T., Bennett, R.S., Erickson, R.J., Hoff, D.J., Hornung, M.W., Johnson, R.D., Mount, D.R., Nichols, J.W., Russom, C.L., 
Schmieder, P.K., Serrrano, J.A., Tietge, J.E., Villeneuve, D.L., 2010. Adverse outcome pathways: A conceptual 
framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 730–741. 
https://doi.org/10.1002/etc.34 
Antoine, D.J., Dear, J.W., Lewis, P.S., Platt, V., Coyle, J., Masson, M., Thanacoody, R.H., Gray, A.J., Webb, D.J., Moggs, J.G., 
Bateman, D.N., Goldring, C.E., Park, B.K., 2013. Mechanistic biomarkers provide early and sensitive detection of 
acetaminophen-induced acute liver injury at first presentation to hospital. Hepatol. Baltim. Md 58, 777–787. 
https://doi.org/10.1002/hep.26294 
Antoine, D.J., Williams, D.P., Kipar, A., Jenkins, R.E., Regan, S.L., Sathish, J.G., Kitteringham, N.R., Park, B.K., 2009. High-mobility 
group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and 
apoptosis in vivo. Toxicol. Sci. Off. J. Soc. Toxicol. 112, 521–531. https://doi.org/10.1093/toxsci/kfp235 
Arinze, I.J., Kawai, Y., 2005. Transcriptional activation of the human Galphai2 gene promoter through nuclear factor-kappaB 
and antioxidant response elements. J. Biol. Chem. 280, 9786–9795. https://doi.org/10.1074/jbc.M414006200 
Arroyo, C.M., Kramer, J.H., Dickens, B.F., Weglicki, W.B., 1987. Identification of free radicals in myocardial ischemia/reperfusion 
by spin trapping with nitrone DMPO. FEBS Lett. 221, 101–104. https://doi.org/10.1016/0014-5793(87)80360-5 
Aschauer, L., Limonciel, A., Wilmes, A., Stanzel, S., Kopp-Schneider, A., Hewitt, P., Lukas, A., Leonard, M.O., Pfaller, W., Jennings, 
P., 2014. Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: A transcriptomic study. 
Toxicol. In Vitro. https://doi.org/10.1016/j.tiv.2014.10.005 
Ascherio, A., Weisskopf, M.G., O’reilly, E.J., Jacobs, E.J., McCullough, M.L., Calle, E.E., Cudkowicz, M., Thun, M.J., 2005. Vitamin 
E intake and risk of amyotrophic lateral sclerosis. Ann. Neurol. 57, 104–110. https://doi.org/10.1002/ana.20316 
Axworthy, D.B., Hoffmann, K.J., Streeter, A.J., Calleman, C.J., Pascoe, G.A., Baillie, T.A., 1988. Covalent binding of acetaminophen 
to mouse hemoglobin. Identification of major and minor adducts formed in vivo and implications for the nature of 
the arylating metabolites. Chem. Biol. Interact. 68, 99–116. 
Babior, B.M., Kipnes, R.S., Curnutte, J.T., 1973. Biological Defense Mechanisms. THE PRODUCTION BY LEUKOCYTES OF 
SUPEROXIDE, A POTENTIAL BACTERICIDAL AGENT. J. Clin. Invest. 52, 741–744. 
Bah, A., Chen, Z., Bush-Pelc, L.A., Mathews, F.S., Cera, E.D., 2007. Crystal structures of murine thrombin in complex with the 
extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc. Natl. Acad. Sci. 104, 11603–
11608. https://doi.org/10.1073/pnas.0704409104 
Banning, A., Deubel, S., Kluth, D., Zhou, Z., Brigelius-Flohé, R., 2005. The GI-GPx gene is a target for Nrf2. Mol. Cell. Biol. 25, 
4914–4923. https://doi.org/10.1128/MCB.25.12.4914-4923.2005 
Barajas, B., Che, N., Yin, F., Rowshanrad, A., Orozco, L.D., Gong, K.W., Wang, X., Castellani, L.W., Reue, K., Lusis, A.J., Araujo, 
J.A., 2011. NF-E2-related factor 2 promotes atherosclerosis by effects on plasma lipoproteins and cholesterol 
 213 
 
 
transport that overshadow antioxidant protection. Arterioscler. Thromb. Vasc. Biol. 31, 58–66. 
https://doi.org/10.1161/ATVBAHA.110.210906 
Belousov, V.V., Fradkov, A.F., Lukyanov, K.A., Staroverov, D.B., Shakhbazov, K.S., Terskikh, A.V., Lukyanov, S., 2006. Genetically 
encoded fluorescent indicator for intracellular hydrogen peroxide. Nat. Methods 3, 281–286. 
https://doi.org/10.1038/nmeth866 
Bilan, D.S., Pase, L., Joosen, L., Gorokhovatsky, A.Y., Ermakova, Y.G., Gadella, T.W.J., Grabher, C., Schultz, C., Lukyanov, S., 
Belousov, V.V., 2013. HyPer-3: a genetically encoded H(2)O(2) probe with improved performance for ratiometric and 
fluorescence lifetime imaging. ACS Chem. Biol. 8, 535–542. https://doi.org/10.1021/cb300625g 
Biteau, B., Labarre, J., Toledano, M.B., 2003. ATP-dependent reduction of cysteine–sulphinic acid by S. cerevisiae sulphiredoxin. 
Nature 425, 980–984. https://doi.org/10.1038/nature02075 
Bittner, G.C.V. de, Dubikovskaya, E.A., Bertozzi, C.R., Chang, C.J., 2010. In vivo imaging of hydrogen peroxide production in a 
murine tumor model with a chemoselective bioluminescent reporter. Proc. Natl. Acad. Sci. 107, 21316–21321. 
https://doi.org/10.1073/pnas.1012864107 
Bjelakovic, G., Nikolova, D., Gluud, L.L., Simonetti, R.G., Gluud, C., 2007. Mortality in randomized trials of antioxidant 
supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297, 842–857. 
https://doi.org/10.1001/jama.297.8.842 
Black, C.N., Bot, M., Scheffer, P.G., Cuijpers, P., Penninx, B.W.J.H., 2015. Is depression associated with increased oxidative 
stress? A systematic review and meta-analysis. Psychoneuroendocrinology, This issue includes a Special Section on 
Biomarkers in the Military - New Findings from Prospective Studies 51, 164–175. 
https://doi.org/10.1016/j.psyneuen.2014.09.025 
Blanchard, N., Lankar, D., Faure, F., Regnault, A., Dumont, C., Raposo, G., Hivroz, C., 2002. TCR Activation of Human T Cells 
Induces the Production of Exosomes Bearing the TCR/CD3/ζ Complex. J. Immunol. 168, 3235–3241. 
https://doi.org/10.4049/jimmunol.168.7.3235 
Bloom, D.A., Jaiswal, A.K., 2003. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the 
release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional 
activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J. Biol. 
Chem. 278, 44675–44682. https://doi.org/10.1074/jbc.M307633200 
Board, W.H.O.E., 1973. Handbook of resolutions and decisions of the World Health Assembly and the Executive Board. World 
Health Organization. 
Boom, R., Sol, C.J., Salimans, M.M., Jansen, C.L., Wertheim-van Dillen, P.M., van der Noordaa, J., 1990. Rapid and simple method 
for purification of nucleic acids. J. Clin. Microbiol. 28, 495–503. 
Boylston, J.A., Brenner, C., 2014. A knockdown with smoke model reveals FHIT as a repressor of Haem oxygenase 1. Cell Cycle 
Georget. Tex 13, 2913–2930. https://doi.org/10.4161/15384101.2014.946858 
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the 
principle of protein-dye binding. Anal. Biochem. 72, 248–254. https://doi.org/10.1016/0003-2697(76)90527-3 
Brown, S.L., Sekhar, K.R., Rachakonda, G., Sasi, S., Freeman, M.L., 2008. Activating Transcription Factor 3 Is a Novel Repressor 
of the Nuclear Factor Erythroid-Derived 2–Related Factor 2 (Nrf2)–Regulated Stress Pathway. Cancer Res. 68, 364–
368. https://doi.org/10.1158/0008-5472.CAN-07-2170 
Browne, S.E., Ferrante, R.J., Beal, M.F., 1999. Oxidative Stress in Huntington’s Disease. Brain Pathol. 9, 147–163. 
https://doi.org/10.1111/j.1750-3639.1999.tb00216.x 
Bruce, C.R., Carey, A.L., Hawley, J.A., Febbraio, M.A., 2003. Intramuscular Heat Shock Protein 72 and Haem Oxygenase-1 mRNA 
Are Reduced in Patients With Type 2 Diabetes: Evidence That Insulin Resistance Is Associated With a Disturbed 
Antioxidant Defense Mechanism. Diabetes 52, 2338–2345. https://doi.org/10.2337/diabetes.52.9.2338 
Bryan, H.K., Olayanju, A., Goldring, C.E., Park, B.K., 2013. The Nrf2 cell defence pathway: Keap1-dependent and -independent 
mechanisms of regulation. Biochem. Pharmacol. 85, 705–717. https://doi.org/10.1016/j.bcp.2012.11.016 
Bulua, A.C., Simon, A., Maddipati, R., Pelletier, M., Park, H., Kim, K.-Y., Sack, M.N., Kastner, D.L., Siegel, R.M., 2011. 
Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in 
TNFR1-associated periodic syndrome (TRAPS). J. Exp. Med. 208, 519–533. https://doi.org/10.1084/jem.20102049 
Burkitt, M.J., Wardman, P., 2001. Cytochrome c Is a Potent Catalyst of Dichlorofluorescin Oxidation: Implications for the Role 
of Reactive Oxygen Species in Apoptosis. Biochem. Biophys. Res. Commun. 282, 329–333. 
https://doi.org/10.1006/bbrc.2001.4578 
Burnette, W.N., 1981. “Western Blotting”: Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels 
to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal. Biochem. 
112, 195–203. https://doi.org/10.1016/0003-2697(81)90281-5 
Bushel, P.R., Heinloth, A.N., Li, J., Huang, L., Chou, J.W., Boorman, G.A., Malarkey, D.E., Houle, C.D., Ward, S.M., Wilson, R.E., 
Fannin, R.D., Russo, M.W., Watkins, P.B., Tennant, R.W., Paules, R.S., 2007. Blood gene expression signatures predict 
exposure levels. Proc. Natl. Acad. Sci. 104, 18211–18216. https://doi.org/10.1073/pnas.0706987104 
Butterfield, D.A., Drake, J., Pocernich, C., Castegna, A., 2001. Evidence of oxidative damage in Alzheimer’s disease brain: central 
role for amyloid beta-peptide. Trends Mol. Med. 7, 548–554. 
Cahuana, G.M., Tejedo, J.R., Jiménez, J., Ramírez, R., Sobrino, F., Bedoya, F.J., 2004. Nitric oxide-induced carbonylation of Bcl-
2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells. Exp. Cell Res. 293, 22–30. 
Cai, J., Wu, M., Nelson, K.C., Sternberg, P., Jones, D.P., 1999. Oxidant-induced apoptosis in cultured human retinal pigment 
epithelial cells. Invest. Ophthalmol. Vis. Sci. 40, 959–966. 
Chae, H.Z., Chung, S.J., Rhee, S.G., 1994. Thioredoxin-dependent peroxide reductase from yeast. J. Biol. Chem. 269, 27670–
27678. 
Chan, K., Han, X.D., Kan, Y.W., 2001. An important function of Nrf2 in combating oxidative stress: detoxification of 
acetaminophen. Proc. Natl. Acad. Sci. U. S. A. 98, 4611–4616. https://doi.org/10.1073/pnas.081082098 
Chan, K., Lu, R., Chang, J.C., Kan, Y.W., 1996. NRF2, a member of the NFE2 family of transcription factors, is not essential for 
murine erythropoiesis, growth, and development. Proc. Natl. Acad. Sci. U. S. A. 93, 13943–13948. 
 214 
 
 
Chan, R.W.Y., Wong, J., Lai, P.B.S., Lo, Y.M.D., Chiu, R.W.K., 2013. The potential clinical utility of serial plasma albumin mRNA 
monitoring for the post-liver transplantation management. Clin. Biochem. 46, 1313–1319. 
https://doi.org/10.1016/j.clinbiochem.2013.04.022 
Chanas, S.A., Jiang, Q., McMahon, M., McWalter, G.K., McLellan, L.I., Elcombe, C.R., Henderson, C.J., Wolf, C.R., Moffat, G.J., 
Itoh, K., Yamamoto, M., Hayes, J.D., 2002. Loss of the Nrf2 transcription factor causes a marked reduction in 
constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and 
Gstm4 genes in the livers of male and female mice. Biochem. J. 365, 405–416. https://doi.org/10.1042/BJ20020320 
Chen, P.-C., Vargas, M.R., Pani, A.K., Smeyne, R.J., Johnson, D.A., Kan, Y.W., Johnson, J.A., 2009. Nrf2-mediated neuroprotection 
in the MPTP mouse model of Parkinson’s disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U. S. A. 106, 
2933–2938. https://doi.org/10.1073/pnas.0813361106 
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., Li, Q., Li, X., Wang, W., Zhang, Y., Wang, J., 
Jiang, X., Xiang, Y., Xu, C., Zheng, P., Zhang, J., Li, R., Zhang, H., Shang, X., Gong, T., Ning, G., Wang, J., Zen, K., Zhang, 
J., Zhang, C.-Y., 2008. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer 
and other diseases. Cell Res. 18, 997–1006. https://doi.org/10.1038/cr.2008.282 
Chen, X.-L., Zhang, Q., Zhao, R., Ding, X., Tummala, P.E., Medford, R.M., 2003. Rac1 and Superoxide Are Required for the 
Expression of Cell Adhesion Molecules Induced by Tumor Necrosis Factor-α in Endothelial Cells. J. Pharmacol. Exp. 
Ther. 305, 573–580. https://doi.org/10.1124/jpet.102.047894 
Cheung, S.T., Fan, S.T., Lee, Y.T., Chow, J.P., Ng, I.O., Fong, D.Y., Lo, C.M., 2008. Albumin mRNA in Plasma Predicts Post-
Transplant Recurrence of Patients With Hepatocellular Carcinoma. Transplantation 85, 81. 
https://doi.org/10.1097/01.tp.0000298003.88530.11 
Chiarugi, P., Pani, G., Giannoni, E., Taddei, L., Colavitti, R., Raugei, G., Symons, M., Borrello, S., Galeotti, T., Ramponi, G., 2003. 
Reactive oxygen species as essential mediators of cell adhesion. J. Cell Biol. 161, 933–944. 
https://doi.org/10.1083/jcb.200211118 
Cho, H.-Y., Reddy, S.P.M., Yamamoto, M., Kleeberger, S.R., 2004. The transcription factor NRF2 protects against pulmonary 
fibrosis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 18, 1258–1260. https://doi.org/10.1096/fj.03-1127fje 
Cho, J.-M., Manandhar, S., Lee, H.-R., Park, H.-M., Kwak, M.-K., 2008. Role of the Nrf2-antioxidant system in cytotoxicity 
mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Lett. 260, 96–108. 
https://doi.org/10.1016/j.canlet.2007.10.022 
Choi, E.-J., Jung, B.-J., Lee, S.-H., Yoo, H.-S., Shin, E.-A., Ko, H.-J., Chang, S., Kim, S.-Y., Jeon, S.-M., 2017. A clinical drug library 
screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant 
lung cancer. Oncogene 36, 5285–5295. https://doi.org/10.1038/onc.2017.153 
Chorley, B.N., Campbell, M.R., Wang, X., Karaca, M., Sambandan, D., Bangura, F., Xue, P., Pi, J., Kleeberger, S.R., Bell, D.A., 2012. 
Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic Acids Res. 
40, 7416–7429. https://doi.org/10.1093/nar/gks409 
Choucha Snouber, L., Bunescu, A., Naudot, M., Legallais, C., Brochot, C., Dumas, M.E., Elena-Herrmann, B., Leclerc, E., 2013. 
Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and Its active metabolite 
hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol. Sci. Off. J. Soc. Toxicol. 132, 8–20. 
https://doi.org/10.1093/toxsci/kfs230 
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., Hayes, J.D., 2013. Nrf2 is controlled by two distinct β-TrCP 
recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765–3781. 
https://doi.org/10.1038/onc.2012.388 
Chowdhury, I., Mo, Y., Gao, L., Kazi, A., Fisher, A.B., Feinstein, S.I., 2009. Oxidant stress stimulates expression of the human 
peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. Free Radic. Biol. 
Med. 46, 146–153. https://doi.org/10.1016/j.freeradbiomed.2008.09.027 
Cincin, Z.B., Unlu, M., Kiran, B., Bireller, E.S., Baran, Y., Cakmakoglu, B., 2014. Molecular Mechanisms of Quercitrin-induced 
Apoptosis in Non-small Cell Lung Cancer. Arch. Med. Res. 45, 445–454. 
https://doi.org/10.1016/j.arcmed.2014.08.002 
Cleasby, A., Yon, J., Day, P.J., Richardson, C., Tickle, I.J., Williams, P.A., Callahan, J.F., Carr, R., Concha, N., Kerns, J.K., Qi, H., 
Sweitzer, T., Ward, P., Davies, T.G., 2014. Structure of the BTB Domain of Keap1 and Its Interaction with the 
Triterpenoid Antagonist CDDO. PLOS ONE 9, e98896. https://doi.org/10.1371/journal.pone.0098896 
Converso, D.P., Taillé, C., Carreras, M.C., Jaitovich, A., Poderoso, J.J., Boczkowski, J., 2006. HO-1 is located in liver mitochondria 
and modulates mitochondrial haem content and metabolism. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 20, 1236–
1238. https://doi.org/10.1096/fj.05-4204fje 
Copple, I.M., Goldring, C.E., Jenkins, R.E., Chia, A.J.L., Randle, L.E., Hayes, J.D., Kitteringham, N.R., Park, B.K., 2008a. The 
hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 48, 
1292–1301. https://doi.org/10.1002/hep.22472 
Copple, I.M., Goldring, C.E., Kitteringham, N.R., Park, B.K., 2008b. The Nrf2–Keap1 defence pathway: Role in protection against 
drug-induced toxicity. Toxicology, Includes Special Issue section on:New Technologies for Toxicology - Meeting 
Future Challenges in Drug Safety 246, 24–33. https://doi.org/10.1016/j.tox.2007.10.029 
Copple, I.M., Lister, A., Obeng, A.D., Kitteringham, N.R., Jenkins, R.E., Layfield, R., Foster, B.J., Goldring, C.E., Park, B.K., 2010. 
Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. 
J. Biol. Chem. 285, 16782–16788. https://doi.org/10.1074/jbc.M109.096545 
Copple, I.M., Shelton, L.M., Walsh, J., Kratschmar, D.V., Lister, A., Odermatt, A., Goldring, C.E., Dinkova-Kostova, A.T., Honda, 
T., Park, B.K., 2014. Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of 
triterpenoids. Toxicol. Sci. Off. J. Soc. Toxicol. 140, 462–469. https://doi.org/10.1093/toxsci/kfu080 
Correa, P., Fontham, E.T.H., Bravo, J.C., Bravo, L.E., Ruiz, B., Zarama, G., Realpe, J.L., Malcom, G.T., Li, D., Johnson, W.D., Mera, 
R., 2000. Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-
Helicobacter pylori Therapy. J. Natl. Cancer Inst. 92, 1881–1888. https://doi.org/10.1093/jnci/92.23.1881 
 215 
 
 
Costantini, D., Verhulst, S., 2009. Does high antioxidant capacity indicate low oxidative stress? Funct. Ecol. 23, 506–509. 
https://doi.org/10.1111/j.1365-2435.2009.01546.x 
Coughlin, S.R., 2000. Thrombin signalling and protease-activated receptors. Nature 407, 258–264. 
https://doi.org/10.1038/35025229 
Cullinan, S.B., Gordan, J.D., Jin, J., Harper, J.W., Diehl, J.A., 2004. The Keap1-BTB Protein Is an Adaptor That Bridges Nrf2 to a 
Cul3-Based E3 Ligase: Oxidative Stress Sensing by a Cul3-Keap1 Ligase. Mol. Cell. Biol. 24, 8477–8486. 
https://doi.org/10.1128/MCB.24.19.8477-8486.2004 
Currier, J.M., Cheng, W.-Y., Menendez, D., Conolly, R., Chorley, B.N., 2016. Developing a Gene Biomarker at the Tipping Point 
of Adaptive and Adverse Responses in Human Bronchial Epithelial Cells. PLOS ONE 11, e0155875. 
https://doi.org/10.1371/journal.pone.0155875 
Curtis, A., Calabro, K., Galarneau, J.-R., Bigio, I.J., Krucker, T., 2011. Temporal variations of skin pigmentation in C57BL/6 mice 
affect optical bioluminescence quantitation. Mol. Imaging Biol. MIB Off. Publ. Acad. Mol. Imaging 13, 1114–1123. 
https://doi.org/10.1007/s11307-010-0440-8 
Dahlin, D.C., Nelson, S.D., 1982. Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-
benzoquinone imine, a proposed toxic metabolite of acetaminophen. J. Med. Chem. 25, 885–886. 
https://doi.org/10.1021/jm00350a001 
Dai, G., He, L., Chou, N., Wan, Y.-J.Y., 2006. Acetaminophen Metabolism Does Not Contribute to Gender Difference in Its 
Hepatotoxicity in Mouse. Toxicol. Sci. 92, 33–41. https://doi.org/10.1093/toxsci/kfj192 
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G.L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers 
Heerspink, H.J., McMurray, J.J., Meyer, C.J., Parving, H.-H., Remuzzi, G., Toto, R.D., Vaziri, N.D., Wanner, C., Wittes, 
J., Wrolstad, D., Chertow, G.M., 2013. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. 
N. Engl. J. Med. 369, 2492–2503. https://doi.org/10.1056/NEJMoa1306033 
DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., 
Scrimieri, F., Winter, J.M., Hruban, R.H., Iacobuzio-Donahue, C., Kern, S.E., Blair, I.A., Tuveson, D.A., 2011. Oncogene-
induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109. 
https://doi.org/10.1038/nature10189 
Dhakshinamoorthy, S., Jain, A.K., Bloom, D.A., Jaiswal, A.K., 2005. Bach1 competes with Nrf2 leading to negative regulation of 
the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and 
induction in response to antioxidants. J. Biol. Chem. 280, 16891–16900. https://doi.org/10.1074/jbc.M500166200 
Ding, V.W., Chen, R.-H., McCormick, F., 2000. Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt 
Signaling. J. Biol. Chem. 275, 32475–32481. https://doi.org/10.1074/jbc.M005342200 
Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., Talalay, P., 2002. Direct 
evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect 
against carcinogens and oxidants. Proc. Natl. Acad. Sci. U. S. A. 99, 11908–11913. 
https://doi.org/10.1073/pnas.172398899 
Dinkova-Kostova, A.T., Liby, K.T., Stephenson, K.K., Holtzclaw, W.D., Gao, X., Suh, N., Williams, C., Risingsong, R., Honda, T., 
Gribble, G.W., Sporn, M.B., Talalay, P., 2005. Extremely potent triterpenoid inducers of the phase 2 response: 
Correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. U. S. A. 102, 4584–4589. 
https://doi.org/10.1073/pnas.0500815102 
Dreger, H., Westphal, K., Weller, A., Baumann, G., Stangl, V., Meiners, S., Stangl, K., 2009. Nrf2-dependent upregulation of 
antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc. Res. 83, 
354–361. https://doi.org/10.1093/cvr/cvp107 
Eakins, R., Walsh, J., Randle, L., Jenkins, R.E., Schuppe-Koistinen, I., Rowe, C., Lewis, P.S., Vasieva, O., Prats, N., Brillant, N., Auli, 
M., Bayliss, M., Webb, S., Rees, J.A., Kitteringham, N.R., Goldring, C.E., Park, B.K., 2015. Adaptation to 
acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome. Sci. Rep. 5, 
16423. https://doi.org/10.1038/srep16423 
Eastman, A., 1983. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-
dichloro(ethylenediamine)platinum(II). Biochemistry (Mosc.) 22, 3927–3933. https://doi.org/10.1021/bi00285a031 
Eisenstein, R.S., Garcia-Mayol, D., Pettingell, W., Munro, H.N., 1991. Regulation of ferritin and haem oxygenase synthesis in rat 
fibroblasts by different forms of iron. Proc. Natl. Acad. Sci. U. S. A. 88, 688–692. 
Eitas, T.K., Stepp, W., Sjeklocha, L., Long, C., Riley, C., Callahan, J., Sanchez, Y., Gough, P., Knowlin, L., van Duin, D., Ortiz-Pujols, 
S., Jones, S., Maile, R., Hong, Z., Berger, S., Cairns, B., 2017. Differential regulation of innate immune cytokine 
production through pharmacological activation of Nuclear Factor-Erythroid-2-Related Factor 2 (NRF2) in burn 
patient immune cells and monocytes. PLoS ONE 12. https://doi.org/10.1371/journal.pone.0184164 
Elaut, G., Henkens, T., Papeleu, P., Snykers, S., Vinken, M., Vanhaecke, T., Rogiers, V., 2006. Molecular mechanisms underlying 
the dedifferentiation process of isolated hepatocytes and their cultures. Curr. Drug Metab. 7, 629–660. 
Eldh, M., Ekström, K., Valadi, H., Sjöstrand, M., Olsson, B., Jernås, M., Lötvall, J., 2010. Exosomes Communicate Protective 
Messages during Oxidative Stress; Possible Role of Exosomal Shuttle RNA. PLOS ONE 5, e15353. 
https://doi.org/10.1371/journal.pone.0015353 
El-Hefnawy, T., Raja, S., Kelly, L., Bigbee, W.L., Kirkwood, J.M., Luketich, J.D., Godfrey, T.E., 2004. Characterization of Amplifiable, 
Circulating RNA in Plasma and Its Potential as a Tool for Cancer Diagnostics. Clin. Chem. 50, 564–573. 
https://doi.org/10.1373/clinchem.2003.028506 
Emter, R., Ellis, G., Natsch, A., 2010. Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in 
vitro. Toxicol. Appl. Pharmacol. 245, 281–290. https://doi.org/10.1016/j.taap.2010.03.009 
Emter, R., Natsch, A., 2015. Dual regulation of skin sensitizer-induced HMOX1 expression by Bach1 and Nrf2: Comparison to 
regulation of the AKR1C2-ARE element in the KeratinoSens cell line. Toxicol. Appl. Pharmacol. 288, 281–288. 
https://doi.org/10.1016/j.taap.2015.07.027 
 216 
 
 
Endo, H., Sugioka, Y., Nakagi, Y., Saijo, Y., Yoshida, T., 2008. A novel role of the NRF2 transcription factor in the regulation of 
arsenite-mediated keratin 16 gene expression in human keratinocytes. Environ. Health Perspect. 116, 873–879. 
https://doi.org/10.1289/ehp.10696 
Engelhart, M.J., Geerlings, M.I., Ruitenberg, A., van Swieten, J.C., Hofman, A., Witteman, J.C.M., Breteler, M.M.B., 2002. Dietary 
intake of antioxidants and risk of Alzheimer disease. JAMA 287, 3223–3229. 
Enomoto, A., Itoh, K., Nagayoshi, E., Haruta, J., Kimura, T., O’Connor, T., Harada, T., Yamamoto, M., 2001. High Sensitivity of 
Nrf2 Knockout Mice to Acetaminophen Hepatotoxicity Associated with Decreased Expression of ARE-Regulated Drug 
Metabolizing Enzymes and Antioxidant Genes. Toxicol. Sci. 59, 169–177. https://doi.org/10.1093/toxsci/59.1.169 
Erickson, A.M., Nevarea, Z., Gipp, J.J., Mulcahy, R.T., 2002. Identification of a variant antioxidant response element in the 
promoter of the human glutamate-cysteine ligase modifier subunit gene. Revision of the ARE consensus sequence. 
J. Biol. Chem. 277, 30730–30737. https://doi.org/10.1074/jbc.M205225200 
Fan, P.-C., Chen, C.-C., Chen, Y.-C., Chang, Y.-S., Chu, P.-H., 2016. MicroRNAs in acute kidney injury. Hum. Genomics 10. 
https://doi.org/10.1186/s40246-016-0085-z 
Fannin, R.D., Russo, M., O’Connell, T.M., Gerrish, K., Winnike, J.H., Macdonald, J., Newton, J., Malik, S., Sieber, S.O., Parker, J., 
Shah, R., Zhou, T., Watkins, P.B., Paules, R.S., 2010. Acetaminophen dosing of humans results in blood transcriptome 
and metabolome changes consistent with impaired oxidative phosphorylation. Hepatol. Baltim. Md 51, 227–236. 
https://doi.org/10.1002/hep.23330 
Fichtinger-Schepman, A.M.J., Van der Veer, J.L., Den Hartog, J.H.J., Lohman, P.H.M., Reedijk, J., 1985. Adducts of the antitumor 
drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry (Mosc.) 
24, 707–713. https://doi.org/10.1021/bi00324a025 
Finkel, T., 2011. Signal transduction by reactive oxygen species. J. Cell Biol. 194, 7–15. https://doi.org/10.1083/jcb.201102095 
Forootan, S.S., Mutter, F.E., Kipar, A., Iwawaki, T., Francis, B., Goldring, C.E., Park, B.K., Copple, I.M., 2017. Real-time in vivo 
imaging reveals localised Nrf2 stress responses associated with direct and metabolism-dependent drug toxicity. Sci. 
Rep. 7, 16084. https://doi.org/10.1038/s41598-017-16491-2 
Fox, R.J., Miller, D.H., Phillips, J.T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M.T., 
Viglietta, V., Dawson, K.T., CONFIRM Study Investigators, 2012. Placebo-controlled phase 3 study of oral BG-12 or 
glatiramer in multiple sclerosis. N. Engl. J. Med. 367, 1087–1097. https://doi.org/10.1056/NEJMoa1206328 
Franco, R., Schoneveld, O., Georgakilas, A.G., Panayiotidis, M.I., 2008. Oxidative stress, DNA methylation and carcinogenesis. 
Cancer Lett., Oxidative Stress and Carcinogenesis Special Issue 266, 6–11. 
https://doi.org/10.1016/j.canlet.2008.02.026 
Fredriksson, L., Wink, S., Herpers, B., Benedetti, G., Hadi, M., de Bont, H., Groothuis, G., Luijten, M., Danen, E., de Graauw, M., 
Meerman, J., van de Water, B., 2014. Drug-induced endoplasmic reticulum and oxidative stress responses 
independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol. Sci. Off. J. Soc. Toxicol. 140, 144–159. 
https://doi.org/10.1093/toxsci/kfu072 
Fried, M., Crothers, D.M., 1981. Equilibria and kinetics of lac repressor-operator interactions by polyacrylamide gel 
electrophoresis. Nucleic Acids Res. 9, 6505–6525. 
Fuse, Y., Nakajima, H., Nakajima-Takagi, Y., Nakajima, O., Kobayashi, M., 2015. Heme-mediated inhibition of Bach1 regulates 
the liver specificity and transience of the Nrf2-dependent induction of zebrafish heme oxygenase 1. Genes Cells 20, 
590–600. https://doi.org/10.1111/gtc.12249 
Gacesa, R., Dunlap, W.C., Barlow, D.J., Laskowski, R.A., Long, P.F., 2016. Rising levels of atmospheric oxygen and evolution of 
Nrf2. Sci. Rep. 6, 27740. https://doi.org/10.1038/srep27740 
Gamboa, J.L., Billings, F.T., Bojanowski, M.T., Gilliam, L.A., Yu, C., Roshanravan, B., Roberts, L.J., Himmelfarb, J., Ikizler, T.A., 
Brown, N.J., 2016. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiol. 
Rep. 4. https://doi.org/10.14814/phy2.12780 
Gao, A., Peng, Y., Deng, Y., Qing, H., 2013. Potential therapeutic applications of differentiated induced pluripotent stem cells 
(iPSCs) in the treatment of neurodegenerative diseases. Neuroscience 228, 47–59. 
https://doi.org/10.1016/j.neuroscience.2012.09.076 
Gao, B., Doan, A., Hybertson, B.M., 2014. The clinical potential of influencing Nrf2 signaling in degenerative and immunological 
disorders. Clin. Pharmacol. Adv. Appl. 6, 19–34. https://doi.org/10.2147/CPAA.S35078 
García, V., García, J.M., Peña, C., Silva, J., Domínguez, G., Lorenzo, Y., Diaz, R., Espinosa, P., de Sola, J.G., Cantos, B., Bonilla, F., 
2008. Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 263, 312–320. 
https://doi.org/10.1016/j.canlet.2008.01.008 
García-González, A., Gaxiola-Robles, R., Zenteno-Savín, T., 2015. Oxidative stress in patients with rheumatoid arthritis. Rev. 
Investig. Clin. Organo Hosp. Enfermedades Nutr. 67, 46–53. 
Garner, M.M., Revzin, A., 1981. A gel electrophoresis method for quantifying the binding of proteins to specific DNA regions: 
application to components of the Escherichia coli lactose operon regulatory system. Nucleic Acids Res. 9, 3047–
3060. 
Giacco, F., Brownlee, M., 2010. Oxidative stress and diabetic complications. Circ. Res. 107, 1058–1070. 
https://doi.org/10.1161/CIRCRESAHA.110.223545 
Gold, R., Kappos, L., Arnold, D.L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M.T., Yang, M., Sheikh, S.I., 
Dawson, K.T., 2012. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. N. Engl. J. Med. 
367, 1098–1107. https://doi.org/10.1056/NEJMoa1114287 
Goldring, C.E.P., Kitteringham, N.R., Elsby, R., Randle, L.E., Clement, Y.N., Williams, D.P., McMahon, M., Hayes, J.D., Itoh, K., 
Yamamoto, M., Park, B.K., 2004. Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 39, 
1267–1276. https://doi.org/10.1002/hep.20183 
Goldstein, L.D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C.E., Holcomb, T., Shames, D.S., 
Hartmaier, R.J., Chmielecki, J., Seshagiri, S., Gentleman, R., Stokoe, D., 2016. Recurrent Loss of NFE2L2 Exon 2 Is a 
Mechanism for Nrf2 Pathway Activation in Human Cancers. Cell Rep. 16, 2605–2617. 
https://doi.org/10.1016/j.celrep.2016.08.010 
 217 
 
 
Gómez-Lechón, M.J., Tolosa, L., Conde, I., Donato, M.T., 2014. Competency of different cell models to predict human 
hepatotoxic drugs. Expert Opin. Drug Metab. Toxicol. 10, 1553–1568. 
https://doi.org/10.1517/17425255.2014.967680 
Gonzales-Vitale, J.C., Hayes, D.M., Cvitkovic, E., Sternberg, S.S., 1977. The renal pathology in clinical trials of cis-platinum (II) 
diamminedichloride. Cancer 39, 1362–1371. 
Gopal, S., Mikulskis, A., Gold, R., Fox, R.J., Dawson, K.T., Amaravadi, L., 2017. Evidence of activation of the Nrf2 pathway in 
multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM 
studies. Mult. Scler. J. 23, 1875–1883. https://doi.org/10.1177/1352458517690617 
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., Bujard, H., 1995. Transcriptional activation by tetracyclines in 
mammalian cells. Science 268, 1766–1769. 
Gray, J.P., Karandrea, S., Burgos, D.Z., Jaiswal, A.A., Heart, E.A., 2016. NAD(P)H-dependent Quinone Oxidoreductase 1 (NQO1) 
and Cytochrome P450 Oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox 
status, survival and metabolism in pancreatic β-cells. Toxicol. Lett. 262, 1–11. 
https://doi.org/10.1016/j.toxlet.2016.08.021 
Greaney, A.J., Maier, N.K., Leppla, S.H., Moayeri, M., 2016. Sulforaphane inhibits multiple inflammasomes through an Nrf2-
independent mechanism. J. Leukoc. Biol. 99, 189–199. https://doi.org/10.1189/jlb.3A0415-155RR 
Greenlee, H., Kwan, M.L., Kushi, L.H., Song, J., Castillo, A., Weltzien, E., Quesenberry, C.P., Caan, B.J., 2012. Antioxidant 
supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. 
Cancer 118, 2048–2058. https://doi.org/10.1002/cncr.26526 
Griendling, K.K., FitzGerald, G.A., 2003. Oxidative Stress and Cardiovascular Injury Part I: Basic Mechanisms and In Vivo 
Monitoring of ROS. Circulation 108, 1912–1916. https://doi.org/10.1161/01.CIR.0000093660.86242.BB 
Groen, J.N., Capraro, D., Morris, K.V., 2014. The emerging role of pseudogene expressed non-coding RNAs in cellular functions. 
Int. J. Biochem. Cell Biol. 54, 350–355. https://doi.org/10.1016/j.biocel.2014.05.008 
Hagemann, T.L., Gaeta, S.A., Smith, M.A., Johnson, D.A., Johnson, J.A., Messing, A., 2005. Gene expression analysis in mice with 
elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and 
neuronal dysfunction. Hum. Mol. Genet. 14, 2443–2458. https://doi.org/10.1093/hmg/ddi248 
Haider, L., Fischer, M.T., Frischer, J.M., Bauer, J., Höftberger, R., Botond, G., Esterbauer, H., Binder, C.J., Witztum, J.L., Lassmann, 
H., 2011. Oxidative damage in multiple sclerosis lesions. Brain 134, 1914–1924. 
https://doi.org/10.1093/brain/awr128 
Hakim, T.S., Sugimori, K., Camporesi, E.M., Anderson, G., 1996. Half-life of nitric oxide in aqueous solutions with and without 
haemoglobin. Physiol. Meas. 17, 267–277. 
Halicka, H.D., Bedner, E., Darzynkiewicz, Z., 2000. Segregation of RNA and Separate Packaging of DNA and RNA in Apoptotic 
Bodies during Apoptosis. Exp. Cell Res. 260, 248–256. https://doi.org/10.1006/excr.2000.5027 
Halliwell, B., 2007. Oxidative stress and cancer: have we moved forward? Biochem. J. 401, 1–11. 
https://doi.org/10.1042/BJ20061131 
Halliwell, B., 2007. Biochemistry of oxidative stress. Biochem. Soc. Trans. 35, 1147–1150. https://doi.org/10.1042/BST0351147 
Hancock, R., Bertrand, H.C., Tsujita, T., Naz, S., El-Bakry, A., Laoruchupong, J., Hayes, J.D., Wells, G., 2012. Peptide inhibitors of 
the Keap1–Nrf2 protein–protein interaction. Free Radic. Biol. Med. 52, 444–451. 
https://doi.org/10.1016/j.freeradbiomed.2011.10.486 
Handa, O., Naito, Y., Yoshikawa, T., 2011. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep. 
Commun. Free Radic. Res. 16, 1–7. https://doi.org/10.1179/174329211X12968219310756 
Harman, D., 1956. Aging: A Theory Based on Free Radical and Radiation Chemistry. J. Gerontol. 11, 298–300. 
https://doi.org/10.1093/geronj/11.3.298 
Hart, S.N., Li, Y., Nakamoto, K., Subileau, E., Steen, D., Zhong, X., 2010. A Comparison of Whole Genome Gene Expression Profiles 
of HepaRG Cells and HepG2 Cells to Primary Human Hepatocytes and Human Liver Tissues. Drug Metab. Dispos. 38, 
988–994. https://doi.org/10.1124/dmd.109.031831 
Hasselbalch, H.C., Thomassen, M., Riley, C.H., Kjær, L., Larsen, T.S., Jensen, M.K., Bjerrum, O.W., Kruse, T.A., Skov, V., 2014. 
Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in 
Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and 
Disease Progression. PLOS ONE 9, e112786. https://doi.org/10.1371/journal.pone.0112786 
Hatakeyama, S., 2011. TRIM proteins and cancer. Nat. Rev. Cancer 11, 792. https://doi.org/10.1038/nrc3139 
Hayakawa, M., Miyashita, H., Sakamoto, I., Kitagawa, M., Tanaka, H., Yasuda, H., Karin, M., Kikugawa, K., 2003. Evidence that 
reactive oxygen species do not mediate NF‐κB activation. EMBO J. 22, 3356–3366. 
https://doi.org/10.1093/emboj/cdg332 
Hayes, J.D., Dinkova-Kostova, A.T., 2014. The Nrf2 regulatory network provides an interface between redox and intermediary 
metabolism. Trends Biochem. Sci. 39, 199–218. https://doi.org/10.1016/j.tibs.2014.02.002 
Heiss, E., Herhaus, C., Klimo, K., Bartsch, H., Gerhäuser, C., 2001. Nuclear factor kappa B is a molecular target for sulforaphane-
mediated anti-inflammatory mechanisms. J. Biol. Chem. 276, 32008–32015. 
https://doi.org/10.1074/jbc.M104794200 
Held, K.D., Epp, E.R., Clark, E.P., Biaglow, J.E., 1988. Effect of Dimethyl Fumarate on the Radiation Sensitivity of Mammalian 
Cells in Vitro. Radiat. Res. 115, 495–502. https://doi.org/10.2307/3577299 
Hendriks, G., Atallah, M., Morolli, B., Calléja, F., Ras-Verloop, N., Huijskens, I., Raamsman, M., Water, B. van de, Vrieling, H., 
2012. The ToxTracker Assay: Novel GFP Reporter Systems that Provide Mechanistic Insight into the Genotoxic 
Properties of Chemicals. Toxicol. Sci. 125, 285–298. https://doi.org/10.1093/toxsci/kfr281 
Herpers, B., Wink, S., Fredriksson, L., Di, Z., Hendriks, G., Vrieling, H., de Bont, H., van de Water, B., 2016. Activation of the Nrf2 
response by intrinsic hepatotoxic drugs correlates with suppression of NF-κB activation and sensitizes toward TNFα-
induced cytotoxicity. Arch. Toxicol. 90, 1163–1179. https://doi.org/10.1007/s00204-015-1536-3 
 218 
 
 
Hiemstra, S., Niemeijer, M., Koedoot, E., Wink, S., Klip, J.E., Vlasveld, M., de Zeeuw, E., van Os, B., White, A., Water, B. van de, 
2017. Comprehensive Landscape of Nrf2 and p53 Pathway Activation Dynamics by Oxidative Stress and DNA 
Damage. Chem. Res. Toxicol. 30, 923–933. https://doi.org/10.1021/acs.chemrestox.6b00322 
Hinoi, E., Fujimori, S., Wang, L., Hojo, H., Uno, K., Yoneda, Y., 2006. Nrf2 Negatively Regulates Osteoblast Differentiation via 
Interfering with Runx2-dependent Transcriptional Activation. J. Biol. Chem. 281, 18015–18024. 
https://doi.org/10.1074/jbc.M600603200 
Hinson, J.A., Roberts, D.W., James, L.P., 2010. Mechanisms of Acetaminophen-Induced Liver Necrosis. Handb. Exp. Pharmacol. 
369–405. https://doi.org/10.1007/978-3-642-00663-0_12 
Hintze, K.J., Theil, E.C., 2005. DNA and mRNA elements with complementary responses to hemin, antioxidant inducers, and iron 
control ferritin-L expression. Proc. Natl. Acad. Sci. U. S. A. 102, 15048–15052. 
https://doi.org/10.1073/pnas.0505148102 
Hintze, K.J., Wald, K.A., Zeng, H., Jeffery, E.H., Finley, J.W., 2003. Thioredoxin Reductase in Human Hepatoma Cells Is 
Transcriptionally Regulated by Sulforaphane and Other Electrophiles via an Antioxidant Response Element–. J. Nutr. 
133, 2721–2727. 
Hirota, M., Ashikaga, T., Kouzuki, H., 2018. Development of an artificial neural network model for risk assessment of skin 
sensitization using human cell line activation test, direct peptide reactivity assay, KeratinoSensTM and in silico 
structure alert parameter. J. Appl. Toxicol. 38, 514–526. https://doi.org/10.1002/jat.3558 
Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., Nakayama, K., Douglas Engel, J., Yamamoto, M., 2012. Nrf2–
MafG heterodimers contribute globally to antioxidant and metabolic networks. Nucleic Acids Res. 40, 10228–10239. 
https://doi.org/10.1093/nar/gks827 
Hirotsu, Y., Katsuoka, F., Itoh, K., Yamamoto, M., 2011. Nrf2 degron-fused reporter system: a new tool for specific evaluation 
of Nrf2 inducers. Genes Cells Devoted Mol. Cell. Mech. 16, 406–415. https://doi.org/10.1111/j.1365-
2443.2011.01496.x 
Hirvonen, T., Pietinen, P., Virtanen, M., Ovaskainen, M.-L., Häkkinen, S., Albanes, D., Virtamo, J., 2001. Intake of Flavonols and 
Flavones and Risk of Coronary Heart Disease in Male Smokers. Epidemiology 12, 62–67. 
Hoeflich, K.P., Luo, J., Rubie, E.A., Tsao, M.S., Jin, O., Woodgett, J.R., 2000. Requirement for glycogen synthase kinase-3beta in 
cell survival and NF-kappaB activation. Nature 406, 86–90. https://doi.org/10.1038/35017574 
Höing, S., Rudhard, Y., Reinhardt, P., Glatza, M., Stehling, M., Wu, G., Peiker, C., Böcker, A., Parga, J.A., Bunk, E., Schwamborn, 
J.C., Slack, M., Sterneckert, J., Schöler, H.R., 2012. Discovery of Inhibitors of Microglial Neurotoxicity Acting Through 
Multiple Mechanisms Using a Stem-Cell-Based Phenotypic Assay. Cell Stem Cell 11, 620–632. 
https://doi.org/10.1016/j.stem.2012.07.005 
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., 
Itoh, K., Yamamoto, M., 2009. Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung 
Cancer. Am. Assoc. Cancer Res. 15, 3423–3432. https://doi.org/10.1158/1078-0432.CCR-08-2822 
Hong, D.S., Kurzrock, R., Supko, J.G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J.P., Meyer, C.J., Ferguson, D.A., Mier, J., 
Konopleva, M., Konoplev, S., Andreeff, M., Kufe, D., Lazarus, H., Shapiro, G.I., Dezube, B.J., 2012. A phase I first-in-
human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. Off. J. 
Am. Assoc. Cancer Res. 18, 3396–3406. https://doi.org/10.1158/1078-0432.CCR-11-2703 
Hsiao, Y.-W., Petersson, C., Svensson, M.A., Norinder, U., 2012. A Pragmatic Approach Using First-Principle Methods to Address 
Site of Metabolism with Implications for Reactive Metabolite Formation. J. Chem. Inf. Model. 52, 686–695. 
https://doi.org/10.1021/ci200523f 
Hu, C., Eggler, A.L., Mesecar, A.D., van Breemen, R.B., 2011. Modification of Keap1 Cysteine Residues by Sulforaphane. Chem. 
Res. Toxicol. 24, 515–521. https://doi.org/10.1021/tx100389r 
Hu, S., Leblanc, A., Gibson, A., Hong, K., Kim, J., Janke, L., Li, L., Vasilyeva, A., Finkelstein, D., Sprowl, J., Sweet, D., Schlatter, E., 
Ciarimboli, G., Schellens, J., Baker, S., Pabla, N., Sparreboom, A., 2017. Identification of OAT1/OAT3 as Contributors 
to Cisplatin Toxicity. Clin. Transl. Sci. n/a-n/a. https://doi.org/10.1111/cts.12480 
Huang, J., Shi, W., Zhang, J., Chou, J.W., Paules, R.S., Gerrish, K., Li, J., Luo, J., Wolfinger, R.D., Bao, W., Chu, T.-M., Nikolsky, Y., 
Nikolskaya, T., Dosymbekov, D., Tsyganova, M.O., Shi, L., Fan, X., Corton, J.C., Chen, M., Cheng, Y., Tong, W., Fang, 
H., Bushel, P.R., 2010. Genomic indicators in the blood predict drug-induced liver injury. Pharmacogenomics J. 10, 
267–277. https://doi.org/10.1038/tpj.2010.33 
Huang, J., Tabbi-Anneni, I., Gunda, V., Wang, L., 2010. Transcription factor Nrf2 regulates SHP and lipogenic gene expression in 
hepatic lipid metabolism. Am. J. Physiol. Gastrointest. Liver Physiol. 299, G1211-1221. 
https://doi.org/10.1152/ajpgi.00322.2010 
Huang, R., Xia, M., Sakamuru, S., Zhao, J., Shahane, S.A., Attene-Ramos, M., Zhao, T., Austin, C.P., Simeonov, A., 2016. Modelling 
the Tox21 10 K chemical profiles for in vivo toxicity prediction and mechanism characterization. Nat. Commun. 7, 
10425. https://doi.org/10.1038/ncomms10425 
Huh, S., Lee, J., Jung, E., Kim, S.-C., Kang, J.-I., Lee, J., Kim, Y.-W., Sung, Y.K., Kang, H.-K., Park, D., 2009. A cell-based system for 
screening hair growth-promoting agents. Arch. Dermatol. Res. 301, 381. https://doi.org/10.1007/s00403-009-0931-
0 
Igarashi, Y., Nakatsu, N., Yamashita, T., Ono, A., Ohno, Y., Urushidani, T., Yamada, H., 2014. Open TG-GATEs: a large-scale 
toxicogenomics database. Nucleic Acids Res. gku955. https://doi.org/10.1093/nar/gku955 
Imai, T., Iwawaki, T., Akai, R., Suzue, K., Hirai, M., Taniguchi, T., Okada, H., Hisaeda, H., 2014. Evaluating experimental cerebral 
malaria using oxidative stress indicator OKD48 mice. Int. J. Parasitol. 44, 681–685. 
https://doi.org/10.1016/j.ijpara.2014.06.002 
Imran, M., Lim, I.K., 2013. Regulation of Btg2/TIS21/PC3 expression via reactive oxygen species–protein kinase C–ΝFκΒ pathway 
under stress conditions. Cell. Signal. 25, 2400–2412. https://doi.org/10.1016/j.cellsig.2013.07.015 
Ishihara, H., Connolly, A.J., Zeng, D., Kahn, M.L., Wu Zheng, Y., Timmons, C., Tram, T., Coughlin, S.R., 1997. Protease-activated 
receptor 3 is a second thrombin receptor in humans. Nature 386, 502–506. https://doi.org/10.1038/386502a0 
 219 
 
 
Ishikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Imanishi, H., Nakada, K., Honma, Y., Hayashi, J.-I., 2008. 
ROS-Generating Mitochondrial DNA Mutations Can Regulate Tumor Cell Metastasis. Science 320, 661–664. 
https://doi.org/10.1126/science.1156906 
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M., 
Nabeshima, Y., 1997. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes 
through antioxidant response elements. Biochem. Biophys. Res. Commun. 236, 313–322. 
Itoh, K., Igarashi, K., Hayashi, N., Nishizawa, M., Yamamoto, M., 1995. Cloning and characterization of a novel erythroid cell-
derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell. Biol. 15, 
4184–4193. 
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J.D., Yamamoto, M., 1999. Keap1 represses nuclear activation 
of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13, 
76–86. 
Jacq, C., Miller, J.R., Brownlee, G.G., 1977. A pseudogene structure in 5S DNA of Xenopus laevis. Cell 12, 109–120. 
Jaeschke, H., Bajt, M.L., 2010. 9.21 - Mechanisms of Acetaminophen Hepatotoxicity, in: McQueen, C.A. (Ed.), Comprehensive 
Toxicology (Second Edition). Elsevier, Oxford, pp. 457–473. https://doi.org/10.1016/B978-0-08-046884-6.01019-8 
Janzen, E.G., Kotake, Y., Randall D., H., 1992. Stabilities of hydroxyl radical spin adducts of PBN-type spin traps. Free Radic. Biol. 
Med. 12, 169–173. https://doi.org/10.1016/0891-5849(92)90011-5 
Jaworska, J.S., Natsch, A., Ryan, C., Strickland, J., Ashikaga, T., Miyazawa, M., 2015. Bayesian integrated testing strategy (ITS) 
for skin sensitization potency assessment: a decision support system for quantitative weight of evidence and 
adaptive testing strategy. Arch. Toxicol. 89, 2355–2383. https://doi.org/10.1007/s00204-015-1634-2 
Jennings, P., Limonciel, A., Felice, L., Leonard, M.O., 2013. An overview of transcriptional regulation in response to toxicological 
insult. Arch. Toxicol. 87, 49–72. https://doi.org/10.1007/s00204-012-0919-y 
Jia, X., McNeill, G., Avenell, A., 2008. Does taking vitamin, mineral and fatty acid supplements prevent cognitive decline? A 
systematic review of randomized controlled trials. J. Hum. Nutr. Diet. Off. J. Br. Diet. Assoc. 21, 317–336. 
https://doi.org/10.1111/j.1365-277X.2008.00887.x 
Jiang, Z.-Y., Lu, M.-C., Xu, L., Yang, T.-T., Xi, M.-Y., Xu, X.-L., Guo, X.-K., Zhang, X.-J., You, Q.-D., Sun, H.-P., 2014. Discovery of 
Potent Keap1–Nrf2 Protein–Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis. J. Med. 
Chem. 57, 2736–2745. https://doi.org/10.1021/jm5000529 
Johnson, D.A., Andrews, G.K., Xu, W., Johnson, J.A., 2002. Activation of the antioxidant response element in primary cortical 
neuronal cultures derived from transgenic reporter mice. J. Neurochem. 81, 1233–1241. 
Johnson, G., Beaver, L., Williams, D.E., Ho, E., Dashwood, R.H., 2015. Abstract B33: Regulation and function of Nrf2-associated 
long noncoding RNA. Cancer Prev. Res. (Phila. Pa.) 8, B33–B33. https://doi.org/10.1158/1940-6215.PREV-14-B33 
Johnson, G.S., Li, J., Beaver, L.M., Dashwood, W.M., Sun, D., Rajendran, P., Williams, D.E., Ho, E., Dashwood, R.H., 2016. A 
functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a co-activator of NQO1 in sulforaphane-treated 
colon cancer cells. Mol. Nutr. Food Res. n/a-n/a. https://doi.org/10.1002/mnfr.201600769 
Jung, D., Biggs, H., Erikson, J., Ledyard, P.U., 1975. New Colorimetric Reaction for End-Point, Continuous-Flow, and Kinetic 
Measurement of Urea. Clin. Chem. 21, 1136–1140. 
Jung, K.-A., Choi, B., Nam, C.-W., Song, M., Kim, S.-T., Lee, J.Y., Kwak, M.-K., 2013. Identification of aldo-keto reductases as 
NRF2-target marker genes in human cells. Toxicol. Lett. 218, 39–49. https://doi.org/10.1016/j.toxlet.2012.12.026 
Kagan, V.E., Tyurin, V.A., Jiang, J., Tyurina, Y.Y., Ritov, V.B., Amoscato, A.A., Osipov, A.N., Belikova, N.A., Kapralov, A.A., Kini, V., 
Vlasova, I.I., Zhao, Q., Zou, M., Di, P., Svistunenko, D.A., Kurnikov, I.V., Borisenko, G.G., 2005. Cytochrome c acts as 
a cardiolipin oxygenase required for release of proapoptotic factors. Nat. Chem. Biol. 1, 223–232. 
https://doi.org/10.1038/nchembio727 
Kahn, M.L., Hammes, S.R., Botka, C., Coughlin, S.R., 1998. Gene and Locus Structure and Chromosomal Localization of the 
Protease-activated Receptor Gene Family. J. Biol. Chem. 273, 23290–23296. 
https://doi.org/10.1074/jbc.273.36.23290 
Kallifatidis, G., Rausch, V., Baumann, B., Apel, A., Beckermann, B.M., Groth, A., Mattern, J., Li, Z., Kolb, A., Moldenhauer, G., 
Altevogt, P., Wirth, T., Werner, J., Schemmer, P., Büchler, M.W., Salnikov, A.V., Herr, I., 2009. Sulforaphane targets 
pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 58, 949–963. 
https://doi.org/10.1136/gut.2008.149039 
Kang, M.-I., Kobayashi, A., Wakabayashi, N., Kim, S.-G., Yamamoto, M., 2004. Scaffolding of Keap1 to the actin cytoskeleton 
controls the function of Nrf2 as key regulator of cytoprotective phase 2 genes. Proc. Natl. Acad. Sci. U. S. A. 101, 
2046–2051. https://doi.org/10.1073/pnas.0308347100 
Kaspar, J.W., Jaiswal, A.K., 2010. An Autoregulatory Loop between Nrf2 and Cul3-Rbx1 Controls Their Cellular Abundance. J. 
Biol. Chem. 285, 21349–21358. https://doi.org/10.1074/jbc.M110.121863 
Kataoka, K., Ekuni, D., Tomofuji, T., Irie, K., Kunitomo, M., Uchida, Y., Fukuhara, D., Morita, M., 2016. Visualization of Oxidative 
Stress Induced by Experimental Periodontitis in Keap1-Dependent Oxidative Stress Detector-Luciferase Mice. Int. J. 
Mol. Sci. 17. https://doi.org/10.3390/ijms17111907 
Katoh, Y., Iida, K., Kang, M.-I., Kobayashi, A., Mizukami, M., Tong, K.I., McMahon, M., Hayes, J.D., Itoh, K., Yamamoto, M., 2005. 
Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein 
by proteasome. Arch. Biochem. Biophys. 433, 342–350. https://doi.org/10.1016/j.abb.2004.10.012 
Katoh, Y., Itoh, K., Yoshida, E., Miyagishi, M., Fukamizu, A., Yamamoto, M., 2001. Two domains of Nrf2 cooperatively bind CBP, 
a CREB binding protein, and synergistically activate transcription. Genes Cells Devoted Mol. Cell. Mech. 6, 857–868. 
Katsuoka, F., Motohashi, H., Engel, J.D., Yamamoto, M., 2005. Nrf2 Transcriptionally Activates the mafG Gene through an 
Antioxidant Response Element. J. Biol. Chem. 280, 4483–4490. https://doi.org/10.1074/jbc.M411451200 
Kaur, P., Kalia, S., Bansal, M.P., 2006. Effect of Diethyl Maleate Induced Oxidative Stress on Male Reproductive Activity in Mice: 
Redox Active Enzymes and Transcription Factors Expression. Mol. Cell. Biochem. 291, 55–61. 
https://doi.org/10.1007/s11010-006-9195-6 
 220 
 
 
Kelley, M.J., Glaser, E.M., Herndon, J.E., Becker, F., Bhagat, R., Zhang, Y.-J., Santella, R.M., Carmella, S.G., Hecht, S.S., Gallot, L., 
Schilder, L., Crowell, J.A., Perloff, M., Folz, R.J., Bergan, R.C., 2005. Safety and Efficacy of Weekly Oral Oltipraz in 
Chronic Smokers. Cancer Epidemiol. Biomarkers Prev. 14, 892–899. https://doi.org/10.1158/1055-9965.EPI-04-0585 
Keum, Y.-S., Yu, S., Chang, P.P.-J., Yuan, X., Kim, J.-H., Xu, C., Han, J., Agarwal, A., Kong, A.-N.T., 2006. Mechanism of action of 
sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of 
antioxidant response element-mediated haem oxygenase-1 in human hepatoma HepG2 cells. Cancer Res. 66, 8804–
8813. https://doi.org/10.1158/0008-5472.CAN-05-3513 
Khoo, N.K.H., Li, L., Salvatore, S.R., Schopfer, F.J., Freeman, B.A., 2018. Electrophilic fatty acid nitroalkenes regulate Nrf2 and 
NF-κB signaling:A medicinal chemistry investigation of structure-function relationships. Sci. Rep. 8, 2295. 
https://doi.org/10.1038/s41598-018-20460-8 
Kim, J.Y., Kim, D.Y., Son, H., Kim, Y.J., Oh, S.H., 2014. Protease-activated receptor-2 activates NQO-1 via Nrf2 stabilization in 
keratinocytes. J. Dermatol. Sci. 74, 48–55. https://doi.org/10.1016/j.jdermsci.2013.11.010 
Kim, K.-H., Jeong, J.-Y., Surh, Y.-J., Kim, K.-W., 2010. Expression of stress-response ATF3 is mediated by Nrf2 in astrocytes. 
Nucleic Acids Res. 38, 48–59. https://doi.org/10.1093/nar/gkp865 
Kim, M.T., Huang, R., Sedykh, A., Wang, W., Xia, M., Zhu, H., 2016. Mechanism Profiling of Hepatotoxicity Caused by Oxidative 
Stress Using Antioxidant Response Element Reporter Gene Assay Models and Big Data. Environ. Health Perspect. 
124, 634–641. https://doi.org/10.1289/ehp.1509763 
Kim, T.H., Eom, J.S., Lee, C.G., Yang, Y.M., Lee, Y.S., Kim, S.G., 2013. An active metabolite of oltipraz (M2) increases mitochondrial 
fuel oxidation and inhibits lipogenesis in the liver by dually activating AMPK. Br. J. Pharmacol. 168, 1647–1661. 
https://doi.org/10.1111/bph.12057 
Kim, Y.-C., Yamaguchi, Y., Kondo, N., Masutani, H., Yodoi, J., 2003. Thioredoxin-dependent redox regulation of the antioxidant 
responsive element (ARE) in electrophile response. Oncogene 22, 1860–1865. 
https://doi.org/10.1038/sj.onc.1206369 
Kim, Y.-J., Ahn, J.-Y., Liang, P., Ip, C., Zhang, Y., Park, Y.-M., 2007. Human prx1 gene is a target of Nrf2 and is up-regulated by 
hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 67, 546–554. https://doi.org/10.1158/0008-
5472.CAN-06-2401 
Kipp, A.P., Deubel, S., Arnér, E.S.J., Johansson, K., 2017. Time- and cell-resolved dynamics of redox-sensitive Nrf2, HIF and NF-
κB activities in 3D spheroids enriched for cancer stem cells. Redox Biol. 12, 403–409. 
https://doi.org/10.1016/j.redox.2017.03.013 
Knudsen, T.B., Houck, K.A., Sipes, N.S., Singh, A.V., Judson, R.S., Martin, M.T., Weissman, A., Kleinstreuer, N.C., Mortensen, 
H.M., Reif, D.M., Rabinowitz, J.R., Setzer, R.W., Richard, A.M., Dix, D.J., Kavlock, R.J., 2011. Activity profiles of 309 
ToxCastTM chemicals evaluated across 292 biochemical targets. Toxicology 282, 1–15. 
https://doi.org/10.1016/j.tox.2010.12.010 
Kobayashi, M., Li, L., Iwamoto, N., Nakajima-Takagi, Y., Kaneko, H., Nakayama, Y., Eguchi, M., Wada, Y., Kumagai, Y., Yamamoto, 
M., 2009. The Antioxidant Defense System Keap1-Nrf2 Comprises a Multiple Sensing Mechanism for Responding to 
a Wide Range of Chemical Compounds. Mol. Cell. Biol. 29, 493–502. https://doi.org/10.1128/MCB.01080-08 
Kola, I., Landis, J., 2004. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711–716. 
https://doi.org/10.1038/nrd1470 
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K.I., Kim, 
M., Nishito, Y., Iemura, S., Natsume, T., Ueno, T., Kominami, E., Motohashi, H., Tanaka, K., Yamamoto, M., 2010. The 
selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of 
Keap1. Nat. Cell Biol. 12, 213–223. https://doi.org/10.1038/ncb2021 
Kon, K., Kim, J.-S., Jaeschke, H., Lemasters, J.J., 2004. Mitochondrial permeability transition in acetaminophen-induced necrosis 
and apoptosis of cultured mouse hepatocytes. Hepatol. Baltim. Md 40, 1170–1179. 
https://doi.org/10.1002/hep.20437 
Kondo, N., Netsu, T., Arai, K., Kanai, T., Sano, H., Kijima, Y., Okumura, G., Fujisawa, J., Endo, N., 2017. Nuclear factor-erythroid 
2-related 2 mRNA and protein are highly expressed in the synovium of patients with rheumatoid arthritis. Internet 
J. Rheumatol. Clin. Immunol. 5. https://doi.org/10.15305/ijrci/v5i1/231 
Konstantinopoulos, P.A., Spentzos, D., Fountzilas, E., Francoeur, N., Sanisetty, S., Grammatikos, A.P., Hecht, J.L., Cannistra, S.A., 
2011. Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer. Cancer Res. 71, 5081–5089. 
https://doi.org/10.1158/0008-5472.CAN-10-4668 
Kraft, A.D., Lee, J.-M., Johnson, D.A., Kan, Y.W., Johnson, J.A., 2006. Neuronal sensitivity to kainic acid is dependent on the Nrf2-
mediated actions of the antioxidant response element. J. Neurochem. 98, 1852–1865. 
https://doi.org/10.1111/j.1471-4159.2006.04019.x 
Kratschmar, D.V., Calabrese, D., Walsh, J., Lister, A., Birk, J., Appenzeller-Herzog, C., Moulin, P., Goldring, C.E., Odermatt, A., 
2012. Suppression of the Nrf2-Dependent Antioxidant Response by Glucocorticoids and 11β-HSD1-Mediated 
Glucocorticoid Activation in Hepatic Cells. PLoS ONE 7, e36774. https://doi.org/10.1371/journal.pone.0036774 
Krauskopf, J., Caiment, F., Claessen, S.M., Johnson, K.J., Warner, R.L., Schomaker, S.J., Burt, D.A., Aubrecht, J., Kleinjans, J.C., 
2015. Application of High-Throughput Sequencing to Circulating microRNAs Reveals Novel Biomarkers for Drug-
Induced Liver Injury. Toxicol. Sci. 143, 268–276. https://doi.org/10.1093/toxsci/kfu232 
Krishnamurthy, N., Hu, Y., Siedlak, S., Doughman, Y.Q., Watanabe, M., Montano, M.M., 2012. Induction of quinone reductase 
by tamoxifen or DPN protects against mammary tumorigenesis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 26, 3993–
4002. https://doi.org/10.1096/fj.12-208330 
Kumar, B., Koul, S., Khandrika, L., Meacham, R.B., Koul, H.K., 2008. Oxidative Stress Is Inherent in Prostate Cancer Cells and Is 
Required for Aggressive Phenotype. Cancer Res. 68, 1777–1785. https://doi.org/10.1158/0008-5472.CAN-07-5259 
Kunsch, C., Medford, R.M., 1999. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 85, 753–766. 
Kuosmanen, S.M., Viitala, S., Laitinen, T., Peräkylä, M., Pölönen, P., Kansanen, E., Leinonen, H., Raju, S., Wienecke-Baldacchino, 
A., Närvänen, A., Poso, A., Heinäniemi, M., Heikkinen, S., Levonen, A.-L., 2016. The Effects of Sequence Variation on 
 221 
 
 
Genome-wide NRF2 Binding-New Target Genes and Regulatory SNPs. Nucleic Acids Res. 44, 1760–1775. 
https://doi.org/10.1093/nar/gkw052 
Kurian, G.A., Rajagopal, R., Vedantham, S., Rajesh, M., 2016. The Role of Oxidative Stress in Myocardial Ischemia and 
Reperfusion Injury and Remodeling: Revisited [WWW Document]. Oxid. Med. Cell. Longev. 
https://doi.org/10.1155/2016/1656450 
Kurz, E.U., Cole, S.P., Deeley, R.G., 2001. Identification of DNA-protein interactions in the 5’ flanking and 5’ untranslated regions 
of the human multidrug resistance protein (MRP1) gene: evaluation of a putative antioxidant response element/AP-
1 binding site. Biochem. Biophys. Res. Commun. 285, 981–990. https://doi.org/10.1006/bbrc.2001.5262 
Kwak, M.-K., Itoh, K., Yamamoto, M., Kensler, T.W., 2002. Enhanced Expression of the Transcription Factor Nrf2 by Cancer 
Chemopreventive Agents: Role of Antioxidant Response Element-Like Sequences in the nrf2 Promoter. Mol. Cell. 
Biol. 22, 2883–2892. https://doi.org/10.1128/MCB.22.9.2883-2892.2002 
Lars Ernster, F.N., 1958. Soluble Diaphorase in Animal Tissues. Acta Chem. Scand. - ACTA CHEM SCAND 12, 595–595. 
https://doi.org/10.3891/acta.chem.scand.12-0595 
Lau, A., Tian, W., Whitman, S.A., Zhang, D.D., 2013. The Predicted Molecular Weight of Nrf2: It Is What It Is Not. Antioxid. Redox 
Signal. 18, 91–93. https://doi.org/10.1089/ars.2012.4754 
Lau, A., Wang, X.-J., Zhao, F., Villeneuve, N.F., Wu, T., Jiang, T., Sun, Z., White, E., Zhang, D.D., 2010. A noncanonical mechanism 
of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol. Cell. Biol. 30, 3275–
3285. https://doi.org/10.1128/MCB.00248-10 
Lauderback, C.M., Hackett, J.M., Huang, F.F., Keller, J.N., Szweda, L.I., Markesbery, W.R., Butterfield, D.A., 2001. The glial 
glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: the 
role of Abeta1-42. J. Neurochem. 78, 413–416. 
Lazarou, J., Pomeranz, B.H., Corey, P.N., 1998. Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of 
Prospective Studies. JAMA J. Am. Med. Assoc. 279, 1200. https://doi.org/10.1001/jama.279.15.1200 
LeCluyse, E.L., Alexandre, E., Hamilton, G.A., Viollon-Abadie, C., Coon, D.J., Jolley, S., Richert, L., 2005. Isolation and culture of 
primary human hepatocytes. Methods Mol. Biol. Clifton NJ 290, 207–229. 
Lee, A.C., Murray, M., 2010. Up-regulation of human CYP2J2 in HepG2 cells by butylated hydroxyanisole is mediated by c-Jun 
and Nrf2. Mol. Pharmacol. 77, 987–994. https://doi.org/10.1124/mol.109.062729 
Lee, W., 2012. Acute Liver Failure. Semin. Respir. Crit. Care Med. 33, 36–45. https://doi.org/10.1055/s-0032-1301733 
Lehane, A.M., McDevitt, C.A., Kirk, K., Fidock, D.A., 2012. Degrees of chloroquine resistance in Plasmodium – Is the redox system 
involved? Int. J. Parasitol. Drugs Drug Resist., Including Articles from Keystone Symposium on “Drug Discovery for 
Protozoan Parasites”; pp. 230–270 2, 47–57. https://doi.org/10.1016/j.ijpddr.2011.11.001 
Leśniak, W., Szczepańska, A., Kuźnicki, J., 2005. Calcyclin (S100A6) expression is stimulated by agents evoking oxidative stress 
via the antioxidant response element. Biochim. Biophys. Acta BBA - Mol. Cell Res. 1744, 29–37. 
https://doi.org/10.1016/j.bbamcr.2004.11.003 
Levings, D., Wang, X., Kohlhase, D., Bell, D., Slattery, M., 2017. 139 - A Distinct Class of Antioxidant Response Elements is 
Consistently Activated in Tumors with Oncogenic NRF2 Mutations. Free Radic. Biol. Med., SfRBM 2017 SfRBM’s 24th 
Annual Meeting Program and Abstracts November 29 - December 2, 2017 Hilton Baltimore Baltimore, MD USA 112, 
101–102. https://doi.org/10.1016/j.freeradbiomed.2017.10.152 
Levonen, A.-L., Landar, A., Ramachandran, A., Ceaser, E.K., Dickinson, D.A., Zanoni, G., Morrow, J.D., Darley-Usmar, V.M., 2004. 
Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in 
response to electrophilic lipid oxidation products. Biochem. J. 378, 373–382. https://doi.org/10.1042/BJ20031049 
Lewis, A., Park, C.S., Shen, Y., Lee, N.K., Lacorazza, H.D., 2017. Chemical Inhibition of the Macrophage Inhibitor Factor (MIF) 
Induces Cell Cycle Arrest and Apoptosis in Lymphoid and Myeloid Leukemia. Blood 130, 1329–1329. 
Li, W., Thakor, N., Xu, E.Y., Huang, Y., Chen, C., Yu, R., Holcik, M., Kong, A.-N., 2010. An internal ribosomal entry site mediates 
redox-sensitive translation of Nrf2. Nucleic Acids Res. 38, 778–788. https://doi.org/10.1093/nar/gkp1048 
Li, Y., Elashoff, D., Oh, M., Sinha, U., St John, M.A.R., Zhou, X., Abemayor, E., Wong, D.T., 2006. Serum Circulating Human mRNA 
Profiling and Its Utility for Oral Cancer Detection. J. Clin. Oncol. 24, 1754–1760. 
https://doi.org/10.1200/JCO.2005.03.7598 
Li, Y., Jaiswal, A.K., 1992. Regulation of human NAD(P)H:quinone oxidoreductase gene. Role of AP1 binding site contained within 
human antioxidant response element. J. Biol. Chem. 267, 15097–15104. 
Liby, K.T., Sporn, M.B., 2012. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for 
prevention and treatment of chronic disease. Pharmacol. Rev. 64, 972–1003. 
https://doi.org/10.1124/pr.111.004846 
Liew, C.Y., Pan, C., Tan, A., Ang, K.X.M., Yap, C.W., 2012. QSAR classification of metabolic activation of chemicals into covalently 
reactive species. Mol. Divers. 16, 389–400. https://doi.org/10.1007/s11030-012-9364-3 
Limonciel, A., Mönks, K., Stanzel, S., Truisi, G.L., Parmentier, C., Aschauer, L., Wilmes, A., Richert, L., Hewitt, P., Mueller, S.O., 
Lukas, A., Kopp-Schneider, A., Leonard, M.O., Jennings, P., 2015. Transcriptomics hit the target: Monitoring of ligand-
activated and stress response pathways for chemical testing. Toxicol. Vitro Int. J. Publ. Assoc. BIBRA. 
https://doi.org/10.1016/j.tiv.2014.12.011 
Lin, Q., Weis, S., Yang, G., Weng, Y.-H., Helston, R., Rish, K., Smith, A., Bordner, J., Polte, T., Gaunitz, F., Dennery, P.A., 2007. 
Haem oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. 
J. Biol. Chem. 282, 20621–20633. https://doi.org/10.1074/jbc.M607954200 
Linker, R.A., Lee, D.-H., Ryan, S., Dam, A.M. van, Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., Ellrichmann, 
G., Brück, W., Dawson, K., Goelz, S., Wiese, S., Scannevin, R.H., Lukashev, M., Gold, R., 2011. Fumaric acid esters 
exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134, 678–
692. https://doi.org/10.1093/brain/awq386 
Liu, J.-F., Hou, S.-M., Tsai, C.-H., Huang, C.-Y., Yang, W.-H., Tang, C.-H., 2012. Thrombin induces haem oxygenase-1 expression 
in human synovial fibroblasts through protease-activated receptor signaling pathways. Arthritis Res. Ther. 14, R91. 
https://doi.org/10.1186/ar3815 
 222 
 
 
Lo, J.Y., Spatola, B.N., Curran, S.P., 2017. WDR23 regulates NRF2 independently of KEAP1. PLoS Genet. 13, e1006762. 
https://doi.org/10.1371/journal.pgen.1006762 
Lobenhofer, E.K., Auman, J.T., Blackshear, P.E., Boorman, G.A., Bushel, P.R., Cunningham, M.L., Fostel, J.M., Gerrish, K., 
Heinloth, A.N., Irwin, R.D., Malarkey, D.E., Merrick, B.A., Sieber, S.O., Tucker, C.J., Ward, S.M., Wilson, R.E., Hurban, 
P., Tennant, R.W., Paules, R.S., 2008. Gene expression response in target organ and whole blood varies as a function 
of target organ injury phenotype. Genome Biol. 9, R100. https://doi.org/10.1186/gb-2008-9-6-r100 
Longbrake, E.E., Ramsbottom, M.J., Cantoni, C., Ghezzi, L., Cross, A.H., Piccio, L., 2016. Dimethyl fumarate selectively reduces 
memory T cells in multiple sclerosis patients. Mult. Scler. J. 22, 1061–1070. 
https://doi.org/10.1177/1352458515608961 
Lou, H., Du, S., Ji, Q., Stolz, A., 2006. Induction of AKR1C2 by Phase II Inducers: Identification of a Distal Consensus Antioxidant 
Response Element Regulated by NRF2. Mol. Pharmacol. 69, 1662–1672. https://doi.org/10.1124/mol.105.019794 
Lundbäck, P., Lea, J.D., Sowinska, A., Ottosson, L., Fürst, C.M., Steen, J., Aulin, C., Clarke, J.I., Kipar, A., Klevenvall, L., Yang, H., 
Palmblad, K., Park, B.K., Tracey, K.J., Blom, A.M., Andersson, U., Antoine, D.J., Erlandsson Harris, H., 2016. A novel 
high mobility group box 1 neutralizing chimeric antibody attenuates drug‐induced liver injury and postinjury 
inflammation in mice. Hepatol. Baltim. Md 64, 1699–1710. https://doi.org/10.1002/hep.28736 
Luo, M., Zhang, J., He, H., Su, D., Chen, Q., Gross, M.L., Kelley, M.R., Georgiadis, M.M., 2012. Characterization of the redox 
activity and disulfide bond formation in apurinic/apyrimidinic endonuclease. Biochemistry (Mosc.) 51, 695–705. 
https://doi.org/10.1021/bi201034z 
MacLeod, A.K., McMahon, M., Plummer, S.M., Higgins, L.G., Penning, T.M., Igarashi, K., Hayes, J.D., 2009. Characterization of 
the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1-
NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-
cycling compounds. Carcinogenesis 30, 1571–1580. https://doi.org/10.1093/carcin/bgp176 
Malstrom, S.E., Jekic-McMullen, D., Sambucetti, L., Ang, A., Reeves, R., Purchio, A.F., Contag, P.R., West, D.B., 2004a. In vivo 
bioluminescent monitoring of chemical toxicity using haem oxygenase-luciferase transgenic mice. Toxicol. Appl. 
Pharmacol. 200, 219–228. https://doi.org/10.1016/j.taap.2004.04.021 
Malstrom, S.E., Jekic-McMullen, D., Sambucetti, L., Ang, A., Reeves, R., Purchio, A.F., Contag, P.R., West, D.B., 2004b. In vivo 
bioluminescent monitoring of chemical toxicity using haem oxygenase-luciferase transgenic mice. Toxicol. Appl. 
Pharmacol. 200, 219–228. https://doi.org/10.1016/j.taap.2004.04.021 
Markvicheva, K.N., Bilan, D.S., Mishina, N.M., Gorokhovatsky, A.Y., Vinokurov, L.M., Lukyanov, S., Belousov, V.V., 2011. A 
genetically encoded sensor for H2O2 with expanded dynamic range. Bioorg. Med. Chem. 19, 1079–1084. 
https://doi.org/10.1016/j.bmc.2010.07.014 
Maruichi, T., Fukami, T., Nakajima, M., Yokoi, T., 2010. Transcriptional regulation of human carboxylesterase 1A1 by nuclear 
factor-erythroid 2 related factor 2 (Nrf2). Biochem. Pharmacol. 79, 288–295. 
https://doi.org/10.1016/j.bcp.2009.08.019 
Marzec, J.M., Christie, J.D., Reddy, S.P., Jedlicka, A.E., Vuong, H., Lanken, P.N., Aplenc, R., Yamamoto, T., Yamamoto, M., Cho, 
H.-Y., Kleeberger, S.R., 2007. Functional polymorphisms in the transcription factor NRF2 in humans increase the risk 
of acute lung injury. FASEB J. 21, 2237–2246. https://doi.org/10.1096/fj.06-7759com 
Matoba, T., Shimokawa, H., Nakashima, M., Hirakawa, Y., Mukai, Y., Hirano, K., Kanaide, H., Takeshita, A., 2000. Hydrogen 
peroxide is an endothelium-derived hyperpolarizing factor in mice. J. Clin. Invest. 106, 1521–1530. 
https://doi.org/10.1172/JCI10506 
Maurer, U., Preiss, F., Brauns-Schubert, P., Schlicher, L., Charvet, C., 2014. GSK-3 - at the crossroads of cell death and survival. 
J. Cell Sci. 127, 1369–1378. https://doi.org/10.1242/jcs.138057 
McCONKEY, S.E., Grant, D.M., Cribb, A.E., 2009. The role of para‐aminophenol in acetaminophen‐induced methemoglobinemia 
in dogs and cats. J. Vet. Pharmacol. Ther. 32, 585–595. https://doi.org/10.1111/j.1365-2885.2009.01080.x 
McConnachie, L.A., Mohar, I., Hudson, F.N., Ware, C.B., Ladiges, W.C., Fernandez, C., Chatterton-Kirchmeier, S., White, C.C., 
Pierce, R.H., Kavanagh, T.J., 2007. Glutamate Cysteine Ligase Modifier Subunit Deficiency and Gender as 
Determinants of Acetaminophen-Induced Hepatotoxicity in Mice. Toxicol. Sci. 99, 628–636. 
https://doi.org/10.1093/toxsci/kfm165 
McCord, J.M., Fridovich, I., 1969. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 
244, 6049–6055. 
McGill, M.R., Lebofsky, M., Norris, H.-R.K., Slawson, M.H., Bajt, M.L., Xie, Y., Williams, C.D., Wilkins, D.G., Rollins, D.E., Jaeschke, 
H., 2013. Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-
response, mechanisms, and clinical implications. Toxicol. Appl. Pharmacol. 269, 240–249. 
https://doi.org/10.1016/j.taap.2013.03.026 
McLaughlin, J.N., Patterson, M.M., Malik, A.B., 2007. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor 
dimerization. Proc. Natl. Acad. Sci. 104, 5662–5667. https://doi.org/10.1073/pnas.0700763104 
McMahon, M., Ding, S., Acosta-Jimenez, L.P., Frangova, T.G., Henderson, C.J., Wolf, C.R., 2018. Measuring in vivo responses to 
endogenous and exogenous oxidative stress using a novel haem oxygenase 1 reporter mouse. J. Physiol. 596, 105–
127. https://doi.org/10.1113/JP274915 
McMahon, M., Itoh, K., Yamamoto, M., Chanas, S.A., Henderson, C.J., McLellan, L.I., Wolf, C.R., Cavin, C., Hayes, J.D., 2001. The 
Cap ‘n’ Collar Basic Leucine Zipper Transcription Factor Nrf2 (NF-E2 p45-related Factor 2) Controls Both Constitutive 
and Inducible Expression of Intestinal Detoxification and Glutathione Biosynthetic Enzymes. Cancer Res. 61, 3299–
3307. 
McMahon, M., Lamont, D.J., Beattie, K.A., Hayes, J.D., 2010. Keap1 perceives stress via three sensors for the endogenous 
signaling molecules nitric oxide, zinc, and alkenals. Proc. Natl. Acad. Sci. U. S. A. 107, 18838–18843. 
https://doi.org/10.1073/pnas.1007387107 
McMahon, M., Thomas, N., Itoh, K., Yamamoto, M., Hayes, J.D., 2004. Redox-regulated Turnover of Nrf2 Is Determined by at 
Least Two Separate Protein Domains, the Redox-sensitive Neh2 Degron and the Redox-insensitive Neh6 Degron. J. 
Biol. Chem. 279, 31556–31567. https://doi.org/10.1074/jbc.M403061200 
 223 
 
 
Miao, W., Hu, L., Scrivens, P.J., Batist, G., 2005. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the 
aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II 
drug-metabolizing enzymes. J. Biol. Chem. 280, 20340–20348. https://doi.org/10.1074/jbc.M412081200 
Middleton, A., Cooper, S., Cull, T., Stark, R., Adeleye, Y., Boekelheide, K., Clewell, R., Jennings, P., Guo, J., Liu, C., McMullen, P., 
Peng, S., Shah, I., Spencer, P., Subramanian, K., Thomas, R.S., van de Water, B., Westmoreland, C., White, A., Zhang, 
Q., Carmichael, P.L., 2017. Case Studies in Cellular Stress: Defining Adversity/Adaptation Tipping Points. Appl. Vitro 
Toxicol. 3, 199–210. https://doi.org/10.1089/aivt.2017.0003 
Miseta, A., Csutora, P., 2000. Relationship between the occurrence of cysteine in proteins and the complexity of organisms. 
Mol. Biol. Evol. 17, 1232–1239. 
Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O’Briant, 
K.C., Allen, A., Lin, D.W., Urban, N., Drescher, C.W., Knudsen, B.S., Stirewalt, D.L., Gentleman, R., Vessella, R.L., 
Nelson, P.S., Martin, D.B., Tewari, M., 2008. Circulating microRNAs as stable blood-based markers for cancer 
detection. Proc. Natl. Acad. Sci. 105, 10513–10518. https://doi.org/10.1073/pnas.0804549105 
Mittal, C.K., Murad, F., 1977. Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological 
regulator of guanosine 3’,5’-monophosphate formation. Proc. Natl. Acad. Sci. 74, 4360–4364. 
Mittal, M., Siddiqui, M.R., Tran, K., Reddy, S.P., Malik, A.B., 2014. Reactive Oxygen Species in Inflammation and Tissue Injury. 
Antioxid. Redox Signal. 20, 1126–1167. https://doi.org/10.1089/ars.2012.5149 
Miyagi, M.Y.S., Seelaender, M., Castoldi, A., de Almeida, D.C., Bacurau, A.V.N., Andrade-Oliveira, V., Enjiu, L.M., Pisciottano, M., 
Hayashida, C.Y., Hiyane, M.I., Brum, P.C., Camara, N.O.S., Amano, M.T., 2014. Long-Term Aerobic Exercise Protects 
against Cisplatin-Induced Nephrotoxicity by Modulating the Expression of IL-6 and HO-1. PLoS ONE 9. 
https://doi.org/10.1371/journal.pone.0108543 
Miyahara, E., Nishikawa, T., Takeuchi, T., Yasuda, K., Okamoto, Y., Kawano, Y., Horiuchi, M., 2014. Effect of myeloperoxidase 
inhibition on gene expression profiles in HL-60 cells exposed to 1, 2, 4,-benzenetriol. Toxicology 317, 50–57. 
https://doi.org/10.1016/j.tox.2014.01.007 
Miyamoto, M., Yanai, M., Ookubo, S., Awasaki, N., Takami, K., Imai, R., 2008. Detection of cell-free, liver-specific mRNAs in 
peripheral blood from rats with hepatotoxicity: a potential toxicological biomarker for safety evaluation. Toxicol. Sci. 
Off. J. Soc. Toxicol. 106, 538–545. https://doi.org/10.1093/toxsci/kfn188 
Mohar, I., Stamper, B.D., Rademacher, P.M., White, C.C., Nelson, S.D., Kavanagh, T.J., 2014. Acetaminophen-induced liver 
damage in mice is associated with gender-specific adduction of peroxiredoxin-6. Redox Biol. 2, 377–387. 
https://doi.org/10.1016/j.redox.2014.01.008 
Moi, P., Chan, K., Asunis, I., Cao, A., Kan, Y.W., 1994. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper 
transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. 
Natl. Acad. Sci. U. S. A. 91, 9926–9930. 
Montano, M.M., Deng, H., Liu, M., Sun, X., Singal, R., 2004. Transcriptional regulation by the estrogen receptor of antioxidative 
stress enzymes and its functional implications. Oncogene 23, 2442–2453. https://doi.org/10.1038/sj.onc.1207358 
Mooradian, A.D., Haas, M.J., Wong, N.C.W., 2004. Transcriptional Control of Apolipoprotein A-I Gene Expression in Diabetes. 
Diabetes 53, 513–520. https://doi.org/10.2337/diabetes.53.3.513 
Morgan, M.J., Liu, Z., 2011. Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 21, 103–115. 
https://doi.org/10.1038/cr.2010.178 
Motahari, P., Sadeghizadeh, M., Behmanesh, M., Sabri, S., Zolghadr, F., 2015. Generation of stable ARE- driven reporter system 
for monitoring oxidative stress. DARU J. Pharm. Sci. 23. https://doi.org/10.1186/s40199-015-0122-9 
Mrowietz, U., Altmeyer, P., Bieber, T., Röcken, M., Schopf, R.E., Sterry, W., 2007. Treatment of psoriasis with fumaric acid esters 
(Fumaderm®). JDDG J. Dtsch. Dermatol. Ges. 5, 716–717. https://doi.org/10.1111/j.1610-0387.2007.06346.x 
Mulcahy, R.T., Wartman, M.A., Bailey, H.H., Gipp, J.J., 1997. Constitutive and β-Naphthoflavone-induced Expression of the 
Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene Is Regulated by a Distal Antioxidant Response 
Element/TRE Sequence. J. Biol. Chem. 272, 7445–7454. https://doi.org/10.1074/jbc.272.11.7445 
Muldrew, K.L., James, L.P., Coop, L., McCullough, S.S., Hendrickson, H.P., Hinson, J.A., Mayeux, P.R., 2002. Determination of 
Acetaminophen-Protein Adducts in Mouse Liver and Serum and Human Serum after Hepatotoxic Doses of 
Acetaminophen Using High-Performance Liquid Chromatography with Electrochemical Detection. Drug Metab. 
Dispos. 30, 446–451. https://doi.org/10.1124/dmd.30.4.446 
Münzel, P.A., Schmohl, S., Buckler, F., Jaehrling, J., Raschko, F.T., Köhle, C., Bock, K.W., 2003. Contribution of the Ah receptor 
to the phenolic antioxidant-mediated expression of human and rat UDP-glucuronosyltransferase UGT1A6 in Caco-2 
and rat hepatoma 5L cells. Biochem. Pharmacol. 66, 841–847. 
Mutter, F.E., Park, B.K., Copple, I.M., 2015. Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress. 
Biochem. Soc. Trans. 43, 657–662. https://doi.org/10.1042/BST20150044 
Myzak, M.C., Karplus, P.A., Chung, F.-L., Dashwood, R.H., 2004. A novel mechanism of chemoprotection by sulforaphane: 
inhibition of histone deacetylase. Cancer Res. 64, 5767–5774. https://doi.org/10.1158/0008-5472.CAN-04-1326 
Nakabeppu, Y., Tsuchimoto, D., Yamaguchi, H., Sakumi, K., 2007. Oxidative damage in nucleic acids and Parkinson’s disease. J. 
Neurosci. Res. 85, 919–934. https://doi.org/10.1002/jnr.21191 
Nakamura, A., Nakajima, M., Higashi, E., Yamanaka, H., Yokoi, T., 2008. Genetic polymorphisms in the 5’-flanking region of 
human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation. Pharmacogenet. 
Genomics 18, 709–720. https://doi.org/10.1097/FPC.0b013e32830500c9 
Nguyen, T., Rushmore, T.H., Pickett, C.B., 1994. Transcriptional regulation of a rat liver glutathione S-transferase Ya subunit 
gene. Analysis of the antioxidant response element and its activation by the phorbol ester 12-O-
tetradecanoylphorbol-13-acetate. J. Biol. Chem. 269, 13656–13662. 
Nguyen, T., Sherratt, P.J., Huang, H.-C., Yang, C.S., Pickett, C.B., 2003. Increased Protein Stability as a Mechanism That Enhances 
Nrf2-mediated Transcriptional Activation of the Antioxidant Response Element DEGRADATION OF Nrf2 BY THE 26 S 
PROTEASOME. J. Biol. Chem. 278, 4536–4541. https://doi.org/10.1074/jbc.M207293200 
 224 
 
 
Nguyen, T., Sherratt, P.J., Nioi, P., Yang, C.S., Pickett, C.B., 2005. Nrf2 Controls Constitutive and Inducible Expression of ARE-
driven Genes through a Dynamic Pathway Involving Nucleocytoplasmic Shuttling by Keap1. J. Biol. Chem. 280, 
32485–32492. https://doi.org/10.1074/jbc.M503074200 
Nielsen, L.B., Wang, C., Sørensen, K., Bang-Berthelsen, C.H., Hansen, L., Andersen, M.-L.M., Hougaard, P., Juul, A., Zhang, C.-Y., 
Pociot, F., Mortensen, H.B., 2012. Circulating Levels of MicroRNA from Children with Newly Diagnosed Type 1 
Diabetes and Healthy Controls: Evidence That miR-25 Associates to Residual Beta-Cell Function and Glycaemic 
Control during Disease Progression [WWW Document]. J. Diabetes Res. https://doi.org/10.1155/2012/896362 
Nioi, P., McMahon, M., Itoh, K., Yamamoto, M., Hayes, J.D., 2003. Identification of a novel Nrf2-regulated antioxidant response 
element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus 
sequence. Biochem. J. 374, 337–348. https://doi.org/10.1042/BJ20030754 
Nioi, P., Nguyen, T., Sherratt, P.J., Pickett, C.B., 2005. The Carboxy-Terminal Neh3 Domain of Nrf2 Is Required for Transcriptional 
Activation. Mol. Cell. Biol. 25, 10895–10906. https://doi.org/10.1128/MCB.25.24.10895-10906.2005 
Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M.A., Beebe, D., Oates, P.J., Hammes, H.-
P., Giardino, I., Brownlee, M., 2000. Normalizing mitochondrial superoxide production blocks three pathways of 
hyperglycaemic damage. Nature 404, 787. https://doi.org/10.1038/35008121 
Niture, S.K., Jain, A.K., Jaiswal, A.K., 2009. Antioxidant-induced modification of INrf2 cysteine 151 and PKC-δ-mediated 
phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased 
drug resistance. J. Cell Sci. 122, 4452–4464. https://doi.org/10.1242/jcs.058537 
Niture, S.K., Jaiswal, A.K., 2012. Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis. J. Biol. 
Chem. 287, 9873–9886. https://doi.org/10.1074/jbc.M111.312694 
Noel, S., Zheng, L., Navas-Acien, A., Fuchs, R.J., 2014. THE EFFECT OF EX VIVO CDDO-ME ACTIVATION ON NUCLEAR FACTOR 
ERYTHROID 2–RELATED FACTOR 2 PATHWAY IN WHITE BLOOD CELLS FROM PATIENTS WITH SEPTIC SHOCK. Shock 
Augusta Ga 42, 392–399. https://doi.org/10.1097/SHK.0000000000000236 
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E.K., Jones, P.K., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, 
S., Atwood, C.S., Petersen, R.B., Smith, M.A., 2001. Oxidative damage is the earliest event in Alzheimer disease. J. 
Neuropathol. Exp. Neurol. 60, 759–767. 
Nyström-Persson, J., Igarashi, Y., Ito, M., Morita, M., Nakatsu, N., Yamada, H., Mizuguchi, K., 2013. Toxygates: interactive toxicity 
analysis on a hybrid microarray and linked data platform. Bioinformatics 29, 3080–3086. 
https://doi.org/10.1093/bioinformatics/btt531 
Oikawa, D., Akai, R., Tokuda, M., Iwawaki, T., 2012. A transgenic mouse model for monitoring oxidative stress. Sci. Rep. 2. 
https://doi.org/10.1038/srep00229 
Okawa, H., Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T.W., Yamamoto, M., 2006. Hepatocyte-specific deletion of the 
keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. 
Commun. 339, 79–88. https://doi.org/10.1016/j.bbrc.2005.10.185 
Okubo, S., Miyamoto, M., Takami, K., Kanki, M., Ono, A., Nakatsu, N., Yamada, H., Ohno, Y., Urushidani, T., 2013. Identification 
of Novel Liver-Specific mRNAs in Plasma for Biomarkers of Drug-Induced Liver Injury and Quantitative Evaluation in 
Rats Treated With Various Hepatotoxic Compounds. Toxicol. Sci. 132, 21–31. https://doi.org/10.1093/toxsci/kfs340 
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., Dorato, M., 
Van Deun, K., Smith, P., Berger, B., Heller, A., 2000. Concordance of the toxicity of pharmaceuticals in humans and 
in animals. Regul. Toxicol. Pharmacol. RTP 32, 56–67. https://doi.org/10.1006/rtph.2000.1399 
Onakpoya, I.J., Heneghan, C.J., Aronson, J.K., 2016. Post-marketing withdrawal of 462 medicinal products because of adverse 
drug reactions: a systematic review of the world literature. BMC Med. 14. https://doi.org/10.1186/s12916-016-
0553-2 
Paek, J., Lo, J.Y., Narasimhan, S.D., Nguyen, T.N., Glover-Cutter, K., Robida-Stubbs, S., Suzuki, T., Yamamoto, M., Blackwell, T.K., 
Curran, S.P., 2012. Mitochondrial SKN-1/Nrf Mediates a Conserved Starvation Response. Cell Metab. 16, 526–537. 
https://doi.org/10.1016/j.cmet.2012.09.007 
Pan, J.-A., Sun, Y., Jiang, Y.-P., Bott, A.J., Jaber, N., Dou, Z., Yang, B., Chen, J.-S., Catanzaro, J.M., Du, C., Ding, W.-X., Diaz-Meco, 
M.T., Moscat, J., Ozato, K., Lin, R.Z., Zong, W.-X., 2016. TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein 
Sequestration to Regulate Redox Homeostasis. Mol. Cell 61, 720–733. https://doi.org/10.1016/j.molcel.2016.02.007 
Papp, D., Lenti, K., Módos, D., Fazekas, D., Dúl, Z., Türei, D., Földvári-Nagy, L., Nussinov, R., Csermely, P., Korcsmáros, T., 2012. 
The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. 
FEBS Lett. 586, 1795–1802. https://doi.org/10.1016/j.febslet.2012.05.016 
Pareek, T.K., Belkadi, A., Kesavapany, S., Zaremba, A., Loh, S.L., Bai, L., Cohen, M.L., Meyer, C., Liby, K.T., Miller, R.H., Sporn, 
M.B., Letterio, J.J., 2011. Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and 
promotes remyelination in autoimmune encephalomyelitis. Sci. Rep. 1, srep00201. 
https://doi.org/10.1038/srep00201 
Park, E.Y., Rho, H.M., 2002. The trascriptional activation of the human copper/zinc superoxide dismutase gene by 2,3,7,8-
tetrachlorodibenzo-p-dioxin through two different regulator sites, the anitoxidant responsive element and 
xenobiotic responsive element. Mol. Cell. Biochem. 240, 47–55. https://doi.org/10.1023/A:1020600509965 
Parrish, A.R., Chen, G., Burghardt, R.C., Watanabe, T., Morisseau, C., Hammock, B.D., 2009. Attenuation of cisplatin 
nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 25, 217–225. 
https://doi.org/10.1007/s10565-008-9071-0 
Pei, B., Sisu, C., Frankish, A., Howald, C., Habegger, L., Mu, X.J., Harte, R., Balasubramanian, S., Tanzer, A., Diekhans, M., 
Reymond, A., Hubbard, T.J., Harrow, J., Gerstein, M.B., 2012. The GENCODE pseudogene resource. Genome Biol. 13, 
R51. https://doi.org/10.1186/gb-2012-13-9-r51 
Pellegrini, K.L., Han, T., Bijol, V., Saikumar, J., Craciun, F.L., Chen, W.W., Fuscoe, J.C., Vaidya, V.S., 2014. MicroRNA-155 Deficient 
Mice Experience Heightened Kidney Toxicity When Dosed with Cisplatin. Toxicol. Sci. 141, 484–492. 
https://doi.org/10.1093/toxsci/kfu143 
 225 
 
 
Peters, T.R., Tosk, J.M., Goulbourne, E.A., 1990. Lucigenin chemiluminescence as a probe for measuring reactive oxygen species 
production in Escherichia coli. Anal. Biochem. 186, 316–319. https://doi.org/10.1016/0003-2697(90)90087-P 
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K., Breckenridge, A.M., 2004. 
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15–19. 
https://doi.org/10.1136/bmj.329.7456.15 
Pompella, A., Sies, H., Wacker, R., Brouns, F., Grune, T., Biesalski, H.K., Frank, J., 2014. The use of total antioxidant capacity as 
surrogate marker for food quality and its effect on health is to be discouraged. Nutrition 30, 791–793. 
https://doi.org/10.1016/j.nut.2013.12.002 
Ponchel, F., Toomes, C., Bransfield, K., Leong, F.T., Douglas, S.H., Field, S.L., Bell, S.M., Combaret, V., Puisieux, A., Mighell, A.J., 
Robinson, P.A., Inglehearn, C.F., Isaacs, J.D., Markham, A.F., 2003. Real-time PCR based on SYBR-Green I 
fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene 
amplifications and micro gene deletions. BMC Biotechnol. 3, 18. https://doi.org/10.1186/1472-6750-3-18 
Posner, G.H., Cho, C.G., Green, J.V., Zhang, Y., Talalay, P., 1994. Design and synthesis of bifunctional isothiocyanate analogs of 
sulforaphane: correlation between structure and potency as inducers of anticarcinogenic detoxication enzymes. J. 
Med. Chem. 37, 170–176. 
Poss, K.D., Tonegawa, S., 1997. Haem oxygenase 1 is required for mammalian iron reutilization. Proc. Natl. Acad. Sci. 94, 10919–
10924. https://doi.org/10.1073/pnas.94.20.10919 
Prochaska, H.J., Santamaria, A.B., 1988. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter 
wells: A screening assay for anticarcinogenic enzyme inducers. Anal. Biochem. 169, 328–336. 
https://doi.org/10.1016/0003-2697(88)90292-8 
Qiu, L.-Q., Abey, S., Harris, S., Shah, R., Gerrish, K.E., Blackshear, P.J., 2015. Global Analysis of Posttranscriptional Gene 
Expression in Response to Sodium Arsenite. Environ. Health Perspect. 123, 324–330. 
https://doi.org/10.1289/ehp.1408626 
Rachakonda, G., Xiong, Y., Sekhar, K.R., Stamer, S.L., Liebler, D.C., Freeman, M.L., 2008. Covalent Modification at Cys151 
Dissociates the Electrophile Sensor Keap1 from the Ubiquitin Ligase CUL3. Chem. Res. Toxicol. 21, 705–710. 
https://doi.org/10.1021/tx700302s 
Rada, P., Rojo, A.I., Chowdhry, S., McMahon, M., Hayes, J.D., Cuadrado, A., 2011. SCF/β-TrCP Promotes Glycogen Synthase 
Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner. Mol. Cell. Biol. 
31, 1121–1133. https://doi.org/10.1128/MCB.01204-10 
Rada, P., Rojo, A.I., Evrard-Todeschi, N., Innamorato, N.G., Cotte, A., Jaworski, T., Tobón-Velasco, J.C., Devijver, H., García-
Mayoral, M.F., Leuven, F.V., Hayes, J.D., Bertho, G., Cuadrado, A., 2012. Structural and Functional Characterization 
of Nrf2 Degradation by the Glycogen Synthase Kinase 3/β-TrCP Axis. Mol. Cell. Biol. 32, 3486–3499. 
https://doi.org/10.1128/MCB.00180-12 
Radjendirane, V., Joseph, P., Lee, Y.-H., Kimura, S., Klein-Szanto, A.J.P., Gonzalez, F.J., Jaiswal, A.K., 1998. Disruption of the DT 
Diaphorase (NQO1) Gene in Mice Leads to Increased Menadione Toxicity. J. Biol. Chem. 273, 7382–7389. 
https://doi.org/10.1074/jbc.273.13.7382 
Radom-Aizik, S., Zaldivar, F., Leu, S.-Y., Galassetti, P., Cooper, D.M., 2008. Effects of 30 min of aerobic exercise on gene 
expression in human neutrophils. J. Appl. Physiol. Bethesda Md 1985 104, 236–243. 
https://doi.org/10.1152/japplphysiol.00872.2007 
Rahman, I., Kode, A., Biswas, S.K., 2007. Assay for quantitative determination of glutathione and glutathione disulfide levels 
using enzymatic recycling method. Nat. Protoc. 1, 3159–3165. https://doi.org/10.1038/nprot.2006.378 
Ramaiahgari, S.C., den Braver, M.W., Herpers, B., Terpstra, V., Commandeur, J.N.M., van de Water, B., Price, L.S., 2014. A 3D in 
vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-
throughput toxicity studies. Arch. Toxicol. 88, 1083–1095. https://doi.org/10.1007/s00204-014-1215-9 
Ramkumar, K.M., Sekar, T.V., Foygel, K., Elango, B., Paulmurugan, R., 2013. Reporter Protein Complementation Imaging Assay 
to Screen and Study Nrf2 Activators in Cells and Living Animals. Anal. Chem. 85, 7542–7549. 
https://doi.org/10.1021/ac401569j 
Ramos-Gomez, M., Dolan, P.M., Itoh, K., Yamamoto, M., Kensler, T.W., 2003. Interactive effects of nrf2 genotype and oltipraz 
on benzo[a]pyrene–DNA adducts and tumor yield in mice. Carcinogenesis 24, 461–467. 
https://doi.org/10.1093/carcin/24.3.461 
Randle, L.E., Goldring, C.E.P., Benson, C.A., Metcalfe, P.N., Kitteringham, N.R., Park, B.K., Williams, D.P., 2008. Investigation of 
the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Toxicology 
243, 249–260. https://doi.org/10.1016/j.tox.2007.10.011 
Reichard, J.F., Motz, G.T., Puga, A., 2007. Haem oxygenase-1 induction by NRF2 requires inactivation of the transcriptional 
repressor BACH1. Nucleic Acids Res. 35, 7074–7086. https://doi.org/10.1093/nar/gkm638 
Reisman, S.A., Lee, C.-Y.I., Meyer, C.J., Proksch, J.W., Sonis, S.T., Ward, K.W., 2014. Topical Application of the Synthetic 
Triterpenoid RTA 408 Protects Mice from Radiation-Induced Dermatitis. Radiat. Res. 181, 512–520. 
https://doi.org/10.1667/RR13578.1 
Richard, A.M., Judson, R.S., Houck, K.A., Grulke, C.M., Volarath, P., Thillainadarajah, I., Yang, C., Rathman, J., Martin, M.T., 
Wambaugh, J.F., Knudsen, T.B., Kancherla, J., Mansouri, K., Patlewicz, G., Williams, A.J., Little, S.B., Crofton, K.M., 
Thomas, R.S., 2016. ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology. Chem. Res. Toxicol. 
29, 1225–1251. https://doi.org/10.1021/acs.chemrestox.6b00135 
Rizzi, N., Rebecchi, M., Levandis, G., Ciana, P., Maggi, A., 2017. Identification of novel loci for the generation of reporter mice. 
Nucleic Acids Res. 45, e37. https://doi.org/10.1093/nar/gkw1142 
Rohrer, P.R., Rudraiah, S., Goedken, M.J., Manautou, J.E., 2014. Is Nuclear Factor Erythroid 2–Related Factor 2 Responsible for 
Sex Differences in Susceptibility to Acetaminophen-Induced Hepatotoxicity in Mice? Drug Metab. Dispos. 42, 1663–
1674. https://doi.org/10.1124/dmd.114.059006 
Rojo, A.I., Medina-Campos, O.N., Rada, P., Zúñiga-Toalá, A., López-Gazcón, A., Espada, S., Pedraza-Chaverri, J., Cuadrado, A., 
2012. Signaling pathways activated by the phytochemical nordihydroguaiaretic acid contribute to a Keap1-
 226 
 
 
independent regulation of Nrf2 stability: Role of glycogen synthase kinase-3. Free Radic. Biol. Med. 52, 473–487. 
https://doi.org/10.1016/j.freeradbiomed.2011.11.003 
Rushmore, T.H., Morton, M.R., Pickett, C.B., 1991. The antioxidant responsive element. Activation by oxidative stress and 
identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 266, 11632–11639. 
Rushworth, S.A., Zaitseva, L., Murray, M.Y., Shah, N.M., Bowles, K.M., MacEwan, D.J., 2012. The high Nrf2 expression in human 
acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance. Blood 120, 5188–5198. 
https://doi.org/10.1182/blood-2012-04-422121 
Russell, W.M.S., Burch, R.L., 1959. The principles of humane experimental technique. Wheathampstead (UK): Universities 
Federation for Animal Welfare. Universities Federation for Animal Welfare., Wheathampstead (UK). 
Russmann, S., Kullak-Ublick, G.A., Grattagliano, I., 2009. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. 
Med. Chem. 16, 3041–3053. 
Salazar, M., Rojo, A.I., Velasco, D., Sagarra, R.M. de, Cuadrado, A., 2006. Glycogen Synthase Kinase-3β Inhibits the Xenobiotic 
and Antioxidant Cell Response by Direct Phosphorylation and Nuclear Exclusion of the Transcription Factor Nrf2. J. 
Biol. Chem. 281, 14841–14851. https://doi.org/10.1074/jbc.M513737200 
Schneider, C.A., Rasband, W.S., Eliceiri, K.W., 2012. NIH Image to ImageJ: 25 years of image analysis. Nat Meth 9, 671–675. 
https://doi.org/10.1038/nmeth.2089 
Schoonbroodt, S., Ferreira, V., Best-Belpomme, M., Boelaert, J.R., Legrand-Poels, S., Korner, M., Piette, J., 2000. Crucial role of 
the amino-terminal tyrosine residue 42 and the carboxyl-terminal PEST domain of I kappa B alpha in NF-kappa B 
activation by an oxidative stress. J. Immunol. Baltim. Md 1950 164, 4292–4300. 
Schwarzländer, M., Wagner, S., Ermakova, Y.G., Belousov, V.V., Radi, R., Beckman, J.S., Buettner, G.R., Demaurex, N., Duchen, 
M.R., Forman, H.J., Fricker, M.D., Gems, D., Halestrap, A.P., Halliwell, B., Jakob, U., Johnston, I.G., Jones, N.S., Logan, 
D.C., Morgan, B., Müller, F.L., Nicholls, D.G., Remington, S.J., Schumacker, P.T., Winterbourn, C.C., Sweetlove, L.J., 
Meyer, A.J., Dick, T.P., Murphy, M.P., 2014. The /`mitoflash/’ probe cpYFP does not respond to superoxide. Nature 
514, E12–E14. https://doi.org/10.1038/nature13858 
Segal, L., Katz, L.S., Shapira, H., Sandbank, J., Geras-Raaka, E., Gershengorn, M.C., Oron, Y., 2014. PAR-3 Knockdown Enhances 
Adhesion Rate of PANC-1 Cells via Increased Expression of Integrinαv and E-Cadherin. PLoS ONE 9, e93879. 
https://doi.org/10.1371/journal.pone.0093879 
Sekhar, K.R., Soltaninassab, S.R., Borrelli, M.J., Xu, Z.Q., Meredith, M.J., Domann, F.E., Freeman, M.L., 2000. Inhibition of the 
26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. 
Biochem. Biophys. Res. Commun. 270, 311–317. https://doi.org/10.1006/bbrc.2000.2419 
Sharkey, J., 2013. Molecular Biomarkers and Regulators of Susceptibility to Drug-Induced Kidney Injury (PhD thesis). University 
of Liverpool. 
Sharma, S., Gao, P., Steele, V.E., 2006. The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J 
mouse lung adenoma model. Carcinogenesis 27, 1721–1727. https://doi.org/10.1093/carcin/bgl052 
Shelton, L.M., Lister, A., Walsh, J., Jenkins, R.E., Wong, M.H.L., Rowe, C., Ricci, E., Ressel, L., Fang, Y., Demougin, P., Vukojevic, 
V., O’Neill, P.M., Goldring, C.E., Kitteringham, N.R., Park, B.K., Odermatt, A., Copple, I.M., 2015. Integrated 
transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney. Kidney Int. 88, 1261–1273. 
https://doi.org/10.1038/ki.2015.286 
Sherratt, P.J., McLellan, L.I., Hayes, J.D., 2003. Positive and negative regulation of prostaglandin E2 biosynthesis in human 
colorectal carcinoma cells by cancer chemopreventive agents. Biochem. Pharmacol. 66, 51–61. 
Shimomura, O., 1985. Bioluminescence in the sea: photoprotein systems. Symp. Soc. Exp. Biol. 39, 351–372. 
Shin, S., Wakabayashi, N., Misra, V., Biswal, S., Lee, G.H., Agoston, E.S., Yamamoto, M., Kensler, T.W., 2007. NRF2 Modulates 
Aryl Hydrocarbon Receptor Signaling: Influence on Adipogenesis. Mol. Cell. Biol. 27, 7188–7197. 
https://doi.org/10.1128/MCB.00915-07 
Shord, S.S., Thompson, D.M., Krempl, G.A., Hanigan, M.H., 2006. Effect of concurrent medications on cisplatin-induced 
nephrotoxicity in patients with head and neck cancer. Anticancer. Drugs 17, 207–215. 
Shuhendler, A.J., Pu, K., Cui, L., Uetrecht, J.P., Rao, J., 2014. Real-time imaging of oxidative and nitrosative stress in the liver of 
live animals for drug-toxicity testing. Nat. Biotechnol. 32, 373–380. https://doi.org/10.1038/nbt.2838 
Shukla, S.J., Huang, R., Simmons, S.O., Tice, R.R., Witt, K.L., VanLeer, D., Ramabhadran, R., Austin, C.P., Xia, M., 2012. Profiling 
Environmental Chemicals for Activity in the Antioxidant Response Element Signaling Pathway Using a High 
Throughput Screening Approach. Environ. Health Perspect. 120, 1150–1156. https://doi.org/10.1289/ehp.1104709 
Sies, H., 2018. On the history of oxidative stress: Concept and some aspects of current development. Curr. Opin. Toxicol. 7, 122–
126. https://doi.org/10.1016/j.cotox.2018.01.002 
Sies, H., 2015. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 4, 180–183. 
https://doi.org/10.1016/j.redox.2015.01.002 
Siewert, S., González, I., Santillán, L., Lucero, R., Ojeda, M.S., Gimenez, M.S., 2013. Downregulation of Nrf2 and HO-1 expression 
contributes to oxidative stress in type 2 diabetes mellitus: A study in Juana Koslay City, San Luis, Argentina. J. 
Diabetes Mellit. 03, 71. https://doi.org/10.4236/jdm.2013.32011 
Silva, J., García, V., García, J.M., Peña, C., Domínguez, G., Díaz, R., Lorenzo, Y., Hurtado, A., Sánchez, A., Bonilla, F., 2007. 
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. BCR 
9, R55. https://doi.org/10.1186/bcr1760 
Simmons, S.O., Fan, C.-Y., Yeoman, K., Wakefield, J., Ramabhadran, R., 2011. NRF2 Oxidative Stress Induced by Heavy Metals is 
Cell Type Dependent. Curr. Chem. Genomics 5, 1–12. https://doi.org/10.2174/1875397301105010001 
Simões, B.M., Alferez, D., Eyre, R., Spence, K., Santiago-Gomez, A., Tanaka, I., Kohler, B., Howat, D., Howell, S.J., Clarke, R.B., 
2015. Abstract 2319: Sulforadex targets breast cancer stem-like cells in patient-derived cells and xenograft tumors. 
Cancer Res. 75, 2319–2319. https://doi.org/10.1158/1538-7445.AM2015-2319 
Singh, A., Happel, C., Manna, S.K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K.W., Wakabayashi, N., 
Dewi, R., Boros, L.G., Gonzalez, F.J., Gabrielson, E., Wong, K.K., Girnun, G., Biswal, S., 2013. Transcription factor NRF2 
 227 
 
 
regulates miR-1 and miR-206 to drive tumorigenesis. J. Clin. Invest. 123, 2921–2934. 
https://doi.org/10.1172/JCI66353 
Singh, A., Ling, G., Suhasini, A.N., Zhang, P., Yamamoto, M., Navas-Acien, A., Cosgrove, G., Tuder, R.M., Thomas, W.K., Watson, 
W.H., Biswal, S., 2009. Nrf2 Dependent Sulfiredoxin-1 Expression Protects Against Cigarette Smoke-induced 
Oxidative Stress in Lungs. Free Radic. Biol. Med. 46, 376–386. https://doi.org/10.1016/j.freeradbiomed.2008.10.026 
Singh, K., Connors, S.L., Macklin, E.A., Smith, K.D., Fahey, J.W., Talalay, P., Zimmerman, A.W., 2014. Sulforaphane treatment of 
autism spectrum disorder (ASD). Proc. Natl. Acad. Sci. 111, 15550–15555. 
https://doi.org/10.1073/pnas.1416940111 
Skardal, A., Murphy, S.V., Devarasetty, M., Mead, I., Kang, H.-W., Seol, Y.-J., Zhang, Y.S., Shin, S.-R., Zhao, L., Aleman, J., Hall, 
A.R., Shupe, T.D., Kleensang, A., Dokmeci, M.R., Lee, S.J., Jackson, J.D., Yoo, J.J., Hartung, T., Khademhosseini, A., 
Soker, S., Bishop, C.E., Atala, A., 2017. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip 
platform. Sci. Rep. 7, 8837. https://doi.org/10.1038/s41598-017-08879-x 
Skog, J., Wurdinger, T., van Rijn, S., Meijer, D., Gainche, L., Sena-Esteves, M., Curry, W.T., Carter, R.S., Krichevsky, A.M., 
Breakefield, X.O., 2008. Glioblastoma microvesicles transport RNA and protein that promote tumor growth and 
provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470–1476. https://doi.org/10.1038/ncb1800 
Skokos, D., Panse, S.L., Villa, I., Rousselle, J.-C., Peronet, R., David, B., Namane, A., Mécheri, S., 2001. Mast Cell-Dependent B 
and T Lymphocyte Activation Is Mediated by the Secretion of Immunologically Active Exosomes. J. Immunol. 166, 
868–876. https://doi.org/10.4049/jimmunol.166.2.868 
Smirnova, N.A., Haskew-Layton, R.E., Basso, M., Hushpulian, D.M., Payappilly, J.B., Speer, R.E., Ahn, Y.-H., Rakhman, I., Cole, 
P.A., Pinto, J.T., Ratan, R.R., Gazaryan, I.G., 2011. Development of Neh2-Luciferase Reporter and Its Application for 
High Throughput Screening and Real-Time Monitoring of Nrf2 Activators. Chem. Biol. 18, 752–765. 
https://doi.org/10.1016/j.chembiol.2011.03.013 
Soriano, F.X., Léveillé, F., Papadia, S., Higgins, L.G., Varley, J., Baxter, P., Hayes, J.D., Hardingham, G.E., 2008. Induction of 
sulfiredoxin expression and reduction of peroxiredoxin hyperoxidation by the neuroprotective Nrf2 activator 3H-
1,2-dithiole-3-thione. J. Neurochem. 107, 533–543. https://doi.org/10.1111/j.1471-4159.2008.05648.x 
Souza, T.M., Kleinjans, J.C.S., Jennen, D.G.J., 2017. Dose and Time Dependencies in Stress Pathway Responses during Chemical 
Exposure: Novel Insights from Gene Regulatory Networks. Front. Genet. 8. 
https://doi.org/10.3389/fgene.2017.00142 
Srivastava, A., Ramachandran, S., Hameed, S.P., Ahuja, V., Hosagrahara, V.P., 2014. Identification and Mitigation of a Reactive 
Metabolite Liability Associated with Aminoimidazoles. Chem. Res. Toxicol. 27, 1586–1597. 
https://doi.org/10.1021/tx500212c 
Starkey Lewis, P.J., Dear, J., Platt, V., Simpson, K.J., Craig, D.G.N., Antoine, D.J., French, N.S., Dhaun, N., Webb, D.J., Costello, 
E.M., Neoptolemos, J.P., Moggs, J., Goldring, C.E., Park, B.K., 2011. Circulating microRNAs as potential markers of 
human drug-induced liver injury. Hepatology 54, 1767–1776. https://doi.org/10.1002/hep.24538 
Steghens, J.-P., Min, K.-L., Bernengo, J.-C., 1998. Firefly luciferase has two nucleotide binding sites: effect of nucleoside 
monophosphate and CoA on the light-emission spectra. Biochem. J. 336, 109–113. 
https://doi.org/10.1042/bj3360109 
Steinberg, P., Behnisch, P.A., Besselink, H., Brouwer, A.A., 2017. Screening of molecular cell targets for carcinogenic heterocyclic 
aromatic amines by using CALUX® reporter gene assays. Cell Biol. Toxicol. 33, 283–293. 
https://doi.org/10.1007/s10565-016-9373-6 
Stewart, D., Killeen, E., Naquin, R., Alam, S., Alam, J., 2003. Degradation of Transcription Factor Nrf2 via the Ubiquitin-
Proteasome Pathway and Stabilization by Cadmium. J. Biol. Chem. 278, 2396–2402. 
https://doi.org/10.1074/jbc.M209195200 
Stirban, A., 2008. Drugs for the treatment of diabetes complications. Zycose: a new player in the field? Drugs Today Barc. Spain 
1998 44, 783–796. https://doi.org/10.1358/dot.2008.44.10.1183086 
Sun, H., Shamy, M., Kluz, T., Muñoz, A.B., Zhong, M., Laulicht, F., Alghamdi, M.A., Khoder, M.I., Chen, L.-C., Costa, M., 2012. 
Gene expression profiling and pathway analysis of human bronchial epithelial cells exposed to airborne particulate 
matter collected from Saudi Arabia. Toxicol. Appl. Pharmacol. 265. https://doi.org/10.1016/j.taap.2012.10.008 
Sun, L., Zhao, Y., Gu, S., Mao, Y., Ji, C., Xin, X., 2014. Regulation of the HMOX1 gene by the transcription factor AP-2δ with unique 
DNA binding site. Mol. Med. Rep. 10, 423–428. https://doi.org/10.3892/mmr.2014.2196 
Suttner, D.M., Sridhar, K., Lee, C.S., Tomura, T., Hansen, T.N., Dennery, P.A., 1999. Protective effects of transient HO-1 
overexpression on susceptibility to oxygen toxicity in lung cells. Am. J. Physiol. 276, L443-451. 
Switzar, L., Kwast, L.M., Lingeman, H., Giera, M., Pieters, R.H.H., Niessen, W.M.A., 2013. Identification and quantification of 
drug-albumin adducts in serum samples from a drug exposure study in mice. J. Chromatogr. B Analyt. Technol. 
Biomed. Life. Sci. 917–918, 53–61. https://doi.org/10.1016/j.jchromb.2012.12.033 
Szent-Gyorgyi, C., Ballou, B.T., Dagnal, E., Bryan, B., 1999. Cloning and characterization of new bioluminescent proteins. 
Presented at the Biomedical Imaging: Reporters, Dyes, and Instrumentation, pp. 4–11. 
https://doi.org/10.1117/12.351015 
Takabe, W., Matsukawa, N., Kodama, T., Tanaka, K., Noguchi, N., 2006. Chemical structure-dependent gene expression of 
proteasome subunits via regulation of the antioxidant response element. Free Radic. Res. 40, 21–30. 
https://doi.org/10.1080/10715760500354430 
Takai, A., Fako, V., Dang, H., Forgues, M., Yu, Z., Budhu, A., Wang, X.W., 2016. Three-dimensional Organotypic Culture Models 
of Human Hepatocellular Carcinoma. Sci. Rep. 6, 21174. https://doi.org/10.1038/srep21174 
Takayama, K., Morisaki, Y., Kuno, S., Nagamoto, Y., Harada, K., Furukawa, N., Ohtaka, M., Nishimura, K., Imagawa, K., Sakurai, 
F., Tachibana, M., Sumazaki, R., Noguchi, E., Nakanishi, M., Hirata, K., Kawabata, K., Mizuguchi, H., 2014. Prediction 
of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc. 
Natl. Acad. Sci. U. S. A. 111, 16772–16777. https://doi.org/10.1073/pnas.1413481111 
Tannenbaum, J., Bennett, B.T., 2015. Russell and Burch’s 3Rs Then and Now: The Need for Clarity in Definition and Purpose. J. 
Am. Assoc. Lab. Anim. Sci. JAALAS 54, 120–132. 
 228 
 
 
Tenhunen, R., Marver, H.S., Schmid, R., 1968. The enzymatic conversion of haem to bilirubin by microsomal haem oxygenase. 
Proc. Natl. Acad. Sci. U. S. A. 61, 748–755. 
Thakur, S., Sarkar, B., Cholia, R.P., Gautam, N., Dhiman, M., Mantha, A.K., 2014. APE1/Ref-1 as an emerging therapeutic target 
for various human diseases: phytochemical modulation of its functions. Exp. Mol. Med. 46, e106. 
https://doi.org/10.1038/emm.2014.42 
Thekkeveedu, R.K., Chu, C., Basu, S.K., Moorthy, B., 2017. Role of NF-E2 Related Factor (Nrf2) in Hyperoxic Lung Injury: 
Implications for Bronchopulmonary Dysplasia and Acute Respiratory Distress Syndrome. Pediatrics 140, 53–53. 
https://doi.org/10.1542/peds.140.1_MeetingAbstract.53 
Théry, C., Boussac, M., Véron, P., Ricciardi-Castagnoli, P., Raposo, G., Garin, J., Amigorena, S., 2001. Proteomic Analysis of 
Dendritic Cell-Derived Exosomes: A Secreted Subcellular Compartment Distinct from Apoptotic Vesicles. J. Immunol. 
166, 7309–7318. https://doi.org/10.4049/jimmunol.166.12.7309 
Thierry-Mieg, D., Thierry-Mieg, J., 2006. AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome 
Biol. 7, S12. https://doi.org/10.1186/gb-2006-7-s1-s12 
THIMMULAPPA, R.K., FUCHS, R.J., MALHOTRA, D., SCOLLICK, C., TRAORE, K., BREAM, J.H., TRUSH, M.A., LIBY, K.T., SPORN, M.B., 
KENSLER, T.W., BISWAL, S., 2007. Preclinical Evaluation of Targeting the Nrf2 Pathway by Triterpenoids (CDDO-Im 
and CDDO-Me) for Protection from LPS-Induced Inflammatory Response and Reactive Oxygen Species in Human 
Peripheral Blood Mononuclear Cells and Neutrophils. Antioxid. Redox Signal. 9, 1963–1970. 
https://doi.org/10.1089/ars.2007.1745 
Thompson, R.A., Isin, E.M., Ogese, M.O., Mettetal, J.T., Williams, D.P., 2016. Reactive Metabolites: Current and Emerging Risk 
and Hazard Assessments. Chem. Res. Toxicol. 29, 505–533. https://doi.org/10.1021/acs.chemrestox.5b00410 
Tian, C., Gao, L., Zucker, I.H., 2017. Myocardial infarction-induced miRNA-enriched exosomes contribute to Nrf2 dysregulation 
in chronic heart failure. FASEB J. 31, 721.5-721.5. 
Tobón-Velasco, J.C., Limón-Pacheco, J.H., Orozco-Ibarra, M., Macías-Silva, M., Vázquez-Victorio, G., Cuevas, E., Ali, S.F., 
Cuadrado, A., Pedraza-Chaverrí, J., Santamaría, A., 2013. 6-OHDA-induced apoptosis and mitochondrial dysfunction 
are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-κB factors. Toxicology 304, 
109–119. https://doi.org/10.1016/j.tox.2012.12.011 
Tong, K.I., Kobayashi, A., Katsuoka, F., Yamamoto, M., 2006. Two-site substrate recognition model for the Keap1-Nrf2 system: 
a hinge and latch mechanism. Biol. Chem. 387, 1311–1320. https://doi.org/10.1515/BC.2006.164 
Tsamandouras, N., Chen, W.L.K., Edington, C.D., Stokes, C.L., Griffith, L.G., Cirit, M., 2017. Integrated Gut and Liver 
Microphysiological Systems for Quantitative <Emphasis Type="Italic">In Vitro</Emphasis> Pharmacokinetic Studies. 
AAPS J. 19, 1499–1512. https://doi.org/10.1208/s12248-017-0122-4 
Tsuji, Y., 2005. JunD activates transcription of the human ferritin H gene through an antioxidant response element during 
oxidative stress. Oncogene 24, 7567–7578. https://doi.org/10.1038/sj.onc.1208901 
Uetrecht, J., Naisbitt, D.J., 2013. Idiosyncratic Adverse Drug Reactions: Current Concepts. Pharmacol. Rev. 65, 779–808. 
https://doi.org/10.1124/pr.113.007450 
Umbright, C., Sellamuthu, R., Li, S., Kashon, M., Luster, M., Joseph, P., 2010. Blood gene expression markers to detect and 
distinguish target organ toxicity. Mol. Cell. Biochem. 335, 223–234. https://doi.org/10.1007/s11010-009-0272-5 
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., 2007. Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659. 
https://doi.org/10.1038/ncb1596 
van der Linden, S.C., von Bergh, A.R.M., van Vught-Lussenburg, B.M.A., Jonker, L.R.A., Teunis, M., Krul, C.A.M., van der Burg, B., 
2014. Development of a panel of high-throughput reporter-gene assays to detect genotoxicity and oxidative stress. 
Mutat. Res. Toxicol. Environ. Mutagen. 760, 23–32. https://doi.org/10.1016/j.mrgentox.2013.09.009 
van Erk, M.J., Blom, W.A.M., van Ommen, B., Hendriks, H.F.J., 2006. High-protein and high-carbohydrate breakfasts 
differentially change the transcriptome of human blood cells. Am. J. Clin. Nutr. 84, 1233–1241. 
Vandeputte, C., Guizon, I., Genestie-Denis, I., Vannier, B., Lorenzon, G., 1994. A microtiter plate assay for total glutathione and 
glutathione disulfide contents in cultured/isolated cells: performance study of a new miniaturized protocol. Cell Biol. 
Toxicol. 10, 415–421. 
Vasquez, K.O., Peterson, J.D., 2017. Early Detection of Acute Drug-Induced Liver Injury in Mice by Noninvasive Near-Infrared 
Fluorescence Imaging. J. Pharmacol. Exp. Ther. 361, 87–98. https://doi.org/10.1124/jpet.116.238378 
Velayutham, M., Villamena, F.A., Fishbein, J.C., Zweier, J.L., 2005. Cancer chemopreventive oltipraz generates superoxide anion 
radical. Arch. Biochem. Biophys. 435, 83–88. https://doi.org/10.1016/j.abb.2004.11.028 
Venugopal, R., Jaiswal, A.K., 1996. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant 
response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U. S. A. 93, 
14960–14965. 
Vinken, M., 2013. The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology 312, 158–165. 
https://doi.org/10.1016/j.tox.2013.08.011 
Vinken, M., Landesmann, B., Goumenou, M., Vinken, S., Shah, I., Jaeschke, H., Willett, C., Whelan, M., Rogiers, V., 2013. 
Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic 
liver injury. Toxicol. Sci. Off. J. Soc. Toxicol. 136, 97–106. https://doi.org/10.1093/toxsci/kft177 
Vivekananthan, D.P., Penn, M.S., Sapp, S.K., Hsu, A., Topol, E.J., 2003. Use of antioxidant vitamins for the prevention of 
cardiovascular disease: meta-analysis of randomised trials. Lancet Lond. Engl. 361, 2017–2023. 
https://doi.org/10.1016/S0140-6736(03)13637-9 
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D.R., 
Harada, T., Engel, J.D., Yamamoto, M., 2003. Keap1-null mutation leads to postnatal lethality due to constitutive 
Nrf2 activation. Nat. Genet. 35, 238–245. https://doi.org/10.1038/ng1248 
Wakabayashi, N., Skoko, J.J., Chartoumpekis, D.V., Kimura, S., Slocum, S.L., Noda, K., Palliyaguru, D.L., Fujimuro, M., Boley, P.A., 
Tanaka, Y., Shigemura, N., Biswal, S., Yamamoto, M., Kensler, T.W., 2014. Notch-Nrf2 axis: regulation of Nrf2 gene 
 229 
 
 
expression and cytoprotection by notch signaling. Mol. Cell. Biol. 34, 653–663. https://doi.org/10.1128/MCB.01408-
13 
Walsh, J., Jenkins, R.E., Wong, M., Olayanju, A., Powell, H., Copple, I., O’Neill, P.M., Goldring, C.E.P., Kitteringham, N.R., Park, 
B.K., 2014. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: 
Biochemical, pharmacological and toxicological implications. J. Proteomics 108, 171–187. 
https://doi.org/10.1016/j.jprot.2014.05.007 
Wang, G.-K., Zhu, J.-Q., Zhang, J.-T., Li, Q., Li, Y., He, J., Qin, Y.-W., Jing, Q., 2010. Circulating microRNA: a novel potential 
biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J. 31, 659–666. 
https://doi.org/10.1093/eurheartj/ehq013 
Wang, K., Yuan, Y., Li, H., Cho, J.-H., Huang, D., Gray, L., Qin, S., Galas, D.J., 2013. The Spectrum of Circulating RNA: A Window 
into Systems Toxicology. Toxicol. Sci. 132, 478–492. https://doi.org/10.1093/toxsci/kft014 
Wang, W., Jaiswal, A.K., 2006. Nuclear factor Nrf2 and antioxidant response element regulate NRH:quinone oxidoreductase 2 
(NQO2) gene expression and antioxidant induction. Free Radic. Biol. Med. 40, 1119–1130. 
https://doi.org/10.1016/j.freeradbiomed.2005.10.063 
Wang, X., Fang, H., Huang, Z., Shang, W., Hou, T., Cheng, A., Cheng, H., 2013. Imaging ROS signaling in cells and animals. J. Mol. 
Med. Berl. Ger. 91, 917–927. https://doi.org/10.1007/s00109-013-1067-4 
Wang, X., Tomso, D.J., Chorley, B.N., Cho, H.-Y., Cheung, V.G., Kleeberger, S.R., Bell, D.A., 2007. Identification of polymorphic 
antioxidant response elements (AREs) in the human genome. Hum. Mol. Genet. 16, 1188–1200. 
https://doi.org/10.1093/hmg/ddm066 
Wang, X.J., Hayes, J.D., Wolf, C.R., 2006. Generation of a stable antioxidant response element-driven reporter gene cell line and 
its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents. Cancer Res. 66, 10983–
10994. https://doi.org/10.1158/0008-5472.CAN-06-2298 
Wang, Y., Xiao, L., Thiagalingam, A., Nelkin, B.D., Casero, R.A., 1998. The identification of a cis-element and a trans-acting factor 
involved in the response to polyamines and polyamine analogues in the regulation of the human 
spermidine/spermine N1-acetyltransferase gene transcription. J. Biol. Chem. 273, 34623–34630. 
Warabi, E., Wada, Y., Kajiwara, H., Kobayashi, M., Koshiba, N., Hisada, T., Shibata, M., Ando, J., Tsuchiya, M., Kodama, T., 
Noguchi, N., 2004. Effect on endothelial cell gene expression of shear stress, oxygen concentration, and low-density 
lipoprotein as studied by a novel flow cell culture system. Free Radic. Biol. Med. 37, 682–694. 
https://doi.org/10.1016/j.freeradbiomed.2004.05.020 
Ward, J., Kanchagar, C., Veksler-Lublinsky, I., Lee, R.C., McGill, M.R., Jaeschke, H., Curry, S.C., Ambros, V.R., 2014. Circulating 
microRNA profiles in human patients with acetaminophen hepatotoxicity or ischemic hepatitis. Proc. Natl. Acad. Sci. 
111, 12169–12174. https://doi.org/10.1073/pnas.1412608111 
Wasserman, W.W., Fahl, W.E., 1997. Functional antioxidant responsive elements. Proc. Natl. Acad. Sci. U. S. A. 94, 5361–5366. 
Wasserman, W.W., Fahl, W.E., 1997. Functional antioxidant responsive elements. Proc. Natl. Acad. Sci. U. S. A. 94, 5361–5366. 
Watai, Y., Kobayashi, A., Nagase, H., Mizukami, M., McEvoy, J., Singer, J.D., Itoh, K., Yamamoto, M., 2007. Subcellular localization 
and cytoplasmic complex status of endogenous Keap1. Genes Cells Devoted Mol. Cell. Mech. 12, 1163–1178. 
https://doi.org/10.1111/j.1365-2443.2007.01118.x 
Watanabe, T., Tahara, M., Todo, S., 2008. The novel antioxidant edaravone: from bench to bedside. Cardiovasc. Ther. 26, 101–
114. https://doi.org/10.1111/j.1527-3466.2008.00041.x 
Wayner, D. d. m., Burton, G. w., Ingold, K. u., Locke, S., 1985. Quantitative measurement of the total, peroxyl radical-trapping 
antioxidant capability of human blood plasma by controlled peroxidation. FEBS Lett. 187, 33–37. 
https://doi.org/10.1016/0014-5793(85)81208-4 
Weerachayaphorn, J., Cai, S.-Y., Soroka, C.J., Boyer, J.L., 2009. NF-E2- related factor 2 (Nrf2) is a positive regulator of human 
bile salt export pump (BSEP) expression. Hepatol. Baltim. Md 50, 1588–1596. https://doi.org/10.1002/hep.23151 
Wester, K., Jönsson, A.K., Spigset, O., Druid, H., Hägg, S., 2008. Incidence of fatal adverse drug reactions: a population based 
study. Br. J. Clin. Pharmacol. 65, 573–579. https://doi.org/10.1111/j.1365-2125.2007.03064.x 
Wetmore, B.A., Brees, D.J., Singh, R., Watkins, P.B., Andersen, M.E., Loy, J., Thomas, R.S., 2010. Quantitative analyses and 
transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury. Hepatology 51, 2127–2139. 
https://doi.org/10.1002/hep.23574 
Williamson, T.P., Amirahmadi, S., Joshi, G., Kaludov, N.K., Martinov, M.N., Johnson, D.A., Johnson, J.A., 2012. Discovery of 
potent, novel Nrf2 inducers via quantum modeling, virtual screening and in vitro experimental validation. Chem. 
Biol. Drug Des. 80, 810–820. https://doi.org/10.1111/cbdd.12040 
Wilmes, A., Crean, D., Aydin, S., Pfaller, W., Jennings, P., Leonard, M.O., 2011. Identification and dissection of the Nrf2 mediated 
oxidative stress pathway in human renal proximal tubule toxicity. Toxicol. Vitro Int. J. Publ. Assoc. BIBRA 25, 613–
622. https://doi.org/10.1016/j.tiv.2010.12.009 
Wilmes, A., Limonciel, A., Aschauer, L., Moenks, K., Bielow, C., Leonard, M.O., Hamon, J., Carpi, D., Ruzek, S., Handler, A., Schmal, 
O., Herrgen, K., Bellwon, P., Burek, C., Truisi, G.L., Hewitt, P., Di Consiglio, E., Testai, E., Blaauboer, B.J., Guillou, C., 
Huber, C.G., Lukas, A., Pfaller, W., Mueller, S.O., Bois, F.Y., Dekant, W., Jennings, P., 2013. Application of integrated 
transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. 
J. Proteomics 79, 180–194. https://doi.org/10.1016/j.jprot.2012.11.022 
Wilson, L.A., Gemin, A., Espiritu, R., Singh, G., 2005. ets-1 is transcriptionally up-regulated by H2O2 via an antioxidant response 
element. FASEB J. 19, 2085–2087. https://doi.org/10.1096/fj.05-4401fje 
Wink, S., Hiemstra, S., Herpers, B., van de Water, B., 2017. High-content imaging-based BAC-GFP toxicity pathway reporters to 
assess chemical adversity liabilities. Arch. Toxicol. 91, 1367–1383. https://doi.org/10.1007/s00204-016-1781-0 
Wink, S., Hiemstra, S., Huppelschoten, S., Danen, E., Niemeijer, M., Hendriks, G., Vrieling, H., Herpers, B., van de Water, B., 
2014. Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety 
assessment. Chem. Res. Toxicol. 27, 338–355. https://doi.org/10.1021/tx4004038 
Wong, M.H.L., Bryan, H.K., Copple, I.M., Jenkins, R.E., Chiu, P.H., Bibby, J., Berry, N.G., Kitteringham, N.R., Goldring, C.E., O’Neill, 
P.M., Park, B.K., 2016. Design and Synthesis of Irreversible Analogues of Bardoxolone Methyl for the Identification 
 230 
 
 
of Pharmacologically Relevant Targets and Interaction Sites. J. Med. Chem. 59, 2396–2409. 
https://doi.org/10.1021/acs.jmedchem.5b01292 
Woo, H.A., Jeong, W., Chang, T.-S., Park, K.J., Park, S.J., Yang, J.S., Rhee, S.G., 2005. Reduction of cysteine sulfinic acid by 
sulfiredoxin is specific to 2-cys peroxiredoxins. J. Biol. Chem. 280, 3125–3128. 
https://doi.org/10.1074/jbc.C400496200 
Woo, H.A., Yim, S.H., Shin, D.H., Kang, D., Yu, D.-Y., Rhee, S.G., 2010. Inactivation of peroxiredoxin I by phosphorylation allows 
localized H(2)O(2) accumulation for cell signaling. Cell 140, 517–528. https://doi.org/10.1016/j.cell.2010.01.009 
WRÓBLEWSKI, F., JERVIS, G., LADUE, J.S., 1956. THE DIAGNOSTIC, PROGNOSTIC AND EPIDEMIOLOGIC SIGNIFICANCE OF SERUM 
GLUTAMIC OXALOACETIC TRANSAMINASE (SGO-T) ALTERATIONS IN ACUTE HEPATITIS*. Ann. Intern. Med. 45, 782–
800. https://doi.org/10.7326/0003-4819-45-5-782 
Wrona, M., Patel, K., Wardman, P., 2005. Reactivity of 2’,7’-dichlorodihydrofluorescein and dihydrorhodamine 123 and their 
oxidized forms toward carbonate, nitrogen dioxide, and hydroxyl radicals. Free Radic. Biol. Med. 38, 262–270. 
https://doi.org/10.1016/j.freeradbiomed.2004.10.022 
Wu, K.C., McDonald, P.R., Liu, J., Klaassen, C.D., 2014. Screening of Natural Compounds as Activators of the Keap1-Nrf2 
Pathway. Planta Med. 80, 97–104. https://doi.org/10.1055/s-0033-1351097 
Wu, K.C., McDonald, P.R., Liu, J.J., Chaguturu, R., Klaassen, C.D., 2012. Implementation of a High-Throughput Screen for 
Identifying Small Molecules to Activate the Keap1-Nrf2-ARE Pathway. PLOS ONE 7, e44686. 
https://doi.org/10.1371/journal.pone.0044686 
Wu, T., Zhao, F., Gao, B., Tan, C., Yagishita, N., Nakajima, T., Wong, P.K., Chapman, E., Fang, D., Zhang, D.D., 2014. Hrd1 
suppresses Nrf2-mediated cellular protection during liver cirrhosis. Genes Dev. 28, 708–722. 
https://doi.org/10.1101/gad.238246.114 
Xanthoudakis, S., Miao, G., Wang, F., Pan, Y.C., Curran, T., 1992. Redox activation of Fos-Jun DNA binding activity is mediated 
by a DNA repair enzyme. EMBO J. 11, 3323–3335. 
Xu, J.J., Diaz, D., O’Brien, P.J., 2004. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of 
human hepatotoxicity potential. Chem. Biol. Interact. 150, 115–128. https://doi.org/10.1016/j.cbi.2004.09.011 
Yaekashiwa, M., Wang, L.-H., 2003. Nrf2 regulates thromboxane synthase gene expression in human lung cells. DNA Cell Biol. 
22, 479–487. https://doi.org/10.1089/10445490360708883 
Yamamoto, T., Kyo, M., Kamiya, T., Tanaka, T., Engel, J.D., Motohashi, H., Yamamoto, M., 2006. Predictive base substitution 
rules that determine the binding and transcriptional specificity of Maf recognition elements. Genes Cells Devoted 
Mol. Cell. Mech. 11, 575–591. https://doi.org/10.1111/j.1365-2443.2006.00965.x 
Yamashita, S., Masuda, D., Ohama, T., Arai, H., Bujo, H., Kagimura, T., Kita, T., Matsuzaki, M., Saito, Y., Fukushima, M., 
Matsuzawa, Y., PROSPECTIVE Study Group, 2016. Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for 
Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. J. Atheroscler. 
Thromb. 23, 746–756. https://doi.org/10.5551/jat.32813 
Yang, H., Magilnick, N., Lee, C., Kalmaz, D., Ou, X., Chan, J.Y., Lu, S.C., 2005. Nrf1 and Nrf2 Regulate Rat Glutamate-Cysteine 
Ligase Catalytic Subunit Transcription Indirectly via NF-κB and AP-1. Mol. Cell. Biol. 25, 5933–5946. 
https://doi.org/10.1128/MCB.25.14.5933-5946.2005 
Yazdani, M., 2015. Concerns in the application of fluorescent probes DCDHF-DA, DHR 123 and DHE to measure reactive oxygen 
species in vitro. Toxicol. Vitro Int. J. Publ. Assoc. BIBRA 30, 578–582. https://doi.org/10.1016/j.tiv.2015.08.010 
Yeager, R.L., Reisman, S.A., Aleksunes, L.M., Klaassen, C.D., 2009. Introducing the “TCDD-Inducible AhR-Nrf2 Gene Battery.” 
Toxicol. Sci. 111, 238–246. https://doi.org/10.1093/toxsci/kfp115 
Yoshino, Y., Ishioka, C., 2015. Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by 
disrupting centrosome regulation in cancer cells. Sci. Rep. 5, 13249. https://doi.org/10.1038/srep13249 
Yu, Y., Huang, X., Zhang, J., Liu, J., Hu, Y., Yang, Y., Cai, J., Huang, Y., Qin, Q., 2016. Fish TRIM16L exerts negative regulation on 
antiviral immune response against grouper iridoviruses. Fish Shellfish Immunol. 59, 256–267. 
https://doi.org/10.1016/j.fsi.2016.10.044 
Yuan, X., Xu, C., Pan, Z., Keum, Y.-S., Kim, J.-H., Shen, G., Yu, S., Oo, K.T., Ma, J., Kong, A.-N.T., 2006. Butylated hydroxyanisole 
regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol. 
Carcinog. 45, 841–850. https://doi.org/10.1002/mc.20234 
Yueh, M.-F., Tukey, R.H., 2007. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic 
UGT1 mice. J. Biol. Chem. 282, 8749–8758. https://doi.org/10.1074/jbc.M610790200 
Zhang, D.D., Hannink, M., 2003. Distinct Cysteine Residues in Keap1 Are Required for Keap1-Dependent Ubiquitination of Nrf2 
and for Stabilization of Nrf2 by Chemopreventive Agents and Oxidative Stress. Mol. Cell. Biol. 23, 8137–8151. 
https://doi.org/10.1128/MCB.23.22.8137-8151.2003 
Zhang, D.D., Lo, S.-C., Cross, J.V., Templeton, D.J., Hannink, M., 2004. Keap1 Is a Redox-Regulated Substrate Adaptor Protein for 
a Cul3-Dependent Ubiquitin Ligase Complex. Mol. Cell. Biol. 24, 10941–10953. 
https://doi.org/10.1128/MCB.24.24.10941-10953.2004 
Zhang, D.D., Lo, S.-C., Sun, Z., Habib, G.M., Lieberman, M.W., Hannink, M., 2005. Ubiquitination of Keap1, a BTB-Kelch Substrate 
Adaptor Protein for Cul3, Targets Keap1 for Degradation by a Proteasome-independent Pathway. J. Biol. Chem. 280, 
30091–30099. https://doi.org/10.1074/jbc.M501279200 
Zhang, J., Goering, P.L., Espandiari, P., Shaw, M., Bonventre, J.V., Vaidya, V.S., Brown, R.P., Keenan, J., Kilty, C.G., Sadrieh, N., 
Hanig, J.P., 2009. Differences in Immunolocalization of Kim-1, RPA-1, and RPA-2 in Kidneys of Gentamicin-, Cisplatin-
, and Valproic Acid-TreatedRats: Potential Role of iNOS and Nitrotyrosine. Toxicol. Pathol. 37, 629–643. 
https://doi.org/10.1177/0192623309339605 
Zhang, L., Bushel, P.R., Chou, J., Zhou, T., Watkins, P.B., 2012. Identification of Identical Transcript Changes in Liver and Whole 
Blood during Acetaminophen Toxicity. Front. Genet. 3. https://doi.org/10.3389/fgene.2012.00162 
Zhang, W., Feng, J.Q., Harris, S.E., Contag, P.R., Stevenson, D.K., Contag, C.H., 2001a. Rapid in vivo functional analysis of 
transgenes in mice using whole body imaging of luciferase expression. Transgenic Res. 10, 423–434. 
 231 
 
 
Zhang, W., Feng, J.Q., Harris, S.E., Contag, P.R., Stevenson, D.K., Contag, C.H., 2001b. Rapid in vivo functional analysis of 
transgenes in mice using whole body imaging of luciferase expression. Transgenic Res. 10, 423–434. 
Zhang, Y., Talalay, P., Cho, C.G., Posner, G.H., 1992. A major inducer of anticarcinogenic protective enzymes from broccoli: 
isolation and elucidation of structure. Proc. Natl. Acad. Sci. 89, 2399–2403. 
Zhao, F., Wu, T., Lau, A., Jiang, T., Huang, Z., Wang, X.-J., Chen, W., Wong, P.K., Zhang, D.D., 2009. Nrf2 promotes neuronal cell 
differentiation. Free Radic. Biol. Med. 47, 867–879. https://doi.org/10.1016/j.freeradbiomed.2009.06.029 
Zhong, X.Y., Holzgreve, W., Huang, D.J., 2008. Isolation of Cell-Free RNA from Maternal Plasma, in: Prenatal Diagnosis, Methods 
in Molecular BiologyTM. Humana Press, pp. 269–273. https://doi.org/10.1007/978-1-59745-066-9_21 
Ziegler, D., Nowak, H., Kempler, P., Vargha, P., Low, P.A., 2004. Treatment of symptomatic diabetic polyneuropathy with the 
antioxidant alpha-lipoic acid: a meta-analysis. Diabet. Med. J. Br. Diabet. Assoc. 21, 114–121. 
Zou, W., Liu, X., Yue, P., Zhou, Z., Sporn, M.B., Lotan, R., Khuri, F.R., Sun, S.-Y., 2004. c-Jun NH2-terminal kinase-mediated up-
regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-
cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 64, 7570–7578. 
https://doi.org/10.1158/0008-5472.CAN-04-1238 
Zweier, J.L., Kuppusamy, P., Lutty, G.A., 1988. Measurement of endothelial cell free radical generation: evidence for a central 
mechanism of free radical injury in postischemic tissues. Proc. Natl. Acad. Sci. 85, 4046–4050. 
 
 
  
 232 
 
 
Appendix 
Table A1 Putative NRF2-regulated gene bioinformatic analysis  
Green = Genes identified for further analysis (- = not measured in dataset, * = not present in 
top 1000 genes upregulated by drug).  
Gene symbol Gene description 
Average mRNA level 
+ 
siNRF2 
in PHH 
(% 
siCON) 
+ 
siKEAP1 
in PHH 
(% 
siCON) 
+ siNRF2 
(% Non-
targeting 
siRNA) 
(Singh et 
al., 2013) 
+ 
siKEA
P1 
(%Non
-
targeti
ng 
siRNA) 
(Agye
man 
et al., 
2012) 
+ 
sulforap
hane  
(% 
vehicle) 
(Agyema
n et al., 
2012) 
 + 200 
µM BHA 
dose  
(% 
vehicle) 
(Igarashi 
et al., 
2014) 
+ 1500 
µM DEM 
dose  
(% 
vehicle) 
(Igarashi 
et al., 
2014) 
F2RL2 
Coagulation factor II (thrombin 
) receptor-like 2 (F2RL2), 
 transcript variant 1, mRNA [NM_004101] 
6% 1828% 15% 603% 4858% 175% 1532% 
LOC344887 
NmrA-like family domain containing 1 
pseudogene 
 (LOC344887), non-coding RNA [NR_033752] 
13% 1714% 15% 
11815
% 
7225% 256% 271% 
AKR1B15 
Aldo-keto reductase family 1, member B15  
(AKR1B15), mRNA [NM_001080538] 
20% 1215% - - - * * 
NQO1 
NAD(P)H dehydrogenase, quinone 1 (NQO1),  
transcript variant 1, mRNA [NM_000903] 
26% 550% 38% 699% 517% 200% 154% 
ALDH3A1 
Aldehyde dehydrogenase 3 family, member A1 
(ALDH3A1), 
 transcript variant 2, mRNA [NM_000691] 
27% 431% 16% 2761% 482% * * 
AKR1CL1 
Aldo-keto reductase family 1, member C-like 1 
(AKR1CL1), 
 non-coding RNA [NR_027916] 
33% 199% - - - * * 
TRIM16L 
Tripartite motif containing 16-like (TRIM16L),  
mRNA [NM_001037330] 
40% 372% 91% 327% 556% 123% * 
PANX2 
Pannexin 2 (PANX2), transcript variant 1,  
mRNA [NM_052839] 
41% 241% 86% 180% 962% 189% 133% 
THC2521366 Unknown 41% 214% - - - 142% * 
LUCAT1 
Lung cancer associated transcript 1 (non-protein 
coding)  
[Source:HGNC Symbol;Acc:48498] 
[ENST00000513626] 
45% 700% - - - * * 
EID3 
EP300 interacting inhibitor of differentiation 3 
(EID3),  
mRNA [NM_001008394] 
46% 263% 63% 528% 802% 237% 407% 
LOC101927592 
Uncharacterized LOC101927592 (LOC101927592), 
 long non-coding RNA [NR_104646] 
46% 404% 94% 109% 135% * * 
UGDH 
UDP-glucose 6-dehydrogenase (UGDH),  
transcript variant 1, mRNA [NM_003359] 
49% 185% 75% 196% 324% * * 
MAP2 
Microtubule-associated protein 2 (MAP2),  
transcript variant 1, mRNA [NM_002374] 
49% 286% 14% 614% 6073% * * 
GSTA7P 
Glutathione S-transferase alpha 7, pseudogene 
(GSTA7P),  
non-coding RNA [NR_033760] 
49% 260% - - - * * 
AKR1C4 
Aldo-keto reductase family 1, member C4 
(AKR1C4),  
mRNA [NM_001818] 
50% 172% 67% 80% 86% * * 
AFP 
Alpha-fetoprotein (AFP),  
mRNA [NM_001134] 
50% 176% 70% 144% 105% * 191% 
XLOC_014512 
linc|BROAD Institute lincRNA (XLOC_014512), 
 lincRNA [TCONS_l2_00013854] 
50% 169% - - - 247% * 
FAM223A 
Family with sequence similarity 223, member A 
(non-protein coding)  
(FAM223A), long non-coding RNA [NR_027401] 
50% 184% 95% - - 163% * 
A_33_P332828
4 
Unknown 51% 181% - - - * * 
BTBD11 
Family with sequence similarity 162, member A  
(FAM162A), mRNA [NM_014367] 
54% 255% 65% 92% 118% 276% * 
ALDH1A1 
Aldehyde dehydrogenase 1 family, member A1 
 (ALDH1A1), mRNA [NM_000689] 
54% 196% 101% 49% 63% * * 
LOC101927136 
Uncharacterized LOC101927136 (LOC101927136), 
 long non-coding RNA [NR_110840] 
54% 204% - - - * * 
SLCO1B1 
Solute carrier organic anion transporter family, 
member 1B1  
(SLCO1B1), mRNA [NM_006446] 
56% 162% 100% 98% 98% * * 
IKBKG 
Inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase gamma 
 (IKBKG), transcript variant 3, mRNA 
[NM_003639] 
57% 145% 93% 312% 428% 298% 141% 
ENST00000449
602 
Q8HCZ3_PTIPL (Q8HCZ3) Nicotinamide 
dehydrogenase subunit 2 
59% 179% - - - * * 
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 (Fragment), partial (5%) [THC2646287] 
SRXN1 Sulfiredoxin 1 (SRXN1), mRNA [NM_080725] 59% 264% 26% 425% 706% 360% 343% 
LOC101927258 
Uncharacterized LOC101927258 (LOC101927258), 
 transcript variant X2, ncRNA [XR_426391] 
59% 163% - - - * * 
SPP1 
Secreted phosphoprotein 1 (SPP1), transcript 
variant 1, 
 mRNA [NM_001040058] 
59% 172% 34% 556% 1576% 320% 237% 
SFN Stratifin (SFN), mRNA [NM_006142] 60% 323% 31% 181% 312% 129% 167% 
LOC101927171 
Uncharacterized LOC101927171 (RP11-345L23.1), 
 ncRNA [XR_242040] 
62% 137% - - - * * 
SULT1A2 
Sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 2  
(SULT1A2), transcript variant 2, mRNA 
[NM_177528] 
62% 168% 97% 238% 528% * * 
MROH2A 
Maestro heat-like repeat family member 2A 
(MROH2A), 
 mRNA [NM_001287395] 
65% 194% 88% 106% 101% * * 
ALDH1L1 
Aldehyde dehydrogenase 1 family, member L1 
(ALDH1L1), 
 transcript variant 2, mRNA [NM_012190] 
65% 187% 93% 125% 90% 168% * 
DKK3 
Dickkopf WNT signaling pathway inhibitor 3 
(DKK3), 
 transcript variant 1, mRNA [NM_015881] 
65% 142% 93% 111% 575% * * 
MLLT11 
Myeloid/lymphoid or mixed-lineage leukemia  
(trithorax homolog, Drosophila); 
 translocated to, 11 (MLLT11), mRNA 
[NM_006818] 
65% 182% 53% 238% 213% 209% 180% 
BHMT2 
Betaine--homocysteine S-methyltransferase 2 
(BHMT2),  
transcript variant 1, mRNA [NM_017614] 
66% 134% 94% 97% 95% 147% * 
ZDHHC18 
Zinc finger, DHHC-type containing 18 (ZDHHC18),  
mRNA [NM_032283] 
66% 178% 79% 202% 176% * 287% 
CCND1 Cyclin D1 (CCND1), mRNA [NM_053056] 67% 146% 60% 96% 253% * * 
ENST00000479
830 
Uncharacterized LOC101928885 (RP11-
141O11.2), 
 transcript variant X1, ncRNA [XR_241811] 
67% 194% - - - * * 
ENST00000430
247 
Uncharacterized LOC102724420 (LOC102724420), 
 ncRNA [XR_425263] 
67% 150% - - - * * 
L3HYPDH 
L-3-hydroxyproline dehydratase (trans-)  
(L3HYPDH), mRNA [NM_144581] 
67% 151% 66% 179% 263% * * 
ADHFE1 
Alcohol dehydrogenase, iron containing, 1 
 (ADHFE1), mRNA [NM_144650] 
69% 171% 99% 274% 934% 256% * 
MYEOV 
Myeloma overexpressed (MYEOV),  
transcript variant 2, mRNA [NM_138768] 
69% 156% 47% 104% 103% * * 
ABHD4 
Abhydrolase domain containing 4  
(ABHD4), mRNA [NM_022060] 
69% 173% 65% 263% 565% 234% 182% 
CES5A 
Carboxylesterase 5A (CES5A), transcript variant 2, 
 mRNA [NM_145024] 
70% 180% 103% 92% 122% * * 
ITGA7 
Itegrin, alpha 7 (ITGA7), transcript variant 2, 
 mRNA [NM_002206] 
70% 230% 86% 126% 217% 148% * 
LOC100505985 
Uncharacterized LOC100505985  
(LOC100505985), ncRNA [XR_108661] 
71% 196% - - - * 226% 
CNTNAP3B 
Contactin associated protein-like 3B  
(CNTNAP3B), mRNA [NM_001201380] 
72% 136% - - - 182% * 
KYNU 
Kynureninase (KYNU), transcript variant 2, 
 mRNA [NM_001032998] 
72% 163% 40% 368% 493% 402% 191% 
LOC102723323 
Uncharacterized LOC102723323 (LOC102723323), 
 ncRNA [XR_424702] 
72% 152% - - - * * 
SLC48A1 
Solute carrier family 48 (haem transporter), 
member 1  
(SLC48A1), mRNA [NM_017842] 
74% 148% 76% 141% 324% * * 
ENST00000479
351 
Contactin associated protein-like 3B (CNTNAP3)  
[Source:HGNC Symbol;Acc:32035] 
[ENST00000479351] 
74% 144% - - - * * 
GBE1 
Glucan (1,4-alpha-), branching enzyme 1  
(GBE1), mRNA [NM_000158] 
76% 154% 94% 105% 354% 164% * 
CCAT1 
Colon cancer associated transcript 1 (non-protein 
coding)  
(CCAT1), long non-coding RNA [NR_108049] 
76% 158% - 127% 115% * * 
SULT1A4 
Sulfotransferase family, cytosolic, 1A, phenol-
preferring, member 4 
 (SULT1A4), mRNA [NM_001017390] 
76% 162% 100% - - * * 
ENST00000521
815 
Cancer susceptibility candidate 19 (non-protein 
coding) 
 [Source:HGNC Symbol;Acc:49476] 
[ENST00000521815] 
77% 148% - - - * * 
MPP3 
Membrane protein, palmitoylated 3  
(MAGUK p55 subfamily member 3) 
 (MPP3), transcript variant 1, mRNA [NM_001932] 
77% 145% 82% 149% 317% 118% * 
CDC14B 
Cell division cycle 14B (CDC14B), transcript 
 variant 2, mRNA [NM_033331] 
78% 138% 85% 106% 177% 175% 265% 
GSTA5 
Glutathione S-transferase alpha 5  
(GSTA5), mRNA [NM_153699] 
78% 180% - 173% 297% * * 
AOC3 
Amine oxidase, copper containing 3 (AOC3),  
transcript variant 1, mRNA [NM_003734] 
78% 123% 101% 89% 450% * 198% 
OTOS Otospiralin (OTOS), mRNA [NM_148961] 78% 130% 99% 88% 132% * * 
CES1P2 
Carboxylesterase 1 pseudogene 2 (CES1P2), 
 non-coding RNA [NR_033740] 
79% 156% - - - 187% 137% 
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ALDH3A2 
Aldehyde dehydrogenase 3 family, member A2 
(ALDH3A2), 
 transcript variant 1, mRNA [NM_001031806] 
79% 147% 48% 196% 144% * * 
TDRD6 
Tudor domain containing 6 (TDRD6), 
 transcript variant 1, mRNA [NM_001010870] 
81% 125% 92% 130% 130% * * 
NLN 
Neurolysin (metallopeptidase M3 family) 
 (NLN), mRNA [NM_020726] 
81% 134% 51% 160% 148% 116% * 
NRG1 
Neuregulin 1 (NRG1), transcript variant  
HRG-gamma, mRNA [NM_004495] 
81% 129% 46% 133% 791% 393% 150% 
AADAC 
Arylacetamide deacetylase (AADAC),  
mRNA [NM_001086] 
82% 117% 100% 85% 96% 162% * 
SFXN5 Sideroflexin 5 (SFXN5), mRNA [NM_144579] 82% 119% 88% 175% 120% * * 
SCCPDH 
Saccharopine dehydrogenase (putative)  
(SCCPDH), mRNA [NM_016002] 
82% 135% 100% 121% 124% 156% * 
FAM162A 
Family with sequence similarity 162, member A  
(FAM162A), mRNA [NM_014367] 
83% 116% 98% 123% 57% 117% * 
CUTC 
CutC copper transporter (CUTC), 
 mRNA [NM_015960] 
83% 129% 57% 134% 116% 194% * 
TCEB3 
Transcription elongation factor B (SIII), 
polypeptide 3  
(110kDa, elongin A) (TCEB3), mRNA [NM_003198] 
84% 126% 73% 107% 126% 124% 271% 
SLC22A3 
Solute carrier family 22 (organic cation 
transporter), member 3  
[Source:HGNC Symbol;Acc:10967] 
[ENST00000392145] 
84% 120% 99% 96% 64% * * 
ENST00000594
829 
Uncharacterized protein [ENST00000594829] 85% 117% - - - * * 
LOC100506922 
Basic proline-rich protein-like  
(LOC100506922), mRNA [XM_005263848] 
86% 120% 41% - - * * 
ICK 
Intestinal cell (MAK-like) kinase (ICK),  
transcript variant 2, mRNA [NM_016513] 
86% 114% 104% 204% 97% * * 
PPARA 
Peroxisome proliferator-activated receptor alpha 
(PPARA), 
 transcript variant 5, mRNA [NM_005036] 
88% 119% 93% 218% 392% 203% 182% 
OR5T3 
Olfactory receptor family 5 subfamily T member 3 
(OR5T3), 
mRNA [NM_001004747.1] 
104% 102% - - - * * 
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Figure A1 NQO1 WT GeneMill plasmid map 
Plasmid map of NQO1 WT, a representative construct from GeneMill. 
 
Figure A2 pGL4.20 plasmid map 
Plasmid map of pGL4.20 Luc/Puro vector. 
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Figure A3 Sub-cloning promoter regions into the pGL4.20 vector 
(A) Multiple cloning site (MCS) of pGL4.20 and (B) a gel to show digestion of the vector with Kpn1 and Nhe1. (C) Removal of promotor inserts from GeneMill 
constructs following restriction digest with the enzymes Kpn1 and Nhe1 
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Figure A4 NQO1 WT GeneMill plasmid map 
Final promotor-reporter plasmid following insertion into pGL4.20. Location of the ARE 
highlighted blue. 
 
Figure A5 pSB-tet-Nrf2 plasmid map 
Map of the inducible Nrf2 over-expression plasmid pSB-tet-Nrf2. 
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Table A2 Summary of EVGEN analogue potencies 
Evgen ID  Compound Structure Compound Name CD (µM) SD (µM) 
EVG01 
(sulforaphane)  
 
1-isothiocyanato-4-(methylsulfinyl)butane 1.45 0.24 
EVG02 
 
1-isothiocyanato-2-(2-(2-(methylsulfinyl)ethoxy)ethoxy)ethane 5.49 2.28 
EVG14 
 
1-isothiocyanato-23-(methylsulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 11.04 2.31 
EVG22 
 
1-isothiocyanato-23-(o-trifluoromethyl-phenylsulfinyl)-3,6,9,12,15,18,21-
heptaoxatricosane 
11.14 0.48 
EVG09 
 
1-isothiocyanato-11-(pyridine-2-sulfinyl)-3,6,9-trioxaundecane 11.27 0.45 
EVG25 
 
N-(isopentyl)-N-(methyl)-11-isothiocyanato-3,6,9-trioxaundecane-1-sulfinamide 11.78 6.24 
EVG03 
 
1-isothiocyanato-11-(butylsulfinyl)-3,6,9-trioxaundecane 11.94 3.46 
EVG18 
 
1-isothiocyanato-23-(p-tolylsulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 12.33 1.42 
EVG13 
 
1-isothiocyanato-11-(1,1,1-trifluoromethyl-ethanesulfinyl)-3,6,9-trioxaundecane 12.47 1.00 
EVG23 
 
1-isothiocyanato-23-(3,5-bis-trifluoromethyl-phenylsulfinyl)-3,6,9,12,15,18,21-
heptaoxatricosane 
12.88 1.96 
S=C=N
O
O
S
O
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EVG32  
 
11-isothiocyanato-N-(phenyl)-3,6,9-trioxaundecane-1-sulfinamide 13.27 3.63 
EVG42  
 
23-isothiocyanato-N-(4-trifluoromethylbenzyl)-3,6,9,12,15,18,21-heptaoxatricosane-
1-sulfinamide 
13.46 1.77 
EVG05 
 
1-isothiocyanato-11-(benzylsulfinyl)-3,6,9-trioxaundecane 13.90 5.57 
EVG06a 
 
1-isothiocyanato-11-(thiophenyl)-3,6,9-trioxaundecane 14.13 4.67 
EVG24 
 
N-(isopentyl)-11-isothiocyanato-3,6,9-trioxaundecane-1-sulfinamide 14.29 2.81 
EVG17 
 
1-isothiocyanato-23-(phenylsulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 14.32 4.05 
EVG04 
 
1-isothiocyanato-11-(tert-butylsulfinyl)-3,6,9-trioxaundecane 14.80 8.36 
EVG37 
 
N-(4-ethynylphenyl)-23-isothiocyanato-3,6,9,12,15,18,21-heptaoxatricosane-1-
sulfinamide 
15.17 7.44 
EVG10 
 
1-isothiocyanato-11-(3,5-bis-trifluoromethyl-phenylsulfinyl)-3,6,9-trioxaundecane 15.56 2.36 
EVG27 
 
11-isothiocyanato-N-(propyl)-3,6,9-trioxaundecane-1-sulfinamide 18.54 5.97 
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EVG26  
 
N-(tert-butyl)-11-isothiocyanato-3,6,9-trioxaundecane-1-sulfinamide 19.54 5.79 
EVG19 
 
1-isothiocyanato-23-(benzylsulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 19.63 5.27 
EVG15 
 
1-isothiocyanato-23-(ethylsulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 20.04 3.17 
EVG30 
 
N-(benzyl)-11-isothiocyanato-3,6,9-trioxaundecane-1-sulfinamide 20.09 2.40 
EVG29 
 
1-((2-(2-(2-(2-isothiocyanatoethoxy)ethoxy)ethoxy)ethyl)sulfinyl)piperidine 20.94 2.39 
EVG06 
 
1-isothiocyanato-11-(phenylsulfinyl)-3,6,9-trioxaundecane 21.18 6.60 
EVG35 
 
23-isothiocyanato-N-phenyl-3,6,9,12,15,18,21-heptaoxatricosane-1-sulfinamide 25.00 5.71 
EVG38 
 
23-isothiocyanato-N-(2,4,6-trifluorophenyl)-3,6,9,12,15,18,21-heptaoxatricosane-1-
sulfinamide 
25.37 7.99 
EVG20 
 
1-isothiocyanato-23-(pyridine-2-sulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 25.53 2.06 
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EVG39 
 
N-(3,5-bis(trifluoromethyl)phenyl)-23-isothiocyanato-3,6,9,12,15,18,21-
heptaoxatricosane-1-sulfinamide 
25.63 3.25 
EVG41 
 
N-benzyl-23-isothiocyanato-3,6,9,12,15,18,21-heptaoxatricosane-1-sulfinamide 27.04 4.83 
EVG34 
 
N-isobutyl-23-isothiocyanato-3,6,9,12,15,18,21-heptaoxatricosane-1-sulfinamide 27.80 1.17 
EVG36 
 
23-isothiocyanato-N-(p-tolyl)-3,6,9,12,15,18,21-heptaoxatricosane-1-sulfinamide 29.72 4.72 
EVG16 
 
1-isothiocyanato-23-(tert-butylsulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 32.50 9.71 
EVG07a 
 
1-isothiocyanato-11-(4-methyl-thiophenyl)-3,6,9-trioxaundecane 33.34 13.94 
EVG40 
 
N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-23-isothiocyanato-3,6,9,12,15,18,21-
heptaoxatricosane-1-sulfinamide 
34.91 1.95 
EVG28 
 
11-isothiocyanato- N-(propyl)-N-(methyl)-3,6,9-trioxaundecane-1-sulfinamide 48.08 19.07 
EVG21 
 
1-isothiocyanato-23-(pyrimidine-2-sulfinyl)-3,6,9,12,15,18,21-heptaoxatricosane 71.12 15.61 
EVG33 
 
N-(tert-butyl)-23-isothiocyanato-3,6,9,12,15,18,21-heptaoxatricosane-1-sulfinamide 89.33 18.39 
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EVG07 
 
1-isothiocyanato-11-(p-tolylsulfinyl)-3,6,9-trioxaundecane ND  
EVG08 
 
1-isothiocyanato-11-(p-methoxy-phenylsulfinyl)-3,6,9-trioxaundecane ND  
EVG11 
 
1-isothiocyanato-11-(p-fluoro-phenylsulfinyl)-3,6,9-trioxaundecane ND  
EVG12 
 
1-isothiocyanato-11-(m-methoxy-phenylsulfinyl)-3,6,9-trioxaundecane ND  
EVG31 
 
N-(benzyl)-N-(methyl)-11-isothiocyanato-3,6,9-trioxaundecane-1-sulfinamide ND  
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Figure A6 Sulforaphane analogues with non-defined CD values  
Concentration-response curves of 8AREL reporter luminescence in the H4IIe cells, after 24 h exposure to sulforaphane analogues (n=3): EVG07 (A), EVG08 
(B), EVG11 (C), EVG12 (D) and EVG31 (E). CD values undetermined. Mean and SD shown. 
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Figure A7 Sulforaphane analogues with CD values greater than 20 µM 
Concentration-response curves of 8AREL reporter luminescence in the H4IIe cells, after 24 h exposure to sulforaphane analogues (n=3) (A-Q). Curve fit 
calculated via non-linear regression. Mean and SD shown.   
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Figure A8 Sulforaphane analogues with CD values between 15 and 20 µM 
Concentration-response curves of 8AREL reporter luminescence in the H4IIe cells, after 24 h exposure to sulforaphane analogues (n=3) (A-E). Curve fit 
calculated via non-linear regression. Mean and SD shown.  
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Figure A9 Sulforaphane analogues with CD values between 10 and 15 µM 
Concentration-response curves of 8AREL reporter luminescence in the H4IIe cells, after 24 h exposure to sulforaphane analogues (n=3) (A-O): EVG14(A), 
EVG22 (B), EVG09 (C), EVG25 (D), EVG03 (E), EVG18 (F), EVG13 (G), EVG23 (H), EVG32 (I), EVG42 (J), EVG05 (K), EVG06a (L), EVG24 (M), EVG17 (N) and 
EVG04 (O). Curve fit calculated via non-linear regression. Mean and SD shown.   
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Figure A10 Compounds in the SFX-01 program with CD values less than 10 µM 
Concentration-response curves of 8AREL reporter luminescence in the H4IIe cells, after 24 h exposure to sulforaphane analogues (n=3): EVG01 (A) and EVG02 
(B). Curve fit calculated via non-linear regression. Mean and SD shown.  
  
 
